Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease

Abstract

Polynucleotide sequences are provided that correspond to genes that are differentially expressed in atherosclerotic disease conditions. Methods for using these sequences to detect gene expression and/or for transcriptional profiling in mammals are also provided. The polynucleotide sequences of the invention may be used, for example, to diagnose atherosclerotic disease, to monitor extent of progression or efficacy of treatment or to assess prognosis of atherosclerotic disease, and/or to identify compounds effective to treat an atherosclerotic disease condition.

Description

FIELD OF THE INVENTION

This application is in the field of atherosclerotic disease. In particular, this invention relates to methods and compositions for diagnosing, monitoring, and development of therapeutics for atherosclerotic disease.

BACKGROUND OF THE INVENTION

Atherosclerosis is the primary cause of heart disease and stroke (Kannel and Belanger (1991) Am. Heart J 121:951-57), and is the most common cause of morbidity and mortality in the United States (NHLBI Morbidity and Mortality Chartbook, National Heart, Lung, and Blood Institute, Bethesda, MD, May, 2002; NHLBI Fact Book, Fiscal Year 2003, pp. 35-53, National Heart, Lung, and Blood Institute, Bethesda, MD, February, 2004). Atherosclerosis is currently conceptualized as a chronic inflammatory disease of the arterial vessel wall that develops due to complex interactions between the environment and the genetic makeup of an individual (Ross (1999) N Engl J Med 340:115-26). Development of an atherosclerotic plaque occurs in stages, beginning with simple fatty streak formation and culminating in complex calcified lesions containing abnormal accumulation of smooth muscle cells, inflammatory cells, lipids, and necrotic debris. It is likely that the various stages of atherosclerotic disease are governed by a set of genes that are expressed by a variety of cell types present in the vessel wall.

The propensity for developing atherosclerosis is dependent on underlying genetic risk, and varies as a function of age and exposure to environmental risk factors. However, despite the chronic nature of atherosclerotic disease, knowledge regarding temporal gene expression during the course of disease progression is very limited. The prolonged, chronic, and unpredictable nature of the disease in humans, by virtue of heterogeneous genetic and environment factors, has limited systematic temporal gene expression studies in humans.

The roles of a limited number of genes that are differentially expressed in vascular disease have been identified, and a few of these genes linked through mechanistic studies to disease processes (Glass and Witztum (2001) Cell 104:503-16; Breslow (1996) Science 272:685-88; Lusis (2000) Nature 407:233-41). Recent efforts to identify disease related gene expression patterns have employed transcriptional profiling with DNA microarrays. However, these studies have included relatively small arrays (Wuttge et al. (2001) Mol Med 7:383-392) as well as limited time points, with the primary comparison between normal and late stage diseased tissue (Archacki et al. (2003) Physiol Genomics 15:65-74; Faber et al. (2002) Curr Opin Lipidol 13:545-552; McCaffrey et al. (2000) J Clin Invest 105:653-662; Randi et al. (2003) J Throm Haemost 1:829-835; Seo et al. (2004) Arterioscler Thromb Vasc Biol 24:1922-1927; Zohlnhofer et al. (2001) Mol Cell 7:1059-1069. Utilizing microarrays in animal models, where a disease process can be studied over time, the impact of individual risk factors and perturbations on the expression of individual genes during disease development can be studied systematically without a priori knowledge of gene identity. The temporal expression patterns of the genes can then be correlated with the well-described disease stages.

There is a need for a comprehensive list of atherosclerosis-related genes that are predictive of atherosclerotic disease conditions, for use as diagnostic markers and for discovery of biochemical pathways involved in development of atherosclerotic disease and discovery and/or testing of new therapeutics.

BRIEF SUMMARY OF THE INVENTION

This invention provides compositions, methods, and kits for detection of gene expression, diagnosis, monitoring, and development of therapeutics with respect to atherosclerotic disease.

In one aspect, the invention provides a system for detecting gene expression, comprising at least two isolated polynucleotide molecules, wherein each isolated polynucleotide molecule detects an expressed gene product from a gene that is differentially expressed in atherosclerotic disease in a mammal. In one embodiment, the differentially expressed gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In another embodiment, the differentially expressed gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 1-927. In various embodiments, a system for detecting gene expression comprises any of at least 3, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, or 100 of the isolated polynucleotide molecules described herein or their polynucleotide complements, or human homologs or orthologs thereof. In one embodiment, the gene expression system comprises at least two isolated polynucleotide molecules, wherein each isolated polynucleotide molecule detects an expressed gene product, wherein the gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 1-927, wherein the gene is differentially expressed in atherosclerotic disease in a mammal, and wherein the gene expression system comprises at least 1, 3, 5, 10, 15, 20, 25, or 30 isolated polynucleotide molecules that detect genes corresponding to the polynucleotide sequences selected from the group consisting of SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

In some embodiments, the isolated polynucleotide molecules are immobilized on an array, which may be selected from the group consisting of a chip array, a plate array, a bead array, a pin array, a membrane array, a solid surface array, a liquid array, an oligonucleotide array, a polynucleotide array, a cDNA array, a microtiter plate, a membrane, and a chip. The isolated polynucleotide molecules may be selected from the group consisting of synthetic DNA, genomic DNA, cDNA, RNA, or PNA. A gene corresponding to an isolated polynucleotide molecules described herein may be differentially expressed in any blood vessel or portion thereof which has developed an atherosclerotic or inflammatory disease, for example, the aorta, a coronary artery, the carotid artery, or a blood vessel of the peripheral vasculature.

In another aspect, the invention provides a kit comprising a system for detecting gene expression as described above. In one embodiment, the kit comprises an array comprising a system for detecting gene expression as described above.

In another aspect, the invention provides a method of detecting gene expression, comprising contacting products of gene expression with the system for detecting gene expression as described above. In one embodiment, the method comprises isolating mRNA, for example from a sample from individual who has or who is suspected of having an atherosclerotic disease, and hybridizing the RNA to the polynucleotide molecules from the system for detecting gene expression. In another embodiment, the method comprises isolating mRNA, converting the RNA to nucleic acid derived from the RNA, e.g., cDNA, and hybridizing the nucleic acid derived from the RNA to the polynucleotide molecules of the system for detecting gene expression. Optionally, the RNA may be amplified prior to hybridization to the system for gene expression. Optionally, the RNA is detectably labeled, and determination of presence, absence, or amount of an RNA molecule corresponding to a gene detected by a polynucleotide molecule of the system for detecting gene expression comprises detection of the label.

In another embodiment, the method for detecting gene expression comprises isolating proteins from an individual who has or who is suspected of having an atherosclerotic disease, and detecting the presence, absence, or amount of one or more proteins corresponding to the gene expression product of a gene that is differentially expressed in atherosclerotic disease and corresponds to a polynucleotide molecule of the system for detecting gene expression as described above. Detection may be via an antibody that recognizes the protein, for example, by contacting the isolated proteins with an antibody array.

In another aspect, the invention provides a method for diagnosing an atherosclerotic disease in an individual, comprising contacting polynucleotides derived from a sample from the individual with a system for detecting gene expression as described above. In one embodiment, the method comprises detecting hybridization complexes formed, if any, wherein presence, absence or amount of hybridization complexes formed from at least one of the polynucleotides from the individual is indicative of presence or absence of the atherosclerotic disease. In another embodiment, the method comprises comparing levels of expression of the genes with a molecular signature indicative of the presence or absence of the atherosclerotic disease.

In another aspect, the invention provides a method for assessing extent of progression of atherosclerotic disease in an individual, comprising contacting polynucleotides derived from a sample from the individual with a system for detecting gene expression as described above. In one embodiment, the method comprises detecting hybridization complexes formed, if any, wherein presence, absence or amount of hybridization complexes formed from at least one of the polynucleotides from the individual is indicative of extent of progression of the atherosclerotic disease. In another embodiment, the method comprises detecting hybridization complexes formed, if any, and comparing levels of expression of the genes with a molecular signature indicative of extent of progression of the atherosclerotic disease.

In another aspect, the invention provides a method of assessing efficacy of treatment of atherosclerotic disease in an individual, comprising contacting polynucleotides derived from a sample from the individual with a system for detecting gene expression as described above. In one embodiment, the method comprises detecting hybridization complexes formed, if any, wherein presence, absence or amount of hybridization complexes formed from at least one of the polynucleotides from the individual is indicative of extent of progression of the atherosclerotic disease. In another embodiment, the method comprises comparing levels of expression of the genes with a molecular signature indicative of extent of progression of the atherosclerotic disease.

In another aspect, the invention provides a method for determining prognosis of atherosclerotic disease in an individual, comprising contacting polynucleotides derived from a sample from the individual with a system for detecting gene expression as described above. In one embodiment, the method comprises detecting hybridization complexes formed, if any, wherein presence, absence or amount of hybridization complexes formed from at least one of the polynucleotides from the individual is indicative of prognosis of the atherosclerotic disease. In another embodiment, the method comprises comparing levels of expression of the genes with a molecular signature indicative of prognosis of the atherosclerotic disease.

In another aspect, the invention provides a method for identifying a compound effective to treat an atherosclerotic disease, comprising administering a test compound to a mammal with an atherosclerotic disease condition and contacting polynucleotides derived from a sample from the mammal with a system for detecting gene expression as described above. In one embodiment, the method comprises detecting hybridization complexes formed, if any, wherein presence, absence or amount of hybridization complexes formed from at least one of the polynucleotides from the individual is indicative of treatment of the disease. In another embodiment, the invention comprises detecting hybridization complexes formed, if any, and comparing levels of expression of the genes with a molecular signature indicative of treatment of the disease.

In another aspect, the invention provides a method of monitoring atherosclerotic disease in a mammal, comprising detecting the expression level of at least one, at least two, at least ten, at least one hundred, or more genes selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 1-927. In some embodiments, at least one of the genes for which expression level is detected is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In one embodiment, the atherosclerotic disease comprises coronary artery disease. In one embodiment, the atherosclerotic disease comprises carotid atherosclerosis. In one embodiment, the atherosclerotic disease comprises peripheral vascular disease. In some embodiments, the expression level of said gene(s) is detected by measuring the RNA expression level. In one embodiment, RNA is isolated from the individual prior to detection of the RNA expression level. Measurement of RNA expression level may comprise amplifying RNA from an individual, for example, by polymerase chain reaction (PCR), using a primer that is complementary to a polynucleotide sequence corresponding to a gene to be detected, wherein the gene corresponds to a polynucleotide sequence selected from the group of genes depicted in SEQ ID NOs: 1-927. In some embodiments, a primer is used that is complementary to a polynucleotide sequence corresponding to a gene to be detected, wherein the gene corresponds to a polynucleotide sequence selected from the group of genes depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. Measurement of RNA expression level may comprise hybridization of RNA from the individual to a polynucleotide corresponding to a gene to be detected, wherein the gene corresponds to a polynucleotide sequence selected from the group of genes depicted in SEQ ID NOs: 1-927. In some embodiments, RNA from the individual is hybridized to a polynucleotide corresponding to a gene to be detected, wherein the gene to be detected is selected from the group of genes depicted in 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In some embodiments, gene expression level is detected by measuring the expressed protein level. In some embodiments, the method further comprises selecting an appropriate therapy for treatment or prevention of the atherosclerotic disease. In some embodiments, gene expression level, for example, RNA or protein level, is detected in serum from an individual.

In another aspect, the invention provides a method of monitoring atherosclerotic disease in an individual, comprising detecting RNA expressed from at least one gene selected from the group of genes corresponding to at least one polynucleotide sequence depicted in SEQ ID NOs: 1-927. In one embodiment, the at least one gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In one embodiment, the method comprises measuring the expressed RNA in serum from the individual.

In another aspect, the invention provides a method of monitoring atherosclerotic disease in an individual, comprising detecting protein expressed from at least one gene selected from the group of genes corresponding to at least one polynucleotide sequence depicted in SEQ ID NOs:1-927. In one embodiment, the at least one gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In one embodiment, the method comprises measuring the expressed protein in serum from the individual.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts the experimental design of the experiments described in Example 1. ApoE deficient mice (C57BL/6J-Apoe^5mlUnc), were fed non-cholate-containing high-fat diet from 4 weeks of age for a maximum period of 40 weeks. Aortas were obtained for transcriptional profiling at pre-determined time intervals corresponding to various stages of atherosclerotic plaque formation. For each time point, aortas from 15 mice were combined into 3 pools for microarray replicate studies. To eliminate gene expression differences due to aging, diet, and genetic differences, a number of control groups were also used at each time point, including apoE deficient mice on normal chow, aw well as C57Bl/6 and C3H/HeJ wild type mice on both normal and atherogenic diets.

FIG. 2 depicts quantification of atherosclerotic disease in the experiments described in Example 1. Percent lesion area was determined by calculating the ratio of atherosclerotic area versus total surface area of the aorta. ApoE-deficient mice (n=7) on high-fat diet were compared to other control mice (n=5-7 for each mouse/diet combination). Representative time intervals were used for analysis, including baseline (TOO) measurements in mice prior to initiation of diet at 4 weeks of age and end point measurements corresponding to 40 weeks (T40) on either high-fat or normal diet. At T00, three were no statistically significant differences in lesion area among the various conditions. At 40 weeks on high-fat diet, the controls did not develop any lesions. In contrast to the control mice, the ApoE-deficient mice on normal chow and on high-fat diet had significantly larger atherosclerotic area (14.00% +/−3.92%, p<0.0001, and 37.98% +/−6.3%, p<0.0001, respectively.)

FIG. 3 depicts atherosclerosis genes identified in the experiments described in Example 1. Employing a newly-developed statistical algorithm which relies on permutation analysis and generalized regression, atherosclerosis-related genes were identified. Selecting the genes on the basis of their false detection rate (FDR<0.05) and depicting their expression with a heatmap (ordered by hierarchical clustering), demonstrates profiles which closely correlate with disease progression. The heatmap is a graphic representation of expression patterns of 6 parallel time course studies with time progressing from left to right for each of the 6 sets of strain-diet combination. Each set of the strain-diet combination therefore contains 15 columns (3 for each of 5 time points). Each row represents the row normalized expression pattern of a single gene. The dominant temporal pattern of expression is one that increases linearly with time (667 genes). Fewer genes (64) reveal an opposite pattern. HF: high-fat diet; NC: normal chow.

FIG. 4 depicts time-related patterns of gene expression in atherosclerosis observed in the experiments described in Example 1. Using AUC analysis, a number of distinct time-related patterns of gene expression in ApoE-deficient mice on high-fat diet were observed. Eight different time-related patterns are depicted, with the y-axis representing normalized gene expression values and the x-axis representing 6 different time points from time 0 to 40 weeks. The genes in each pattern were clustered based on positive correlation values. The mean distance of genes from the center of each cluster is noted in parentheses for each pattern. Using enrichment analysis for each cluster of genes, specific pathways were found to be associated with these patterns that reflect particular biological processes.

FIG. 5 depicts the identification and validation of mouse atherosclerotic disease classifier genes as determined in the experiments described in Example 1. FIG. 5A depicts identification of the classification gene set. The SVM algorithm described in Example 1 was employed to rank genes based on their abilities to accurately discriminate between 5 time points in ApoE-deficient mice on high-fat diet. An optimal set of 38 genes was identified to classify the experiments at a minimal error rate of 15%. The optimal 15% error rate was determined with a 1000 step cross-validation method with 25% of the experiments employed as the test group and the rest as the training group. FIG. 5B depicts classification of an independent mouse atherosclerosis data set. Aortas of ApoE-deficient mice aged 16 weeks were used for gene expression profiling utilizing a different microarray and labeling protocol than in the experiment depicted in FIG. 5A. Using the SVM algorithm, where known experiments were the five time points in the original experimental design and the independent set of experiments was the test set, these mice most closely classified with the 24 week time point. SVM scores for each experiment based on one-versus-all comparisons are represented graphically in a heatmap.

FIG. 6 depicts expression of atherosclerosis-related genes in human coronary artery disease, as described in Example 1. To investigate the expression profile of differently regulated mouse genes in human coronary artery atherosclerosis, 40 coronary artery samples with and without atherosclerotic lesions were used for transcriptional profiling. Atherosclerosis-associated mouse genes were matched to human orthologs/homologs by gene symbol and by known homology, and their expression was compared in human atherosclerotic plaques classified as lesion versus no lesion (SAM FDR<0.025). The expression of the top genes is represented graphically as a heatmap, where rows represent row normalized expression of each gene and the columns represent coronary artery samples. Calculated SAM FDR<0.009 for d-score 4.25-2.45, FDR<0.015 for d-score 2.41-2.357, FDR<0.025 for d-score 2.33-2.05.

FIG. 7 depicts the experimental design of the experiments described in Example 2. FIG. 7A: Four-week-old female C3H/HeJ (C3H) and C57B16 (C57) mice were fed normal chow vs. high-fat diet for the maximum period of 40 weeks. Triplicate microarray experiments were performed for each time point using 3 pools of 5 aortas at 0, 4, 10, 24, and 40 weeks on either diet (total of 15 mice per time point). FIG. 7B: Data analysis overview. Of the 20,283 genes present on the array, 311 genes were found to be significantly differentially expressed between C3H and C57 mice at baseline (SAM FDR 10% and >1.5-fold change). Differential gene expression during aging was determined by comparing C57 vs. C3H time-course differences on normal and atherogenic high-fat diets using AUC analysis.

FIG. 8 depicts differential gene expression between C3H and C57 mice at baseline. The SAM analysis shown was associated with an FDR of 10%, and a total of 311 probes were identified as differentially regulated at this level of confidence. Lists represent a select group of genes (expressed sequence tags excluded) with higher expression in C3H (top 20 ranking genes) and C57 (top 45 ranking genes). The heatmap reflects normalized gene expression ratios and is organized with individual hybridizations for each of the 3 replicates for each mouse strain arranged along the x axis.

FIG. 9 depicts differential gene expression between C3H and C57 mice in response to normal aging. FIG. 9A: Response to aging was determined by comparing C57 vs. C3H time-course differences on normal diet (AUC analysis F statistic>10). FIG. 9B: Functional annotation of the 413 differentially expressed genes reveals differences in various biological processes, including growth and differentiation. The probability rates provided area based on Fisher exact test (P<0.02). FIG. 9C: K-means clustering of the 413 genes reveals several profiles of gene expression. Clusters 1, 4, and 9 reveal increased gene expression in C3H vs. C57 mice, whereas clusters 2, 6, and 14 reveal the opposite pattern.

FIG. 10 depicts differential gene expression between C3H and C57 mice in response to high-fat diet. FIG. 10A: Response to atherogenic stimulus was determined by comparing C57 vs. C3H time-course differences on high -fat diet (AUC analysis F statistic>10). FIG. 1OB: Functional annotation of the 509 differentially expressed genes reveals differences in various biological processes and cellular components. The probability rates provided are based on Fisher exact test (P<0.02). FIG. 1OC: K-means clustering of the 509 differentially expressed genes revealed several patterns of gene expression with clusters 3 and 9 exhibiting increased gene expression in C3H vs. C57 mice and clusters 8 and 10 with the opposite pattern.

FIG. 11 shows the results of evaluation in the apoe knockout model of genes identified as differentially expressed between C3H and C57 strains. FIG. 11A: ApoE knockout mice (C57BL/6J-Apoe^™lUnc) were fed normal chow versus high-fat diet for the maximum period of 40 weeks. Triplicate microarray experiments were preformed for each time point using 3 pools of 5 aortas at 0, 4, 10, 24, and 40 weeks for regular and high-fat diet groups (total of 15 mice per time point). SOMs were used to visualize patterns of expression of genes of interest. Genes which were differentially regulated by aging (FIG. 9, K-means clusters 1, 4, and 9 with higher expression in C3H and clusters 4, 6, and 14 with higher expression in C57) and genes identified with atherogenic stimuli (FIG. 10, K-means clusters 3 and 9 with higher expression in C3H and clusters 8 and 10 with opposite pattern) as well as genes which were differentially expressed at the baseline time point (FIG. 8), were grouped and their expression was studied using SOM analysis. SOM analysis reveals diverse patterns of expression of these genes throughout the development of atherosclerosis in apoe knockout mice. Cluster 8 contains genes that are consistently increasing in expression with progression of atherosclerosis. Pie charts reflect the analysis group from which the genes populating each cluster were derived. The relative size of sectors of the pie chart indicates the relative number of genes that are derived from the various staging groups. FIG. 11B lists genes with higher expression in C57 mice at baseline and in C3H mice at baseline or on a high fat diet.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides polynucleotide sequences that correspond to genes that are differentially expressed in atherosclerotic disease conditions, and methods for using these sequences to detect gene expression and/or for transcriptional profiling in mammals. The polynucleotide sequences provided herein may be used, for example, to diagnose, assess extent of progression, assess efficacy of treatment of, to determine prognosis of, and/or to identify compounds effective to treat an atherosclerotic disease condition. The polynucleotide sequences herein may also be used in methods for elucidation of biochemical pathways that are involved in development and/or maintenance of atherosclerotic disease conditions.

General Techniques

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as: Molecular Cloning: A Laboratory Manual, vol. 1-3, third edition (Sambrook et al., 2001); Oligonucleotide Synthesis (M.J. Gait, ed., 1984); Methods in Enzymology (Academic Press, Inc.); Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987); PCR Cloning Protocols, (Yuan and Janes, eds., 2002, Humana Press).

In addition to the above references, protocols for in vitro amplification techniques, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), Qβ-replicase amplification, and other RNA polymerase mediated techniques (e.g., NASBA), useful, e.g., for amplifying oligonucleotide probes of the invention, are found in Mullis et al., U.S. Pat. No. (1987) 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds.) Academic Press, Inc., San Diego, CA (1990); Amnheim and Levinson (1990) C&EN 36; The Journal of NIH Research (1991) 3:81; Kwoh et al. (1989) Proc Natl Acad Sci USA 86:1173; Guatelli et al. (1990) Proc Natl Acad Sci USA 87:1874; Lomell et al. (1989) J Clin Chem 35:1826; Landegren et al. (1988) Science 241:1077; Van Brunt (1990) Biotechnology 8:291; Wu and Wallace (1989) Gene 4:560; Barringer et al. (1990) Gene 89:117; Sooknanan and Malek (1995) Biotechnology 13:563. Additional methods, useful for cloning nucleic acids, include Wallace et al., U.S. Patent No. 5,426,039. Improved methods of amplifying large nucleic acids by PCR are summarized in Cheng et al. (1994) Nature 369:684, and the references therein.

Definitions

Unless defined otherwise, all scientific and technical terms are understood to have the same meaning as commonly used in the art to which they pertain. For the purpose of the present invention, the following terms are defined below.

As used herein, the term “gene expression system” or “system for detecting gene expression” refers to any system, device or means to detect gene expression and includes candidate libraries, oligonucleotide sets or probe sets.

The term “diagnostic oligonucleotide set” generally refers to a set of two or more oligonucleotides that, when evaluated for differential expression of their products, collectively yields predictive data. Such predictive data typically relates to diagnosis, prognosis, monitoring of therapeutic outcomes, and the like. In general, the components of a diagnostic oligonucleotide set are distinguished from nucleotide sequences that are evaluated by analysis of the DNA to directly determine the genotype of an individual as it correlates with a specified trait or phenotype, such as a disease, in that it is the pattern of expression of the components of the diagnostic nucleotide set, rather than mutation or polymorphism of the DNA sequence that provides predictive value. It will be understood that a particular component (or member) of a diagnostic nucleotide set can, in some cases, also present one or more mutations, or polymorphisms that are amenable to direct genotyping by any of a variety of well known analysis methods, e.g., Southern blotting, RFLP, AFLP, SSCP, SNP, and the like.

A “disease specific target oligonucleotide sequence” is a gene or other oligonucleotide that encodes a polypeptide, most typically a protein, or a subunit of a multi-subunit protein, that is a therapeutic target for a disease, or group of diseases.

A “candidate library” or a “candidate oligonucleotide library” refers to a collection of oligonucleotide sequences (or gene sequences) that by one or more criteria have an increased probability of being associated with a particular disease or group of diseases. The criteria can be, for example, a differential expression pattern in a disease state, tissue specific expression as reported in a sequence database, differential expression in a tissue or cell type of interest, or the like. Typically, a candidate library has at least 2 members or components; more typically, the library has in excess of about 10, or about 100, or about 500, or even more, members or components.

The term “disease criterion” is used herein to designate an indicator of a disease, such as a diagnostic factor, a prognostic factor, a factor indicated by a medical or family history, a genetic factor, or a symptom, as well as an overt or confirmed diagnosis of a disease associated with several indicators. A disease criterion includes data describing a patient's health status, including retrospective or prospective health data, e.g., in the form of the patient's medical history, laboratory test results, diagnostic test results, clinical events, medications, lists, response(s) to treatment and risk factors, etc.

The terms “molecular signature” or “expression profile” refers to the collection of expression values for a plurality (e.g., at least 2, but frequently at least about 10, about 30, about 100, about 500, or more) of members of a candidate library. In many cases, the molecular signature represents the expression pattern for all of the nucleotide sequences in a library or array of candidate or diagnostic nucleotide sequences or genes. Alternatively, the molecular signature represents the expression pattern for one or more subsets of the candidate library.

The terms “oligonucleotide” and “polynucleotide” and “nucleic acid,” used interchangeably herein, refer to a polymeric form of two or more nucleotides of any length and any three-dimensional structure (e.g., single-stranded, double-stranded, triple-helical, etc.), which contain deoxyribonucleotides, ribonucleotides, and/or analogs or modified forms of deoxyribonucleotides or ribonucleotides. Nucleotides may be DNA or RNA, and may be naturally occurring, or synthetic, or non-naturally occurring. A nucleic acid of the present invention may contain phosphodiester bonds or an alternate backbone, comprising, for example, phosphoramide, phosphorothioate, phosphorodithioate, O-methylphosphoroamidite linkages, and peptide nucleic acid backbones and linkages. The term polynucleotide includes peptide nucleic acids (PNA).

The terms “polypeptide,”“peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The term also includes variants on the traditional peptide linkage joining the amino acids making up the polypeptide.

An “isolated” or “purified” polynucleotide or polypeptide is one that is substantially free of the materials with which it is associated in nature. By substantially free is meant at least 50%, preferably at least 70%, more preferably at least 80%, and even more preferably at least 90% free of the materials with which it is associated in nature.

As used herein, “individual” refers to a vertebrate, typically a mammal, such as a human, a nonhuman primate, an experimental animal, such as a mouse or rat, a pet animal, such as a cat or dog, or a farm animal, such as a horse, sheep, cow, or pig.

The term “healthy individual,” as used herein, is relative to a specified disease or disease criterion, e.g., the individual does not exhibit the specified disease criterion or is not diagnosed with the specified disease. It will be understood that the individual in question can exhibit symptoms, or possess various indicator factors, for another disease.

Similarly, an “individual diagnosed with a disease” refers to an individual diagnosed with a specified disease (or disease criterion). Such an individual may, or may not, also exhibit a disease criterion associated with, or be diagnosed with another (related or unrelated) disease.

An “array” is a spatially or logically organized collection, e.g., of oligonucleotide sequences or nucleotide sequence products such as RNA or proteins encoded by an oligonucleotide sequence. In some embodiments, an array includes antibodies or other binding reagents specific for products of a candidate library.

When referring to a pattern of expression, a “qualitative” difference in gene expression refers to a difference that is not assigned a relative value. That is, such a difference is designated by an “all or nothing” valuation. Such an all or nothing variation can be, for example, expression above or below a threshold of detection (an on/off pattern of expression). Alternatively, a qualitative difference can refer to expression of different types of expression products, e.g., different alleles (e.g., a mutant or polymorphic allele), variants (including sequence variants as well as post-translationally modified variants), etc.

In contrast, a “quantitative” difference, when referring to a pattern of gene expression, refers to a difference in expression that can be assigned a numerical value, such as a value on a graduated scale, (e.g., a 0-5 or 1-10 scale, a +-+++ scale, a grade 1-grade 5 scale, or the like; it will be understood that the numbers selected for illustration are entirely arbitrary and in no-way are meant to be interpreted to limit the invention).

The term “monitoring” is used herein to describe the use of gene sets to provide useful information about an individual or an individual's health or disease status. “Monitoring” can include, for example, determination of prognosis, risk-stratification, selection of drug therapy, assessment of ongoing drug therapy, determination of effectiveness of treatment, prediction of outcomes, determination of response to therapy, diagnosis of a disease or disease complication, following of progression of a disease or providing any information relating to a patient's health status over time, selecting patients most likely to benefit from experimental therapies with known molecular mechanisms of action, selecting patients most likely to benefit from approved drugs with known molecular mechanisms where that mechanism may be important in a small subset of a disease for which the medication may not have a label, screening a patient population to help decide on a more invasive/expensive test, for example, a cascade of tests from a non-invasive blood test to a more invasive option such as biopsy, or testing to assess side effects of drugs used to treat another indication.

System for Detecting Gene Expression

The invention provides a system for detecting expression of genes that are differentially expressed in atherosclerotic disease. In one embodiment, the system for detecting gene expression detects at least two expressed gene products of genes selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In another embodiment, the system for detecting gene expression detects at least two expressed gene products of genes selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 1-927. The term “corresponding” as used herein in the context of a gene corresponding to a polynucleotide sequence depicted in the Sequence Listing refers to a gene that is detectable by interaction of a product of expression of the gene (e.g., mRNA, protein) or a product derived from a product of expression of the gene (e.g., cDNA) with the system for detecting gene expression. The polynucleotide sequences represented by Sequence Identification Nos. 1-927 and accompanying identifying information are depicted in Table 1 below. These sequences have been shown to be differentially expressed in atherosclerosis in mice (see Example 1). The 60 mer sequences represented in Table I are encompassed within the genes indicated therein. The gene sequences are obtainable from publicly available databases such as GenBank, and at http://www.ncbi.nlm.nih.gov or http://source.stanford.edu/cgi-bin/source/sourceSearch, using the identifying information provided in Table 1.

In one embodiment, the system for detecting gene expression includes at least two isolated polynucleotide molecules, each of which detects an expressed gene product of a gene that is differentially expressed in atherosclerotic disease in a mammal. The gene expression system includes at least two isolated polynucleotides that each comprise at least a portion of a sequence depicted in the Sequence Listing or its complement (i.e., a polynucleotide sequence capable of hybridizing to a sequence depicted in the sequence listing). A system for detecting gene expression in accordance with the invention may include any of at least 2, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 polynucleotides each comprising at least a portion of a polynucleotide depicted in the Sequence Listing or a polynucleotide complement thereof.

It is understood that the polynucleotides of the invention may have slightly different sequences than those identified herein. Such sequence variations are understood to those of ordinary skill in the art to be variations in the sequence that do not significantly affect the ability of the sequences to detect gene expression. For example, homologs and variants of the polynucleotides disclosed herein may be used in the present invention. Homologs and variants of these polynucleotide molecules possess a relatively high degree of sequence identity when aligned using standard methods. Polynucleotide sequences encompassed by the invention have at least 40-50, 50-60, 70-80, 80-85, 85-90, 90-95 or 95-100% sequence identity to the sequences disclosed herein.

It is understood that for expression profiling, variations in the disclosed polynucleotide sequences will still permit detection of gene expression. The degree of sequence identity required to detect gene expression varies depending on the length of an oligonucleotide. For example, for a 60mer (i.e., an oligonucleotide with 60 nucleotides), 6-8 random mutations or 6-8 random deletions do not affect gene expression detection. Hughes, T. R., et al. (2001) Nature Biotechnology 19:343-347. As the length of the polynucleotide sequence is increased, the number of mutations or deletions permitted while still allowing gene expression detection is increased.

As will be appreciated by those skilled in the art, the sequences of the present invention may contain sequencing errors. For example, there may be incorrect nucleotides, frameshifts, unknown nucleotides, or other types of sequencing errors in any of the sequences; however, the correct sequences will fall within the homology and stringency definitions herein.

In some embodiments, polynucleotide molecules are less than about any of the following lengths (in bases or base pairs): 10,000; 5000; 2500; 2000; 1500; 1250; 1000; 750; 500; 300; 250; 200; 175; 150; 125; 100; 75; 50; 25; 10. In some embodiments, polynucleotide molecules are greater than about any of the following lengths (in bases or base pairs): 10; 15; 20; 25; 30; 40; 50; 60; 75; 100; 125; 150; 175; 200; 250; 300; 350; 400; 500; 750; 1000; 2000; 5000; 7500; 10,000; 20,000; 50,000. Alternately, a polynucleotide molecule can be any of a range of sizes having an upper limit of 10,000; 5000; 2500; 2000; 1500; 1250; 1000; 750; 500; 300; 250; 200; 175; 150; 125; 100; 75; 50; 25; or 10 and an independently selected lower limit of 10; 15; 20; 25; 30; 40; 50; 60; 75; 100; 125; 150; 175; 200; 250; 300; 350; 400; 500; 750; 1000; 2000; 5000; or 7500, wherein the lower limit is less than the upper limit.

The isolated polynucleotides of the system for detecting gene expression may include DNA or RNA or a combination thereof, and/or modified forms thereof, and/or may also include a modified polynucleotide backbone. In some embodiments, the isolated polynucleotides are selected from the group consisting of synthetic oligonucleotides, genomic DNA, cDNA, RNA, or PNA.

In one embodiment, the system for detecting gene expression comprises two antibody molecules or antigen binding fragments thereof, each of which detects an expressed gene product (e.g., a polypeptide) of a gene that is differentially expressed in atherosclerotic disease in a mammal.

As used herein, “atherosclerotic disease” refers to a vascular inflammatory disease characterized by the deposition of atheromatous plaques containing cholesterol, lipids, and inflammatory cells within the walls of large and medium-sized blood vessels, which can lead to hardening of blood vessels, stenosis, and thrombotic and embolic events. Atherosclerosis includes coronary vascular disease, cerebral vascular disease, and peripheral vascular disease. The term “atherosclerotic disease” as used herein includes any condition associated with atherosclerosis in a mammal in which differential gene expression may be detected by a system for detecting gene expression as described herein. Examples of such atherosclerotic disease conditions include, but are not limited to, coronary artery disease (e.g., stable angina, unstable angina, exertional angina, myocardial infarction, congestive heart failure, sudden cardiac death, atrial fibrillation), cerebral vascular disease (e.g., stroke, cerebrovascular accident (CVA), transient ischemic attack (TIA), cerebral infarction, cerebral intermittent claudication), peripheral vascular disease (e.g., claudications), extracranial carotid disease, carotid plaque, and carotid bruit.

Arrays

In some embodiments, a system for detecting gene expression in accordance with the invention is in the form of an array. “Microarray” and “array,” as used interchangeably herein, comprise a surface with an array, preferably ordered array, of putative binding (e.g., by hybridization) sites for a biochemical sample (target) which often has undetermined characteristics. In one embodiment, a microarray refers to an assembly of distinct polynucleotide or oligonucleotide probes immobilized at defined positions on a substrate. Arrays may be formed on substrates fabricated with materials such as paper, glass, plastic (e.g., polypropylene, nylon, polystyrene), polyacrylamide, nitrocellulose, silicon, optical fiber or any other suitable solid or semi-solid support, and configured in a planar (e.g., glass plates, silicon chips) or three-dimensional (e.g., pins, fibers, beads, particles, microtiter wells, capillaries) configuration. Probes forming the arrays may be attached to the substrate by any number of ways including (i) in situ synthesis (e.g., high-density oligonucleotide arrays) using photolithographic techniques (see, Fodor et al., Science (1991), 251:767-773; Pease et al., Proc. Natl. Acad. Sci. U.S.A. (1994), 91:5022-5026; Lockhart et al., Nature Biotechnology (1996), 14:1675; U.S. Pat. Nos. 5,578,832; 5,556,752; and 5,510,270); (ii) spotting/printing at medium to low-density (e.g., cDNA probes) on glass, nylon or nitrocellulose (Schena et al, Science (1995), 270:467-470, DeRisi et al, Nature Genetics (1996), 14:457-460; Shalon et al., Genome Res. (1996), 6:639-645; and Schena et al., Proc. Natl. Acad Sci. U.S.A. (1995), 93:10539-11286); (iii) by masking (Maskos and Southern, Nuc. Acids. Res. (1992), 20:1679-1684) and (iv) by dot-blotting on a nylon or nitrocellulose hybridization membrane (see, e.g., Sambrook et al., Eds., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Vol. 1-3, Cold Spring Harbor Laboratory (Cold Spring Harbor, N.Y.)). Probes may also be noncovalently immobilized on the substrate by hybridization to anchors, by means of magnetic beads, or in a fluid phase such as in microtiter wells or capillaries. The probe molecules are generally nucleic acids such as DNA, RNA, PNA, and cDNA but may also include proteins, polypeptides, oligosaccharides, cells, tissues and any permutations thereof which can specifically bind the target molecules.

For example, microarrays, in which either defined cDNAs or oligonucleotides are immobilized at discrete locations on, for example, solid or semi-solid substrates, or on defined particles, enable the detection and/or quantification of the expression of a multitude of genes in a given specimen.

Several techniques are well-known in the art for attaching nucleic acids to a solid substrate such as a glass slide. One method is to incorporate modified bases or analogs that contain a moiety that is capable of attachment to a solid substrate, such as an amine group, a derivative of an amine group or another group with a positive charge, into the amplified nucleic acids. The amplified product is then contacted with a solid substrate, such as a glass slide, which is coated with an aldehyde or another reactive group which will form a covalent link with the reactive group that is on the amplified product and become covalently attached to the glass slide. Microarrays comprising the amplified products can be fabricated using a Biodot (BioDot, Inc. Irvine, Calif.) spotting apparatus and aldehyde-coated glass slides (CEL Associates, Houston, Tex.). Amplification products can be spotted onto the aldehyde-coated slides, and processed according to published procedures (Schena et al., Proc. Natl. Acad. Sci. U.S.A. (1995) 93:10614-10619). Arrays can also be printed by robotics onto glass, nylon (Ramsay, G., Nature Biotechnol. (1998), 16:40-44), polypropylene (Matson, et al., Anal Biochem. (1995), 224(l):110-6), and silicone slides (Marshall, A. and Hodgson, J., Nature Biotechnol. (1998), 16:27-31). Other approaches to array assembly include fine micropipetting within electric fields (Marshall and Hodgson, supra), and spotting the polynucleotides directly onto positively coated plates. Methods such as those using amino propyl silicon surface chemistry are also known in the art, as disclosed at www.cmt.corning.com and http://cmgm.stanford.edu/pbrown/.

One method for making microarrays is by making high-density polynucleotide arrays. Techniques are known for rapid deposition of polynucleotides (Blanchard et al., Biosensors & Bioelectronics, 11:687-690). Other methods for making microarrays, e.g., by masking (Maskos and Southern, Nuc. Acids. Res. (1992), 20:1679-1684), may also be used. In principle, and as noted above, any type of array, for example, dot blots on a nylon hybridization membrane, could be used. However, as will be recognized by those skilled in the art, very small arrays will frequently be preferred because hybridization volumes will be smaller.

In one embodiment, the invention provides an array comprising at least two isolated polynucleotide molecules, wherein each isolated polynucleotide molecule detects an expressed gene product of a gene selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927, and wherein the gene is differentially expressed in atherosclerotic disease in a mammal. In one embodiment, the invention provides an array comprising at least two isolated polynucleotide molecules, wherein each isolated polynucleotide molecule detects an expressed gene product of a gene selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs:1-927, and wherein the gene is differentially expressed in atherosclerotic disease in a mammal. In various embodiments, an array in accordance with the invention comprises any of at least 2, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 polynucleotides each comprising at least a portion of a polynucleotide depicted in the Sequence Listing or a polynucleotide complement thereof.

In another embodiment, the invention provides an array comprising at least two antibody molecules or antigen binding fragments thereof, wherein each antibody molecule or antigen binding fragment thereof detects an expressed gene product of a gene selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927, and wherein the gene is differentially expressed in atherosclerotic disease in a mammal. In another embodiment, the invention provides an array comprising at least two antibody molecules or antigen binding fragments thereof, wherein each antibody molecule or antigen binding fragment thereof detects an expressed gene product of a gene selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs:1-927, and wherein the gene is differentially expressed in atherosclerotic disease in a mammal. In various embodiments, an antibody array in accordance with the invention comprises any of at least 2, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 antibodies or antigen binding fragments thereof each recognizing an expression product (e.g., a polypeptide) of a gene corresponding to a polynucleotide sequence depicted in the Sequence Listing.

Methods of the Invention

Methods for Detecting Gene Expression

The invention provides methods for detecting gene expression, comprising contacting products of gene expression (e.g., mRNA, protein) in a sample with a system for detecting gene expression as described above, and detecting interaction between the products of gene expression in the sample and the system for detecting gene expression. The methods for detecting gene expression described herein may be used to detect or quantify differential expression and/or for expression profiling of a sample. As used herein, “differential expression” refers to increased (upregulated) or decreased (downregulated) production of an expressed product of a gene (e.g., mRNA, protein). Differential expression may be assessed qualitatively (presence or absence of a gene product) and/or quantitatively (change in relative amount, i.e., increase or decrease, of a gene product).

In one embodiment, MRNA from a sample is contacted with a system for detecting gene expression comprising isolated polynucleotide molecules as described above, and hybridization complexes formed, if any, between the mRNA in the sample and the polynucleotide sequences of the system for detecting gene expression, are detected. In other embodiments, the mRNA is converted to nucleic acid derived from the mRNA, for example, cDNA, and/or amplified, prior to contact with the system for detecting gene expression.

In another embodiment, polypeptides from a sample are contacted with a system for detecting gene expression comprising antibodies or antigen fragments thereof that bind to polypeptide expression products of genes corresponding to the polynucleotide sequences described herein, and binding between the antibodies and polypeptides in the sample, if any, is detected.

Methods for Expression Profiling

An “expression profile” or “molecular signature” is a representation of gene expression in a sample, for example, evaluation of presence, absence, or amount of a plurality of gene expression products, such as mRNA transcripts, or polypeptide translation products of mRNA transcripts. Expression patterns constitute a set of relative or absolute expression values for a number of RNA or protein products corresponding to the plurality of genes evaluated, referred to as the subject's “expression profile” for those nucleotide sequences. In various embodiments, expression patterns corresponding to at least about 2, 5, 10, 20, 30, 50, 100, 200, or 500, or more nucleotide sequences are obtained. The expression pattern for each differentially expressed component member of the expression profile may provide a specificity and sensitivity with respect to predictive value, e.g., for diagnosis, prognosis, monitoring treatment, etc. In some embodiments, a molecular signature is determined by a statistical algorithm that determines the optimal relation between patterns of expression for various genes.

In some embodiments, an expression profile from an individual is compared with a reference expression profile to determine, for example, presence or absence of a disease condition, symptom, or criterion, extent of progression of disease, effectiveness of treatment of disease, or prognosis for prophylaxis, therapy, or cure of disease.

As used herein, the term “subject” refers to an individual regardless of health and/or disease status. For example, a subject may be a patient, a study participant, a control subject, a screening subject, or any other class of individual from whom a sample is obtained and assessed in the context of the invention. Accordingly, a subject may be diagnosed with a disease, can present with one or more symptom of a disease, or may have a predisposing factor, such as a genetic or medical history factor, for a disease. Alternatively, a subject may be healthy with respect to any of the aforementioned disease factors or criteria. It will be appreciated that the term “healthy” as used herein, is relative to a specified disease condition, factor, or criterion. Thus, an individual described as healthy with reference to any specified disease or disease criterion, can be diagnosed with any other one or more disease, or may exhibit any other one or more disease criterion.

Methods for Obtaining Expression Data

Numerous methods for obtaining expression data are known, and any one or more of these techniques, singly or in combination, are suitable for determining expression profiles in the context of the present invention. For example, expression patterns can be evaluated by northern analysis, PCR, RT-PCR, Taq Man analysis, FRET detection, monitoring one or more molecular beacon, hybridization to an oligonucleotide array, hybridization to a CDNA array, hybridization to a polynucleotide array, hybridization to a liquid microarray, hybridization to a microelectric array, molecular beacons, cDNA sequencing, clone hybridization, cDNA fragment fingerprinting, serial analysis of gene expression (SAGE), subtractive hybridization, differential display and/or differential screening (see, e.g., Lockhart and Winzeler (2000) Nature 405:827-836, and references cited therein).

For example, specific PCR primers are designed to a member(s) of a candidate nucleotide library (e.g., a polynucleotide member of a system for detecting gene expression). cDNA is prepared from subject sample RNA by reverse transcription from a poly-dT oligonucleotide primer, and subjected to PCR. Double stranded cDNA may be prepared using primers suitable for reverse transcription of the PCR product, followed by amplification of the cDNA using in vitro transcription. The product of in vitro transcription is a sense-RNA corresponding to the original member(s) of the candidate library. PCR product may be also be evaluated in a number of ways known in the art, including real-time assessment using detection of labeled primers, e.g. TaqMan or molecular beacon probes. Technology platforms suitable for analysis of PCR products include the ABI 7700, 5700, or 7000 Sequence Detection Systems (Applied Biosystems, Foster City, Calif.), the MJ Research Opticon (MJ Research, Waltham, Mass.), the Roche Light Cycler (Roche Diagnostics, Indianapolis, Ind.), the Stratagene MX4000 (Stratagene, La Jolla, Calif.), and the Bio-Rad iCycler (Bio-Rad Laboratories, Hercules, Calif.). Alternatively, molecular beacons are used to detect presence of a nucleic acid sequence in an unamplified RNA or CDNA sample, or following amplification of the sequence using any method, e.g., IVT (in vitro transcription) or NASBA (nucleic acid sequence based amplification). Molecular beacons are designed with sequences complementary to member(s) of a candidate nucleotide library, and are linked to fluorescent labels. Each probe has a different fluorescent label with non-overlapping emission wavelengths. For example, expression of ten genes may be assessed using ten different sequence-specific molecular beacons.

Alternatively, or in addition, molecular beacons are used to assess expression of multiple nucleotide sequences simultaneously. Molecular beacons with sequences complimentary to the members of a diagnostic nucleotide set are designed and linked to fluorescent labels. Each fluorescent label used must have a non-overlapping emission wavelength. For example, 10 nucleotide sequences can be assessed by hybridizing 10 sequence specific molecular beacons (each labeled with a different fluorescent molecule) to an amplified or non-amplified RNA or cDNA sample. Such an assay bypasses the need for sample labeling procedures.

Alternatively, or in addition, bead arrays can be used to assess expression of multiple sequences simultaneously (see, e.g., LabMAP 100, Luminex Corp, Austin, Tex.). Alternatively, or in addition, electric arrays can be used to assess expression of multiple sequences, as exemplified by the e-Sensor technology of Motorola (Chicago, Ill.) or Nanochip technology of Nanogen (San Diego, Calif.).

Of course, the particular method elected will be dependent on such factors as quantity of RNA recovered, practitioner preference, available reagents and equipment, detectors, and the like. Typically, however, the elected method(s) will be appropriate for processing the number of samples and probes of interest. Methods for high-throughput expression analysis are discussed below.

Alternatively, expression at the level of protein products of gene expression is performed. For example, protein expression in a sample can be evaluated by one or more method selected from among: western analysis, two-dimensional gel analysis, chromatographic separation, mass spectrometric detection, protein-fusion reporter constructs, calorimetric assays, binding to a protein array (e.g., antibody array), and characterization of polysomal mRNA. One particularly favorable approach involves binding of labeled protein expression products to an array of antibodies specific for members of the candidate library. Methods for producing and evaluating antibodies are well known in the art, see, e.g., Coligan, supra; and Harlow and Lane (1989) Antibodies: A Laboratory Manual, Cold Spring Harbor Press, NY (“Harlow and Lane”). Additional details regarding a variety of immunological and immunoassay procedures adaptable to the present invention by selection of antibody reagents specific for the products of candidate nucleotide sequences can be found in, e.g., Stites and Terr (eds.) (1991) Basic and Clinical Immunology, 7th ed. Another approach uses systems for performing desorption spectrometry. Commercially available systems, e.g., from Ciphergen Biosystems, Inc. (Fremont, Calif.) are particularly well suited to quantitative analysis of protein expression. Protein Chip.RTM. arrays (see, e.g., the website, ciphergen.com) used in desorption spectrometry approaches provide arrays for detection of protein expression. Alternatively, affinity reagents, (e.g., antibodies, small molecules, etc.) may be developed that recognize epitopes of one or more protein products. Affinity assays are used in protein array assays, e.g., to detect the presence or absence of particular proteins. Alternatively, affinity reagents are used to detect expression using the methods described above. In the case of a protein that is expressed on a cell surface, labeled affinity reagents are bound to a sample, and cells expressing the protein are identified and counted using fluorescent activated cell sorting (FACS).

High Throughput Expression Assays

A number of suitable high throughput formats exist for evaluating gene expression. Typically, the term high throughput refers to a format that performs at least about 100 assays, or at least about 500 assays, or at least about 1000 assays, or at least about 5000 assays, or at least about 10,000 assays, or more per day. When enumerating assays, either the number of samples or the number of candidate nucleotide sequences evaluated can be considered. For example, a northern analysis of, e.g., about 100 samples performed in a gridded array, e.g., a dot blot, using a single probe corresponding to a polynucleotide sequence as described herein can be considered a high throughput assay. More typically, however, such an assay is performed as a series of duplicate blots, each evaluated with a distinct probe corresponding to a different polynucleotide sequence of a system for detecting gene expression. Alternatively, methods that simultaneously evaluate expression of about 100 or more polynucleotide sequences in one or more samples, or in multiple samples, are considered high throughput.

Numerous technological platforms for performing high throughput expression analysis are known. Generally, such methods involve a logical or physical array of either the subject samples, or the candidate library, or both. Common array formats include both liquid and solid phase arrays. For example, assays employing liquid phase arrays, e.g., for hybridization of nucleic acids, binding of antibodies or other receptors to ligand, etc., can be performed in multiwell, or microtiter, plates. Microtiter plates with 96, 384 or 1536 wells are widely available, and even higher numbers of wells, e.g., 3456 and 9600 can be used. In general, the choice of microtiter plates is determined by the methods and equipment, e.g., robotic handling and loading systems, used for sample preparation and analysis. Exemplary systems include, e.g., the ORCA.TM. system from Beckman-Coulter, Inc. (Fullerton, Calif.) and the Zymate systems from Zymark Corporation (Hopkinton, Mass.).

Alternatively, a variety of solid phase arrays can favorably be employed to determine expression patterns in the context of the invention. Exemplary formats include membrane or filter arrays (e.g., nitrocellulose, nylon), pin arrays, and bead arrays (e.g., in a liquid “slurry”). Typically, probes corresponding to nucleic acid or protein reagents that specifically interact with (e.g., hybridize to or bind to) an expression product corresponding to a member of the candidate library, are immobilized, for example by direct or indirect cross-linking, to the solid support. Essentially any solid support capable of withstanding the reagents and conditions necessary for performing the particular expression assay can be utilized. For example, functionalized glass, silicon, silicon dioxide, modified silicon, any of a variety of polymers, such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, polycarbonate, or combinations thereof can all serve as the substrate for a solid phase array.

In one embodiment, the array is a “chip” composed, e.g., of one of the above-specified materials. Polynucleotide probes, e.g., RNA or DNA, such as cDNA, synthetic oligonucleotides, and the like, or binding proteins such as antibodies or antigen-binding fragments or derivatives thereof, that specifically interact with expression products of individual components of the candidate library are affixed to the chip in a logically ordered manner, i.e., in an array. In addition, any molecule with a specific affinity for either the sense or anti-sense sequence of the marker nucleotide sequence (depending on the design of the sample labeling), can be fixed to the array surface without loss of specific affinity for the marker and can be obtained and produced for array production, for example, proteins that specifically recognize the specific nucleic acid sequence of the marker, ribozymes, peptide nucleic acids (PNA), or other chemicals or molecules with specific affinity.

Detailed discussion of methods for linking nucleic acids and proteins to a chip substrate, are found in, e.g., U.S. Pat. No. 5,143,854, “Large Scale Photolithographic Solid Phase Synthesis Of Polypeptides And Receptor Binding Screening Thereof,” to Pirrung et al., issued, Sep. 1, 1992; U.S. Pat. No. 5,837,832, “Arrays Of Nucleic Acid Probes On Biological Chips,” to Chee et al., issued Nov. 17, 1998; U.S. Pat. No. 6,087,112, “Arrays With Modified Oligonucleotide And Polynucleotide Compositions,” to Dale, issued Jul. 11, 2000; U.S. Pat. No. 5,215,882, “Method Of Immobilizing Nucleic Acid On A Solid Substrate For Use In Nucleic Acid Hybridization Assays,” to Bahl. et al., issued Jun. 1, 1993; U.S. Pat. No. 5,707,807, “Molecular Indexing For Expressed Gene Analysis,” to Kato, issued Jan. 13, 1998; U.S. Pat. No. 5,807,522, “Methods For Fabricating Microarrays Of Biological Samples,” to Brown et al., issued Sep. 15, 1998; U.S. Pat. No. 5,958,342, “Jet Droplet Device,” to Gamble et al., issued Sep. 28, 1999; U.S. Pat. No. 5,994,076, “Methods Of Assaying Differential Expression,” to Chenchik et al., issued Nov. 30, 1999; U.S. Pat. No. 6,004,755, “Quantitative Microarray Hybridization Assays,” to Wang, issued Dec. 21, 1999; U.S. Pat. No. 6,048,695, “Chemically Modified Nucleic Acids And Method For Coupling Nucleic Acids To Solid Support,” to Bradley et al., issued Apr. 11, 2000; U.S. Pat. No. 6,060,240, “Methods For Measuring Relative Amounts Of Nucleic Acids In A Complex Mixture And Retrieval Of Specific Sequences Therefrom,” to Kamb et al., issued May 9, 2000; U.S. Pat. No. 6,090,556, “Method For Quantitatively Determining The Expression Of A Gene,” to Kato, issued Jul. 18, 2000; and U.S. Pat. No. 6,040,138, “Expression Monitoring By Hybridization To High Density Oligonucleotide Arrays,” to Lockhart et al., issued Mar. 21, 2000.

For example, cDNA inserts corresponding to candidate nucleotide sequences, in a standard TA cloning vector, are amplified by a polymerase chain reaction for approximately 30-40 cycles. The amplified PCR products are then arrayed onto a glass support by any of a variety of well-known techniques, e.g., the VSLIPS.TM. technology described in U.S. Pat. No. 5,143,854. RNA, or cDNA corresponding to RNA, isolated from a subject sample, is labeled, e.g., with a fluorescent tag, and a solution containing the RNA (or cDNA) is incubated under conditions favorable for hybridization, with the “probe” chip. Following incubation, and washing to eliminate non-specific hybridization, the labeled nucleic acid bound to the chip is detected qualitatively or quantitatively, and the resulting expression profile for the corresponding candidate nucleotide sequences is recorded. Multiple cDNAs from a nucleotide sequence that are non-overlapping or partially overlapping may also be used.

In another approach, oligonucleotides corresponding to members of a candidate nucleotide library are synthesized and spotted onto an array. Alternatively, oligonucleotides are synthesized onto the array using methods known in the art, e.g. Hughes, et al. supra. The oligonucleotide is designed to be complementary to any portion of the candidate nucleotide sequence. In addition, in the context of expression analysis for, e.g. diagnostic use of diagnostic nucleotide sets, an oligonucleotide can be designed to exhibit particular hybridization characteristics, or to exhibit a particular specificity and/or sensitivity, as further described below.

Oligonucleotide probes may be designed on a contract basis by various companies (for example, Compugen, Mergen, Affymetrix, Telechem), or designed from the candidate sequences using a variety of parameters and algorithms as indicated at the website genome.wi.mit.edu/cgi-bin/prtm-er/primer3.cgi. Briefly, the length of the oligonucleotide to be synthesized is determined, preferably at least 16 nucleotides, generally 18-24 nucleotides, 24-70 nucleotides and, in some circumstances, more than 70 nucleotides. The sequence analysis algorithms and tools described above are applied to the sequences to mask repetitive elements, vector sequences and low complexity sequences. Oligonucleotides are selected that are specific to the candidate nucleotide sequence (based on a Blast n search of the oligonucleotide sequence in question against gene sequences databases, such as the Human Genome Sequence, UniGene, dbEST or the non-redundant database at NCBI), and have<50% G content and 25-70% G+C content. Desired oligonucleotides are synthesized using well-known methods and apparatus, or ordered from a commercial supplier.

A hybridization signal may be amplified using methods known in the art, and as described herein, for example use of the Clontech kit (Glass Fluorescent Labeling Kit), Stratagene kit (Fairplay Microarray Labeling Kit), the Micromax kit (New England Nuclear, Inc.), the Genisphere kit (3DNA Submicro), linear amplification, e.g., as described in U.S. Pat. No. 6,132,997 or described in Hughes, T R, et al. (2001) Nature Biotechnology 19:343-347 (2001) and/or Westin et al. (2000) Nat Biotech. 18:199-204. In some cases, amplification techniques do not increase signal intensity, but allow assays to be done with small amounts of RNA.

Alternatively, fluorescently labeled cDNA are hybridized directly to the microarray using methods known in the art. For example, labeled cDNA are generated by reverse transcription using Cy3-and Cy5-conjugated deoxynucleotides, and the reaction products purified using standard methods. It is appreciated that the methods for signal amplification of expression data useful for identifying diagnostic nucleotide sets are also useful for amplification of expression data for diagnostic purposes.

Microarray expression may be detected by scanning the microarray with a variety of laser or CCD-based scanners, and extracting features with numerous software packages, for example, Imagene (Biodiscovery), Feature Extraction Software (Agilent), Scanalyze (Eisen, M. 1999. SCANALYZE User Manual; Stanford Univ., Stanford, Calif. Ver 2.32.), GenePix (Axon Instruments).

In another approach, hybridization to microelectric arrays is performed, e.g., as described in Umek et al (2001) J Mol Diagn. 3:74-84. An affinity probe, e.g., DNA, is deposited on a metal surface. The metal surface underlying each probe is connected to a metal wire and electrical signal detection system. Unlabelled RNA or cDNA is hybridized to the array, or alternatively, RNA or cDNA sample is amplified before hybridization, e.g., by PCR. Specific hybridization of sample RNA or cDNA results in generation of an electrical signal, which is transmitted to a detector. See Westin (2000) Nat Biotech. 18:199-204 (describing anchored multiplex amplification of a microelectronic chip array); Edman (1997) NAR 25:4907-14; Vignali (2000) J Immunol Methods 243:243-55.

Evaluation of Expression Patterns

Expression patterns can be evaluated by qualitative and/or quantitative measures. Certain of the above described techniques for evaluating gene expression (e.g., as RNA or protein products) yield data that are predominantly qualitative in nature, i.e., the methods detect differences in expression that classify expression into distinct modes without providing significant information regarding quantitative aspects of expression. For example, a technique can be described as a qualitative technique if it detects the presence or absence of expression of a candidate nucleotide sequence, i.e., an on/off pattern of expression. Alternatively, a qualitative technique measures the presence (and/or absence) of different alleles, or variants, of a gene product.

In contrast, some methods provide data that characterize expression in a quantitative manner. That is, the methods relate expression on a numerical scale, e.g., a scale of 0-5, a scale of 1-10, a scale of +-+++, from grade 1 to grade 5, a grade from a to z, or the like. It will be understood that the numerical, and symbolic examples provided are arbitrary, and that any graduated scale (or any symbolic representation of a graduated scale) can be employed in the context of the present invention to describe quantitative differences in nucleotide sequence expression. Typically, such methods yield information corresponding to a relative increase or decrease in expression.

Any method that yields either quantitative or qualitative expression data is suitable for evaluating expression of candidate nucleotide sequences in a subject sample. In some cases, e.g., when multiple methods are employed to determine expression patterns for a plurality of candidate nucleotide sequences, the recovered data, e.g., the expression profile, for the nucleotide sequences is a combination of quantitative and qualitative data.

In some embodiments, qualitative and/or quantitative expression data from a sample is compared with a reference molecular signature that is indicative of, for example, presence or absence of a disease condition, symptom, or criterion, extent of progression of disease, effectiveness of treatment of disease, or prognosis for prophylaxis, therapy, or cure of disease. The reference molecular signature may be from a reference healthy individual (e.g., an individual who does not exhibit symptoms of the disease condition to be evaluated) or an individual with a disease condition for comparison with the sample (e.g., an individual with the same or different stage of disease for comparison with the individual being evaluated, or with a genotype or phenotype that indicates, for example, prognosis for successful treatment), or the reference molecular signature may be established from a compilation of data from multiple individuals

In some applications, expression of a plurality of candidate polynucleotide sequences is evaluated sequentially. This is typically the case for methods that can be characterized as low-to moderate throughput. In contrast, as the throughput of the elected assay increases, expression for the plurality of candidate polynucleotide sequences in a sample or multiple samples is typically assayed simultaneously. Again, the methods (and throughput) are largely determined by the individual practitioner, although, typically, it is preferable to employ methods that permit rapid, e.g. automated or partially automated, preparation and detection, on a scale that is time-efficient and cost-effective.

Genotyping

In addition to, or in conjunction with, the correlation of expression profiles and clinical data, it is often desirable to correlate expression patterns with a subject's genotype at one or more genetic loci or to correlate both expression profiles and genetic loci data with clinical data. The selected loci can be, for example, chromosomal loci corresponding to one or more member of the candidate library, polymorphic alleles for marker loci, or alternative disease related loci (not contributing to the candidate library) known to be, or putatively associated with, a disease (or disease criterion). Indeed, it will be appreciated that where a (polymorphic) allele at a locus is linked to a disease (or to a predisposition to a disease), the presence of the allele can itself be a disease criterion.

Numerous well known methods exist for evaluating the genotype of an individual, including southern analysis, restriction fragment length polymorphism (RFLP) analysis, polymerase chain reaction (PCR), amplification length polymorphism (AFLP) analysis, single stranded conformation polymorphism (SSCP) analysis, single nucleotide polymorphism (SNP) analysis (e.g., via PCR, Taqman or molecular beacons), among many other useful methods. Many such procedures are readily adaptable to high throughput and/or automated (or semi-automated) sample preparation and analysis methods. Often, these methods can be performed on nucleic acid samples recovered via simple procedures from the same sample as yielded the material for expression profiling. Exemplary techniques are described in, e.g., Sambrook, and Ausubel, supra.

Samples

Samples which may be evaluated for differential expression of the polynucleotide sequences described herein include any blood vessel or portion thereof with atherosclerotic and/or inflammatory disease. Such blood vessels include, but are not limited to, the aorta, a coronary artery, the carotid artery, and peripheral blood vessels such as, for example, iliac or femoral arteries. In one embodiment, the sample is derived from an arterial biopsy. In another embodiment, the sample is derived from an atherectomy. Samples may also be derived from peripheral blood cells or serum.

Samples may be stabilized for storage by addition of reagents such as Trizol. Total RNA and/or protein may be isolated using standard techniques known in the art for expression profiling experiments.

Methods for RNA isolation include those described in standard molecular biology textbooks. Commercially available kits such as those provided by Qiagen (RNeasy Kits) may also be used for RNA isolation.

Methods for Diagnosing Atherosclerotic Disease

The invention provides methods for diagnosing an atherosclerotic disease condition in an individual. Diagnosis includes, for example, determining presence or absence of a disease condition or a symptom of a disease condition in an individual who has, who is suspected of having, or who may be suspected of being predisposed to an atherosclerotic disease. In accordance with methods of the invention for diagnosing atherosclerotic disease, gene expression products (e.g., RNA or proteins) from a sample from an individual are contacted with a system for detecting gene expression as described above. In one embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In another embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 1-927.

In some embodiments, qualitative and/or quantitative levels of gene expression in a test sample are compared with levels of expression in a molecular signature that is indicative of presence or absence of an atherosclerotic disease condition for which diagnosis is desired. To obtain a diagnosis, the levels of gene expression in a sample may be compared to one or more than one molecular signature, each of which may be indicative of presence or absence one or more than one atherosclerotic disease condition.

In some embodiments, polynucleotides derived from a sample from an individual (e.g., mRNA or polynucleotides derived from mRNA, for example cDNA) are contacted with isolated polynucleotide molecules in a system for detecting gene expression as described above, wherein each isolated polynucleotide molecule detects an expressed product of a gene that is differentially expressed in atherosclerotic disease in a mammal, and hybridization complexes formed, if any, are detected, wherein presence, absence, or amount of hybridization complexes formed from at least one of the isolated polynucleotides is indicative of presence or absence of an atherosclerotic disease in the individual. In some embodiments, presence, absence, or amount of the polynucleotides derived from the sample is compared with presence, absence, or amount of polynucleotides in a molecular signature indicative of presence or absence of a disease condition, criterion, or symptom for which diagnosis is desired.

In some embodiments, polypeptides derived from a sample from an individual are contacted with a system for detecting gene expression as described above which comprises molecules capable of detectably binding to polypeptides that are differentially expressed in atherosclerotic disease, for example, antibodies or antigen binding fragments thereof, that detect expressed polypeptide products of genes corresponding to polynucleotide sequences depicted in the Sequence Listing, wherein presence, absence, or amount of bound polypeptide is indicative of presence or absence of an atherosclerotic disease in the individual. In some embodiments, presence, absence, or amount of the polypeptides derived from the sample is compared with presence, absence, or amount of polypeptides in a molecular signature indicative of presence or absence of a disease condition, criterion, or symptom for which diagnosis is desired.

Methods for Assessing Extent of Progression of Atherosclerotic Disease

The invention provides methods for assessing extent of progression of an atherosclerotic disease condition in an individual. For example, a stage to which a disease condition or particular symptom has progressed may be assessed. In accordance with methods of the invention for assessing extent of progression of atherosclerotic disease, gene expression products (e.g., RNA or proteins) from a sample from an individual are contacted with a system for detecting gene expression as described above. In one embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In another embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 1-927.

In some embodiments, qualitative and/or quantitative levels of gene expression in a test sample are compared with levels of expression in a molecular signature that is indicative of extent of progression of an atherosclerotic disease condition for which assessment is desired. The levels of gene expression may be compared to one or more than one molecular signature, each of which may be indicative of extent of progression of one or more than one atherosclerotic disease condition.

In some embodiments, polynucleotides derived from a sample from an individual (e.g., mRNA or polynucleotides derived from mRNA, for example CDNA) are contacted with isolated polynucleotide molecules in a system for detecting gene expression as described above, wherein each isolated polynucleotide molecule detects an expressed product of a gene that is differentially expressed in atherosclerotic disease in a mammal, and hybridization complexes formed, if any, are detected, wherein presence, absence, or amount of hybridization complexes formed from at least one of the isolated polynucleotides is indicative of extent of progression of an atherosclerotic disease in the individual. In some embodiments, presence, absence, or amount of the polynucleotides derived from the sample is compared with presence, absence, or amount of polynucleotides in a molecular signature indicative of extent of progression of a disease condition for which diagnosis is desired.

In some embodiments, polypeptides derived from a sample from an individual are contacted with a system for detecting gene expression as described above which comprises molecules capable of detectably binding to polypeptides that are differentially expressed in atherosclerotic disease, for example, antibodies or antigen binding fragments thereof, that detect expressed polypeptide products of genes corresponding to polynucleotide sequences depicted in the Sequence Listing, wherein presence, absence, or amount of bound polypeptide is indicative of extent of progression of an atherosclerotic disease in the individual. In some embodiments, presence, absence, or amount of the polypeptides derived from the sample is compared with presence, absence, or amount of polypeptides in a molecular signature indicative of extent of progression of a disease condition for which diagnosis is desired.

Methods for Assessing Efficacy of Treatment of Atherosclerotic Disease

The invention provides methods for assessing extent of progression of an atherosclerotic disease condition in an individual. For example, a stage to which a disease condition or particular symptom has progressed may be assessed by the methods of the invention. In accordance with methods of the invention for assessing extent of progression of atherosclerotic disease, gene expression products (e.g., RNA or proteins) from a sample from an individual are contacted with the system for detecting gene expression as described above. In one embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In another embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 1-927.

In some embodiments, qualitative and/or quantitative levels of gene expression in a test sample are compared with levels of expression in a molecular signature that is indicative of extent of progression of an atherosclerotic disease condition for which assessment is desired. The levels of gene expression may be compared to one or more than one molecular signature, each of which may be indicative of extent of progression of one or more than one atherosclerotic disease condition.

In some embodiments, polynucleotides derived from a sample from an individual (e.g, mRNA or polynucleotides derived from mRNA, for example cDNA) are contacted with isolated polynucleotide molecules in a system for detecting gene expression as described above, wherein each isolated polynucleotide molecule detects an expressed product of a gene that is differentially expressed in atherosclerotic disease in a mammal, and hybridization complexes formed, if any, are detected, wherein presence, absence, or amount of hybridization complexes formed from at least one of the isolated polynucleotides is indicative of extent of progression of an atherosclerotic disease in the individual. In some embodiments, presence, absence, or amount of the polynucleotides derived from the sample is compared with presence, absence, or amount of polynucleotides in a molecular signature indicative of extent of progression of a disease condition for which assessment is desired.

In some embodiments, polypeptides derived from a sample from an individual are contacted with a system for detecting gene expression as described above which comprises molecules capable of detectably binding to polypeptides that are differentially expressed in atherosclerotic disease, for example, antibodies or antigen binding fragments thereof, that detect expressed polypeptide products of genes corresponding to polynucleotide sequences depicted in the Sequence Listing, wherein presence, absence, or amount of bound polypeptide is indicative of extent of progression of an atherosclerotic disease in the individual. In some embodiments, presence, absence, or amount of the polypeptides derived from the sample is compared with presence, absence, or amount of polypeptides in a molecular signature indicative of extent of progression of a disease condition for which assessment is desired.

Methods for Assessing Efficacy of Treatment

The invention provides methods for assessing efficacy of treatment of an atherosclerotic disease symptom or condition in an individual. As used herein, “efficacy of treatment” refers to achievement of a desired therapeutic outcome (e.g., reduction or elimination of one or more symptoms of atherosclerotic disease). “Treatment” as used herein may refer to prophylaxis, therapy, or cure with respect to one or more symptoms of an atherosclerotic disease or condition. Treatment includes administration of one or more compounds or biological substances with potential therapeutic benefit and/or alterations in environmental factors, such as, for example, diet and/or exercise. In one embodiment, administration of the one or more compounds or biological substances comprises administration via a medical device such as, for example, a drug eluting stent. In other embodiments, treatment may include gene therapy or any other method that alters expression of the polynucleotide sequences described herein. In accordance with methods of the invention for assessing efficacy of treatment of atherosclerotic disease, gene expression products (e.g., RNA or proteins) from a sample from an individual are contacted with a system for detecting gene expression as described above. In one embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In another embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 1-927.

In some embodiments, qualitative and/or quantitative levels of gene expression in a test sample are compared with levels of expression in a molecular signature that is indicative of efficacy of treatment of an atherosclerotic disease symptom or condition for which assessment is desired. The levels of gene expression may be compared to one or more than one molecular signature, each of which may be indicative of extent of effectiveness of treatment of one or more than one atherosclerotic disease symptom or condition.

In some embodiments, polynucleotides derived from a sample from an individual (e.g., mRNA or polynucleotides derived from mRNA, for example cDNA) are contacted with isolated polynucleotide molecules in a system for detecting gene expression as described above, wherein each isolated polynucleotide molecule detects an expressed product of a gene that is differentially expressed in atherosclerotic disease in a mammal, and hybridization complexes formed, if any, are detected, wherein presence, absence, or amount of hybridization complexes formed from at least one of the isolated polynucleotides is indicative of efficacy of treatment of an atherosclerotic disease symptom or condition in the individual. In some embodiments, presence, absence, or amount of the polynucleotides derived from the sample is compared with presence, absence, or amount of polynucleotides in a molecular signature indicative of efficacy of treatment of a disease symptom or condition for which assessment is desired.

In some embodiments, polypeptides derived from a sample from an individual are contacted with a system for detecting gene expression as described above which comprises molecules capable of detectably binding to polypeptides that are differentially expressed in atherosclerotic disease, for example, antibodies or antigen binding fragments thereof, that detect expressed polypeptide products of genes corresponding to polynucleotide sequences depicted in the Sequence Listing, wherein presence, absence, or amount of bound polypeptide is indicative of efficacy of treatment of an atherosclerotic disease condition in the individual. In some embodiments, presence, absence, or amount of the polypeptides derived from the sample is compared with presence, absence, or amount of polypeptides in a molecular signature indicative of efficacy of treatment of a disease condition for which assessment is desired.

Methods for Identifying Compounds Effective for Treatment of Atherosclerotic Disease

The invention provides methods for identifying compounds effective for treatment of an atherosclerotic disease symptom or condition in an individual. In accordance with methods of the invention for identifying compounds effective for treatment of atherosclerotic disease, at least one test compound (i.e., one or more than one test compound) is administered, for example as a pharmaceutical composition comprising the at least one test compound and a pharmaceutically acceptable excipient, to an individual with an atherosclerotic disease symptom or condition or suspected of having an atherosclerotic disease symptom or condition, or to an individual who is predisposed to or suspected of being predisposed to development of an atherosclerotic disease symptom or condition. Gene expression products (e.g., RNA or proteins) from a sample from the individual are contacted with a system for detecting gene expression as described above. In one embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In another embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 1-927.

In some embodiments, qualitative and/or quantitative levels of gene expression in a test sample from the individual to whom the at least one test compound has been administered are compared with levels of expression in a molecular signature that is indicative of efficacy of treatment of the atherosclerotic disease symptom or condition for which assessment is desired. The levels of gene expression may be compared to one or more than one molecular signature, each of which may be indicative of extent of effectiveness of treatment of one or more than one atherosclerotic disease symptom or condition.

In some embodiments, polynucleotides derived from a sample from an individual (e.g., mRNA or polynucleotides derived from mRNA, for example cDNA) to whom at least one test compound has been administered are contacted with isolated polynucleotide molecules in a system for detecting gene expression as described above, wherein each isolated polynucleotide molecule detects an expressed product of a gene that is differentially expressed in atherosclerotic disease in a mammal, and hybridization complexes formed, if any, are detected, wherein presence, absence, or amount of hybridization complexes formed from at least one of the isolated polynucleotides is indicative of efficacy of treatment of an atherosclerotic disease symptom or condition in the individual. In some embodiments, presence, absence, or amount of the polynucleotides derived from the sample is compared with presence, absence, or amount of polynucleotides in a molecular signature indicative of efficacy of treatment of a disease symptom or condition for which assessment is desired.

In some embodiments, polypeptides derived from a sample from an individual to whom at least one test compound has been administered are contacted with a system for detecting gene expression as described above which comprises molecules capable of detectably binding to polypeptides that are differentially expressed in atherosclerotic disease, for example, antibodies or antigen binding fragments thereof, that detect expressed polypeptide products of genes corresponding to polynucleotide sequences depicted in the Sequence Listing, wherein presence, absence, or amount of bound polypeptide is indicative of efficacy of treatment of an atherosclerotic disease condition in the individual. In some embodiments, presence, absence, or amount of the polypeptides derived from the sample is compared with presence, absence, or amount of polypeptides in a molecular signature indicative of efficacy of treatment of a disease condition for which assessment is desired.

Methods for Determining prognosis of Atherosclerotic Disease

The invention provides methods for determining prognosis of atherosclerotic disease in an individual, comprising contacting polynucleotides derived from a sample from the individual with a system for detecting gene expression as described above. “Prognosis” as used herein refers to the probability that an individual will develop an atherosclerotic disease symptom or condition, or that atherosclerotic disease will progress in an individual who has an atherosclerotic disease. Prognosis is a determination or prediction of probable course and/or outcome of a disease condition, i.e., whether an individual will exhibit or develop symptoms of the disease, i.e., a clinical event. In cardiovascular medicine, a common measure of prognosis is (but is not limited to) MACE (major adverse cardiac event). MACE includes mortality as well as morbidity measures, such as myocardial infarction, angina, stroke, rate of revascularization, hospitalization, etc.

For determination of prognosis of atherosclerotic disease, gene expression products (e.g., RNA or proteins) from a sample from an individual are contacted with the system for detecting gene expression as described above. In one embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 133, 745, 806, 824, 886, 882, 901, 905, 913, and 927. In another embodiment, the genes for which expression is detected are selected from the group of genes corresponding to SEQ ID NOs: 1-927.

In some embodiments, qualitative and/or quantitative levels of gene expression in a sample from the individual are compared with levels of expression in a molecular signature that is indicative of prognosis of the atherosclerotic disease symptom or condition for which assessment is desired. The levels of gene expression may be compared to one or more than one molecular signature, each of which may be indicative of prognosis for one or more than one atherosclerotic disease symptom or condition.

In some embodiments, polynucleotides derived from a sample from an individual (e.g., mRNA or polynucleotides derived from mRNA, for example cDNA) are contacted with isolated polynucleotide molecules in a system for detecting gene expression as described above, wherein each isolated polynucleotide molecule detects an expressed product of a gene that is differentially expressed in atherosclerotic disease in a mammal, and hybridization complexes formed, if any, are detected, wherein presence, absence, or amount of hybridization complexes formed from at least one of the isolated polynucleotides is indicative of prognosis for development or progression an atherosclerotic disease symptom or condition in the individual. In some embodiments, presence, absence, or amount of the polynucleotides derived from the sample is compared with presence, absence, or amount of polynucleotides in a molecular signature indicative of prognosis for development or progression of a disease symptom or condition for which assessment is desired.

In some embodiments, polypeptides derived from a sample from an individual are contacted with a system for detecting gene expression as described above which comprises molecules capable of detectably binding to polypeptides that are differentially expressed in atherosclerotic disease, for example, antibodies or antigen binding fragments thereof, that detect expressed polypeptide products of genes corresponding to polynucleotide sequences depicted in the Sequence Listing, wherein presence, absence, or amount of bound polypeptide is indicative of prognosis for development or progression of an atherosclerotic disease symptom or condition in the individual. In some embodiments, presence, absence, or amount of the polypeptides derived from the sample is compared with presence, absence, or amount of polypeptides in a molecular signature indicative of prognosis for development or progression of an atherosclerotic disease symptom or condition for which assessment is desired.

Novel Polynucleotide Sequences

The invention provides novel polynucleotide sequences that are differentially expressed in atherosclerotic disease. We have identified unnamed (not previously described as corresponding to a gene or an expressed gene, and/or for which no function has previously been assigned) polynucleotide sequences herein. The novel differentially expressed nucleotide sequences of the invention are useful in a system for detecting gene expression, such as a diagnostic oligonucleotide set, and are also useful as probes in a diagnostic oligonucleotide set immobilized on an array. The novel polynucleotide sequences may be useful as disease target polynucleotide sequences and/or as imaging reagents as described herein.

As used herein, “novel polynucleotide sequence” refers to (a) a polynucleotide sequence containing at least one of the polynucleotide sequences disclosed herein (as depicted in the Sequence Listing); (b) a polynucleotide sequence that encodes the amino acid sequence encoded by a polynucleotide sequence disclosed herein; (c) a polynucleotide sequence that hybridizes to the complement of a coding sequence disclosed herein under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.×SSC/0.1% SDS at 68° C. (Ausubel, F.M. et al., eds. (1989) Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.01.3); (d) a polynucleotide sequence that hybridizes to the complement of a coding sequence disclosed herein under less stringent conditions, such as moderately stringent conditions, e.g., washing in 0.2×SSC/0.1% SDS at 42° C. (Ausubel et al. (1989), supra), yet which still encodes a functionally equivalent gene product; and/or (e) a polynucleotide sequence that is at least 90% identical, at least 80% identical, or at least 70% identical to the coding sequences disclosed herein, wherein % identity is determined using standard algorithms known in the art.

The invention also includes polynucleotide molecules that hybridize to, and are therefore the complements of, novel polynucleotide molecules as described in (a) through (c) in the preceding paragraph. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances wherein the polynucleotide molecules are deoxyoligonucleotides, highly stringent conditions may refer to, e.g., washing in 6×SSC/0.05% sodium pyrophosphate at 37° C. (for 14-base oligonucleotides), 48° C. (for 17-base oligonucleotides), 55° C. (for 20-base oligonucleotides, and 60° C. (for 23-base oligonucleotides). These polynucleotide molecules may act as target nucleotide sequence antisense molecules, useful, for example, in target nucleotide sequence regulation and/or as antisense primers in amplification reactions of target nucleic acid sequences. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for target nucleotide sequence regulation. Such molecules may also be used as components of diagnostic methods whereby the presence of a disease-causing allele may be detected.

The invention also encompasses nucleic acid molecules contained in full-length gene sequences that are related to or derived from novel polynucleotide sequences as described above and as depicted in the Sequence Listing. One sequence may map to more than one full-length gene.

The invention also encompasses (a) polynucleotide vectors that contain any of the foregoing novel polynucleotide sequences and/or their complements; (b) polynucleotide expression vectors that contain any of the foregoing novel polynucleotide sequences and/or their complements; and (c) genetically engineered host cells that contain any of the foregoing novel polynucleotide sequences operatively associated with a regulatory element that directs expression of the polynucleotide in the host cell. As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators, and other elements known to those skilled in the art that drive and regulate gene expression.

The invention includes fragments of the novel polynucleotide sequences described above. Fragments may be any of at least 5, 10, 15, 20, 25, 50, 100, 200, or 500 nucleotides, or larger.

Novel Polypeptide Products

The invention includes novel polypeptide products, encoded by genes corresponding to the novel polynucleotide sequences described above, or functionally equivalent polypeptide gene products thereof. “Functionally equivalent,” as used herein, refers to a protein capable of exhibiting a substantially similar in vivo function, e.g., activity, as a novel polypeptide gene product encoded by a novel polynucleotide of the invention.

Equivalent novel polypeptide products may include deletions, additions, and/or substitutions of amino acid residues within the amino acid sequence encoded by a gene corresponding to a novel polynucleotide sequence of the invention as described above, but which results in a “silent” change (i.e., a change which does not substantially change the functional properties of the polypeptide). Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.

Novel polypeptide products of genes corresponding to novel polynucleotide sequences described herein may be produced by recombinant nucleic acid technology using techniques that are well known in the art. For example, methods that are well known to those skilled in the art may be used to construct expression vectors containing novel polynucleotide coding sequences and appropriate transcriptional/translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Sambrook et al., 1989, supra, and Ausubel et al., 1989, supra. Alternatively, PNA capable of encoding novel nucleotide sequence protein sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in “Oligonucleotide Synthesis” (1984) Gait, M. J. ed., IRL Press, Oxford. A variety of host-expression vector systems may be utilized to express the novel nucleotide sequence coding sequences of the invention. Ruther et al. (1983) EMBO J 2:1791; Inouye & Inouye (1985) Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster (1989) J Biol. Chem. 264:5503; Smith et al. (1983) J Virol. 46: 584; Smith, U.S. Pat. No. 4,215,051; Logan & Shenk (1984) Proc. Natl. Acad Sci. USA 81:3655-3659; Bittner et al. (1987) Methods in Enzymol. 153:516-544; Wigler, et al. (1977) Cell 11:223; Szybalska & Szybalski (1962) Proc. Natl. Acad. Sci. USA 48:2026; Lowy, et al. (1980) Cell 22:817; Wigler, et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567; O'Hare, et al. (1981) Proc. Natl. Acad. Sci. USA 78:1527; Mulligan & Berg (1981) Proc. Natl. Acad. Sci. USA 78:2072; Colberre-Garapin, etal. (1981) J Mol. Biol. 150:1; Santerre, etal. (1984) Gene 30:147; Janknecht, etal. (1991) Proc. Natl. Acad. Sci. USA 88: 8972-8976. When recombinant DNA technology is used to produce the protein encoded by a gene corresponding to the novel polynucleotide sequence, it may be advantageous to engineer fusion proteins that can facilitate labeling, immobilization and/or detection.

Antibodies

The invention also provides antibodies or antigen binding fragments thereof that specifically bind to novel polypeptide products encoded by genes that correspond to novel polynucleotide sequences as described above. Antibodies capable of specifically recognizing one or more novel nucleotide sequence epitopes may be prepared by methods that are well known in the art. Such antibodies include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be used, for example, in the detection of a novel polynucleotide sequence in a biological sample, or, alternatively, as a method for the inhibition of abnormal gene activity, for example, the inhibition of a disease target nucleotide sequence, as further described below. Thus, such antibodies may be utilized as part of a disease treatment method, and/or may be used as part of diagnostic techniques whereby patients may be tested for abnormal levels of novel nucleotide sequence encoded proteins, or for the presence of abnormal forms of the such proteins.

For the production of antibodies that bind to a polypeptide encoded by a novel nucleotide sequence, various host animals may be immunized by injection with a novel protein encoded by the novel nucleotide sequence, or a portion thereof. Such host animals may include, but are not limited to rabbits, mice, and rats. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as novel polypeptide gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be immunized by injection with novel polypeptide gene product supplemented with adjuvants as also described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein (1975) Nature 256:495-497; and U.S. Pat. No. 4,376,110, the human B-cell hybridoma technique (Kosbor et al. (1983) Immunology Today 4:72; and Cole et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al. (1985) Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. A hybridoma producing a mAb may be cultivated in vitro or in vivo.

In addition, techniques developed for the production of “chimeric antibodies” by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. Morrison et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger et al. (1984) Nature 312:604-608; Takeda et al. (1985) Nature 314:452-454. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies can be adapted to produce novel nucleotide sequence-single chain antibodies. (U.S. Pat. No. 4,946,778; Bird (1988) Science 242:423-426; Huston et al. (1988) Proc. NatL. Acad. Sci. USA 85:5879-5883; and Ward et al. (1989) Nature 334:544-546) Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al. (1989) Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with a desired specificity.

Disease Specific Target Polynucleotide Sequences

The invention also provides disease specific target polynucleotide sequences, and sets of disease specific target polynucleotide sequences. The diagnostic oligonucleotide sets, individual members of the diagnostic oligonucleotide sets and subsets thereof, and novel polynucleotide sequences, as described above, may also serve as disease specific target polynucleotide sequences. In particular, individual polynucleotide sequences that are differentially regulated or have predictive value that is strongly correlated with an atherosclerotic disease or disease criterion are especially favorable as atherosclerotic disease specific target polynucleotide sequences. Sets of genes that are co-regulated may also be identified as disease specific target polynucleotide sets. Such polynucleotide sequences and/or their complements and/or the expression products of genes corresponding to such polynucleotide sequences (e.g., mRNA, proteins) are targets for modulation by a variety of agents and techniques. For example, disease specific target polynucleotide sequences (or the expression products of genes corresponding to such polynucleotide sequences, or sets of disease specific target polynucleotide sequences) can be inhibited or activated by, e.g., target specific monoclonal antibodies or small molecule inhibitors, or delivery of the polynucleotide sequence or an expression product of a gene corresponding to the polynucleotide sequence to patients. Also, sets of genes can be inhibited or activated by a variety of agents and techniques. The specific usefulness of the target polynucleotide sequence(s) depends on the subject groups from which they were discovered, and the disease or disease criterion with which they correlate.

Kits

The invention provides kits containing a system for detecting gene expression, a diagnostic nucleotide set, candidate nucleotide library, one or novel polynucleotide sequence, one or more polypeptide products of the novel polynucleotide sequences, and/or one or more antibodies that recognize polypeptide expression products of the differentially regulated polynucleotide sequences described herein. A kit may contain a diagnostic nucleotide probe set, or other subset of a candidate library (e.g., as a cDNA, oligonucleotide or antibody microarray or reagents for performing an assay on a diagnostic gene set using any expression profiling technology), packaged in a suitable container. The kit may further comprise one or more additional reagents, e.g., substrates, labels, primers, reagents for labeling expression products, tubes and/or other accessories, reagents for collecting tissue or blood samples, buffers, hybridization chambers, cover slips, etc., and may also contain a software package, e.g., for analyzing differential expression using statistical methods as described herein, and optionally a password and/or account number for accessing the compiled database. The kit optionally further comprises an instruction set or user manual detailing preferred methods of performing the methods of the invention, and/or a reference to a site on the Internet where such instructions may be obtained.

TABLE 1
Polynucleotide sequences which detect differentially expressed
genes in atherosclerotic disease
SEQ
ID		GENE	GENE	CLONE	UG	CHR_LOCATION	6O mer
NO:	CLONE ID	SYMBOL	NAME	NAME	CLUSTER	PENG [A]	SEQUENCE
1.	C0267B04-3		C0267B04-5N	C0267B04		No chromosome	ATGAGCCTAGA
			NIA Mouse			location	ACTCACATGCA
			7.5 dpc Whole			info available	TTTTCCTGACT
			Embryo cDNA				TCTATCATTAG
			Library (Long)				AATAAGTTCAT
			Mus musculus				CAAGA
			cDNA clone
			NIA:C0267B04
			IMAGE:30017
			007 5′, MRNA
			sequence
2.	M29697.1	I17r	interleukin 7	M29697	Mm.389	Chromosome 15	CCTATTGTTGA
			receptor				GTGTCAAACAT
							CACCACTAAGT
							GGATGGTTATG
							TAGTCCATTAT
							CCAAA
3.	L0304D03-3	Wnt4	wingless-	L0304D03	Mm.103301	Chromosome 4	TACCTGAACCA
			related MMTV				CTCTCTACTGT
			integration site				TGTTGTCACAA
			4				GGCAAAAGTG
							GCATTCCTTCC
							TCCAAG
4.	L0237D12-3	Cstd	cathepsin D	L0237D12	Mm.231395	Chromosome 7	CCCTTTGCTGT
							GTGGGCAGTAC
							TCTGAAGCAGG
							CAAATGGGTCT
							TAGGATCCCTC
							CCAGA
5.	C0266b08-3	BM204200	ESTs	C0266B08	Mm.222000	Chromosome 6	TCCAAAGATAA
			BM204200				AATGAGCAAC
							CGCACTGGCTT
							AGCCATAGATG
							ACTGACAGTGA
							TTGGAA
6.	J0537C05-3	Pfdn2	prefoldin 2	J0537C05	Mm.10756	Chromosome 1	TGCCTTGGAGG
							GCAACAAGGA
							GCAGATACAG
							AAGATCATTGA
							GACACTGTTCA
							CAGCAGC
7.	L0216F02-3	C430008C19Rik	RIKEN cDNA	L0216F02	Mm.268474	Chromosome 10	CATGAATTCCA
			C430008C19				AACCAGTTATT
			gene				ATTAACATGAA
							CCTGAACCTGA
							ACAATTATGAC
							TGTGC
8.	NM_017372.1	Lyzs	lysozyme	NM_017372	Mm.45436	Chromosome 10	TTTCTGTCACT
							GCTCAGGCCAA
							GGTCTATGAAC
							GTTGTGAGTTT
							GCCAGAACTCT
							GAAAA
9.	C0271B02-3	4732437J24Rik	RIKEN cDNA	C0271B02	Mm.39102	Chromosome 4	TTCATACCAAG
			4732437J24				GAACCTGACCT
			gene				CTCTGACAATT
							GCATTTTGAAC
							ATTGTTGTCCC
							CAAAG
10.	H3022C10-3	AA408868	expreexpressed	H3022C10	Mm.247272	Chromosome 16	CATTGGAAACA
			sequence				GACACGTTTGT
			AA408868				AGGCATTTGCG
							TATTCTTGAAG
							AGACTGTTTTA
							TGAAT
11.	L0806E05-3	Gtl2	GTL2,	L0806E05	Mm.200506	Chromosome 12	GTAATGGAGA
			imprinted				ATGTATCTGAA
			maternally				CCCATATCAAG
			expressed				CCATCTCTCTT
			untranslated				CCTTAACATGT
			mRNA				TAAGCA
12.	H3111E06-5	Acas21	acetyl-	H3111E06	Mm.7044	Chromosome 2	ACACCTCTAAC
			Coenzyme A				TCCCAAGAAG
			synthetase 2				ACGGAGTGAA
			(AMP				TGTCCTCTCCT
			forming)-like				ATCATTT
13.	H3091H05-3	Hras1	Harvey rat	H3091H05	Mm.6793	Chromosome 7	GTGAGATTCGG
			sarcoma virus				CAGCATAAATT
			oncogene 1				GCGGAAACTG
							AACCCACCCGA
							TGAGAGTGGTC
							CTGGCT
14.	K0324B10-3	Timp1	tissue inhibitor	K0324B10	Mm.8245	Chromosome X	TCATAAGGGCT
			of				AAATTCATGGG
			metalloproteina				TTCCCCAGAAA
			se 1				TCAACGAGACC
							ACCTTATACCA
							GCGTT
15.	K0508B06-3		transcribed	K0508B06	Mm.217234	Chromosome 5	AAAGACTGAG
			sequence with				AGGAGTCATG
			moderate				AACCAGGGTA
			similarity to				AAACTTATTGG
			protein				TGCTTTGAGAC
			ref:NP_077285.1				TTCCAGCA
			(H. spaiens)
			A20-binding
			inhibitor of NF-
			kappaB
			activation 2;
			LKB1-
			interacting
			protein [Homo
			sapiens]
16.	C0176A01-3	Syngr1	synaptogyrin 1	C0176A01	Mm.230301	Chromosome 15	GCAGCATCGCT
							TCCTTGGTTTA
							TTCTTTGTGTTT
							GTTCCTTCAGT
							AAACATTTATT
							GAGC
17.	J0748G02-3		AU018093	J0748G02		Chromosome 2	TTTTAACGGAG
			Mouse two-cell				CCTGAATATAG
			stage embryo				CAGGTTTAAAA
			cDNA Mus				TTTAAACAGGT
			musculus				ATAAAATGAA
			cDNA clone				AAATAA
			J0748G02 3′,
			MRNA
			sequence
18.	J0035G10-3	C77672	ESTs C77672	J0035G10	Mm.36571	Chromosome 4	TAGCATGAACC
							ACCATGTTTGG
							CAATACTGTAT
							TTTAGAAAGAA
							TTAATGGACTG
							GAGAG
19.	C0630C02-3	Cxcl16	chemokine (C-	C0630C02	Mm.46424	Chromosome 11	CCTGAGCTCAC
			X-C motif)				TGTTTCTCATG
			ligand 16				CTGTCTTGAGA
							CAAAGTATCCA
							TATGGAACCTA
							GGTTA
20.	K0313A10-3	5430435G22Rik	RIKEN cDNA	K0313A10	Mm.44508	Chromosome 1	GCTGGTGTTTG
			5340435G22				TGTCAAGAAA
			gene				ATGGCTGAAGC
							TTGTTTCCAGG
							CTGTAGGAATG
							TTGAAC
21.	L0070E11-3	Cbfa2t1H	CBFA2T1	L0070E11	Mm.4909	Chromosome 4	ACTTAAGTTAT
			identified gene				CTGCATAGAGG
			homolog				CAATCCTCCTG
			(human)				GGTTTGCTTTA
							TGTCTCGAAAA
							TCTAA
22.	H3072E02-3	BG069076	ESTs	H3072E02	Mm.26437	Chromosome 12	GGGCAAAGGT
			BG069076				ACTTTCTGACA
							AACTGAGTACC
							TGAGATCAACC
							CCCAAGAAGG
							GAAAAAA
23.	H3079B06-3		Mus musculus	H3079B06	Mm.295683	Chromosome 5	ACTATGCAATT
			unkknown				GGACAGATGG
			mRNA				ATTACCAAGGA
							GACTAAAAAT
							ATATTCTTTGA
							CTTTGGG
24.	H3002D08-3	4833412N02Rik	RIKEN cDNA	H3002D08	Mm.195099	Chromosome 5	TCACTGACCTC
			4833412N02				AACCCCTCCTG
			gene				CAGAGAAGCC
							TGAAGACCCCA
							AAAGCTGCCA
							GTCCAAA
25.	H3159A08-3	Gp49b	glycoprotein 49	H3159A08	Mm.196617	Chromosome 10	GATATAATGTG
			B				ATAAAGTTCCA
							AAAGGATCTCT
							CTGGCTGAAGG
							AGATACTGGAT
							GGAAC
26.	C0612F12-3	BM207436	ESTs	C0612F12	Mm.260421	No Chromosome	CTGAACCCCAA
			BM207436			location	TTAATAGCAAA
						info available	GGATATATCTC
							TCTTCAAAAAC
							GGATAGATTTC
							TGAAG
27.	H3108A03-3	Apobec1	apolipoprotein	H3108A03	Mm.3333	Chromosome 6	TTTTGTTCTCTC
			B editing				CATCTGTTAGC
							CGTTCTGAGGA
							CTGAATGCAGA
							TTGTCAGCTCA
							AAAA
28.	C0180G01-3	BI076556	ESTs BI076556	C0180601	Mm.37657	Chromosome 16	GCCAATCTCAG
							AACCCACATAG
							AAGGGTCTGCA
							GTATTATTCCT
							GTTTCATGTGT
							GCACA
29.	C0938A03-3	Sf3a1	splicing factor	C0938A03	Mm.156914	Chromosome 11	AGTGCAAAATT
			3a, subunit 1				TGGTTTGTTGG
							TGTGCTTTTCT
							GGTTTAGGAGC
							CTGAAACAAG
							CACACT
30.	J0703E02-3	Ogdh	oxoglutarate	J0703E02	Mm.30074	Chromosome 11	CATGAGTAAGT
			dehydrogenase				TGTGAAGGCTG
			(lipoamide)				GACCCACATCT
							TGATACTTGTT
							TTCTGCATCTT
							GGGCA
31.	C0274D12-3		transcribed	C0274D12	Mm.217705	Chromosome 12	TAGACGTTGTA
			sequence with				AAAAGGAGCC
			moderate				AAGTTTATCAT
			similarity to				TTTGTTCCTTA
			protein				AATCCGTCATA
			pir:S12207				TGTGGG
			(M. musculus)
			S12207
			hypothetical
			protein (B2
			element)-
			mouse
32.	H3097H03-3	Expi	extracellular	H3097H03	Mm.1650	Chromosome 11	ACTGTGGTGAC
			proteinase				AGCTTCCTAAC
			inhibitor				GTGTTTGTGTC
							TAAAATAAACT
							ATCCTTAGCAT
							CCTTC
33.	H3074D10-3		transcribed	H3074D10	Mm.103987	Chromosome 15	TATAAATAGAA
			sequence with				AGTGAACCTGT
			weak similarity				AACCTACCACG
			to protein				GTATCTATCAT
			ref:NP_081764.1				AACACTAGACT
			(M. musculus)				TTCAG
			RIKEN cDNA
			5730493B19
			[Mus musculus]
34.	M14222.1	Ctsb	cathepsin B	M14222	Mm.22753	Chromosome 14	CATCCTACAAA
							GAGGATAAGC
							ACTTTGGGTAC
							ACTTCCTACAG
							CGTGTCTAACA
							GTGTGA
35.	C0176G01-3	2400006H24Rik	RIKEN cDNA	C0176G01	Mm.143774	Chromosome Multiple	CCTGAAAATCT
			2400006H24			Mappings	GTCATGTCCAC
			gene				CTTGGAGCCTG
							AGTAACTTTGA
							ACAGCTGGTAA
							CTAGT
36.	H3092F08-5		UNKNOWN:	H3092F08		Chromosome 17	AGTCAAGGAG
			Similar to Mus				CCTAAAGATTA
			musculus				TTATGTCAGAG
			immediate-				AGACCAGCTTT
			early antigen				AGATACACCCC
			(E-beta) gene				TGAGCA
			partial intron 2
			sequence
37.	H3054F02-3	1200003C15Rik	RIKEN cDNA	H3054F02	Mm.19325	Chromosome 10	TTATGCTGCAG
			1200003C15				TTTCACTTGGA
			gene				AAAGGGACAA
							GGAGCCTTCTA
							TTGTCCCCTGT
							TTGTAG
38.	C0012F07-3	3010021M21Rik	RIKEN cDNA	C0012F07	Mm.100525	Chromosome 9	GTAACCAAGA
			3010021M21				GCCCTGAATAA
			gene				GGAATTCATTG
							TAGTAGTGAAA
							GGGAAACTAA
							TGCTCTT
39.	L0955A10-3	9030409G11Rik	RIKEN cDNA	L0955A10	Mm.32810	Chromosome 4	TCCCATGCCTT
			9030409G11				CCCAGAGGGA
			gene				ATTTTAACAAT
							GTAACAATAA
							ATGCTTGGCCT
							TGAAGCT
40.	L0045B05-3		transcribed	L0045b05	Mm.182645	Chromosome 9	AGGACATCTTC
			sequence with				CCAGATCTCAA
			moderate				AAGAAGAAGA
			similarity to				GAGCCTGTAAC
			protein				CACCTCCATGA
			ref:NP_081764.1				CCTAAA
			(M. musculus)
			RIKEN cDNA
			5730493B19
			[Mus musculus]
41.	H3049A10-3	BG066966	ESTs	H3049A10	Mm.262549	Chromosome 6	TCCTGTGGGAG
			BG066966				ATCCCATAAAT
							CCTGAACCTCA
							CGTAGTGTTAC
							TTTTCCAGGTC
							ATTCT
42.	X70298.1	Sox4	SRY-box	X70298	Mm.253853	Chromosome 13	GGACGACGAG
			containing gene				TTCGAAGACGA
			4				CCTGCTCGACC
							TGAACCCCAGC
							TCAAACTTTGA
							GAGCAT
43.	L0001C09-3		transcribed	L0001C09	Mm.171544	Chromosome 12	GAAGAGATGG
			sequence with				AAGATGGTAGT
			weak similarity				GCCTTGAACAC
			to protein				AGCCACCCAA
			ref:NP_081764.1				GCAAAGTTGA
			(M. musculus)				AGAACAGG
			RIKEN cDNA
			570493B19
			[Mus musculus]
44.	H3010D12-5		UNKNOWN:	H3010D12	Data not found	Chromosome 9	GCCTGCAGGA
			Similar to Mus				GTTTGTGTTGG
			musculus				TAGCCTCCAAG
			RIKEN cDNA				GAGCTGAAGAT
			8430421I07				GTGCTGAAGAT
			gene				CCAGGCT
			(8430421I07Ri
			k), mRNA
45.	C0923E12-3	Ptpns1	protein tyrosine	C0923E12	Mm.1682	Chromosome 2	CTGTCTTCTAA
			phosphatase,				TTCCAAAGGGT
			non-receptor				TGGTTGGTAAA
			type substrate 1				GCTCCACCCCC
							TTTTCCTTTGC
							CTAAA
46.	C0941E09-3	D330001F17Rik	RIKEN cDNA	C0941E09	Mm.123240	No Chromosome	TTCACAGGGTT
			D330001F17			location	CCTGGTGTTGC
			gene			info available	ATGCAGAGCCT
							GAACAAAAGA
							CTCAGGTGGAC
							CTGGAA
47.	K0534C04-3	Tce1	T-complex	K0534C04	Mm.41932	Chromosome 17	TCTACAAGGAA
			expressed gene				GCATTCAACCA
			1				CCAAGAGGAG
							CTTGGACCACG
							TTCACTCTGTA
							TTCTTT
48.	H3064E11-3	BG068254	ESTs	H3064E11	Mm.173544	Chromosome 4	GGGCCTGAACT
			BG068354				ATGGCTTAATT
							TACATTAATTA
							GTTAACATTAA
							TCACACAGTAA
							GGAGC
49.	L0957C02-3	E130319B15Rik	RIKEN cDNA	L0957C02	Mm.149539	Chromosome 2	TGTGTTGTGAT
			E130319B15				TTCAACTCCCA
			gene				AGACGCCCTTT
							ATGTCCATTCT
							GGAAAAATAC
							AATAAA
50.	L0240C12-3	Clqa	conplement	L0240C12	Mm.370	Chromosome 4	ACTGATGTTTC
			component 1, q				TGCACACTGCC
			subcomponent,				CAGTGGTTTCT
			alpha				TTAAGCACTTT
			polypeptide				CTGGAATAAAC
							GATCC
51.	J0018H07-3	Rnf149	ring finger	J0018H07	Mm.28614	Chromosome 1	TCACAGATGTA
			protein 149				TGTGGAGGGGT
							TGTTTTCTGAG
							TACTAGACTAC
							CCTCTGTGGTT
							ATAAA
52.	K0508E12-3	Rin3	Ras and Rab	K0508E12	Mm.24145	Chromosome 12	TCGGGGATGG
			interactor 3				AGCTGAGATGT
							TCCCACCACAAC
							CCAAGATCTAA
							GAGTATTGTTT
							TGAAGA
53.	L0208A01-3	4933437L13Rik	RIKEN cDNA	L0208A01	Mm.159218	Chromosome 16	GGAGACTGAA
			4933437K13				GCTTTTATTGT
			gene				TTAATGTTGAA
							GATATTGATCT
							ACAAGGTGGG
							AATGGTG
54.	C0239G03-3	BM202478	EST	C0239G03	Mm.217664	Chromosome 2	AACTGTGGGTA
			BM202478				TAATTGTAAGA
							GCCTGAAACTT
							CCAGAACTGG
							AGAAACTGTCA
							CTGGGA
55.	L0518C11-3	1700016K05Rik	RIKEN cDNA	L0518C11	Mm.221743	Chromosome 17	GTGTTGTGATT
			1700016K05				GTCGTCCCTGC
			gene				TTAATGAACCC
							ACCTGAGGGA
							CAGTTAGTGTC
							TTACCC
56.	H3054C09-3	Oas1c	2′-5′	H3054C09	Mm.206775	Chromosome 5	CTATATGAACT
			oligoadenylate				GAGAAACAAC
			synthetase 1C				ACGTATGCTGA
							ACCCCAATTCT
							ACAACAAAGT
							CTACGCC
57.	L0811E07-3	3110087O12Rik	RIKEN cDNA	L0811E07	Mm.32373	Chromosome 3	GGAATATATTA
			3110057O12				TGTAGACTATT
			gene				CTGGCCTGAAC
							CTTGTGGTTGA
							CTGATGCTCTG
							CCTCC
58.	JO948A06-3		Mus musculus	J0948A06	Mm.261771	Chromosome 14	TTGGGTGATCC
			mRNA similar				ATATTTTTCAA
			to RIKEN				ACCCATACTCC
			cDNA				CAAAAGGAGA
			4930503E14				CCTACTTAAAT
			gene (cDNA				TTCTCT
			clone
			MGC:58418
			IMAGE:67081
			14,) complete
			cds
59.	C0931B05-3		transcribed	C0931B05	Mm.252843	Chromosome 10	GTTCCTGAAGC
			sequence with				TCTTGATATTT
			weak similarity				TAGGACAAAA
			to protein				CCCACCACGAC
			ref:NP_081764.1				AAAATGAGAA
			(M. musculus)				GGAATTT
			RIKEN cDNA
			5730493B19
			[Mus usculus]
60.	H3022A09-3	Esp812	EPS8-like	H3022A09	Mm.27451	Chromosome 7	TGACTTCAAAT
							GTCCCATCCCA
							CCCAAAGAGC
							CTGTGATAACA
							GATGTCTCTGG
							CTATAT
61.	G0118B03-3	Usf2	upstream	G0118B03	Mm.15781	Chromosome 7	TGGGTAGGTTC
			transcription				CTAGGTCTCCC
			factor 2				TGATATCTAA
							CTACAGTTATA
							CTGTAGCTGTG
							TGACA
62.	H3156C12-3	Ms4a6d	membrane-	H3156C12	Mm.170657	Chromosome 19	CCTGTCTCAGA
			spanning 4-				ACTCAAGAAT
			domains,				AAATCCAGTGT
			subfamily A,				ATCTTCAGAGT
			member 6D				CACTTTGTAAC
							CCTAC
63.	H3074G06-3	9530020G05Rik	RIKEN cDNA	H3074G06	Mm.15120	Chromosome 6	TACTCCCTGGA
			9530020G05				GACTAGAACC
			gene				GTGGCTATAGC
							GGAGCATGCTC
							CAGAGCACAG
							GACTGAT
64.	NM_003254.1	TIMP1	tissue inhibitor	NM_003254	Hs.5831	No Chromosome	GGGACACCAG
			of			location	AAGTCAACCA
			metalloproteinase			info available	GACCACCTTAT
			1 (erythroid				ACCAGCGTTAT
			potentiating				GAGATCAAGA
			activity,				TGACCAAG
			collagenase
			inhibitor)
65.	K0647H07-3	I17r	interleukin 7	K0647H07	Mm.389	Chromosome 15	GAAAACCAAA
			receptor				ACTCTTGGTCA
							GAGACAATAT
							GCAAAACAGA
							GATGTCAAGTA
							CTATGTCC
66.	J0257F12-3	Rnf25	ring finger	J0257F12	Mm.86910	Chromosome 1	TCAAGGAGACT
			protein 25				GTAGACTTAAA
							GGCAGAACCC
							CGTAACAAAG
							GGCTCACAGGT
							CATCCTC
67.	H3083G02-3	Lcn2	lipocalin 2	H3083G02	Mm.9537	Chromosome 2	CACCACGGACT
							ACAACCAGTTC
							GCCATGGTATT
							TTTCCGAAAGA
							CTTCTGAAAAC
							AAGCA
68.	M64086.1	Serpina3n	serine (or	M64086	Mm.22650	Chromosome 12	GTACCCTCTGA
			cysteine)				CTGTATATTTC
			proteinase				AATCGGCCTTT
			inhibitor, clade				CCTGATAATGA
			A, member 3N				TCTTTGACACA
							GAAAC
69.	C0906B05-3	Cenpc	centromere	C0906B05	Mm.221600	Chromosome 5	AAGAACTACTG
			autoantigen C				ATACAGAACC
							ACTTCAGTTGT
							TCAGTTAGAAT
							CTTTTTAAGAC
							TCTCTC
70.	H3094B08-3	BG071051	ESTs	H3094B08	Mm.173358	Chromosome 2	CTTGACCTTTA
			BG071051				GATGGAAATTG
							TACCTAGAGAC
							GAGAAGGAGC
							CAAACTAAGGT
							CTGTCA
71.	K0110F02-3	Pstpip1	proline-serine-	K0110F02	Mm.2534	Chromosome 9	GGAACGGACA
			threonine				ACGTGGCTTTG
			phosphatase-				TCCCTGGGTCG
			interacting				TACTTGGAGAA
			protein 1				GCTCTGAGGAA
							AGGCTA
72.	L0072G08-3	Renbp	renin binding	L0072G08	Mm.28280	Chromosome X	TTCGAATGCAC
			protein				ATCATTGACAA
							GTTTCTCTTAT
							TGCCTTTCCAC
							TCTGGATGGGA
							CCCTG
73.	J0088G06-3	49304272G13Rik	RIKEN cDNA	J0088G06	Mm.23172	No Chromosome	GCCTGGAGACT
			4930475G13			loction	GAAGGCAGTTT
			gene			info available	TACAAAGGAA
							AACTTAGATTT
							CTATTCATTTG
							CTTTTG
74.	K0121F05-3	Fcgr2b	Fc receptor,	K0121F05	Mm.10809	Chromosome 1	CTGGATGAAG
			IgG, low				AAACAGAGCA
			affinity IIb				TGATTACCAGA
							ACCACATTTAG
							TCTCCCTTGGC
							ATTGGGA
75.	K0124E12-3	Wbscr5	Williams-	K0124E12	Mm.23955	Chromosome 5	TTAATATTGTC
			Beuren				AATGTCAGGG
			syndrome				GGTTCCCTGTC
			chromosome				TCAGAGCATTA
			region 5				TGTGTACTAAC
			homolog				TGTAGC
			(human)
76.	K0649H05-3	F730038I15Rik	RIKEN cDNA	K0649H05	Mm.268680	No Chromosome	CCAGAGTTTTT
			F730038I15			location	TCCATCATGTT
			gene			info available	TTGCCCCAAAG
							ACCTCGGTTTG
							TAGAAGCCCA
							AGGAAA
77.	K0154C05-3	D230024O04	hypothetical	K0154C05	Mm.90241	Chromosome 6	GACAGGGTCA
			protein				ATGTTTATTAT
			D230024O04				ACATACTGCAC
							TGATGAGAAC
							AATATCATATG
							TGAAGAG
78.	C0185E05-3	Hmox1	heme	C0182E05	Mm.230635	Chromosome 8	ACTCTCAGCTT
			oxygenase				CCTGTTGGCAA
			(decycling) 1				CAGTGGCAGTG
							GGAATTTATGC
							CATGTAAATGC
							AATAC
79.	L0823E04-3		transcribed	L0823E04	Mm.270136	Chromosome 7	GACAGGGACT
			sequence with				CCATATGGAAG
			weak similarity				TAAGGACGTTT
			to protein				ACCTCATTACT
			pir:T26134				AAGTCTCGTCA
			(C. elegans)				AAAGAA
			T26134
			hypothectical
			protein
			W04A4.5-
			Caenorhabditis
			elegans
80.	K0310E05-3	9830126M18	hypothetical	K0130E05	Mm.266485	Chromosome 15	CTCGGATCTTC
			protein				ATGTTCTTCAG
			9830126M18				TAAGAATCTCT
							CTGTGGATTTG
							GAACAATCGTA
							AATAA
81.	C0908B11-3	P2ry6	pyrimidinergic	C0908B11	Mm.3929	Chromosome 7	CTAAGACACCT
			receptor P2Y,				GTGATTTGGCA
			G-protein				ACTGGTCAATT
			coupled, 6				CATGCTTGTTA
							CATTCAGAACT
							CAGGA
82.	K0438A08-3	Ccl2	chemokine (C-	K0438A08	Mm.145	Chromosome 11	TCCCTCTCTGT
			C motif) ligand				GAATCCAGATT
			2				CAACACTTTCA
							ATGTATGAGAG
							ATGAATTTTGT
							AAAGA
83.	H3082C12-3	Spp1	secreted	H3082C12	Mm.288474	Chromosome 5	TTCTCAGTTCA
			phosphoprotein				GTGGATATATG
			1				TATGTAGAGAA
							AGAGAGGTAA
							TATTTTGGGCT
							CTTAGC
84.	H3014A12-3	Capg	capping protein	H3014A12	Mm.18626	Chromosome 6	CTGACCAAGGT
			(actin filament),				GGCTGACTCCA
			gelsolin-like				GCCCTTTTGCC
							TCTGAACTGCT
							AATTCCAGATG
							ACTGC
85.	H3089C11-3	BG070621	ESTs	H3089C11	Mm.173282	Chromosome 4	GATACCTGGCT
			BG070621				TATCTTTTATC
							AACAGCAAATT
							ATGCAGTGGTG
							GAAATGTCATC
							ACAGA
86.	X67783.1	Vcam1	vascular cell	X67783	Mm.76649	Chromosome 3	GTTTGAGAAGA
			adhesion				GACATTATTTA
			molecule 1				TAAAACCCAG
							ATCCTTAATAC
							TGTTTATTACA
							GCCCCG
87.	J0509D03-3		AU018874	J0509D03		Chromosome 13	CTCTGATACTG
			Mouse eight-				AATAAACCTGA
			cell stage				TGTGATGTACT
			embryo cDNA				TATAGTCCTTA
			Mus musculus				AGTCTTGAGAG
			cDNA clone				TTAGA
			J0509D03 3′,
			MRNA
			sequence
88.	H3055A11-5		UNKNOWN:	H3055A11	Data not found	Chromosome 3	GGCAACTACG
			Similar to				ACTTTGTAGAG
			Homo sapiens				GCCATGATTGT
			KIAA1363				GAACAATCAC
			protein				ACTTCACTTGA
			(KIAA1363),				TGTAGAA
			mRNA
89.	C0455A05-3	AW413625	expressed	C0455A05	Mm.1643	Chromosome 19	ACTTCATAGGA
			sequence				TTCACAATGGA
			AW413625				GAGGGCTAGG
							AAGATACTGG
							ACAATTTTCAG
							CAGTGTG
90.	NM_019732.1	Runx3	runt related	NM_019732	Mm.247493	Chromosome 4	CACCTCTTGTC
			transcription				TCCAGCCATGC
			factor 3				CCAGGATCAAT
							TCTAGAATCAG
							AGGCTACCCCT
							GCCTG
91.	L0008A03-3	AW546412	ESTs	L0008A03	Mm.182599	Chromosome 16	CGTCAGTGACC
			AW546412				CACTCAATACT
							GTGGTGGGAA
							GTAAGATGATG
							CCAAATCTATA
							ACCTGT
92.	K0329C10-3	Thbs1	thrombospondin	K0329C10	Mm.4159	Chromosome 12	CGAATGAGAA
			1				TGCATCTTCCA
							AGACCATGAA
							GAGTTCCTTGG
							GTTTGCTTTTG
							GGAAAGC
93.	H3115H03-3	BC019206	cDNA sequence	H3115H03	Mm.259061	Chromosome 10	CCGGCGGGCCC
			BC019206				TAGTTTCTATG
							TATTTAGAATG
							AACTCGTGTAC
							ATATGTAAAGA
							TCTTT
94.	C0643F09-3	Usp18	ubiquitin	C0643F09	Mm.27498	Chromosome 6	CAAGCTGGTTG
			specific				GAGCCTCCAGC
			protease 18				CTTCAAAATTC
							TGAATCTAATA
							AACATTAATGC
							ACACT
95.	X84046.1	Hgf	hepatocyte	H84046	Mm.267078	Chromosome 5	CAATCCTAGAA
			growth factor				CAACTACTTGA
							GTGTTGTGAGT
							GTTCAGATACT
							CATTAATATAT
							ATGGG
96.	L0236C05-3	Aldh1b1	aldehyde	L0236C05	Mm.24457	Chromosome 4	TCCCACCTCTC
			dehydrogenase				TGATGAGTTAT
			1 family,				AGCCAAGAAG
			member B1				CCTTAGGAGTC
							TCCATAAGGCA
							TATTCA
97	H3055E08-3	Mcoln2	mucolipin 2	H3055E08	Mm.116862	Chromosome 3	AAGAAATATTC
							CCACTTCAGAG
							TGTGTAAGCAA
							TATTTAAACCC
							AGATAAAGAT
							GCATGC
98.	H3009F12-3	BG06369	ESTs	H3009F12	Mm.196869	Chromosome 5	TTTGGGAGTGG
			BG063639				GCTTCATGAAT
							GCGCTCTTACC
							AAAGGAGCCA
							TGTTTCCATTG
							TATCAA
99.	J0208G12-3	Cxc11	chemokine (C-	J0208G12	Mm.21013	No Chromosome	TTTCATTAAAC
			X-C motif)			location	TAATATTTATT
			ligand 1			info available	GGGAGACCAC
							TAAGTGTCAAC
							CACTGTGCTAG
							TAGAAG
100.	K0300C11-3	9130025P16Rik	RIKEN cDNA	K0300C11	Mm.153315	Chromosome 1	AAGTGACTCCA
			9130025P16				TTTTCATATGT
			gene				ACTTAAACACA
							GAGTTCCTGTG
							GCCTCTGTAAG
							CTCAG
101.	H3104F03-5	Krt1-18	keratin complex	H3104F03	Mm.22479	Chromosome 15	CAAGGTGAAG
			1, acidic, gene				AGCCTGGAAA
			18				CTGAGAACAG
							GAGACTGGAG
							AGCAAAATCC
							GGGAACATCT
102.	L0858D08-3	Trim2	tripartite motif	L0858D08	Mm.44876	Chromosome 3	GCATGTGATTG
			protein				ATTCATGATTT
							CCCCTTAGAGA
							GCAAGTGTTAC
							CAAAGTTCTGT
							TGAGC
103.	L0508H09-3	BY564994	EST BY564994	L0508H09	Mm.290934	Chromosome 12	TGCTCCAGATG
							TGAAACTTATA
							GACGTAGACTA
							CCCTGAAGTGA
							ATTTCTATACA
							GGAAG
104.	L0701G07-3	BM194833	ESTs	L0701G07	Mm.221788	Chromosome 2	TGTACAACTGA
			BM194833				ACTCACCTCTT
							GTGAAGAATTA
							TGATTGTCTTA
							CTTGTAAAGAA
							AGCAC
105.	K0102A10-3	E430015L02Rik	RIKEN cDNA	K0102A10	Mm.33498	Chromosome 16	TTTTGCAGGGG
			E430025L02				TCGAGTGTGAT
			gene				GCATTGAAGGT
							TAAAACTGAA
							ATTTGAAAGAG
							TTCCAT
106.	C0190H11-3	Spn	sialophorin	C0190H11	Mm.87180	Chromosome 7	CAAACAGAAA
							ACAGGGAGAT
							GTAAAACAGTT
							TCAACTCCATC
							AGTTATGAAAC
							CATAGCT
107.	L0514A11-3	2810457I06Rik	RIKEN cDNA	L0514A11	Mm.133615	Chromosome 9	TCAGCAAATTG
			2810457I06				GCGATTTCGGA
			gene				ATCCTATGACA
							CCTACATCAAT
							AGGAGTTTCCA
							GGTGA
108.	J0911E11-3	Nefl	neurofilament,	J0911E11	Mm.1956	Chromosome 14	CATGTGCAACC
			light				TCATGGGAAA
			polypeptide				AATAGTAACTT
							GAATCTTCAGT
							GGTTAGAAATT
							AAAGAC
109.	K0647E02-3	Def6	differentially	K0647E02	Mm.60230	Chromosome 17	GTCTCAAGGAT
			expressed in				CTGGGACCAG
			FDCP 6				AACTGGGAAA
							GAAAAGGAAT
							GACCAAGACA
							AGATCATAC
110.	H3091E09-3	Eifla	eukaryotic	H3091E09	Mm.143141	Chromosome Un	TGAATCAGAG
			translation				AAAAGAGAGT
			initiation factor				TGGTGTTTAAA
			1A				GAATATGGGC
							AAGAGTATGCT
							CAGGTGAC
111.	AF286725.1	Pdgfc	platelet-derived	AF286725	Mm.40268	Chromosome 3	AAAGGAAATC
			growth factor,				ATATCAGGATA
			C polypeptide				AGATTTGTATC
							TGATGAGTATT
							TTCCATCTGAA
							CCCGGA
112.	D31942.1	Osm	oncostatin M	D31942	18413	Chromosome 11	CAGTCCTCTTG
							AAAGGTCTCAG
							AAGCTGGTGA
							GCAATTACTTG
							GAGGGACATG
							ACTAATT
113.	L0046b04-3	Alcam	activated	L0046B04	Mm.2877	Chromosome 16	AGAGGAGTCTC
			leukocyte cedl				CTTATATTAAT
			adhesion				GGCAGGCATTA
			molecule				TAGTAAAATTA
							TCATTTCCCCT
							GAGGA
114.	K0131D09-3	LOC217304	similar to	K0131D09	Mm.297591	Chromosome 11	GCATGAGTGTA
			triggering				TAGGTGAAGGT
			receptor				TTCACTTTAAG
			expressed on				ATGCTGTCTTC
			myeloid cells 5				AGTTCTCTTGC
			(LOC217304),				CTATG
			mRNA
115.	H3024C07-3	Hexa	hexosaminidase	H3024C07	Mm.2284	Chromosome 9	ATCGTCTCTGA
			A				TTATGACAAGG
							GCTATGTGGTG
							TGGCAGGAGG
							TATTTGATAAT
							AAAGTG
116.	L0251A07-3	B4galt1	UDP-	L0251A07	Mm.15622	Chromosome 4	CTGTTCGTGTT
			Gal:betaGlcNA				GGGTTTTGTTC
			c beta 1,4-				ATGTCAGATAC
			galactosyl-				GTGGTTCATTC
			transferase,				TCAGGACCAA
			polypeptide 1				GGGAAA
117.	C0612G04-3	Grip 1	glutamate	C0612G04	Mm.196692	Chromosome 10	GTGCAATAGA
			receptor				AATATATGATT
			interacting				TCAAACACATT
			protein 1				TCTGAACTGCC
							AGGGCAAGAA
							AGTATAG
118.	C0357B04-3		C0357B04-3	C0357B04		No Chromosome	CTTGTCGTTTT
			NIA Mouse			loction	TGGGGGTTGTA
			Undifferentiated			info available	ATATCTAAGGG
			ES Cell				TGAAAAAATTA
			cDNA Library				ATTTCCAAAGC
			(Short) Mus				CAAGA
			musculus
			cDNA clone
			C0357B04 3′,
			MRNA
			sequence
119.	L0529E02-3	Egfl3	EGF-like-	L0529E02	Mm.29268	Chromosome 4	CAACTGTTTAC
			domain,				CTGGAAATGTA
			multiple 3				GTCCAGACCAT
							ATTTATATAAG
							GTATTTATGGG
							CATCT
120.	L0218E05-3	Dnase2a	deoxyribonuclease	L0218E05	Mm.220988	Chromosome 8	CCTTCCAGAGC
			II alpha				TTTGCCAAATT
							TGGAAAATTTG
							GAGATGACCTG
							TACTCCGGATG
							GTTGG
121.	H3074C12-3	Dutp	deoxyuridine	H3074C12	Mm.173383	Chromosome 2	TAGGTGAGTTA
			triphosphatase				GGAATCTGCCA
							TAAGGTCGTTT
							ATAGGATCTGT
							TTATATGAAGT
							AATGG
122.	H3072F09-3	Icsbp1	interferon	H3072F09	Mm.249937	Chromosome 8	ATGACTTTCTC
			consensus				TGCTTGGTTGG
			sequence				AGAAGAAGAA
			binding protein				TCTTTACTATT
			1				CAGCTTCTTTT
							CTTTTT
123.	c0829f05-3	4632404H22Rik	RIKEN cDNA	C0829F05	Mm.28559	Chromosome X	CCGGGGTGGG
			4632404H22				AAGTTGTTTTT
			gene				TCCTGGGGGTT
							TTTTCCCCTTA
							TTTGTTTTGGG
							GCCCCT
124.	L0063A12-3		similar to	L0063A12	Mm.38094	Chromosome X	GGAAGATGGG
			ubiquitin-				TAAATAGTAGA
			conjugating				CTGTGGTGTAT
			enzyme UBCi				TTGGAACAAG
			(LOC245350),				GTAGCTTTAAA
			mRNA				GACACAA
125.	C0143E09-3	6330548O06Rik	RIKEN cDNA	C0143E09	Mm.41694	Chromosome 5	CCAGGTTCAGA
			6330548O06				GCGGACTGCTA
			gene				ATAATAATGTG
							TGTATTGATCG
							AGGAAAAAGT
							GCGGAG
126.	K0127G03-3		transcribed	K0127G03	Mm.32947	Chromosome 14	TGCATGGGAA
			sequence with				ATTTCTACGTG
			weak similarity				GCTCACTTCAC
			to protein				CAAGGCTTATT
			ref:NP_000072.1				GCACTGGGAA
			(H. spaiens)				AAGAAGA
			beige protein
			homolong;
			Lysosomal
			trafficking
			regulator
			[Homo sapiens]
127.	H3109D03-3	Lamp2	lysosomal	H3109D03	Mm.486	Chromosome X	TTAACCTAAAG
			membrane				GTGCAACCTTT
			glycoprotein 2				TAATGTGACAA
							AAGGACAGTA
							TTCTACAGCTC
							AAGACT
128.	J0034B02-3	Dhx16	DEAH (Asp-)	J0034B02	Mm.5624	Chromosome 17	TCCCCACTACT
			Glu-Ala-His)				ATAAGGCCAA
			box polypeptide				GGAGCTAGAA
			16				GATCCCCATGC
							TAAGAAAATG
							CCCAAAAA
129.	K0428C07-3	Plcb3	phospholipase	K0428C07	Mm.6888	Chromosome 19	ATAGGTACTCC
			C, beta 3				CCGATTCCCAA
							GGAGCAGCTA
							GTGGAACCCTG
							GAGTTTTGGGT
							AGTAGA
130.	K0119F10-3	Ccl9	chemokine (C-	K0119F10	Mm.2271	No Chromosome	AGTAGTATTTC
			C motif) ligand			location	CAGTATTCTTT
			9			info available	ATAAATTCCCC
							TTGACATGACC
							ATCTTGAGCTA
							CAGCC
131.	J0046B07-3	Tuba4	tubulin, alpha 4	J0046B07	Mm.1155	Chromosome 1	ACCGCTACTTG
							GAGCCTGTTCA
							CTGTGTTTATT
							GCAAAATCCTT
							TCGAAATAAAC
							AGTCT
132.	C0117E11-3	Neu1	neuraminidase	C0117E11	Mm.8856	Chromosome 17	TGAACTCTGAC
			1				CTTTTGCAACT
							TCTCATCAACA
							GGGAAGTCTCT
							TGGTTATGACT
							TAACA
133.	C0101C01-3	Sdc1	sydecan 1	C0101C01	Mm.2580	No Chromosome	GTCTGTTCTTG
						location	GGAATGGTTTA
						info available	AGTAATTGGGA
							CTCTAGCTCAT
							CTTGACCTAGG
							GTCAC
134.	K0245A03-3	9130012B15Rik	RIKEN cDNA	K0245A03	Mm.35104	No Chromosome	CCAGCCTGACC
			9130012B15			location	AGATTTTAGTT
			gene			info available	ACCTTTTAAGG
							AAGAGAGATTT
							ATTCTAATGCC
							ATAAA
135.	H3109A02-3	Fcerlg	Fc receptor,	H3109A02	Mm.22673	Chromosome 1	CACCTCTGTGC
			lgE, high				TTTGAAGGTTG
			affinity I,				GCTGACCTTAT
			gamma				TCCCATAATGA
			polypeptide				TGCTAGGTAGG
							CTTTA
136.	L0819C05-3	Mapk8ip	mitogen	L0819C05	Mm.2720	Chromosome 2	CTGAGCTCAGG
			activated				CTGAGCCCACG
			protein kinase 8				CACCTCCAAAG
			interacting				GACTTTCCAGT
			protein				AAGGAAATGG
							CAACGT
137.	U77083.1	Anpep	alanyl	U77083	Mm.4487	Chromosome 7	AGAACAGCAG
			(membrane)				TTAGTTCCTGG
			aminopeptidase				TTCTGAGAACC
							ACTTGTCCCAG
							TATGACACCTC
							TTACTA
138.	C0164B01-3	Tnfaip2	tumor necrosis	C0164B01	Mm.4348	Chromosome 12	ATGTGTGTACT
			factor, alpha-				CAGGACAGAA
			induced protein				TCCAGAGATTT
			2				CTTTTTTATAT
							AGCTTGATATA
							AAACAG
139.	H3085G03-3	Cyba	cytochrome b-	H3085G03	Mm.448	Chromosome 8	ACGTTTCACAC
			245, alpha				AGTGGTATTTC
			polypeptide				GGCGCCTACTC
							TATCGCTGCAG
							GTGTGCTCATC
							TGTCT
140.	H3074F04-3	Abcc3	ATP-binding	H3074F04	Mm.23942	Chromosome 11	TTTTTTAATTCT
			cassette, sub-				GCAAATTGTCT
			family C				CACAGTGGAAT
			(CFTR/MRP),				GAGGAAATGA
			member 3				GTTAGAGATCA
							CAGCC
141.	H3145E02-3	Wbp1	WW domain	H3145Eo2	Mm.1109	Chromosome 6	GTGCTATCTTT
			binding protein				ACTCACTCCCA
			1				AGACATACAC
							AGGAGCCTTTA
							ATCTCATTAAA
							GAGACA
142.	K0609F07-3	Cd53	CD53 antigen	K0609F07	Mm.2692	Chromosome 3	GAGGTCCAAGT
							TTAAATGTTAG
							TCTCCTAACAA
							CTGTCAAATCA
							ATTTCTAGCCT
							CTAAA
143.	K0205H04-3	9830148O20Rik	RIKEN cDNA	K0205H04	Mm.21630	Chromosome 9	CTTCTAGATCC
			9830148O20				TTCTGCAGAAA
			gene				TCATCGTCCTA
							AAGGAGCCTCC
							AACTATTCGAC
							CGAAT
144.	H3095H04-3	2410002I16Rik	RIKEN cDNA	H3095H04	Mm.17537	Chromosome 18	ACTTATTCATC
			2410002I16				CTTGCCTATAC
			gene				CCACCCCCCAA
							AAACAGGTTTT
							ATTAATAAAAA
							ATGTG
145.	C0623H08-3	Tm7sfl	transmembrane	C0623H08	Mm.1585	Chromosome 13	TACAGTAACAA
			7 superfamily				GCAAGCTATCA
			member 1				TCCATTTTTAC
							AATAAAGTTGT
							CAGCATTCATG
							TCAGC
146.	L0242F05-3	2700088M22Rik	RIKEN cDNA	L0242F05	Mm.103104	Chromosome 15	TTATTTACTTT
			2700088M22				ATCTTAGTATG
			gene				TAACCTTAGCT
							GACCTGAAACC
							CACTGGTAGAC
							TAGAC
147.	C0177F02-3	Sdc3	sydecan 3	C0177F02	Mm.206536	Chromosome 4	CCTGTCCTGAG
							TTCATGGCCAA
							AACTTAAATAA
							GAGAAGGAGG
							AGAGGGTCAG
							ATGGATA
148.	L0803B02-3	Ppp1r9a	protein	L0803B02	Mm.156600	Chromosome 6	AAAGGGGCCT
			phosphatase 1,				GAGTATACGCT
			regulatory				GTTGCAAGCTG
			(inhibitor)				TATACTTCATT
			subunit 9A				TCCTTCGGCTG
							GTTTAT
149.	H3061D01-3	BB172728	ESTs	H3061D01	Mm.254385	Chromosome 3	TATCCGGACAG
			BB172728				TCTATGTGAAA
							TAGGACCAAG
							GTCGAAAGCC
							GGAAAGACAT
							CAACAGAA
150.	L0259D11-3	Clqb	complement	L0259D11	Mm.2570	Chromosome 4	CTGCTTTTCCC
			component 1, q				TGACATGGATG
			subcomponent,				CGTAATCACGG
			beta				GGTCAAATTAC
			polypeptide				ACCTATCCAAC
							ACCAT
151.	H3011D10-3	Lcpl	lymphocyte	H3011D10	Mm.153911	Chromosome 14	AACAAAGAGG
			cytosolic				ACAGTATGAAT
			protein 1				TTGAATAGCTC
							CCACTAGATAA
							GCAATTTCCAC
							GAGAAC
152.	H3052B11-3	Pctk3	PCTAIRE-	H3052B11	Mm.28130	Chromosome 1	CTGACTGTGAA
			motif protein				TGTCGTGACTC
			kinase 3				AGAGCAAAGA
							CAGAGAATAT
							ATTTAATTCAT
							GTTGTAC
153.	k0413h04-3	Anxa8	annexin A8	K0413H04	Mm.3267	Chromosome 14	GCCTGAAGAA
							CATGACAGAA
							CTCTTCTCAAT
							ATTCGTTGGGC
							TTTCAGAATCA
							TAAACAT
154.	H3054F05-3	Lyzs	lysozyme	H3054F05	Mm.45436	Chromosome 10	CCTGTGTGAAT
							AAAAATACAA
							GAACTGCTTAT
							AGGAGACCAG
							TTGATCTTGGG
							AAACAGC
155.	H3060F11-3	Cybb	cytochrome b-	H3060F11	Mm.200362	Chromosome X	GTAAGAAATAT
			245, beta				TAGACTGATTG
			polypeptide				GAGTTAAAGTA
							GCACTCTACAT
							TTACCATGGTG
							TTTGG
156.	H3012F08-3	9430068N19Rik	RIKEN cDNA	H3012F08	Mm.143819	Chromosome 1	TGTGAAAGATT
			9430068N19				GTGCATCTGCA
			gene				TTCAACTACCC
							TGAACCCTTAG
							GGAAGAAATG
							GATTCC
157.	G0106B08-3	Abr	active BCR-	G0106B08	Mm.27923	Chromosome 11	AGCTGCCTACT
			related gene				AGCAGTTTAAC
							AAGGAGCCTTG
							CTGTCTCAGAC
							AGGTGAAAGA
							AAATGT
158.	L0287A12-3	Tdrkh	tudor and KH	L0287A12	Mm.40894	Chromosome 3	CCATGTTTGAA
			domain				AGTATGTAATG
			containing				AAGAGGAGCC
			protein				TATTAACCATA
							TGAAAGACAG
							GAATACT
159.	H3083D01-3	AY007814	hypothetical	H3083D01	Mm.160389	Chromosome 7	GTGAATTGGAT
			protein,				GCATAGCATGT
			12H19.01.T7				TTTGTATGTAA
							ATGTTCCTTAA
							AAGTGTCACCA
							TGAAC
160.	H313F02-3	BGO74151	ESTs	H3131F02	Mm.142524	Chromosome 8	ACCCACTGACT
			BG074151				AGGATAACTG
							GAAAGGAGTC
							TGACCTGAATG
							ACGCATTAAAC
							TCCTGCA
161.	C0172H02-3	Lgals3	lectin, galactose	C0172H02	Mm.2970	Chromsome 14	CCCGCTTCAAT
			binding, soluble				GAGAACAACA
			3				GGAGAGTCATT
							GTGTGTAACAC
							GAAGCAGGAC
							AATAACT
162.	K0542E07-3	Cd44	CD44 antigen	K0542E07	Mm.24138	Chromosome 2	ATATTAACTCT
							ATAAAAATAAG
							GCTGTCTCTAA
							AATGGAACTTC
							CTTTCTAAGGG
							TCCCAC
163.	C0450H11-3	E430019N21Rik	RIKEN cDNA	C0450H11	Mm.275894	Chromosome 14	TGTGGGTTTTT
			E430019N21				TGAAGAATTAA
			gene				TGAGCATGTAC
							ATAGAAATAGT
							GACTGCTTGAA
							TCCTG
164.	K0216A08-3	Orc51	origin	K0216A08	Mm.566	Chromosome 5	CTACTCTTAAT
			recognition				AGATGTTAT-
			complex,				CTT
			subunit 5-like				AACACTGAAAT
			(S. cerevisiaae)				TGCCTGAAACC
							CATTTACTTAG
							GACTG
165.	H3122D03-3	Pdgfc	platelet-derived	H3122D03	Mm.40268	Chromosome 3	TCAGACCA-
			growth factor,				TTTC
			C polypeptide				TAGGCACAGTG
							TTCTGGGCTAT
							GGCGCTGTATG
							GACATATCCTA
							TTTAT
166.	C0037H07-3	Il13ral	interleukin 13	C0037H07	Mm.24208	Chromosome X	TCTGAATCTGG
			receptor, alpha				GCACTGAAGG
			1				GATGCATAAA
							ATAATGTTAAT
							GTTTTCAGTAA
							TGTCTTC
167.	H30554F04-3	2610318I15Rik	RIKEN cDNA	H3054F04	Mm.34490	Chromosome 11	GATCCTTAGGT
			2610318I15				CTCCATAGGAT
			gene				GATTTTTGAGG
							TAGTTAATCAG
							TGTAAACTCTT
							ACACA
168.	L0908A12-3	Blnk	B-cell linker	L0908A12	Mm.9749	Chromosome 19	CTCAGCAGTAA
							CAGAGAAAAG
							ATGAATGAAG
							CCACTGAGGCT
							TCGTGAATGAA
							TGAATCT
169.	G0111E06-3	Car7	carbonic	G0111E06	Mm.154804	Chromosome 8	CTTTGTTCCTA
			anhydrase 7				CCCAGCCACCA
							AAGCCACCTAC
							ATAACAATCCA
							CTCATGTACTA
							GCAAA
170.	L0284B06-3	Ngfrap1	nerve growth	L0284b06	Mm.90787	Chromosome X	AAATTGTCTAC
			factor receptor				GCATCCTTATG
			(TNFRSF16)				GGGGAGCTGTC
			associated				TAACCACCACG
			protein 1				ATCACCATGAT
							GAATT
171.	K0145G06-3	Tcfec	transcription	K0145G06	Mm.36217	Chromosome 6	ACATGATGTGA
			factor EC				AAGAATCATTG
							AAGATCACAGT
							TGTCTACCGAG
							TTCAGATTTCC
							TTACA
172.	H3001B08-3	Lyn	Yamaguchi	H3001B08	Mm.1834	Chromosome 4	CACCCCCCAGA
			sarcoma viral				AAATGAGACT
			(v-yes-1)				ATTGAACATTT
			oncogene				TCCTTTGTGGT
			homolog				AAGATCACTGG
							ACAGGA
173.	G0117F12-3	Prkcsh	protein kinase	G0117F12	Mm.214593	Chromosome 9	AGTGATGGGG
			C substrate				ACCATGACGA
			80K-H				GCTGTAGCCTG
							AACCTCAAGGC
							CTGAACCAGT
							CTACTGA
174.	C0903A11-3	2510004l01Rik	RIKEN cDNA	C0903A11	Mm.24045	Chromosome 12	AAAGGTCCCA
			2510004L01				GGTTTCGATCT
			gene				GTTTGGAGTTT
							GGAGTCTAATG
							GTTGCATAGAT
							AAACAG
175.	L0062C10-3	Rasa3	RAS p21	L0062C10	Mm.18517	Chromosome 8	TCTATGTGCAT
			protein				TAGGGGGTGA
			activator 3				CCCAGGGAAA
							TCCAAAGGGA
							ACAGTATTTGA
							TTTCTCAC
176.	L0939G09-3	Cd38	CD38 antigen	L0939G09	Mm.249873	Chromosome 5	CTACACATGTA
							CTTTAGGATTC
							TAGGTTTCTCC
							CTGAGCCCTGC
							TTTCGATGTAA
							CACTG
177.	H3115B07-3	S100a9	S100calcium	H3115B07	Mm.2128	Chromosome 3	AAGTCTAAAG
			binding protein				GGAATGGCTTA
			A9 (calgranulin				CTCAATGGCCT
			B)				TTGTTCTGGGA
							AATGATAAGAT
							AAATAA
178.	K0608H07-3	Fyb	FYN binding	K0608H07	Mm.254240	Chromosome 15	GGAAGAAAAA
			protein				GACCTCAGGA
							AAAAATTTAAG
							TACGACGGTGA
							AATTCGAGTTC
							TATATTC
179.	C0104E07-3	Tcirg1	T-cell, immune	C0104E07	Mm.19185	Chromosome 19	GGATGAAGAA
			regulator 1				ACTGAGTTTGT
							CCCTTCTGAGA
							TCTTCATGCAC
							CAAGCAATCCA
							CACCAT
180.	K0431D02-3	Wisp1	WNT1	K0431D02	Mm.10222	Chromosome 15	CTGTTCAGGCT
			inducible				CAAACAATGG
			signaling				GTTCCTCCTTG
			pathway protein				GGGACATTCTA
			1				CATCATTCCAA
							GGAAAA
181.	L0837H10-3	Igfbp2	insulin-like	L0837H10	Mm.141936	Chromosome 1	AGGAGTTCCCA
			growth factor				GTTTTGACACA
			binding protein				TGTATTTATAT
			2				TTGGAAAGAG
							ACCAACACTGA
							GCTCAG
182.	C0159A08-3	Mta3	metastasis	C0159A08	Mm.18821	Chromosome 17	CTCAATAAAAG
			associated 3				CTCTAAGGAGA
							CATCACAACCC
							AGTCTTAAGGG
							TTCATGAGGTT
							TTAAT
183.	K0649D06-3	Ms4a6b	membrane-	K0649D06	Mm.29487	Chromosome 19	ACTTAAAATGT
			spanning 4-				AGACTGTTCAT
			domains,				ACAGTGGGTAC
			subfamily A,				CAGTATGAGTT
			member 6B				GAATGTGTGTA
							TTACT
184.	K0609D11-3	Manla	mannosidase 1,	K0609D11	Mm.117294	Chromosome 10	TTTCATAATAG
			alpha				AACCGTCTACC
							AGTGACCTCTT
							GATTATGATTT
							GATTTGACTGC
							AAAAC
185.	C0907B04-3	Mcoln3	mucolipin 3	C0907B04	Mm.114683	Chromosome 3	ATCCATGTGGC
							ATCAATTCAAT
							TATGTATAATA
							ATGACTTTACA
							AGGGCCCCTTA
							AAACC
186.	H3020D08-3	Edem 1	ER degradation	H3020D08	Mm.21596	Chromosome 6	CACAAAAGTC
			enhancer,				AAATGTGGATA
			mannosidase				TCGTACGCTGC
			alpha-like 1				ATCACGTCATA
							GACAAGTCTAA
							AGAAGA
187.	J0039F05-3	Gdf3	growth	J0039F05	Mm.4213	Chromosome 6	CTATCAGGATA
			differentiation				GTGATAAGAA
			factor 3				CGTCATTCTCC
							GACATTATGAA
							GACATGGTAGT
							CGATGA
188.	C0906C11-3	BM218094	ESTs	C0906C11	Mm.212279	Chromosome 6	GGAGATCATCA
			BM218094				CTCTTGTATGA
							AATATACTAAC
							TCCAAACCTTT
							TTAGAGCAGAT
							TAGGC
189.	L0266E10-3	B930060C03	hypothetical	L0266E10	Mm.89568	Chromosome 12	ACTATTAAGCA
			protein				CTCAGGAGAAT
			B930060C03				GTAGGAAAGA
							TTTCCTTTGCT
							ACAGTTTTTGT
							TCAGTA
190.	H3060D11-3	M115	myeloid/lymph	H3060D11	Mm.10878	Chromosome 5	AAAGAGAAAA
			oid or mixed-				TATGTCAGATG
			lineage				GTGATACCAGT
			leukemia 5				GCAACTGAAA
							GTGGTGATGAA
							GTTCCTG
191.	L0062E01-3	Tnc	tenascin C	L0062E01	Mm.980	Chromosome 4	GAGAGAGGAA
							TGGGGCCCAG
							AGAAAAGAAA
							GGATTTTTACC
							AAAGCATCAA
							CACAACCAG
192.	K0132G08-3	A1662270	expressed	K0132G08	Mm.37773	No Chromosome	GTTGTACTACT
			sequence			location	GGAAAGATTTT
			A1662270			info available	GCTGGGACATA
							CAATATGTGTG
							AGAAAAATAG
							AGTTGT
193.	H3114D08-3	Arpc3	actin related	H3114D08	Mm.24498	Chromosome 5	AGACCAAAGA
			protein 2/3				CACGGACATTG
			complex,				TGGATGAAGCC
			subunit 3				ATCTACTACTT
							CAAGGCCAAT
							GTCTTCT
194.	C0649E02-3	Unc93b	unc-93	C0649E02	Mm.28406	Chromosome 19	CAGAGCAGGG
			homolog B (C.				GGCTTTTATTT
			elegans)				TTATTTTTTAA
							TGGAAAATAAT
							CAATAAAGACT
							TTTGTA
195.	L0293H10-3	2510048K03Rik	RIKEN cDNA	L0293H10	Mm.39856	Chromosome 7	CTTGGCAGCTC
			2510048K03				TCCTTACTTCT
			gene				GGGACATTTGC
							CACTGTGGTAC
							TGCCAGGAAG
							GAATCT
196.	H3024C03-3	1110008B24Rik	RIKEN cDNA	H3024C03	Mm.275813	Chromosome 12	ACTTATAGAAA
			1110008B24				AGGACAGGTT
			gene				GAAGCCTAAG
							AAGAAAGAGA
							AGAAAGATCC
							GAGCGCGCT
197.	H3055002-3	Ctsc	cathepsin C	H3055G02	Mm.684	Chromosome 7	TAGTTCAGTGA
							ACAAGTATCTG
							TCAATGAGTGA
							GCTGTGTCAAA
							ATCAAGTTATA
							TGTTC
198.	K0518A04-3	BM238476	ESTs	K0518A04	Mm.217227	Chromosome 2	CATGAATGTCA
			BM238476				AAACCTAATTA
							CAAAGCATCG
							GTCTCTTTGTT
							GTGAGGTATCA
							GAACCC
199.	K0128H01-3	Parvg	parvin, gamma	K0128H01	Mm.202348	Chromosome 15	CCTGTCTCATG
							GGAGATTTGAA
							TCATAAGGAG
							AATCACTTTTT
							GTAACTTTATT
							GAGGAA
200.	K0649F04-3	Ccr2	chemokine (C-	K0649F04	Mm.6272	Chromosome 9	AAGTAAATATG
			C) receptor 2				CAAAGGAGAG
							AAGTTAGAGA
							AACTCCTCTCA
							TAAGAAAAAT
							GTCTTCCC
201.	K0603E03-3	Vav1	vav 1 oncogene	K0603E03	Mm.254859	Chromosome 17	TCGGAACTGTC
							CCTTAAGGAGG
							GTGATATCATC
							AAGATCCTCAA
							TAAGAAGGGA
							CAGCAA
202.	K0649A02-3	Stat1	signal	K0649A02	Mm.8249	Chromosome 1	TTAGTGGGCTG
			transducer and				AACCTATCGGT
			activator of				TTTAACTGGTT
			transcription 1				GTCTTAATTAA
							CCATAAACTTG
							GAGAA
203.	H3013D11-3	Mt2	metallothionein	H3013D11	Mm.147226	Chromosome 8	TTTTGTACAAC
			2				CCTGACTCGTT
							CTCCACAACTT
							TTTCTATAAAG
							CATGTAACTGA
							CAATA
204.	H3013B02-3	Atp6vlb2	ATPase, H +	H3013B02	Mm.10727	Chromosome 8	AGACTTGGAA
			transporting,				AAGGCTTGGGT
			V1 subunit B,				ACAATTAAGA
			isoform 2				AAAACCCTACA
							TCCCACCCTCC
							TCTTGAC
205.	L0541H09-3		transcribed	L0541H09	Mm.221768	Chromosome 6	TAATAAAGAA
			sequence with				ACTGTGGAAAT
			weak similarity				ACTTGGATTTC
			to protein				TACTGAAGACA
			pir:S12207				AAAGACTTCTA
			(M. musculus)				GGCTGG
			S12207
			hypothetical
			protein (B2
			element) -
			mouse
206.	K0516E03-3		Mus musculus	K0516E03	Mm.214742	Chromosome 10	AGGTTAAACAT
			12 days embryo				ATATTCTTGGA
			embryonic				AACATGAAATC
			body between				ACAACTCTCAA
			diaphragm				AAACCGTGAA
			region and neck				CCACCA
			cDNA, RIKEN
			full-length
			enriched
			library,
			clone:9430012
			B12
			product:unknown
			EST, full
			insert sequence.
207.	H3034A10-3	Plaur	urokinase	H3034A10	Mm.1359	Chromosome 7	CCTCGTGTTGT
			plasminogen				CTTCTTTGGAC
			activator				CTCAGTTTTTC
			receptor				CATGAACCAG
							AAGAGAATTG
							GAACAAG
208.	C0910G05-3	BM218419	ESTs	C0910G05	Mm.217839	Chromosome 10	AATAGCAATGT
			BM218419				ATCAAACAATG
							GATGTGAAAA
							AGATGCGCTCT
							ATCATCATGAA
							AATGCC
209.	C0262H12-3	Msh2	mutS homolog	C0262H12	Mm.4619	Chromosome 17	TCTCTGGAGAA
			2 (E. coli)				ATCAGTAACTG
							CAAAAGGAAG
							AGAGGGTCTTT
							AAAGCACATGT
							AGTAAT
210.	H3078C11-3	BG069620	ESTs	H3078C11	Mm.173427	Chromosome 2	TGGAATGTTGA
			BG069620				AGAATGAAAT
							CTCGAGGGAAT
							TAGAGGTTGAG
							GTCATCTGGAT
							ATTCAG
211.	L0926H09-3	6030440G05Rik	RIKEN cDNA	L0926H09	Mm.27789	Chromosome 6	ATAGAACCAAT
			6030440G05				GTAGGAAAAT
			gene				CAGGCAAAAT
							AAAATGATGAT
							CAGTCCATGTC
							ATCATGG
212.	J0076H03-3		C80125 Mouse	J0076H03		No Chromosome	AGATGGGAAA
			3.5-dpc			location	AAGTACTGTAG
			blastocyst			info available	GTTCCTGAACT
			cDNA Mus				CTGGATCTCAA
			musculus				GCAGAAATGT
			cDNA clone				ACTGTCT
			J0076H03 3′,
			MRNA
			sequence
213.	L0817B08-3	transcribed	L0817B08		Mm.221816	Chromosome 18 not	AGGAAAACCC
			sequence with			placed	CGGTAGTTAGG
			strong				ACATCTGAATT
			similarity to				CTCAATTATTG
			protein				GATTGCCAAAA
			sp:P00722 (E.				GTGAAA
			coli)
			BGAL_ECOLI
			Beta
			galactosidase
			(Lactase)
214.	H3065D11-3	Crnkl1	Cm, crooked	H3065D11	Mm.273506	Chromosome 2	GTTTTTGGAAT
			neck-like 1				TTGGACCTGAA
			(Drosophila)				AATTGTACCTC
							ATGGATTAAGT
							TTGCAGAATTA
							GAGAC
215.	H3157E02-3	5630401J11Rik	RIKEN cDNA	H3157E02	Mm.21104	Chromosome 17	TGGGACCTGTG
			5630401J11				AAGCGACTGA
			gene				AGAAAATGTTT
							GAAACAACAA
							GATTGCTTGCA
							ACAATTA
216.	H3007C11-3	BG063444	ESTs	H3007C11	Mm.182542	No Chromosome	TCCATTATTAC
			BG063444			location	ATACAACAATC
						info available	AAGAAAAAGA
							CAGAAAACTA
							CCCTTAGAGAG
							ATCAGGG
217.	K0517E07-3	C53005OH1ORik	RIKEN cDNA	K0517E07	Mm.260378	Chromosome 4	ATTCAACAGCA
			C530050H10				TTCTAGGAAAA
			gene				TGGCAAGAAA
							GTAAATTATCA
							TCCATTTCAGG
							TCTGTG
218.	H3150B11-5	Ptpn2	protein tyrosine	H3150B11	Mm.260433	Chromosome 18	CCATATGATCA
			phosphatase,	CAGTCGTGTTA
			non-receptor	AACTGCAAAGT
			type 2	ACTGAAAATG
							ATTATATTAAT
							GCCAGC
219.	C0199C01-3	9930104E21Rik	RIKEN cDNA	C0199C01	Mm.29216	Chromosome 18	GGGCCATATTT
			9930104E21				TAAAGATAAG
			gene				GAGAGAGAAA
							CTAGCATACAG
							AATTTTCCTCA
							TATTGAG
220.	H3063A09-3	Rassf5	Ras association	H3063A09	Mm.248291	Chromosome 1	GAAAGGCGTTT
			(RaLGDS/AF-6)				ATTCAGAAAAT
			domain family				GATGGTAAGAT
			5				TCAGACTTTAA
							AGCACAGTTAG
							ACCCA
221.	K0445A07-3	Hfe	hemochromatosis	K0445A07	Mm.2681	Chromosome 13	TAAGGTGTTTT
							CTCCAGTTAAG
							TTCAGTTCCTG
							AATAGTAGTGA
							TTGCCCCAGTT
							GCAAC
222.	H3123G07-3	C630007C17Rik	RIKEN cDNA	H3123G07	Mm.119383	Chromosome 2	CCACCATAAAG
			C630007C17				GAAAAAGGAC
			gene				ATGTGTATGAG
							TAGGTGTTCAT
							CTATGTGCATA
							ATTGGC
223.	H3094C03-3	Bazla	bromodomain	H3094C03	Mm.263733	Chromosome 12	GCACAAGATG
			adjacent to zinc				GAGTCATTAAA
			finger domain				ATTAAGGCATC
			1A				ATCATTTTCAG
							CATATAACATA
							GCAGAG
224.	L0845H04-3	BM117070	ESTs	L0845H04	Mm.221860	Chromosome 1	GATTAAAAAC
			BM117070				ATTAGGGATGA
							GAAATAATAA
							GGGCTTGCAAC
							TGTGTAGAAGC
							TAGAGCC
225.	C0161F01-3	BC010311	cDNA sequence	C0161F01	Mm.46455	Chromosome 4	TGAAGTACACT
			BC010311				CTCTAAATGAA
							AATGGGCTATA
							AATATGTTTGA
							GTAGGATAGG
							AGGAAG
226.	H3034E07-3	BG065726	ESTs	H3034E07	Mm.5522	Chromosome 9	GTGTAAGAAA
			BG065726				AGATGGGACT
							GACAATAAAA
							ATGAAGGTCA
							GGTAAGAAGT
							ACCAGACTCC
227.	J0419G11-3	Cldn8	claudin 8	J0419G11	Mm.25836	Chromosome 16	GGGAAATATG
							CAGCGTTCTAT
							GTTTCCATAAG
							TGATTTTAGCA
							GAATGAGGTAT
							TATGTG
228.	C0040C08-3	Cxcr4	chemokine (C-	C0040C08	Mm.1401	Chromosome 1	GTAGGACTGTA
			X-C motif)				GAACTGTAGA
			receptor 4				GGAAGAAACT
							GAACATTCCAG
							AATGTGTGGTA
							AATTGAA
229.	K0612H02-3	BM241159	ESTs	K0612H02	Mm.222325	Chromosome 16	TCATAGGTCTC
			BM241159				CATTTAGTTCA
							AGTGTTTTATG
							GACAATCAGC
							AAGTTTAGGCT
							CATAGG
230.	J0460B09-3		AU024759	J0460B09		No Chromosome	TTGGAATATAT
			Mouse			location	GAATGACAAA
			unfertilized egg			info available	GAAATGGGAA
			cDNA Mus				AAACTGCTGAA
			musculus				CCCGAGTCTCT
			cDNA clone				GAATGTC
			J0460B09 3′,
			MRNA
			sequence
231.	H3103F07-3		Mus musculus	H3103F07	Mm.174026	Chromosome 10	CTATCTTGAAT
			transcribed				TGCTAGATTAA
			sequence with				AGAGAAAGAA
			weak similarity				AATGTTAGAGC
			to protein				AAAATAGGAA
			ref:NP_081764.1				CCTGGCC
			(M. musculus)
			RIKEN cDNA
			5730493B19
			[Mus musculus]
232.	H3079H09-3	BG069769	ESTs	H3079H09	Mm.173446	Chromosome 9	AATCCCTAGAG
			BG069769				AAAATGGGAA
							TAGAAATAAG
							CTGCATACAAA
							CTCAAAGACAC
							AGATACT
233.	H3130D06-3	BG074061	ESTs	H3130D06	Mm.182873	Chromosome 1	AGACTGAAGA
			BG074061				AAACCTTAAAA
							TACCCAAAATT
							CAGGGGAGAC
							ATAGCAACTGA
							GTCTCAT
234.	H3071D08-3	Lcp2	lymphocyte	H3071D08	Mm.1781	Chromosome 11	AGAGGACTTCC
			cytosolic				TGTCTGTATCA
			protein 2				GATATTATTGA
							CTACTTCAGGA
							AAATGACGCTG
							TTGCT
235.	K0218E07-3		Mus musculus	K0218E07	Mm.216167	Chromosome 10	ATGGAGATGTG
			10 days neonate				TAAACAGTAG
			olfactory brain				GACATTTCGAT
			cDNA, RIKEN				AACTATGTCAG
			full-length				GTCAGTTCTTA
			enriched				GTTCAG
			library,
			clone:E530016
			P10
			product:weakly
			similar to
			ONCOGENE
			TLM [Mus
			musculus], full
			insert sequence.
236.	C0907H07-3	BM218221	ESTs	C0907H07	Mm.221604	Chromosome 12	GAGGCTATTAT
			BM218221				AAATAACCTGA
							AATGCATATGA
							GAACTGAACGT
							GTAATAATTCA
							GCTCC
237.	K0605B09-3	BM240642	ESTs	K0605B09	Mm.222320	Chromosome X	AAGTCGGAAT
			BM240642				ATGTCTTAGTG
							TTCTTCTCACT
							TAGCTCAGTGT
							AAGATGGTAG
							CTCAAGT
238.	C0322F05-3	Eya3	eyes absent 3	C0322F05	Mm.1430	Chromosome 4	CACTTTTCTAT
			homolog				GAAGAAAGCC
			(Drosophila)				GTGTGTAAAGT
							TTCCGTGACAG
							TAGTAATGGAA
							ATATCT
239.	J0004A01-3	C76123	ESTs C76123	J0004A01	Mm.24905	Chromosome 15	TGTAAGAATAC
							AAGGTAAAAC
							AAAATAGAGA
							AATACAGGCAT
							CATATCTGCAA
							ATCGCCG
240.	K0139H06-3	BM223668	ESTs	K0139H06	Mm.221718	Chromosome 3	CAGAAACAGT
			BM223668				AGTATGGGGTT
							AAATCACAATG
							AGGGAAATTAT
							AGGGATATGC
							AGCCAAG
241.	L0941F06-3	BM120591	ESTs	L0941F06	Mm.217090	Chromosome 9	ACTGAAAGTTG
			BM120591				GGGAGATACA
							TGTAATTTAAT
							AGGATAGGGT
							ACTTAGGTCCA
							GACAACC
242.	C0300G03-3	3021401C12Rik	RIKEN cDNA	C0300G03	Mm.102470	Chromosome 15	AAGCTGTTGAA
			3021401C12				TATGGACGTAA
			gene				CTGTAAATCCC
							AGAGTGTTTTA
							TtTTGAGATGA
							GAGTT
243.	C0925E03-3		transcribed	C0925E03	Mm.217865	Chromosome 6	TTTATCAAACA
			sequence with				TGGAAACATCT
			moderate				AGAGACTATG
			similarity to				GGAGAGAAAA
			protein				TGGGTTTTTAG
			pir:S12207				ATATGGG
			(M. musculus)
			S12207
			hypothetical
			protein (B2
			element) -
			mouse
244.	H3083B07-5	BG082983	ESTs	H3083B07	Mm.203206	No Chromosome	GGAAGTTAATA
			BG082983			location	GAACTGTTCAA
						info available	AATGTGAAAGT
							GGAAATAGCG
							TCAATAAGGA
							AAGCCCC
245.	H3056F01-3	Gdf9	growth	H3056F01	Mm.9714	Chromosome 11	AGTGTAGTTTT
			differentiation				CAGTGGACAG
			factor 9				ATTTGTTAGCA
							TAAGTCTCGAG
							TAGAATGTAGC
							TGTGAA
246.	J0259A06-3	C88243	EST C88243	J0259A06	Mm.249965	No Chromosome	GAAAGTGGGG
						location	AATGAAAAGT
						info available	ATAACAAAGT
							AAAAAGAGAA
							TTTCTAGGCCC
							TTTAGGCCC
247.	C0124B09-3	BC0425 13	cDNA sequence	C0124B09	Mm.11186	Chromosome 11	GGTTTTCTCTT
			BC0425 13				GTTTTATCATG
							ATTCTTTTTAT
							GAAGCAATAA
							ATCCATTTCCC
							TGTTGG
248.	L0933E02-3		L0933E02-3	L0933E02		No Chromosome	CTTTTTGAGGT
			NIA Mouse			location	TTATTTTTCCA
			Newbom			info available	CAGTTTTCATT
			Kidney cDNA				TGTTCATTAGG
			Library (Long)				CATTTTCCCTT
			Mus musculus				TTACT
			cDNA clone
			L0933E02 3′,
			MRNA
			sequence
249.	H3072B12-3	BG069052	ESTs	H3072B12	Mm.250102	Chromosome 9	AGTGTTTTTCT
			BG069052				TTAATTCTTGA
							GGTTGTTATTG
							TAATATTTACA
							TATAGTGCAAG
							AATGT
250.	L0266C03-3	D930020B18Rik	RIKEN cDNA	L0266C03	Mm.138048	Chromosome 10	TAAAGTATCCA
			D930020B18				CTGAAGTCACT
			gene				ATGGAAAACA
							GCCTTTTGATT
							TATGGACTATT
							TAGCTC
251.	K0423B04-3	Zfp91	zinc finger	K0423B04	Mm.212863	Chromosome 19	GCCTAGTTTTT
			protein 91				TCAGCATCAAT
							TTTGGAAAACC
							TTAGACCACAG
							GCATATTTCGT
							CAAGT
252.	J0403C04-3		AUO21859	J0403C04		No Chromosome	TCATTTTTCAA
			Mouse			location	GTCGTCAAGGG
			unfertilized egg			info available	GATGTTTCTCA
			cDNA Mus				TTTTCCGTGAC
			musculus				GACTTGAAAA
			cDNA clone				ATGACG
			J0403C04 3′,
			MRNA
			sequence
253.	J0248E12-3	1700011103Rik	RIKEN cDNA	J0248E12	Mm.78729	No Chromosome	CTGAAAATCAC
			1700011103			location	GGAAAATGAG
			gene			info available	AAATACACACT
							TTAGGACGTGA
							AATATGTCGAG
							GAAAAC
254.	J0908H04-3	Rpl24	ribosomal	J0908H04	Mm.107869	No Chromosome	GCGAGAAAAC
			protein L24			location	TGAAAATCACG
						info available	GAAAATGAGA
							AATACACACTT
							TAGGACGTGA
							AATATGGC
255.	K0205H10-3	Madd	MAP-kinase	K0205H10	Mm.36410	Chromosome 2	AGAAAGCTAT
			activating death				GGACTGGATA
			domain				GGAGGAGAAT
							GTAAATATTTC
							AGCTCCACATT
							ATTTATAG
256.	C0507E09-3	Gpr22	G protein-	C0507E09	Mm.68486	Chromosome 12	ACAAAAAGGT
			coupled				TACCTATGAAG
			receptor 22				ACAGTGAAAT
							AAGAGAGAAA
							TGTTTAGTACC
							TCAGGTTG
257.	J0005B1 1-3		Mus musculus	J0005B11	Mm.249862	Chromosome 7	CTAAGGGAGG
			transcribed				AAATGTTGGTA
			sequence with				TAAAATGTTTA
			weak similarity				AAAGAACTTG
			to protein				GAGGCAAACTT
			ref:NP_083358.1				GGAGTGG
			(M. musculus)
			RIKEN cDNA
			5830411J07
			[Mus musculus]
258.	L0201E08-3	AW551705	ESTs	L0201E08	Mm.182670	Chromosome 6	CCACATCATTG
			AW551705				GAAAGAAATA
							CACTTATCTTA
							ATTGCCATGGA
							ATAGGAGCAT
							GAAAGTC
259.	J0426H03-3	AU023164	ESTs	J0426H03	Mm.221086	Chromosome 4	ATGAGAAATA
			AU023164				CACACTTTAGG
							ACGTGAAATAT
							GGCGAGGAAA
							ACTGAAAAAG
							GTCTATTC
260.	C0649D06-3	Cdkn2b	cyclin-	C0649D06	Mm.269426	Chromosome 4	CCTGTGAACTG
			dependent				AAAATGCAGA
			kinase inhibitor				TGATCCACAGG
			2B (p15,				CTAAATGGGA
			inhibits CDK4)				AACCTGGAGA
							GTAGATGA
261.	J0421D03-3	Rpl24	ribosomal	J0421D03	Mm.107869	No Chromosome	GCGAGAAAAC
			protein L24			location	TGAAAATCACG
						info available	GAAAATGAGA
							AATACACACTT
							TAGGACCAGA
							AATATGGC
262.	K0643F07-3		ESTs	K0643F07	Mm.25571	Chromosome X	TGGAGGAAATT
			BQ563001				GATTGAAAAA
							CGATTGGTCAA
							ATCGAAAATG
							GAGAAAACTC
							ATGTTCAC
263.	H3103C12-3	Slamfl	signaling	H3103C12	Mm.103648	Chromosome 1	CTTCATCCTGG
			lymphocytic				TTTTCACGGCA
			activation				ATAATAATGAT
			molecule				GAAAAGACAA
			family member				GGTAAATCAA
			1				ATCACTG
264.	J0416H11-3	Pscdbp	pleckstrin	J0416H11	Mm.123225	No Chromosome	ACTGAAAATCA
			homology, Sec7			location	TGGAAAATGA
			and coiled-coil			info available	GAAACATCCAC
			domains,				TTGACGACTTG
			binding protein				AAAAATGACG
							AAATCAC
265.	AF015770.1	Rfng	radical fringe	AF015770	Mm.871	Chromosome 11	CAAGCACTGTG
			gene homolog				CTGCAAAATGT
			(Drosophila)				CGGTGGAATAT
							GATAAGTTCCT
							AGAATCTGGAC
							GAAAA
266.	C0933C05-3		ESTs	C0933C05	Mm.217877	Chromosome 1	TTTGAGAAGAA
			BQ551952				AGGCATACACT
							TGAAATAAAG
							GCAAAAACATT
							ATACTGTCTAC
							CGAGAC
267.	C0931A05-3	E130304F04Rik	RIKEN cDNA	C0931A05	Mm.38058	Chromosome 13	GAAGAAAACG
			E130304F04				AGGTGAAGAG
			gene				CACTTTAGAAC
							ACTTGGGGATT
							ACAGACGAAC
							ATATCCGG
268.	J0030C02-3	C77383	ESTs C77383	J0030C02	Mm.43952	Chromosome 13	ATCATAAAAAC
							TGTGGAAATCC
							ATATTGCCCTT
							TTAAAAGAAA
							ACTATGGGGAT
							GGAGAG
269.	H3061A07-3	Srpk2	serine/arginine-	H3061A07	Mm.8709	Chromosome 5	AAATGGCAGA
			rich protein				AGAAAGGGTT
			specific kinase				AATGGCTGGA
			2				AAAATGGATC
							AGTAGTCTTGC
							AGAGGAACC
270.	J0823B08-3		AUO41035	J0823B08		Chromosome 10	ATTUAGGGGG
			Mouse four-				CTTTATTGUA
			cell-embryo				CTTGACGTGGA
			cDNA Mus				ATTTGAAAACT
			musculus				AAAAAGATGA
			cDNA clone				GTCTGG
			J0823B08 3′,
			MRNA
			sequence
271.	L0942H08-3		Mus musculus	L0942H08	Mm.276728	Chromosome 11	GTGGAAATCA
			transcribed				GAGATCTAAGT
			sequence with				ACGTTTATGCA
			moderate				TAGGAGTAGG
			similarity to				AATGAGGGGTT
			protein				ATTAAAG
			ref:NP_081764.1
			(M. musculus)
			RIKEN cDNA
			5730493B19
			[Mus musculus]
272.	C0280H06-3	Mrp150	mitochondrial	C0280H06	Mm.30052	Chromosome 4	AAACCCCCCAA
			ribosomal				GTAGCCCAAA
			protein L50				GGCCCGCTTCC
							CACCAAAATGT
							TTTTTATGTTTT
							AAGGA
273.	L0534E07-3	4632417D23	hypothetical	L0534E07	Mm.105080	Chromosome 16	ATTATGATGCC
			protein				TGTAACACACA
			4632417D23				GAAGTATCTGA
							CTGTGAACGAA
							TCAACCTCATG
							GATGA
274.	U22339.1	Il15ra	interleukin 15	U22339	16169	Chromosome 2	AGAAGAGATA
			receptor, alpha				CTGAGCCAATG
			chain				AACCCTTTCGT
							GACAAAACCA
							AACTCAG
275.	L0533C12-3		L0533C12-3	L0533C12		No Chromosome	CTGCCTTCCCA
			NIA Mouse			location	TAAAAATAAA
			Newborn Heart				AGGCATGCAA
			cDNA Library				AACCAATTTTT
			Mus musculus				GGCCAGGCCC
			cDNA clone				AGTTAAGA
			L0533C12 3′,
			MRNA
			sequence
276.	C0909E04-3	Mvk	mevalonate	C0909E04	Mm.28088	Chromosome 5	ACAAGCCCTGG
			kinase				GCCTCTGAGAC
							CACCCGACACA
							CCATCCTACCA
							AGAAGCCTCTA
							AGTAT
277.	J0093B09-3	Bhmt2	betaine-	J0093B09	Mm.29981	Chromosome 13	CAAGTCAGCA
			homocysteine				AGAAGCCAAC
			methyltransferase				CTTGGTGAAAT
			2				AATTCTGGTTG
							TTTGAAAGCTA
							GGTCTTG
278.	H3066D09-3	BG068517	ESTs	H3066D09	Mm.250067	Chromosome 1	GGTCAAGAGA
			BG068517				GTGCCAACTAG
							CTTTGTTTAAA
							AAATCCTAGTC
							CTGAATCCACA
							AGCCTG
279.	C0346F01-3	BM197260	ESTs	C0346F01	Mm.222100	Chromosome 9	AGTGGAAGCCT
			BM197260				TATAAGCATTG
							AACCCAGGAT
							GAGTCGCTCGT
							ATTTCCACCTT
							ACTCAT
280.	K0125A06-3	Hdac7a	histone	K0125A06	Mm.259829	Chromosome 15	CTTCCCACAAC
			deacetylase 7A				CCCACCGTACC
							TTGTCTATGTA
							TGCATGTTTTT
							GTAAAAAAGA
							AAAAAG
281.	J0214H07-3		C85807 Mouse	J0214H07		No Chromosome	TGCCTGACTCC
			fertilized one-			location	AAGAAAAGAA
			cell-embryo			info available	GCCAGAACTCG
			cDNA Mus				GAACCATAGTC
			musculus				ATCTTTAAAGA
			cDNA clone				TCTTCT
			J0214H07 3′,
			MRNA
			sequence
282.	C0309H10-3	5930412E23Rik	RIKEN cDNA	C0309H10	Mm.45194	No Chromosome	GTTAATATTAT
			5930412E23			location	TAACTGAGCCT
			gene			info available	GCCCATACCCC
							CCGTGGTCATT
							GGTGTTGGGTG
							CAGTG
283.	C0351C04-3	2610034E13Rik	RIKEN cDNA	C0351C04	Mm.157778	Chromosome 7	GGAGGACGAC
			2610034E13				ATCCTCATGGA
			gene				CCTCATCTGAA
							CCCAACACCCA
							ATAAAGTTCCT
							TTTAAC
284.	K0204G07-3	Arf3	ADP-	K0204G07	Mm.295706	Chromosome 15 not	TCTGAACCTCA
			ribosylation			placed	ACCCATCACCA
			factor 3				ACCCCGTGTCT
							TCAACATTACT
							TCCAAAAAAG
							TCTGG
285.	L0928B09-3		transcribed	L0928B09	Mm.217064	Chromosome 10	AGGAGCCTGTG
			sequence with				TCCTTATAGAG
			strong				TTGGAATTAAC
			similarity to				TTCAGCCCTCT
			protein				ATCTCACTTCC
			pir:S12207				TCTGT
			(M. musculus)
			S12207
			hypothetical
			protein (B2
			element) -
			mouse
286.	H3059A09-3	C430004E15Rik	RIKEN cDNA	H3059A09	Mm.29587	Chromosome 2	GAAAAAAGAT
			C430004E 15				GAGATCTCCTC
			gene				CATGACAAGA
							GCCTGCATACA
							ACATTTGAGTA
							CCCTTCT
287.	C0949D03-3		UNKNOWN	C0949D03	Data not found	No Chromosome	TTTGATTTTAG
			C0949D03			location	CAGAAACCAC
						info available	CACCAAAATTG
							TGCCTTAGCTG
							TATTTCTGTTT
							AGGGGA
288.	K0118A04-3	Rgs1	regulator of G-	K0118A04	Mm.103701	Chromosome 1	AGATACTATGG
			protein				TACTGTCATGA
			signaling 1				AATGCAGTGG
							GACTCTATTCA
							AACAACCCTCC
							AAAATG
289.	H3123F11-3		transcribed	H3123F11	Mm.157781	Chromosome 7	AGAGAACCCA
			sequence with				CACTCCTTTCA
			moderate				TCAAGACTTGC
			similarity to				AGAGCATCCCA
			protein				CAACCAAGAT
			ref:NP_081764.1				GCTATTT
			(M. musculus)
			RIKEN cDNA
			5730493B19
			[Mus musculus]
290.	H3154A06-3	Gng13	guanine	H3154A06	Mm.218764	Chromosome 17	TATGAGCCTGA
			nucleotide				CCCACACTCTC
			binding protein				TGTAAGGTGTG
			13, gamma				ACTTTATAAAT
							AGACTTCTCCG
							GGTGT
291.	L0534E01-3		L0534E01-3	L0534E01		Chromosome 9	ATACCCCACCA
			NIA Mouse				CAACCTCTCAA
			Newbom Heart				AAGAGGGCTCT
			cDNA Library				TAACTTGGAAG
			Mus musculus				GATAAAATAA
			cDNA clone				ATCAGG
			L0534E01 3′,
			MRNA
			sequence
292.	L0250B10-3	Ap4m1	adaptor-related	L0250B10	Mm.1994	No Chromosome	TATCCTCCCAC
			protein			location	AAAGATGAGA
			complex AP-4,			info available	GGAGCCCATCC
			mu 1				AGTGTTACTGT
							TAGAAGTCACA
							GTGAAA
293.	L0518G04-3	BM12304S	ESTs	L0518004	Mm.221745	Chromosome 3	TATTGTCCAAT
			BM123045				GAAACCCACA
							AACTACCCTCT
							ATCTGGAGTTG
							GAACATTTATC
							TGCATT
294.	J1020E03-3		transcribed	J1020E03	Mm.250157	Chromosome 9	TAAGGAGACT
			sequence with				GCCCTACAAAA
			moderate				CTACGATACTA
			similarity to				CTATCACTTTA
			protein				AAAATTAGTGT
			pir:S12207				AAAGGG
			(M. musculus)
			S12207
			hypothetical
			protein (B2
			element).
			mouse
295.	X12616.1	Fes	feline sarcoma	X12616	Mm.48757	Chromosome 7	TCAAGGCCAA
			oncogene				GTTTCTGCAAG
							AAGCAAGGAT
							CCTGAAACAGT
							ACAACCACCCC
							AACATTG
296.	J0026H02-3	C77164	expressed	J0026H02	97587	Chromosome X	GATTGCCAGAG
			sequence				ACTTACACTTA
			C77164				ATAGAGTCATA
							AAGCCCATAG
							AGCCTGAGTGA
							GAGCCA
297.	H3154D11-5	Taf71	TAF7-like	H3154D11	Mm.103259	Chromosome X	TTATTCCTGAA
			RNA				GCCCCCGCTAC
			polymerase II,				AGATGTTTCCA
			TATA box				CAACCGAAGA
			binding protein				AGCGGTCTCCA
			(TBP)-				AAGAGC
			associated
			factor
298.	H3054H04-3	Kcnn4	potassium	H3054H04	Mm.9911	Chromosome 7	AGCTCCACATG
			intermediate/sm				AACTCACAGA
			all conductance				AGAACCAGGC
			calcium-				TAAGTACCCAA
			activated				GGACCGAGCTC
			channel,				AAGGACA
			subfamily N,
			member 4
299.	J0425B03-3	R75183	expressed	J0425B03	Mm.276293	Chromosome 15	ACCATTATTCT
			sequence				TTTAAAAAACC
			R75183				CAAAAACCAC
							CAGCAAGGGG
							GCCTTTGGTTG
							GCCTCAA
300.	C0930C02-3	0610037D15Rik	RIKEN cDNA	C0930C02	Mm.218714	No Chromosome	CTTCATCTTAA
			0610037D15			location	AACTCCAGAAC
			gene			info available	AACTCCCTTCC
							TAACCTGGAAC
							CCAGCAGCTTT
							CAGTT
301.	L0812A11-3		ESTs B1793430	L0812A11	Mm.261348	No Chromosome	CTGCACGCCCC
						location	AGGAGCCTGG
						info available	GTGAAGCATCA
							CAGCACTAAGT
							CATGTTAAAAG
							GAGTCT
302.	J0243F04-3	9530020D24Rik	RIKEN cDNA	J0243F04	Mm.200585	Chromosome 2	CACTGGAGCAC
			9530020D24				TGAACATGATG
			gene				TACAAGTATCA
							CACAGAAAAG
							CAGCACTGGAC
							TGTACT
303.	C0335A03-311	10035014Rik	RIKEN cDNA	C0335A03	Mm.202727	Chromosome 12	ATAAGAACTTA
			1130035014				TAGGAACCCCA
			gene				ACTCCCCATGA
							AAAATATAAG
							ACCTCAAGGCC
							TGGGGA
304	H3003B10-3	BG063111	ESTs	H3003B10	Mm.100527	Chromosome 3	GCCCACCAACT
			BG063111				CTAATTTGTGC
							TACTTATATAT
							ATTCCTGGGAG
							TAGGACTGTCC
							TCCTG
305	U97073.1	Prtn3	proteinase 3	U97073	Mm.2364	Chromosome 10	CAGTCAGGTCT
							TCCAGAACAAT
							TACAACCCCGA
							GGAGAACCTC
							AATGACGTGCT
							TCTCCT
306.	K0300D08-3	Afmid	arylformamidasc	K0300D08	Mm.169672	Chromosome 11	CGTAGCTCGCT
							GGTAGAAAGC
							CTGACCACCAT
							GCATACGATCC
							TGGGTTTCAAC
							AAGGAA
307.	H3029H06-3	Sf3b2	splicing factor	H3029H06	Mm.196532	Chromosome 19	GAGCCTGAGAT
			3b, subunit 2				CTACGAGCCCA
							ATTTCATCTTC
							TTCAAGAGGAT
							TTTTGAGGCTT
							TCAAG
308.	H3074D09-3	Drg2	developmentally	H3074D09	Mm.41803	Chromosome 11	GAGTCTGTGGG
			regulated				TAUCGCCTGA
			GIP binding				ACAAGCATAA
			protein 2				GCCCAACATCT
							ATTTCAAGCCC
							AAGAAA
309.	K0647G12-3	Plek	pleckstrin	K0647G12	Mm.98232	Chromosome 11	AGCATCAAAC
							AAAGCACATA
							AACTCGTACAT
							AAGCAAGGGA
							TGTCCTTATTG
							GTCAAACA
310.	H3137A08-3		Mus musculus	H3137A08	Mm.197271	Chromosome 2	GGGAAAAAAT
			transcribed				AGCAAAACCC
			sequence with				CAAACTCCACA
			moderate				ACCACAAAAA
			similarity to				CCTGTTAATTA
			protein				TGGTGGCA
			pir:S12207
			(M. musculus)
			S12207
			hypothetical
			protein (B2
			element) -
			mouse
311.	C0166D06-3	Slc38a3	solute carrier	C0166D06	Mm.30058	Chromosome 9	ACACAGAGCC
			family 38,				AGAAAACCCA
			member 3				GGCCTGAAGA
							CATCCCCTAGT
							CCTGCTGAGAG
							ACCACAGT
312.	K0406B07-3	Sirt7	sirtuin 7 (silent	K0406B07	Mm.259849	Chromosome 11	CGACCAATCTG
			mating type				CCTGGGAAAC
			information				AACACCCCACA
			regulation 2,				GAACGGGGCTT
			homolog) 7 (S.				CAGAAACACG
			cerevisiae)				TGAGTGA
313.	H3085D10-3	Gda	guanine	H3085D10	Mm.45054	Chromosome 19	GTTTAGGTGAG
			deaminase				TTTTCCATTGTA
							TCTTATAACAG
							AGAAACCCATT
							AGGCAGTAGTT
							AGTTC
314.	H3099C09-3	Igf1	insulin-like	H3099C09	Mm.268521	Chromosome 10	TCGAAACACCT
			growth factor 1				ACCAAATACCA
							ATAATAAGTCC
							AATAACATTAC
							AAAGATGGGC
							ATTTCC
315.	H3099B07-5	2610028H24Rik	RIKEN cDNA	H3099B07	76964	No Chromosome	TGCTACCCTCC
			2610028H24			location	AGGACCAACG
			gene			info available	ATGGATGCACC
							ACGGAGTCCCA
							AGAGCTGAAA
							AGCAGAA
316.	H3114H10-3	Rec8L1	REC8-like 1	H3114H10	Mm.23149	Chromosome 14	CGGAGCTCTTC
			(yeast)				AGAACCCCAA
							CTCTCTCTGGC
							TGGCTACCCCC
							AGAACTCCTAG
							GTTTAT
317.	L0703E03-3	Lipc	lipase, hepatic	L0703E03	Mm.362	Chromosome 9	ATAAAGAGAA
							TTCCCACCACC
							CTGOGCGAAG
							GAATTACCAGC
							AATAAAACCTA
							TTCCTTC
318.	H3074H08-3	BG069302	ESTs	H3074H08	Mm.11484	Chromosome 7:not	ACTTTCAAGTC
			BG069302			placed	TGAATCCTATG
							AGCCTGAAGTG
							AGATCTTATTT
							AGAAACAGAA
							CCCCAA
319.	K0443D01-3	Bazlb	bromodomain	K0443D01	Mm.40331	Chromosome 5	GACAAGCCCTT
			adjacent to zinc				AGGGAGCCAG
			finger domain,				AAAAAGAGCA
			1B				GGAAGAAGTT
							AAAATGTTTAA
							TTTTTTAA
320.	J0409E10-3	AU022163	ESTs	J0409E10	Mm.188475	Chromosome 16	GCCCAAGAGCT
			AU022163				AGAAAACCTA
							CTCTATGTGTA
							GAGATACTTCC
							TATTAAAATAA
							TAGTAC
321.	L0528E01-3	BM123655	EST	L0528E01	Mm.216782	Chromosome 9	CTCCACTTTTA
			BM123655				AAGTCTGTAGG
							AATAGGAGCC
							GATTAGACAAC
							TCTCGGTCTCA
							TGCTCA
322.	L0031B11-3	Alcam	activated	L0031B11	Mm.2877	Chromosome 16	TTTCTGGGATC
			leukocyte cell				CCACTGCACCG
			adhesion				CCATTTCTTCC
			molecule				CAGATTTATGT
							GTATAACTTAA
							ACTGG
323.	G0115A06-3	Femla	feminization 1	G0115A06	Mm.27723	Chromosome 17	ATACAGTAGAT
			homolog a (C.				GCTGAACACAC
			elegans)				TTGAGTCCATC
							ATGAGGGGGT
							AATAAGTCTCA
							CCAGCA
324.	L0947C07-3	Mal	myelin and	L0947C07	Mm.39040	Chromosome 2	TCTTATACTTT
			lymphocyte				CAACAAAGCT
			protein, T-cell				GAACCCTAACA
			differentiation				TTACACTAACC
			protein				AGCAGCTCAAC
							ACGAGT
325.	H3101A05-3	AU040576	expressed	H3101A05	Mm.26700	Chromosome 7	CTGAATGTATA
			sequence				CACACCCACAG
			AU040576				GAGACTGTGGC
							TGAGCGTTCAT
							CCAAATAAATT
							TGAAT
326.	H3064E10-3	BG068353	ESTs	H3064E10	Mm.35046	Chromosome 4	GTTCCTGTTCA
			BG068353				GAGTGCCTGAA
							AACCCAAAGT
							GTCTGAGAGTC
							TGAAGGAATTC
							AACTGT
327.	K0505H05-3	Ian6	immune	K0505H05	Mm.24781	Chromosome 6	AAACACCCAC
			associated				ACTTGAAACTT
			nucleotide 6				CCATGAACCCA
							CTCAAATTCAT
							TTCTATCCCCC
							TTTGGA
328.	H3082E12-3	Ptpre	protein tyrosine	H3082E12	Mm.945	Chromosome 7	TCATGGAGATA
			phosphatase,				TAACTATAGAG
			receptor type, E				ATAAAGAGCG
							ACACCCTGTCT
							GAAGCAATCA
							GCGTCCG
329.	H3088A06-3	2310047N01Rik	RIKEN cDNA	H3088A06	Mm.31482	Chromosome 4	GGACACTGTGA
			2310047N01				ACACTGTGTGG
			gene				ACAGAGCCCA
							CAACTTCTCCA
							TTTGTGTCTGG
							CAGCAA
330.	K0635B07-3	Ccr5	chemokine (C-	K0635B07	Mm.14302	Chromosome 9	AGGAAAGAAA
			C motif)				GGGGTTAGAAT
			receptor 5				CTCTCAGGAGA
							TTAAAGTTTTCT
							GCCTAACAAG
							AGGTGTT
331.	C0153A12-3	1110025F24Rik	RIKEN cDNA	C0153A12	Mm.28451	Chromosome 16	CTCAAGACTTT
			1110025F24				GCCAACATGTT
			gene				CCGTTTCTTAC
							ACCCTGAACCC
							TGATCGGAACA
							TTCAT
332.	C0143E02-3	BC022145	cDNA sequence	C0143E02	Mm.200891	Chromosome 11	TCTGTACATGG
			BC022145				CCGAAAATCA
							GAGTCCACCAT
							ATTCTTTTGAA
							TATCCAGGGTT
							CTCTGA
333.	L0863F12-3	Nr2c2	nuclear receptor	L0863F12	Mm.193835	Chromosome 6	TTCTGGCTCCT
			subfamily 2,				TATTTCAGTTC
			group C,				TCTTTAAAACC
			member 2				AGTTCAACACC
							AGTGTGTTAAA
							AAGAA
334.	H3045F02-3	LOC214424	hypothetical	H3045F02	Mm.31129	Chromosome 9	GCAGATTTAAC
			protein				AACTAGCAACT
			LOC214424				CTGTCATCTTT
							TTCTAAAAATG
							ACCAACTGCTG
							ATTAC
335.	H3035005-3	BG065832	ESTs	H3035G05	Mm.154695	Chromosome 17	CTTAAAAAGG
			BG065832				GAGATACAGTT
							TTACTCTGATC
							CAGCAAATCTA
							GTTAAGACACT
							AGAATG
336.	H3137D02-3	Hnrpl	heterogeneous	H3137D02	Mm.9043	Chromosome 7	CTTCCTGAACC
			nuclear				ATTACCAGATG
			ribonucleoprote				GAAAACCCAA
			in L				ATGGCCCGTAC
							CCATATACTCT
							GAAGTT
337	H3097F07-3	AU040829	expressed	H3097F07	Mm.134338	Chromosome 11	GTAACGGAGC
			sequence				CTGGGGGTTGA
			AU040829				AGGTTATCTTT
							ACATATATGTA
							CAAACTGTTGT
							CAAGAG
338.	J0029C02-3	Frag 1-pending	FGF receptor	J0029C02	Mm.259795	Chromosome 7	TCCCCACCACT
			activating				CATGGGGATCT
			protein 1				TCAAGAAGCAT
							CACCATTCACT
							GAAAGGTCCTA
							AAAAA
339.	BB416014.1		Mus musculus	BB416014	Mm.24449	Chromosome 10	GCGCAGAGGC
			B6-derived				AAACCAACGT
			CDII + ve				GGAGCCAGAC
			dendritic cells				ATTGGTGAACC
			cDNA, RIKEN				CAACCTATCCA
			full-length				CACCTTCA
			enriched
			library,
			clone:F730035
			A01
			product:similar
			to SWI/SNF
			COMPLEX
			170 KDA
			SUBUNIT
			[Homo
			sapiens], full
			insert sequence.
340.	H3087E01-3	Anxa4	annexin A4	H3087E01	Mm.259702	Chromosome 6	CTTATTTTAGA
							CAGATCCAAA
							GTTCTCACAAG
							CCCCCTTTCTT
							TGCTCTGCCTA
							TCATCG
341.	H3088E08-3	BG070548	ESTs	H3088E08	Mm.11161	Chromosome 8	AACCTCTGAAC
			BG070548				CTAATCACTGT
							GGATTCCCACC
							AACACCATATA
							TGAAAATGCA
							GGCCGA
342.	AF179424.1		Mus musculus	AF179424	Mm.1428	Chromosome 14	TGCGGAAGGA
			13 days embryo				GGGGATTCAA
			male testis				ACCAGAAAAC
			eDNA, RIKEN				GGAAGCCCAA
			full-length				GAACCTGAATA
			enriched				AATCTAAGA
			library,
			clone:6030408
			M17
			product:GATA
			binding protein
			4, full insert
			sequence
343.	J0258C01-3		Mus musculus	J0258C01	Mm.275718	Chromosome 2	CCCTAGTCCGT
			mRNA for				TTTCTGATCAG
			mKIAA1335				TCAGAACCCAC
			protein				AATAACTACTA
							GTAGTCCTGTG
							GCTTT
344.	K0507B09-3		ESTs	K0507B09	Mm.218038	Chromosome 9	GTAGCCACCAA
			BM238095				GCCACAAGTA
							ACAAATGATCT
							CTGTGAATGCC
							ATATGGAAACT
							TTTATT
345.	L0846F07-3	BM117131	ESTs	L0846F07	Mm.216977	Chromosome 9	GGCTCCATTTC
			BM117131				TGAACTCTGTG
							TTAAGCTAATA
							AGATTTTAAAT
							AAACGCTGATG
							AAAGC
346.	U48866.1	CEBPE	CCAAT/enhancer	U48866	Hs.158323	No Chromosome	TGCTGGGGGCC
			binding			location	TAGAACCCTGA
			protein			info available	GACATAGACC
			(C/EBP),				ATGGATAAATG
			epsilon				GCAACCGGGG
							TGGCAAA
347.	K0301B06-3	Fech	ferrochelatase	K0301B06	Mm.217130	Chromosome 18	AACGCAAAGA
							GCAAGAACCA
							AACAAAGACA
							GGAACAACTC
							GCAGAAGAAA
							TCCCGCCTGG
348.	NM_009756.1	Bmp10	bone	NM_009756	Mm.57171	Chromosome 6	TGTTTTCTGAT
			morphogenetic				GACCAAAGCA
			protein 10				ATGACAAGGA
							GCAGAAAGAA
							GAACTGAACG
							AATTGATCA
349.	NM_010100.1	Edar	ectodysplasin-A	NM_010100	Mm.174523	Chromosome 10	CCCACCACTGA
			receptor				ATATAGACCAT
							ACTGTGAGAG
							GACCATAATTA
							GGTCCTGAATT
							TTTAAT
350.	G0115E06-3	C430014D17Rik	RIKEN cDNA	G0115E06	Mm.103389	Chromosome 3	GTATGACTTCC
			C430014D17				AACCAGAAAA
			gene				AGGCTCTAAAA
							GCTGAACACAC
							TAACCGGCTGA
							AAAACG
351.	L0266D11-3	Ppp3ca	protein	L0266D11	Mm.80565	Chromosome 3	CTTCTGGCTCC
			phosphatase 3,				CTTACATGAAG
			catalytic				GACTGATTTAA
			subunit, alpha				GAAACCAGAC
			isoform				CATTCCTTTAC
							TTTGAA
352.	L0526F10-3		Mus musculus	L0526F10	Mm.215689	Chromosome X	GCAGGGTGCTT
			10 days neonate				ACTTTCTCAGA
			cortex cDNA,				GCCTGAAGTTA
			RIKEN full-				CTTCCATTGTT
			length enriched				TTGGCACTGAA
			library,				TAACA
			clone:A830020
			C2 I
			product:unknown
			EST, full
			insert sequence.
353	H3047C10-3	Slc6a6	solute carrier	H3047C10	Mm.200518	Chromosome 6	TTAGCACAAGA
			family 6				GAAAAGCTGA
			(neurotransmitter				GAACGTGGGTT
			transporter,				TTGCCTCCTTC
			taurine),				AGAAATATGTC
			member 6				TGGCTC
354	K0322G06-3	BC042620	cDNA sequence	K0322G06	Mm.152289	Chromosome 17	ACACAGCACCC
			BC042620				ACAACTAATCT
							TGGGACACCCC
							TATCTGGTTGG
							AAGAGAGTAA
							ACTAAT
355.	NM_009580.1	Zp1	zona pellucida	NM_009580	Mm.24767	Chromosome 19	CAATGGCCTAT
			glycoprotein 1				TCTGTCAGATG
							GGTGTCCTTTC
							AAGGGTGACA
							ACTACAGAAC
							ACAAGTA
356.	H3150E08-3	Map4k5	mitogen-	H3150E08	Mm.260244	Chromosome 12	AAAGTAGGTTC
			activated				ACACAGTAAA
			protein kinase				GGGATAATACC
			kinase kinase				ATCTGGAACAA
			kinase 5				TGATCAGTGTA
							GAGTTA
357.	J0059G03-3	C79059	ESTs C79059	J0059G03	Mm.249888	Chromosome 4	CACCTGGGTCT
							ACAGCTACTCT
							GATTCTACAAA
							GACAGGGTCA
							AGCATCTCTAA
							CAAAGT
358.	U93191.1	Hdac2	histone	U93191	15182	Chromosome 10	TATTAAACCCA
			deacetylase 2				GGAGATACAA
							GGAGTCTGCCA
							TTAACCTCTCT
							GTAACTCAAGA
							GTAGTT
359.	H3033C04-5		H3033C04-5	H3033C04		No Chromosome	TTCCTCCCAAA
			NIA Mouse			location	ATGGAGTTTCC
			15K cDNA			info available	TCTTCAAACCA
			Clone Set Mus				CAGCTCCCCCA
			musculus				AGATCTATCCT
			cDNA clone				GATAT
			H3033C04 5′,
			MRNA
			sequence
360.	H3085C01-3	2700038N03Rik	RIKEN cDNA	H3085C01	Mm.21836	Chromosome 5	TATGTCTTGAT
			2700038N03				ACTGGACCCAC
			gene				ACTACTGGGGC
							ACTCCAAAAA
							ACCGTTGTGAA
							CTACAA
361.	J0412G02-3	BB336629	ESTs	J0412G02	Mm.208743	Chromosome 11	AGTAAAGGGC
			BB336629				ACCGGAAATGT
							TAAATCCTTGT
							TTAGGATATGA
							AAGGAATTAG
							GGGATGG
362.	K0527H09-3	BM239048	ESTs	K0527H09	Mm.217288	Chromosome 11	GAATGTCTGAT
			BM239048				ACATGACCCAT
							CAGTTAGGAAC
							CACTGAACTAG
							AGGAGTAGCT
							AAACTC
363.	H3009C10-3	Serpinb9b	serine (or	H3009C10	Mm.45371	Chromosome 13	GCTTCTACTGG
			cysteine)				CTCTTGTATGC
			proteinase				ATATGTGCACT
			inhibitor, dade				TATCCAGACTG
			B, member 9b				AGGATTTTACA
							AAGCA
364.	H3142D11-3		Mus musculus	H3142D11	Mm.113272	Chromosome X	CTGTCTAAGCG
			mRNA similar				CTGAACCACTT
			to hypothelical				AGCAGAAATG
			protein				ACACCCATATG
			FLJ2O811				AGAGCTTGTGC
			(cDNA clone				CAAATA
			MGC:27863
			IMAGE:34925
			16), complete
			cds
365.	H3094B07-3		Mus musculus	H3094B07	Mm.173357	Chromosome 14	AAAGGAGACT
			transcribed				GCATCAGGTAT
			sequence with				TCTGATAGAGA
			weak similarity				GCTGAGGAAG
			to protein				AGATTGAGGTA
			sp:P11369				TGGGATT
			(M. musculus)
			POL2_MOUSE
			Retrovirus
			related POL
			polyprotein
			[Contains:
			Reverse
			transcriptase;
			Endonuclease]
366.	J0068F09-3	C79588	ESTs C79588	J0068F09	Mm.234023	No Chromosome	TGACTGGAATC
						location	ACCACCCTTGC
						info available	CTGAGTTTGCG
							ATCTCACAGTT
							GGAACTGAGA
							GTTTCC
367.	H3039B03-5	EO30024M05Rik	RIKEN cDNA	H3039B03	Mm.5675	Chromosome 12	GGATCAGATG
			E030024M05				ATGCACCATUG
			gene				CTTTCCATTTGC
							TACATTTAAAA
							TCTTTTACTAG
							TCAACC
368.	H3068B03-3	BG068673	ESTs	H3068B03	Mm.11978	Chromosome 1	TTGAGACCTTA
			BG068673				AAGAAATAAC
							AAACTCAAGG
							AAGATTAGGGT
							CCAGTGTTTAA
							GTCATGG
369.	C0250F05-3	BM203195	ESTs	C0250F05	Mm.228379	Chromosome 12	GTCTCCTTTGT
			BM203195				GTTATTGCCTT
							CCCAACACTTC
							TAAGTCCCAGC
							TCAACAGCTAC
							TTCTA
370.	H3110C11-3	Mlph	melanophilin	H3110C11	Mm.17675	Chromosome 1	CACAGCTGCTT
							GTAGTCATCAT
							TCCAGTGAGGA
							GTAAGAAGAA
							TTTTATGTGTG
							TCTCTA
371.	H3121F01-3	Wnt4	wingless-	H3121F01	Mm.20355	Chromosome 4	AACTTAAACAG
			related MMTV				TCTCCCACCAC
			integration site				CTACCCCAAAA
			4				GATACTGGTTG
							TATTTTTTGTTT
							TGGT
372.	J1012G09-3	Brd3	bromodomain	J1012G09	Mm.28721	Chromosome 2	CAGCAGAAAA
			containing 3				GGCTCCCACCA
							AGAAGGCCAA
							CAGCACAACC
							ACAGCCAGCA
							GGATGTGTT
373	L0952B09-3	Usp49	ubiquitin	L0952B09	Mm.25072	Chromosome 17	GGCTTCACATC
			specific				TAAGTGGGGA
			protease 49				CTATTTTAACT
							TATTTACAGGT
							ATATGGTGTGG
							AAATAA
374.	K0131B12-3	I14ra	interleukin 4	K0131B12	Mm.233802	Chromosome 7	CGCTCAGTTGT
			receptor, alpha				AGAAAGCAAC
							AAGGACACAA
							ACTTGATTGCC
							CAAAGTCACTG
							CCAGTTA
375.	H3046E09-3	Nfatc2ip	nuclear factor	H3046E09	Mm.1389	Chromosome 7	GTCTGAACACA
			of activated T-				CTATTATGTAT
			cells,				CCATCCAATCT
			cytoplasmic 2				CAACTGAATAA
			interacting				AGGGAGATGC
			protein				CTTTTG
376.	K0520805-3		transcribed	K0520B05	Mm.221547	Chromosome 14	AAAGAATTTCA
			sequence with				AGAACGAAGC
			weak similarity				ATAGGTGGTTA
			to protein				TGTAGTTTGAT
			pir:158401				TACAGAAAAG
			(M. musculus)				AGATGCC
			158401 protein
			tyrosine kinase
			(EC2.7.1.112)
			JAK3 - mouse
377.	K0315G05-3	Stat5a	signal	K0315G05	Mm.4697	Chromosome 11	AAACCACCTTC
			transducer and				AGTGTGAGGA
			activator of				GCCCACGTCAG
			transcription				TTGTAGTATCT
			5A				CTGTTCATACC
							AACAAT
378.	H3086F07-3	BC003332	cDNA sequence	H3086F07	Mm.100116	Chromosome 6	GCACTCCAGCC
			BC003332				TGATTCTTTGA
							GACTTTGGGGT
							ACACATATTGA
							AAGTACTTTGA
							ATTTG
379.	H3156A10-5	Ctsd	cathepsin D	H3156A10	Mm.231395	Chromosome 7	ACTGTATCGGT
							TCCATGTAAGT
							CTGACCAGTCA
							AAGGCAAGAG
							GTATCAAGGTG
							GAGAAA
380.	C0890D02-3		C0890D02-3	C0890D02		Chromosome 18	GTGTTTGAATT
			NIA Mouse				AAAACCCCCAC
			Blastocyst				CCTCGGAGGCC
			cDNA Library				TTTAAAGAAAT
			(Long) Mus				GGTTTTTGTCC
			musculus				GTTGT
			cDNA clone
			C0890D02 3′,
			MRNA
			sequence
381.	L0245G03-3	6430519N07Rik	RIKEN cDNA	L0245G03	Mm.149642	Chromosome 6	CTCTCGACAAA
			6430519N07				ATATAAATGGA
			gene				CAGTACCAAAC
							TAAGAGGGAT
							ATAAGTGGGA
							GCAAAGG
382.	J0447A10-3		Mus musculus	J0447A10	Mm.202311	Chromosome 11	TATGGTACGAG
			cDNA clone				TTTAGGGCTTA
			IMAGE:12820				GTCAGTTTACA
			81, partial cds				ATGGGGATTGA
							ATTTTGTGTCA
							AAACC
383.	J1031A09-3		Mus musculus	J1031A09	Mm.235234	No Chromosome	CTGGCTCCTAC
			transcribed			location	TGGCAACAGG
			sequence with			info available	CATACTTGTGG
			weak similarity				TTTAATACAGA
			to protein				GAAACAAAAC
			pir:158401				ATTCATA
			(M. musculus)
			158401 protein
			tyrosine kinase
			(EC2.7.1.112)
			JAK3 - mouse
384.	L0072H04-3	A630084M22Rik	RIKEN cDNA	L0072H04	Mm.27968	Chromosome 1	TTTGACCTAAT
			A630084M22				GAAATACCCAT
			gene				TTCATCTGTGA
							CAACACATAGC
							CCAGTAAACAT
							CACTG
385.	J0050E03-3		transcribed	J0050E03	Mm.37806	Chromosome 14	CCTGTTCCTAG
			sequence with				TATCCTGOCGT
			weak similarity				CCACATATACC
			to protein				CAAAGTTAGGC
			ref:NP_081764.1				ATACTAACCAA
			(M. musculus)				GAGAT
			RIKEN cDNA
			5730493B19
			[Mus musculus]
386.	H3039C11-3	Tyro3	TYRO3 protein	H3039C11	Mm.2901	Chromosome 2	CTGGAACTCAG
			tyrosine kinase				CACTGCCCACC
			3				ACACTTGGTCC
							GAAATGCCAG
							GTTTGCCCCTC
							TTAAGT
387.	C0324F11-3	6720458F09Rik	RIKEN cDNA	C0324F11		Chromosome 12	CCTGGAGGTCT
			6720458F09				CCACCTGAAGT
			gene				TCCCTGATGCA
							GGGTCAGTCCA
							GCCTTGGTAAG
							GGCCA
388.	L0018F11-3	AW547199	ESTs	L0018F11	Mm.182611	Chromosome 12	AAATGAGAAC
			AW547 199				CAGATTACCAA
							AATTACCACTA
							CCACCAAAATA
							ACCCCTCTGAT
							TCCTTG
389.	X69902.1	Itga6	integrin alpha 6	X69902	Mm.225096	Chromosome 2	CAGATAGATG
							ACAGCAGGAA
							ATTTTCTTTATT
							TCCTGAAAGAA
							AATACCAGACT
							CTCAAC
390.	H3105A09-3		transcribed	H3105A09	Mm.174047	No Chromosome	GGTGCCAAATG
			sequence with			location	CGGCCATGGTG
			weak similarity			info available	CTGAACAATTT
			to protein				ATCGTCAGAGG
			ref:NP_416488.1				GGAAGAACAG
			(E. coli)				TTGACC
			putative
			transport
			protein,
			shikimate
			[Escherichia
			coli K12].
391.	H3159F01-5		UNKNOWN	H3159F01	Data not found	No Chromosome	CCAAAACAGA
			H3159F01			location	GCCAACACCAC
						info available	CGACAACAAC
							CCCACAGCAA
							ACCCGGAGAG
							AAACCCAAA
392.	K0522B04-3	F5	coagulation	K0522B04	Mm.12900	Chromosome 1	TTTCAACCCGC
			factor V				CCATTATTTCC
							AGATTTATCCG
							CATCATTCCTA
							AAACATGGAA
							CCAGAG
393	C0123F08-3	A1843918	expressed	C0123F08	Mm.143742	Chromosome 5	TGGAGACTGA
			sequence				GTTCGACAATC
			A1843918				CCATCTACGAG
							ACTGGCGAAA
							CAAGAGAGTA
							TGAAGTTT
394	H3067G08-3	BG068642	ESTs	H3067008	Mm.250079	Chromosome 11	GATACAACAG
			BG068642				CATCTGTTTTC
							CAAGGAGAAA
							TCATTTGAGGA
							ACAAAACCTAT
							CAAGAGA
395.	K0349B03-3	Stam2	signal	K0349B03	Mm.45048	Chromosome 2	AACTAGAAAA
			transducing				CATAGATGCAC
			adaptor				AGGACTCGGAT
			molecule (SH3				CCATGATATTT
			domain and				ACACTGGGAA
			ITAM motif) 2				ATGTTCT
396.	C0620D11-3	Bid	BH3 interacting	C0620D11	Mm.34384	Chromosome 6	ATCTCAAGATT
			domain death				TCTATCCAAGT
			agonist				GGAAACAAAC
							TGAATCATGCA
							CACGACTTATC
							TGTGTG
397.	C0189H10-3	4930486L24Rik	RIKEN cDNA	C0189H10	Mm.19839	Chromosome 13	AGAGGAGCCA
			4930486L24				CACTTGATGTG
			gene				AATTAAACTCA
							TAAACATTATG
							CCACTAACAGC
							TTTTAT
398.	H3140A02-3	Slc9a1	solute carrier	H3140A02	Mm.4312	Chromosome 4	CTGCCGCCTGT
			family 9				ACAAAGGAAA
			(sodium/hydrogen				CTGAACCTTTT
			exchanger),				TCATATTCTAA
			member 1				TAAATCAATGT
							GAGTTT
399.	K0645B04-3	Smc411	SMC4	K0645B04	Mm.206841	Chromosome 3	AAGCTGAGATT
			structural				AAACGGCTAC
			maintenance of				ACAATACCATC
			chromosomes				ATAGATATCAA
			4-like 1 (yeast)				CAACCGAAAA
							CTCAAGG
400.	C0300008-3	6720460106Rik	RIKEN cDNA	C0300008	Mm.28865	Chromosome 4	GACTTGGGAA
			6720460106				AACAATGCAA
			gene				CTCCCATAAAC
							CAAAACTCCAA
							TTCCATGCCTA
							ACTTGCT
401.	M59378.1	Tnfrsf1b	tumor necrosis	M59378	Mm.2666	Chromosome 4	AGCAGGGAAC
			factor receptor				AATTTGAGTGC
			superfamily,				TGACCTATAAC
			member 1b				ACATTCCTAAA
							GGATGGGCAG
							TCCAGAA
402.	NM_009399.1	Tnfrsfl 1a	tumor necrosis	NM_009399	Mm.6251	Chromosome 1	AGCTCCAACTC
			factor receptor				AACAGATGGCT
			superfamily,				ACACAGGCAG
			member 11a				TGGGAACACTC
							CTGGGGAGGA
							CCATGAA
403.	C0168E12-3	2810442122Rik	RIKEN cDNA	C0168E12	Mm.103450	Chromosome 10	ACTAGCTGCAT
			2810442122				TGTAAAGAAA
			gene				CAAATCGAAA
							CTGAGTCTTTT
							CACATATTGTG
							ACGGACA
404.	L0228H10-3	CLr	complement	L0228H10	Mm.24276	Chromosome 6	GTAGGGTCATC
			component 1, r				ATACACCCAGA
			subComponent				CTACCGCCAAG
							ATGAACCTAAC
							AATTTTGAAGG
							AGACA
405.	H3088B10-3	BG070515	ESTs	H3088B10	Mm.11092	Chromosome 11	TCCCCACCACG
			BG070515				AATTATCGTGG
							CTAGTGGATGA
							AGGCCACTAAT
							ACAGGTTCAAA
							TTGTT
406.	K0409D10-3	Lrrc5	leucine-rich	K0409D10	Mm.23837	Chromosome 5	TATGTGCATAG
			repeat-				GCTGGAGTTTT
			containing 5				GGTTATACATG
							GTACACTTTTG
							GGCCAATATAA
							TAGGA
407.	H3056D02-3		transcribed	H3056D02	Mm.9706	Chromosome 12	CCACACTCCCT
			sequence with				GGAGACAATG
			moderate				TCTGCCATTTT
			similarity to				TGCATCACTTG
			protein				TCAAACCACTA
			ref:NP_079108.1				ACTTCT
			(H. sapiens)
			hypothetical
			protein
			FLJ22439
			[Homo sapiens]
408.	J0430F08-3	AU023357	ESTs	J0430F08	Mm.173615	Chromosome 6	TCGGTTGACCT
			AU023357				GATTCCACCAA
							GGAGAAGGAG
							ATCAAGGAAG
							AGTAAACTGTA
							AGAGCAT
409.	H3158C06-3	2810457106Rik	RIKEN cDNA	H3158C06	Mm.133615	Chromosome 9	GAGTGCTTTGA
			2810457106				TGGTTGTTAGG
			gene				GACCGTAAGA
							ATAGTCCTGTG
							TCAGACAGCA
							GATTCTA
410.	M85078.1	Csf2ra	colony	M85078	Mm.255931	Chromosome 19	AACTGTCATAA
			stimulating				AATCCAACGTG
			factor 2				CCTTCATGATC
			receptor, alpha,				AAAGTTCGATA
			low-affinity				GTCAGTAGTAC
			(granulocyte-				TAGAA
			macrophage)
411.	C0145E06-3	Satb1	special AT-rich	C0145E06	Mm.289605	Chromosome 5	ACTCTCATCTG
			sequence				TAAAGCCTTCC
			binding protein				CATCTCATTAT
			1				TCCTTGCACTA
							ACCACAGCCAC
							TAGGA
412.	H3015B08-3	BG064069	ESTs	H3015B08	Mm.197224	Chromosome 11	CAGACTGAAA
			BG064069				GGAAATTCCAA
							AGAAAACAAA
							AACCTTTCAAT
							CTATGAACTCA
							ATGGCTG
413.	C0842H05-3	Fbln1	fibulin 1	C0842H05	Mm.219663	Chromosome 15	CTGAGAATAAC
							CTACTACCACC
							TCTCTTTTCCC
							ACCAACATCCA
							AGTGCCAGCG
							GTGGTT
414.	G0117D07-3	Otx2	orthodenticle	G0117D07	Mm.134516	Chromosome 14	AGCGACATGC
			homolog 2				AACCAAATACC
			(Drosophila)				ACTCAAAACA
							AAAATCCAGC
							AAAACTGAGTT
							GTGAGGGA
415.	L0806E03-3	Stmn4	stathmin-like	4L0806E03	Mm.35474	Chromosome 14	GTTTGTACATG
							TAAAAGATTGA
							CCAGTGAAGCC
							ATCCTATTTGT
							TTCTGGGGAAC
							AATGA
416.	H3073B06-3	BG069137	ESTs	H3073B06	Mm.173781	Chromosome 3	ACTTAGACCAC
			BG069137				AACAGCATCTA
							AGCATCATTAC
							CTTAAGTACTA
							AAGCAAAAAT
							CTAGTC
417.	H3082G08-3	Myo10	myosin X	H3082G08	Mm.60590	Chromosome 15	TAAACCACTCT
							TAAACTGCTGG
							CTCCAGTGTTT
							TTAGAATGATA
							TGAAGTCATTT
							TGGAG
418.	C0141F07-3	C3arl	complement	C0141F07	Mm.2408	Chromosome 6	AGTAAGTGCCA
			component 3a				TTATCCACCCA
			receptor 1				ACTACCAACCA
							ATGCCTAAGCA
							GATTCTATATC
							TTAGC
419.	K0525G09-3	5830411120	hypothetical	K0525G09	Mm.31672	Chromosome 5	GCTTCTGGCAG
			protein				AGATCTGTTTA
			5830411120				GCATAGTGTGG
							TATTAATTATA
							GCAAATGTTAA
							GGTAG
420.	H3064D01-3		transcribed	H3064D01	Mm.250054	Chromosome 15	GTTGTCTGAAT
			sequence with				AATAGCACCCA
			weak similarity				AGAAAAAGTG
			to protein				TGGAGATCAGT
			ref:NP_001362.1				AGGTATTCATT
			(H. sapiens)				AAGCAT
			dynein,
			axonemal,
			heavy
			polypeptide 8
			[Homo sapiens]
421.	C0120F08-3	6330406L22Rik	RIKEN cDNA	C0120F08	Mm.5202	Chromosome 10	TAAAGGAGCTT
			6330406L22				TCCACATGAAC
			gene				TCACAATTTTC
							TTGAAATAAAC
							TTCTTAACCAA
							CTGCC
422.	H3105G04-3	Map4k4	mitogen-	H3105G04	Mm.987	Chromosome 1	GTCACTTGGAT
			activated				GGTGTATTTAT
			protein kinase				GCACAAAAGG
			kinase kinase				GCTCAGAGACT
			kinase 4				AAAGTTCCTGT
							GTGAAC
423.	J0800D09-3	2310004L02Rik	RIKEN cDNA	J0800D09	Mm.159956	Chromosome 7	GTCATGAACCC
			2310004L02				AATACACTGTG
			gene				GAAATGTGTGA
							TTCTTTATATT
							AAACGTCTGCT
							GTTCA
424.	L0226H02-3	5830411120	hypothetical	L0226H02	Mm.31672	Chromosome 5	TGTCGATACCA
			protein				TCTAAAGACCA
			5830411120				CAACTTCTAGC
							CATAGGGTATT
							TCATATATGTC
							CATTT
425.	L0529D10-3	BM123730	ESTs	L0529D10	Mm.221754	Chromosome 7	ATGCAAACCTA
			BM123730				AAAAGCACCC
							AAAAAATTCAC
							ATTGGACTGAA
							GAAGAGTGAT
							CCAAGCA
426.	H3088E05-3	Gla	galactosidase,	H3088E05	Mm.1114	Chromosome X	TTTGAGACCCT
			alpha				TTCATAAGCCC
							AATTATACAGA
							TATCCAATATT
							ACTGCAATCAT
							TGGAG
427.	K0621H11-3		K0621H11-3	K0621H11		Chromosome 13	ACCTAAATTTC
			NIA Mouse				CACAGGCAACT
			Hematopoictic				TACTTTGTTAT
			Stem Cell (Lin-				TAAATTTGGGG
			/c-Kit-/Sca-1+)				ATCATATCCTG
			cDNA Library				TGCCC
			(Long) Mus
			musculus
			cDNA clone
			NIA:K0621H11
			IMAGE:30070
			846 3′, MRNA
			sequence
428.	C0846H03-3	D330025I23Rik	RIKEN cDNA	C0846H03	Mm.260376	Chromosome 9	TTTTTTCAGAC
			D330025I23				TTAAGAACAGC
			gene				TAAACAAAAC
							CTTCCTCTAGC
							TTTTTCATCAC
							ATCCAG
429.	J0058E06-3	C78984	ESTs C78984	J0058E06	Mm.249886	Chromosome 17	ATAATGATGAT
							GATAACAACA
							AGAAAACAGA
							CTCGAACCTAA
							AGACGCTGGTC
							TCAGATA
430.	K0325E09-3	Ibsp	integrin binding	K0325E09	Mm.4987	Chromosome 5	CGCAAACATAC
			sialoprotein				CCTGTATAAGA
							AGGCTCCTAAC
							GAGAGATTTAT
							TAACAACACTA
							TATAT
431.	K0336F07-3	Pycs	pyrroline-5-	K0336F07	Mm.233117	Chromosome 19	TTTGACTGGGA
			carboxylate				CCAGCCCAGCC
			synthetase				ATTCTCAGCCT
			(glutamate				CTCGACATGTA
			gamma-				ATTTCATTTCT
			semialdehyde				TTTAC
			synthetase)
432.	H3013B04-3	B230106124Rik	RIKEN cDNA	H3013B04	Mm.24576	Chromosome 3	AGGACTCATAG
			B230106124				ACTTACAGAAT
			gene				GATGCCGAATG
							GAATGTTTTGT
							GCATGACCTTT
							TAACC
433	L0238A07-3	Midn	midnolin	L0238A07	Mm.143813	No Chromosome	CCACCTCGCCC
						location	AAGTCTCCTTT
						info available	TACTGAAATAA
							AATTTGAGGGG
							AAGAGAAAAA
							ATTTAC
434.	L0929C04-3	Tnfrsfl lb	tumor necrosis	L0929C04	Mm.15383	Chromosome 15: not	GATGTTCTTCT
			factor receptor			placed	GTAAAAGTTAC
			superfamily,				TAATATATCTG
			member 1 lb				TAAGACTATTA
			(osteoprotegerin)				CAGTATTGCTA
							TTTAT
435.	L0020F05-3	6330583M11Rik	RIKEN cDNA	L0020F05	Mm.23572	Chromosome 2	CTTAAGATTCA
			6330583M11				GGAAAATGGTT
			gene				CTTTCTGCCCT
							TCCTAGCGTTT
							ACAGAACAGA
							CTCCGA
436.	H3012H07-3	Cd44	CD44 antigen	H3012H07	Mm.24138	Chromosome 2	TATATTGACAT
							CCATAACACCA
							AAAACTGTCTT
							TTTAGCTAAAA
							TCGACCCAAGA
							CTGTC
437.	K0240E11-3	Myo5a	myosin Va	K0240E11	Mm.3645	Chromosome 9	TCTTTAGTGCT
							GCATTTAAGTG
							GCATACAAAAT
							ACAATCCCATA
							TGTATGAACTG
							TTGTG
438.	K0401C06-3	Col8a1	procollagen,	K0401C06	Mm.86813	Chromosome 16	AATCTATGCCA
			type VIII, alpha				GATACTGTATA
			1				TTCTACCATGG
							TGCTAATATCA
							GAGCTAAATG
							ATACTC
439.	C0917F02-3	Frzb	frizzled-related	C0917F02	Mm.136022	Chromosome 2	AATTTACACAT
			protein				GTGGTAGTAGT
							AGGTCCAGATT
							CCTAAGTTACA
							GTGTGCTGAAA
							AATAA
440.	H3104C03-3	1500015O10Rik	RIKEN cDNA	H3104C03	Mm.11819	Chromosome 1	ATGAGGCTAA
			1500015O10				ATTTGAAGATG
			gene				ATGTCAACTAT
							TGGCTAAACAG
							AAATCGAAAC
							GGCCATG
441.	K0438D09-3	Col8al	procollagen,	K0438D09	Mm.86813	Chromosome 16	TCTACTACTTT
			type VIII, alpha				GCTTATCATGT
			1				TCACTGCAAGG
							GAGGCAACGT
							ATGGGTTGCTC
							TCTTCA
442.	H3152C04-3	Usp16	ubiquitin	H3152C04	Mm.196253	Chromosome 16	GTACTGAACTC
			specific				ACAAGCGTATC
			protease 16				TCCTATTTTAT
							GAGAGAATAC
							TGTGATAACAA
							AAAGTG
443.	H3079D12-3	Pld3	phospholipase	H3079D12	Mm.6483	Chromosome 7	TTGGCCCACCC
			D3				CCAAAGGGCC
							AAGATTATAAG
							TAAATAATTGT
							CTGTATAGCCT
							GTGCTT
444.	L0020E08-3	Clqg	complement	L0020E08	Mm.3453	Chromosome 4	CTGGGAACCAC
			component 1, q				CTAATGGTATT
			subcomponent,				ATTCCTGTGGC
			gamma				CATTTATCAAT
			polypeptide				ACCTTATGAGA
							CTATT
445.	J0025G01-3	Yars	tyrosyl-tRNA	J0025G01	Mm.22929	Chromosome 4	TCCTCTGGGGT
			synthetase				AAATGAGCTTG
							ACCTTGTGCAA
							ATGGAGAGAC
							CAAAAGCCTCT
							GATTTT
446.	L0832H09-3	Mafb	v-maf	L0832H09	Mm.233891	Chromosome 2	GCCGCAACGC
			musculoaponeu				AACAGAAATT
			rotic				GTTTTTAATTT
			fibrosarcoma				CATGTAAAATA
			oncogene				AGGGATCAATT
			family, protein				TCAACCC
			B (avian)
447.	C0451C02-3	2700094L05Rik	RIKEN cDNA	C0451C02	Mm.25941	No Chromosome	ACTTTTGGGTC
			2700094L05			location	TTTAGAACTGA
			gene			info available	GCCCACCTACT
							GAGTCTCAGTT
							TCTGTTGGTGT
							GACCT
448.	H3063A08-3	Lgmn	legumain	H3063A08	Mm.17185	Chromosome 12	TGCTTACTAAG
							AAGCCAGTTTG
							GGTGGGTAAA
							GCTCTCTGGAA
							GAAGGAACTTT
							GCTTCT
449.	K0629D05-3	Evi2a	ecotropic viral	K0629D05	Mm.3266	Chromosome 11	TCCCAATGTGT
			integration site				AGAATTCAACT
			2a				ATGTAACGCAA
							TGGTACATTCT
							CACTGGATGAG
							ATAGA
450.	G0111D11-3	Cts1	cathepsin L	G0111D11	Mm.930	Chromosome 13	CTTATGGACAC
							TATGTCCAAAG
							GAATTCAGCTT
							AAAACTGACC
							AAACCCTTATT
							GAGTCA
451.	H3077D05-3	Npc2	Niemann Pick	H3077D05	Mm.29454	Chromosome 12	GCCATATGATG
			type C2				AACAGAATTTC
							AAGAATGCTGT
							TTTATGCCTTT
							TAACCTCCAAA
							GCAGT
452.	G0104C04-3	Dab2	disabled	G0104C04	Mm.288252	Chromosome 15	TCATTTTCCTG
			homolog 2				TCTAGGCTAAA
			(Drosophila)				GCTAAACTTAA
							ACTATGGCTTT
							ACGTAAATTAA
							GCTCC
453.	L0502D10-3	Plala	phospholipase	L0502D10	Mm.24223	Chromosome 16	CAACATCTAAC
			A1 member A				GCTTTACATAA
							ATGCCCTTTTA
							GCTTCTCTATT
							TCGACACAACT
							GTGAT
454.	H3126B08-3	Pla2g7	phospholipase	H3126B08	Mm.9277	Chromosome 17	TTACCCAAATA
			A2, group VII				AGCATTTTTTA
			(platelet-				AATATACCCTG
			activating factor				TACTGTAGGAT
			acetylhydrolase,				AGTGATGAAC
			plasma)				GCCTAG
455.	J0034A07-3	Creg	cellular	J0034A07	Mm.459	Chromosome 1	ATAAGCCGTAT
			repressor of				CTGGGTCTTGG
			EIA-stimulated				ACTACTTTGGT
			genes				GGACCTAAAGT
							AGTGACACCTG
							AAGAA
456.	H3114B07-3	Slcl2a4	solute carrier	H3114B07	Mm.4190	Chromosome 8	AAGTGGAATG
			family 12,				GAGCCGGCCA
			member 4				AGCTGAGCCTG
							ACTTTTTTCAA
							TAAAACATTGT
							GTACTTC
457.	K0339H12-3	Thbs1	thrombospondin	K0339H12	Mm.4159	Chromosome 2	CTTAAAACTAC
			1				TGTTGTGTCTA
							AAAAGTCGGT
							GTTGTACATAG
							CATAAAAATCC
							TTTGCC
458.	H3028C09-3	Adk	adenosine	H3028C09	Mm.19352	Chromosome 14	CAGCTGCCTAA
			kinase				CCCGCAACATT
							TGCATTATGTT
							CAGACTGTAAC
							CTGCTTACTGA
							TGGTA
459.	L0277B06-3	Psap	prosaposin	L0277B06	Mm.233010	Chromosome 10	CTGTGGTACCA
							AGGAGTTATTT
							TGGATGATTAG
							AAGCACAGAA
							TGATCAGGCCT
							TTAGAG
460.	H3013F05-3	Sdc1	syndecan 1	H3013F05	Mm.2580	Chromosome Multiple	TTGTTTTTGTTT
						Mappings	TTAACCTAGAA
							GAACCAAATCT
							GGACGCCAAA
							ACGTAGGCTTA
							GTTTG
461.	H3084A06-3	Spin	spindlin	H3084A06	Mm.42193	Chromosome 13	TGCCTGAAAAC
							ACTTAACACTG
							ATTGTCTAAGA
							GATGAAAGTCC
							TCCAAAGATGA
							CACAG
462.	H3077F04-3	Osbpl8	oxysterol	H3077F04	Mm.134712	Chromosome 10	ACTTCAGTTAA
			binding protein-				TGGGTTTATAA
			like 8				AGTCAAGCACT
							GGCATTGGTCA
							GTTTTGTATGA
							TAGGA
463.	K0324A06-3	Itgal 1	integrin, alpha	K0324A06	Mm.34883	Chromosome 9	TCCCCTATGCG
			11				GTACGACCTTT
							ACTGTCAGAAA
							TATATTTAAGA
							AAATGTTCTAA
							ACGGT
464.	C0115E05-3	2010110K16Rik	RIKEN cDNA	C0115E05	Mm.9953	Chromosome 9	GATCCAGCCTT
			2010110K16				CTATGAAGAAT
			gene				GCAAACTGGA
							GTATCTCAAGG
							AAAGGGAAGA
							ATTCAGA
465.	C0668G11-3	Fabp5	fatty acid	C0668G11	Mm.741	Chromosome Multiple	CATGACTGTTG
			binding protein			Mappings	AGTTCTCTTTA
			5, epidermal				TCACAAACACT
							TTACATGGACC
							TTCATGTCAAA
							CTTGG
466.	L0030A03-3	Alox5ap	arachidonate 5-	L0030A03	Mm.19844	Chromosome 5	CTTGTAATCAG
			lipoxygenase				ACACGTGTTTT
			activating				CCTAAAATAAA
			protein				GGGTATAGAC
							AAAATTTAAGC
							CCATGG
467.	H3009E1 1-3	Socs3	suppressor of	H3009E11	Mm.3468	Chromosome 11	TGTCTGAAGAT
			cytokine				GCTTGAAAAAC
			signaling 3				TCAACCAAATC
							CCAGTTCAACT
							CAGACTTTGCA
							CATAT
468.	L0010B01-3	Abcal	ATP-binding	L0010B01	Mm.369	Chromosome 4	TACTCCCATTA
			cassette, sub-				CTATTTGCTGG
			family A				TAATAGTGTAA
			(ABC1),				CGCCACAGTAA
			member 1				TACTGTTCTGA
							TTCAA
469.	G0116C07-3	Ctsb	cathepsin B	G0116C07	Mm.22753	Chromosome 14	CAGCCGATGCT
							TTTTCAATAGG
							ATTTTTATGCT
							TTGTGTACCTC
							AACCAAGTATG
							AAGAG
470.	K0426E09-3	Eps8	epidermal	K0426E09	Mm.2012	Chromosome 6	GGGACACTTAA
			growth factor				TTTACATGTAC
			receptor				TTTAACCCCAT
			pathway				GAAAGAGTCT
			substrate 8				AGATAGAGAG
							AAGACAC
471.	H3102F08-3	AsahI	N-	H3102F08	Mm.22547	Chromosome 8	GCCTGCCAGTA
			acylsphingosine				ACCCCAGGAA
			amidohydrolase				GAGTCTAGCTT
			1				CAAAAACCCA
							CAAACTCATTA
							TTTTTAA
472.	L0825G08-3	Dcamk11	double cortin	L0825G08	Mm.39298	Chromosome 3	AATCTAGATGT
			and				TAGAAATCAAT
			calcium/calmod				GTGTATGATGT
			ulin-dependent				ATTGTATTTAG
			protein kinase-				ACCATACCCGT
			like 1				GACCG
473.	K0306B10-3	Fgf7	fibroblast	K0306B10	Mm.57177	Chromosome 2	ACGATGAGCA
			growth factor 7				GTGTTTGAAAG
							CTTTCCAGTGA
							GAACTATAATC
							CGGAAAAATG
							AATGTTT
474.	H3127F04-3	Chst11	carbohydrate	H3127F04	Mm.41333	Chromosome 10	GATGCGTGAA
			sulfotransferase				ATGTTCCTCCA
			11				GGAAAAGCCA
							TTCAAGCCTGA
							TTATTTTTCTA
							AGTAACT
475.	L0208A08-3	1200013B22Rik	RIKEN cDNA	L0208A08	Mm.100666	Chromosome 1	CATCTTAGATC
			1200013B22				TCAGAGACTTG
			gene				AACCTTGAAGC
							TGTTCCTAGTA
							CCCAGATGTGG
							ATGGA
476.	H3026G09-3	Col2a1	procollagen,	H3026G09	Mm.2423	Chromosome 15	CGTGTCCTACA
			type 11, alpha 1				CAATGGTGCTA
							TTCTGTGTCAA
							ACACCTCTGTA
							TTTTTTAAAAC
							ATCAA
477	C0218D02-3	Madh1	MAD homolog	C0218D02	Mm.15185	Chromosome 8	AAGGAGCCAC
			1 (Drosophila)				GATAATACTTG
							ACCTCTGTGAC
							CAACTATTGGA
							TTGAGAAACTG
							ACAAGC
478.	J1031F04-3	Dfna5h	deafness,	J1031F04	Mm.20458	No Chromosome	GTTTATAGGTA
			autosomal			location	GACCTAAGAG
			dominant 5			info available	ATAAAACTGCA
			homolog				GGGTATCACAT
			(human)				TAACGTTGGTT
							AAAAGA
479.	L0276A08-3	Rail4	retinoic acid	L0276A08	Mm.26786	Chromosome 15	AAACTTGAGAC
			induced 14				ATTTTGTAGGA
							CGCCTGACAAA
							GCGTAGCCTTT
							TTCTTGTGTCA
							GGATG
480.	C0508H08-3	Sptlc2	serine	C0508H08	Mm.565	Chromosome 12	CTCATACCAAA
			palmitoyltransf				GAAATACTTGA
			erase, long				CACTGCTTTGA
			chain base				AGGAGATAGA
			subunit 2				TGAAGTTGGGG
							ATCTGC
481.	J0042D09-3	C78076	ESTs C78076	J0042D09	Mm.290404	Chromosome 12	AAATCCAGCCT
							TTAAAAGCTCA
							GTTTCTTCCTC
							TAAGTGAATGT
							CATTACTCTGG
							TATAC
482.	J0013B06-3	Akrlb8	aldo-keto	J0013B06	Mm.5378	Chromosome 6	ACCAGGAACTC
			reductase				TGGTAACATTT
			family 1,				GAGGGCATGC
			member B8				AGATAAAATA
							ATAAAGAATG
							AGAACATT
483.	H3158D11-3	Mmp2	matrix	H3158D11	Mm.29564	Chromosome 8	TCAACATCTAT
			metalloproteinase				GACCTTTTTAT
			2				GGTTTCAGCAC
							TCTCAGAGTTA
							ATAGAGACTG
							GCTTAG
484.	H3001D04-3	Hist2h3c2	histone 2, H3c2	H3001D04	Mm.261624	Chromosome 13	GACCGAGAGC
							CACCACAAGG
							CCAAGGGAAA
							ATAAGACCAG
							CCGTTCACTCA
							CCCGAAAAG
485.	C0664G04-3	Ppicap	peptidylprolyl	C0664G04	Mm.3152	Chromosome 11	TTCTACCTCAC
			isomerase C-				TAACTCCACTG
			associated				ACATGGTGTAA
			protein				ATGGTACATCT
							CAGTGGTGGTG
							ATGCA
486.	H3091E10-3	Nupr1	nuclear protein	H3091E10	Mm.18742	Chromosome 7	TTGGAGAAATT
			1				AGGAGTTGTAA
							GCAGGACCTA
							GGCCTGCTTGA
							TTCTTTCCCAC
							CTAAGT
487.	X98792.1	Ptgs2	prostaglandin-	X98792	Mm.3137	Chromosome 1	TTATTGAAAAG
			endoperoxide				TTTGAAGTTAG
			synthase 2				AACTTAGGCTG
							TTGGAATTTAC
							GCATAAAGCA
							GACTGC
488.	L0908B12-3	Ptpn1	protein tyrosine	L0908B12	Mm.227260	Chromosome 2	CACCATTTCCA
			phosphatase,				ACTTGCTGTCT
			non-receptor				CACTAATGGGT
			type 1				CTGCATTAGTT
							GCAACAATAA
							ATGTTT
489.	H3081D02-3	Bok	Bcl-2-related	H3081D02	Mm.3295	Chromosome 1	AACAAGAGAT
			ovarian killer				CCTGTGGATGA
			protein				GGGGGTCTGTA
							TAAGTTATACT
							CCAATAAAGCT
							TTACCT
490.	C0127E12-3	Cln5	ceroid-	C0127E12	Mm.38783	No Chromosome	TTTTGACCAGT
			lipofuscinosis,			location	TGAACCCATTT
			neuronal 5			info available	TGTTTTCCTAG
							CGAACACTAGC
							ATAATATTGGA
							AAAGC
491.	K0310G10-3	Col5a2	procollagen,	K0310G10	Mm.257899	Chromosome 1	GTGAGGATTGG
			type V, alpha 2				AATTAGAACAT
							TCATAAGAAA
							ATATGACCCAA
							CATTTCTTAGC
							ATGACC
492.	H3023H09-3	Ftl 1	ferritin light	H3023H09	Mm.7500	Chromosome 7	CGCCCTGGAGC
			chain 1				CTCTGTCAAGT
							CTTGGACCAAG
							TAAAAATAAA
							GCTTTTTGAGA
							CAGCAA
493.	G0104B11-3	Slc7a7	solute carrier	G0104B11	Mm.142455	Chromosome 14	AAGATGGAGA
			family 7				GTTGTCCAAAC
			(cationic amino				AAGATCCCAA
			acid transporter,				GTCTAAATAGA
			y+ system),				GCAAGGGATTC
			member 7				TGAGGTG
494.	C0123F05-3	B4galt5	UDP-	C0123F05	Mm.200886	Chromosome 2	GTTTTAAAAGG
			Gal:betaGlcNAc				TGCCAGGGGTA
			beta 1,4-				CATTTTTGCAC
			galactosyltrans-				TGAAACCTAAA
			ferase,				GATGTTTTAAA
			polypeptide 5				AACAC
495.	H3082D01-3	1801105C04Rik	RIKEN cDNA	H3082D01	Mm.25311	Chromosome 15	TCTGAGGTATT
			1810015C04				AAAATATCTAG
			gene				ACTGAATTTTG
							CCAAATGTAAG
							AGGGAGAAAG
							TTCCTG
496.	C0121E07-3	AW539579	EST	C0121E07	Mm.282049	No Chromosome	AAGTATTGCTA
			AW539579			location	GACTGAAACC
						info available	ACTTGAACTTC
							TCAGAGAGGTT
							AGACTGACAG
							AAGGTGT
497	H3153H08-3	Hs6st2	heparan sulfate	H3153H08	Mm.41264	Chromosome X	ACATTTTTGTC
			6-O-				ATCATCATGTA
			sulfotransferase				AATCCCACGAT
			2				TTCAAACTGTA
							AACATCTGTTC
							AGTGG
498.	J0238C08-3	4930579A11Rik	RIKEN cDNA	J0238C08	Mm.24584	Chromosome 11	CTGGGGAAATT
			4930579A11				GATCTTTAAAT
			gene				TTTGAAACAGT
							ATAAGGAAAA
							TCTGGTTGGTG
							TCTCAC
499	L0942B10-3	Msr2	macrophage	L0942B10	Mm.45173	Chromosome 3	AGGACTCAAA
			scavenger				ACTATATTAAT
			receptor 2				CTGCTCTGAGA
							TAATGTTCCAA
							AAGCTCCAAA
							GAAAGCC
500.	J0915B05-3	Cdcal	cell division	J0915B05	Mm.151315	Chromosome 1	GCTCCAACATG
			cycle associated				CCATGTATTGT
			1				ATAGACTTTTA
							CTACAATTCAA
							ATAACGTGTAC
							AGCTT
501.	H3058B09-3	Lypla3	lysophospholipase	H3058B09	Mm.25492	Chromosome 8	CAGCTGAATGG
			3				GTTTTGGTTTG
							CAGGAAAACA
							GTCCAGAGCTT
							TGAAAAGGCTC
							CTAAGA
502.	C0197E01-3	D630023B12	hypothetical	C0197E01	Mm.227732	Chromosome 3	TGTTTTTATTG
			protein				TGTTTGGTGGA
			D630023B12				GAAGAATAAT
							ACACTTCTTGC
							CTAAATCCAGA
							AGCCCC
503.	J0802G04-3	0610011104Rik	RIKEN cDNA	J0802004	Mm.27061	Chromosome 6	TCCAGTTCCCG
			0610011104				AAGAAGCTGA
			gene				TAGGAATTGCC
							CTTGTGCATAT
							ACTACACAAGC
							ATGCTA
504.	H3039E08-3	Sh3d3	SH3 domain	H3039E08	Mm.4165	Chromosome 19	CATAAAGACAT
			protein 3				AGTGGAGGTTC
							TGTTTACTCAG
							CCGAATGTGGA
							GCTGAACCAGC
							AGAAT
505.	L0210A08-3	B130023014Rik	RIKEN cDNA	L0210A08	Mm.27098	Chromosome 5	GGATTCGGCTC
			B130023014				GATGAATGAA
			gene				GCACTTTATGG
							ACTGCGGGGAT
							CAGTTACTGCC
							ACACCC
506.	H3114C10-3	Ppgb	protective	H3114C10	Mm.7046	Chromosome 2	TGCTTTTACCA
			protein for beta-				TGTTCTCGAGG
			galactosidase				TTCCTGAACAA
							AGAGCCTTACT
							GATAGTTCCGC
							TGCAA
507.	C0322A01-3	2810441C07Rik	RIKEN cDNA	C0322A01	Mm.29329	Chromosome 4	TGAAGCAAAA
			2810441C07				AACATAAAAC
			gene				CTCACCACTGC
							CTGCTGAACCT
							AGAACCTTTTG
							TTGGGGC
508.	L0256F11-3	Adfp	adipose	L0256F11	Mm.381	Chromosome 4	GAATCCTTAGA
			differentiation				TGAAGTTATGG
			related protein				ATTACTTTGTT
							AACAACACGC
							CTCTCAACTGG
							CTGGTA
509.	L0939H06-3	Mgat5	mannoside	L0939H06	Mm.38399	Chromosome 1	GATATTAGTAG
			acetylglucosami				TATATCATAAA
			nyltransferase 5				ACTTGAGAAAT
							AAAGATGCGCT
							CACCCCCTATC
							TGTTG
510.	C0503B05-3	Dcanikl1	double cortin	C0503B05	Mm.39298	Chromosome 3	TGTGATAAAGT
			and				TGTGACATACG
			calcium/calmod				TATTAGTTGGC
			ulin-dependent				ACATATTTAAG
			protein kinase-				CTCCAAATCAG
			like 1				TTTGC
511.	H3136H11-3	Map4k5	mitogen-	H3136H11	Mm.260244	Chromosome 12	TAAAAGTTAAA
			activated				GTAAGCGAAG
			protein kinase				AAAGGAAGCT
			kinase kinase				GTATCTACACT
			kinase 5				GCTTTCCAGTT
							TAATCAG
512.	K0349A04-3	Fnl	fibronectin 1	K0349A04	Mm.193099	Chromosome 1	GGAGATTTTTC
							TCTTCAGGGTG
							TCTACATACCT
							TACACACACTT
							GTGTCTTAATA
							AGCAA
513.	C0177C04-3	Ctsz	cathepsin Z	C0177C04	Mm.156919	Chromosome 2	AATCCATGGGA
							GGGGGGAACA
							AGTCCAGACTG
							CTTAAGAAATG
							AGTAAAATATC
							TGGCTT
514.	C0668D08-3	Grn	granulin	C0668D08	Mm.1568	Chromosome 11	AATGTGGAGTG
							TGGAGAAGGG
							CATTTCTGCCA
							TGATAACCAGA
							CCTGTTGTAAA
							GACAGT
515.	C0106D12-3	Anxal	annexin A1	C0106D12	Mm.14860	Chromosome 19	TGACATGAATG
							ATTTTACCAGA
							AGAAGTATGG
							AATCTCTCTTT
							GCCAAGC
516.	H3078E09-3	Hexb	hexosaminidase	H3078E09	Mm.27816	Chromosome 13	ACTGGATACTG
			B				TAACTATGAGA
							ATAAAATATAG
							AAGTGACAGA
							CGTCTACAGCA
							TTCCAG
517.	L0033F05-3	2810442122Rik	RIKEN cDNA	L0033F05	Mm.275696	Chromosome 10	ATACAAGCAA
			2810442122				GCTGTTAAAGA
			gene				TCTTGGATCCC
							ATTCTATAGTG
							TGTATACCTAA
							ATCAAC
518.	K0144G04-3	Ifi203	interferon	K0144G04	Mm.245007	Chromosome 1 not	AGCATCAACTG
			activated gene			placed	TCCTGTCAAGC
			203				ACAAAAAATG
							AAGAAGAAAA
							TAATTACCCAA
							AAGATGG
519.	H3144E05-3	4933426M11Rik	RIKEN cDNA	H3144E05	Mm.27112	Chromosome 12	CCTCTGTTCTG
			4933426M11				AGGAACATTCT
			gene				AGCATAGAAA
							ATGGAATATGC
							TGCAAACATTT
							CTAGAT
520.	K0336D02-3	Ifi16	interferon,	K0336D02	Mm.212870	Chromosome 1	GTGTAGAAGCC
			gamma-				TATTGAAATAT
			inducible				CAGTCCTATAA
			protein 16				AGACCATCTCT
							TAATTCTAGGA
							AATGG
521.	H3004B12-3	Hpn	hepsin	H3004B12	Mm.19182	Chromosome 7	CTGATCCCGCC
							TCATCTCGCTG
							CTCCGTGCTGC
							CCTAGCATCCA
							AAGTCAAAGTT
							GGTTT
522.	K0617G07-3	Atp6vlb2	ATPase, H+	K0617G07	Mm.10727	Chromosome 8	TGTAGAAAATG
			transporting,				TGGCCTCTCGT
			V1 subunit B,				TATAAATGAAA
			isofonn 2				ATAAATGTTTA
							ATTTAATGGGA
							GTTTC
523.	L0849B10-3	Pltp	phospholipid	L0849B10	Mm.6105	Chromosome 2	GGTGCCACAG
			transfer protein				AGAAGAGCCC
							AGTTGGAAGCT
							ATACCCGATTT
							AATTCCAGAAT
							TAGTCAA
524.	L0019H03-3	Fnl	fibronectin 1	L0019H03	Mm.193099	Chromosome 1	CAGTGTTGTTT
							AAGAGAATCA
							AAAGTTCTTAT
							GGTTTGGTCTG
							GGATCAATAG
							GGAAACA
525.	J0099E12-3	Slc6a6	solute carrier	J0099E12	Mm.200518	Chromosome 6	ATAACTATATA
			family 6				TACTTAGAGTC
			(neurotransmitter				TGTCATACACT
			transporter,				TTGCCACTTGA
			taurine),				ATTGGTCTTGC
			member 6				CAGCA
526.	J0023G04-3	BC004044	cDNA sequence	J0023G04	Mm.6419	Chromosome 5	CCTTGGGACAT
			BC004044				TTTTGTGGAGT
							AGTTTGCAGTG
							AGATAACAGT
							GCAATAAAGA
							TACAGCA
527.	C0913D04-3	4933433D23Rik	RIKEN cDNA	C0913D04	Mm.46067	Chromosome 14	TCTATACCTGG
			4933433D23				ATAAAAAGAA
			gene				ACCTACACTTC
							ACTGTAAAACT
							TCATGTTTCAA
							GGCAAG
528.	H3020C02-3	Mt1	metallothionein	H3020C02	Mm.192991	Chromosome 8	CCTGTTTACTA
			1				AACCCCCGTTT
							TCTACCGAGTA
							CGTGAATAATA
							AAAGCCTGTTT
							GAGTC
529.	C0217B11-3	Sema4d	sema domain,	C0217B11	Mm.33903	Chromosome 13	ACCGTGTAGAC
			immunoglobulin				ACTCATATTTT
			domain (Ig),				GCATGACATGA
			transmembrane				TCTACCATTCG
			domain (TM)				GTGTAAACATT
			and short				TGTGT
			cytoplasmic
			domain,
			(semaphorin)
			4D
530.	C0917E01-3	Bhlhb2	basic helix-	C0917E01	Mm.2436	Chromosome 6	GCCAAAGGAA
			loop-helix				AATGTTTCAGA
			domain				TGTCTATTGT
			containing,				ATAATTACTTG
			class B2				ATCTACCCAGT
							GAGGAA
531.	H3132B12-5	Deafi	deformed	H3132B12	Mm.28392	Chromosome 7	TCCAGAAGCTG
			epidermal				CATTGCCAACA
			autoregulatoiy				TCACACCCCAA
			factor 1				AATTGTCCTGA
			(Drosophila)				CATCGCTGCCC
							GCATT
532.	L0270C04-3	Mppl	membrane	L0270C04	Mm.2814	Chromosome X	AAGGACTCTGA
			protein,				GGCCATCCGTA
			palmitoylated				GTCAGTATGCT
							CATTACTTTGA
							CCTCTCTTTGG
							TGAAT
533.	J0709H10-3		transcribed	J0709H10	Mm.296913	Chromosome 13	ATCTCCCAAGG
			sequence with				CAAAGAACTG
			moderate				AAACTCAGAG
			similarity to				CTGTCTGGATT
			protein				GAAGAAATGT
			pir:A38712				GTGTTGTT
			(H. sapiens)
			A38712
			fibrillarin
			[validated]-
			human
534.	C0166A10-3	Car2	carbonic	C0166A10	Mm.1186	Chromosome 3	ATGAAGGTAG
			anhydrase 2				GATAATTAATT
							ACAAGTCCACA
							TCATGAGACAA
							ACTGAAGTAAC
							TTAGGC
535.	L0511A03-3	BM122519	ESTs	L0511A03	Mm.296074	Chromosome 1	GGTGTAGCCAT
			BM122519				ACAATACACA
							AATACAATAG
							ATATTCTCTCT
							ACAATCTTTAT
							GGTGTGG
536.	H3029F09-3	Atp6v1e1	ATPase, H+	H3029F09	Mm.29045	Chromosome 6	GGAGAAGCAG
			transporting,				ATTATCTGTGT
			VI subunit E				GGCTTCCTCTT
			isoform 1				TCTGTTCTAAT
							ACTGGTAATCA
							GTGGAC
537.	J0716H11-3	Kdtl	kidney cell line	J0716H11	Mm.1314	Chromosome 6	GTGAACACCA
			derived				GAATTTAATTT
			transcript 1				CCATACTTGTA
							CAGGTAGGACT
							ATTCTTCAGCT
							CTCTAC
538.	C0102C01-3	Acp5	acid	C0102C01	Mm.46354	Chromosome 9	GGCTTCACACA
			phosphatase 5,				TGTGGAGATAA
			tartrate resistant				GCCCCAAAGA
							AATGACCATCA
							TATATGTGGAA
							GCCTCT
539.	C0641C07-3	Pdgfb	platelet derived	C0641C07	Mm.144089	Chromosome 15	GTTTGTAAAGT
			growth factor,				TGGTGATTATA
			B polypeptide				TTTTTTGGGGG
							CTTTCTTT-
							TTAT
							TTTTTAAATGT
							AAAG
540.	C0147C09-3	Tct7	tetratricopeptide	C0147C09	Mm.77396	Chromosome 17	ATGGAATTCTG
			repeat domain				TTAGAGTAAAA
			7				AAGAGAAAAG
							CAGATACTATT
							GGCTGGCCTTG
							GAGGTC
541.	K0301G02-3	94300025M21Rik	RIKEN cDNA	K0301G02	Mm.87452	Chromosome 1	AATAGTGCTGA
			9430025M21				ATTTGTCTAAA
			gene				CAGAATTGAG
							AGGTCATAGA
							AATCCTTAACA
							GGGTAAC
542.	H3002D05-3	Tpbpb	trophoblast	H3022E05	Mm.297991	Chromosome 13	TATGAAGATTT
			specific protein				GGGAAAGAAC
			beta				AGCTATCTGAC
							ACCTGGAAGG
							CTCAGCCAGAG
							TAACAGT
543.	H3007C09	Sh3bgr13	SH3 domain	H3007C09	Mm.22240	Chromosome 4	GAGGCAACATT
			binding				CCTTATTCACC
			glutamic acid-				AACTAGTCTCA
			rich protein-like				AAAGATTGTCT
			3				TAAGCCCTGAC
							GATGG
544.	L0820G02-3	Igsf4	immunoglobulin	L0820G02	Mm.248549	Chromosome 9	TAATGAAGGAT
			superfamily,				GTATAATTGAT
			member 4				GCCAAATAAG
							CTTGTTCTTTA
							GTCACGATGAC
							GTCTTG
545.	C0120H11-3	4933433D23Rik	RIKEN cDNA	C0120H11	Mm.46067	Chromosome 14	CAGTTTGCGAA
			4933433D23				GTAGAATTTTG
			gene				TTTCTAAAAGT
							AAAAGCTAAG
							TTGAAGTCCTC
							ACGAG
546.	J1016E08-3	1810046J19Rik	RIKEN cDNA	J1016E08	Mm.259614	Chromosome 11	TAGAAAAGAT
			1810046J19				CACCAACAGCC
			gene				GGCCTCCCTGT
							GTCATCCTGTG
							ACTAAGAAAT
							GATTCTT
547.	L0822D10-3	Prkcb	protein kinase	L0822D10	Mm.4182	Chromosome 7	TATCTAAGAGC
			C, beta				CAAGTCTATGG
							CATTAGCTGTG
							AGAAGTAGTTA
							CCACTGTAATT
							CACCT
548.	H3050H09-3	Ppp2r5c	protein	H3050H09	Mm.36389	Chromosome 12	AAATTATCACT
			phosphatase 2,				TGATACGGA
			regulatory				GGAACATGACT
			subunit B				AGGCACATTTT
			(B56), gamma				ATGAATACTCC
			isoform				AAATCC
549.	J0442H09-3		Mus musculus	J0442H09	Mm.11982	Chromosome 10	AACTATGGTG
			hypothetical				GTATATTTTTG
			LOC237436				AACACAGGTTA
			(LOC237436),				ACTGTGGAGGT
			mRNA				TATCTGCTAAT
							AGCAA
550.	H3141E06-3	Sra1	steroid receptor	H3151E06	Mm.29058	Chromosome 18	ACCTCTGGAAC
			RNA activator				AGGCATTGGA
			1				GGACTGCCATG
							GTCACACAAA
							GAAACAGAAC
							TTTTACAT
551.	C0171H06-3	Adss2	adenylosuccinate	C0170H06	Mm.132946	Chromosome 1	CCAGTATACCT
			synthetase 2,				ACAAAATGAC
			non muscle				CCACAAGTAAC
							CCGCATGAGTC
							CAAGTTGTCAG
							CCATAT
552.	K0344C08-3	Emp1	epithelial	K0344C08	Mm.30024	Chromosome 6	GTAAAGGGAC
			membrane				CATTACTAAGT
			protein 1				GTATTTCTCTA
							GCATATTATGT
							TTAAGGGACTG
							TTCAAG
553.	J0907F03-3	Npl	N-	J0907F03	Mm.24887	Chromosome 1	CTCTAAGTCAT
			acetylneuraminate				TCATTTTGTAA
			pyruvatelyase				AATTATTATAG
							AGAAATCTCTA
							CTTATACAGAT
							GCAAT
554.	J1008C10-3	Ptpn1	protein tyrosine	J1008C10	Mm.2668	Chromosome 2	TCTAATCTCAG
			phosphatase,				GGCCTTAACCT
			non-receptor				GTTCAGGAGA
			type 1				AGTAGAGGAA
							ATGCCAAATAC
							TCTTCTT
555.	K0103F09-3	2500002K03Rik	K0103F09	Mm.29181	Chromosome 6	ATTCAGATCAG
			2500002K03				GAAAGGTTGA
			gene				AATGGTCTTCG
							TTACCAGGAGG
							TCTACATTTAT
							TAATTT
556.	C0837H01-3	Adam9	a disinegrin	C0837H01	Mm.28908	Chromosome 8	CAGTTATGGGC
			and				TTCCATTTTCA
			metalloproteinase				AATATCTTTTC
			domain 9				AACTGTAATGA
			(meltrin				CTATGACAGGA
			gamma)				ACTGA
557.	J0207H07-3	Runx2	runt related	J0207H07	Mm.4509	Chromosome 17	GCTTTCTATGC
			transcription				ACGTATTGTAC
			factor 2				AAATTGTGCTT
							TGTGCCACAGG
							TCATGATCGTG
							GATGA
558.	J0246C10-3	Tpd52	tumor protein	J0246C10	Mm.2777	Chromosome Multiple	TGGCTAGATTT
			D52			Mappings	AATTGAGGATA
							AGGTTTCTGCA
							AACCAGAATTG
							AAAAGCCACA
							GTGTCG
559.	H3158E12-3	BC003324	cDNA sequence	H3158E12	Mm.29656	Chromosome 5	AGAGGACCATT
			BC003324				ATGAAGAAGC
							TGTTCTCTTTC
							CGGTCAGGGA
							AGCATACCTAG
							ACTGAAA
560.	H3094A04-3	Dnajc3	DnaJ (Hsp40)	H3094A04	Mm.12616	Chromosome 14	AGAAAAGAAA
			homolog,				AAGCAGAGA
			subfamily C,				AAAAGTTCATT
			member 3				GACATAGCAG
							CTGCTAAAGAA
							GTCCTCTC
561.	L0231F01-3	Evl	Ena-vasodilator	L0231F01	Mm.2144	Chromosome 12	ATATTTGCTTA
			stimulated				TTTAAGCGTAC
			phosphoprotein				GTTCCTTTGGT
							TTATAGAGAAC
							ACCCCCAAATC
							ACCTG
562.	K0512E10-3	Myo5a	myosin Va	K0512E10	Mm.222258	Chromosome 9	GACTCTCCCAAC
							TTACAGACTTT
							TATCAGATATG
							GAGAAGATAA
							TGTTAAGAGAC
							TTCACA
563.	K0608H09-3	Ptprc	protein tyrosine	K0608H09	Mm.143846	Chromosome 1	TAAAATCCCAT
			phosphatase,				TGAAAGTGGA
			receptor type, C				CTCAGTTGTAA
							GAATAACAAT
							GTGTACCATTC
							TGGAATG
564.	L0842E04-3	Prkcb	protein kinase	L0842E04	Mm.4182	Chromosome 7	CCAATGAACCG
			C, beta				ACAGTGTCAAA
							ACTTAACTGTG
							TCCAATACCAA
							AATGCTTCAGT
							ATTTG
565.	H3121G01-3	BG073361	ESTs	H3121G01	Mm.182649	Chromosome 11	TCAAATCAGTT
			BG073361				TCAACTTTCAT
							AAAATGGATTC
							TTTAATGGATG
							GAGACTTACTC
							GTCGG
566.	C0947F04-3	5830411K21Rik	RIKEN cDNA	C0947F04	Mm.160141	Chromosome 2	CTATACACAAG
			5830411K21				ATATGCTAGGA
			gene				GATGTGAAAG
							ATAATGGAGA
							CTTTCCAGTAA
							GCACTTT
567.	H3009D03-5	Plac8	placenta-	H3009D03	Mm.34609	Chromosome 5	CTGAGATTTTT
			specific 8				CAAATCTTTGG
							CAACTGAGATG
							GGATGGATCCA
							TTTAATTAGAG
							AACGG
568.	H3132E07-3	Lxn	latexin	H3132E07	Mm.2632	Chromosome 3	AAATGTCTTTC
							CAACAGTAATG
							GTACTATGTCT
							ATCCCCTAATA
							AAACTTCACTT
							CAGCC
569.	H3054C01-3	Nr2e3	nuclear receptor	H3054C01	Mm.9652	Chromosome X	TGAACATTCAC
			subfamily 2,				AGGATTTCTAA
			group E,				CTATACTGATA
			member 3				TAAACCCAGTG
							TTTTCTGGACT
							CAGGG
570.	H3013h03-3	Manla	mannosidase 1,	H3013H03	Mm.117294	Chromosome 10	CAACAAAGTTG
			alpha				ATTTACATGTA
							TAATCCACACC
							CTTAAAGATGA
							ACAGTTAGAGT
							AGCAC
571.	J0058F02-3	ank	progressive	J0058F02	Mm.142714	Chromsome 15	TGGACACAGTT
			ankylosis				CACTAAATTCC
							TGATTTAGTCA
							AAGTAACTAG
							ACTGAAAGAA
							CCTAAAC
572.	L0829D10-3	Snca	synuclein, alpha	L0829D10	Mm.17484	Chromosome 6	TTGTTGTGGCT
							TCACACTTAAA
							TTGTTAGAAGA
							AACTTAAAACA
							CCTAAGTGACT
							ACCAC
573.	H3037H02-3	1110018O12Rik	RIKEN cDNA	H3037H02	Mm.28252	Chromosome 18	TGAACACATCA
			1110018O12				AGTATTCTGGA
			gene				GCTTCAGCGGC
							AGTTAAATGCC
							AGTGACGAAC
							ATGGAA
574.	K0105H12-3	Cdk6	cyclin-	K0105H12	Mm.88747	Chromsome 5	AAGGTCCAAA
			dependent				ATACAGACATT
			kinase 6				TTTGCTAGGGC
							CTAGAAATCGA
							CCATAAAACAC
							ACTGCA
575.	C0105D10-3		C0105D10-3	C0105D10		No Chromosome	GACTGAAATG
			NIA Mouse			location	AAAGTTCCACT
			E7.5			info available	AACGGTATTTG
			Extraembryonic				CTCTAGTGATA
			Portion cDNA				TGTGGACATTG
			Library Mus				TGATAT
			musculus
			cDNA clone
			C0105D10 3′,
			MRNA
			sequence
576.	L0229E05-3	Prkx	putative	L0229E05	Mm.106185	Chromosome X	TCAAATAAAA
			serine/threonine				AACCCTTAATC
			kinase				AGGCTGTAAAT
							CAAATGACACT
							ATGCGATGTCA
							CTACAG
577.	L0931H07-3		ESTs	L0931H07	Mm.221935	Chromosome 1	GCACTATAAAT
			BQ557106				TTCATCTTTTG
							AAGGTTGTTGA
							CTACAAGGGTA
							CAAAAATGAT
							ACAGGC
578.	K0138B11-3	Trim25	tripartite motif	K0138B11	Mm.4973	Chromosome 11	CTTGCATGAGT
			protein 25				GCGTGTTTAAG
							TTCTCGGAATT
							TCCTGAGAGGA
							TGGAGTGCCAT
							TGTTA
579.	H3019H03-3	Lass6	longevity	H3019H03	Mm.265620	Chromosome 2	AGTGTTAGCTG
			assurance				CAAAGCTACA
			homolog 6 (S.				AAGCTCTGGA
			cerevisiae)				TGGTTACATTA
							TGATTCTGGAA
							CGTTCG
580.	J0051F04-3	Ifi30	interferon	J0051F04	Mm.30241	Chromosome 8	TCCAGACTTCT
			gamma				CAGAGACAAG
			inducible				GATCTTGCCTT
			protein 30				ATTTTCAAATG
							GTGCTAAATTT
							AAATTC
581.	H3106G04-3	Cacnald	calcium	H3106G04	Mm.9772	Chromosome 14	AGTGACTTCCA
			channel,				CCTTTTAATGT
			voltage-				CATTAAAAGCA
			dependent, L				GGAGCTTAAAC
			type, alpha 1D				TAAAAGCAGC
			subunit				ATTCCA
582.	L0701D10-3	Arhgdib	Rho, GDP	L0701D10	Mm.2241	Chromosome 6	ACATACATTTC
			dissociation				ATCACCAATAT
			inhibitor (GDI)				GTTTTATCTTA
			beta				CCCCATCTCTC
							AGAGTGTTCCC
							TGCAA
583.	H3137A02-3		Mus Musculus	H3137A02	Mm.21657	Chromosome 4	TTTTTTGTATT
			10 days neonate				ATTGTGTTTTG
			cerebellum				TGCTACTGTAG
			cDNA RIKEN				TTTTGGTGTGG
			full-length				CACTATTATAA
			enriched				TTAAA
			library
			clone:B930053
			B19
			product:unknown
			EST, full
			insert sequence.
584.	L0043D10-3	A5310090O1Rik	RIKEN cDNA	L0043D10	Mm.40298	Chromosome 15	CTTAGGGAGAC
			A530090O15				TACTAACATGG
			gene				AGAGAATGCC
							GTGTATACCTC
							ACGTACTGTGT
							GCTTTA
585.	H3087D06-3	Etfl	eukaryotic	H3087D06	Mm.3845	Chromosome 18	CATACATAGAA
			translation				GCAAAATACTT
			termination				TAACTGCTGTA
			factor 1				AACCTTCAAAA
							GTTAGTAGACG
							TGAGG
586.	C0827E01-3		Mus musculus	C0827E01	Mm.45759	Chromosome 10	ACTTCCTGCAA
			15 days embryo				TACATCCCAGT
			head cDNA				AGGTACACCTA
			RIKEN full-				GTTTACAATTT
			length enriched				AAACTAGTTTG
			library,				TGAAA
			clone:D930031
			H08
			product:unknown
			EST, full
			insert sequence.
587.	H3053E01-3	B130024B19Rik	RIKEN cDNA	H3053E01	Mm.34557	Chromosome 10	GGAGGCACAT
			B130024B19				AATTCCAAGCA
			gene				ATACAGGCTGT
							TAAAATATAAA
							TAATGGGAACT
							GTGATT
588.	K0117C08-3	BM222243	ESTs	K0117C08	Mm.221706	Chromosome 1	AAGCGTTAGG
			BM222243				AAGGAAATTTC
							CTGGAAGGAT
							AGGTTGTCTTC
							CTAGCAGCCTC
							GTCAATA
589.	H3056D11-3	Ptgfm	prostaglandin	H3056D11	Mm.24807	Chromosome 3	TTTTTTAACTT
			F2 receptor				CACTCATGACA
			negative				ACAGAGGAAG
			regulator				AAAGGAATTG
							AGGTTTAGGTA
							AGTTCTC
590.	C0228C02-3	2510004L01Rik	RIKEN cDNA	C0228C02	Mm.24045	Chromosome 12	AGGCATATCTC
			2510004L01				ATAGAGCCTTA
			gene				AGTTAGAATCT
							TACTCTTATGG
							AAGGAGTTATT
							TCCTA
591.	H3144F09-3	Rab711	RAB7, member	H3144F09	Mm.34027	Chromosome 1	GATCACCTCAT
			RAS oncogene				TCCTCGACTGT
			family-like 1				GAGATGAGTTT
							ATGAAAAGAA
							TTAAAAGTGAG
							CACTTG
592.	H3052B06-3	Abcb1b	ATP-binding	H3052B06	Mm.6404	Chromosome 5	TAAAGGTAACT
			cassette, sub-				CCATCAAGATG
			family B				AGAAGCCTTCC
			(MDR/TAP),				GAGACTTTGTA
			member 1B				ATTAAATGAAC
							CAAAA
593.	L0273B08-3	Tgif	TG interacting	L0273B08	Mm.8155	Chromosome 17	GGCCAGGTATA
			factor				TGTGTACCAGT
							GCTCTTCAAAG
							GGAGAACCATT
							AAAACCAACA
							TGGAAT
594.	K0406A08-3	Siat4c	sialytransferase	K0406A08	Mm.2793	Chromosome 9	CCAAGAGATTA
			4C (beta-				TTTAACATTTT
			galactoside				ATTTAATTAAG
			alpha-2,3-				GGGTAGGAAA
			sialytransferase)				ATGAATGGGCT
							GGTCCC
595.	AF075136.1	Sap30	sin3 associated	AF075136	Mm.118	Chromosome 8	AGTGAACGAA
			polypeptide				AAAGACACCTT
							AACATGTTTCA
							TCTACTCAGTG
							AGGAACGACA
							AGAACAA
596.	K0644H12-3	Prkch	protein kinase	K0644H12	Mm.8040	Chromosome 12	GATATTTATTG
			C, eta				AGTGTCAAATA
							AAAAGGTGCC
							ATAATCTTCAG
							TAGCGTACACA
							GTAGAG
597.	H3108A04-3	Clu	clusterin	H3108A04	Mm.200608	Chromosome 14	GTGTTACCAGA
							AGAAGTCTCTA
							AGGATAACCCT
							AAGTTTATGGA
							CACAGTGGCG
							GAGAAG
598.	H3020F06-3	Snx10	sorting nexin 10	H3020G06	Mm.29101	Chromosome 6	TGTCTTTATTTT
							AATGCCAAAA
							GGAAGTGATTA
							TGCAGCTGTGT
							GTAGAGTTTCA
							GAGCA
599.	L0066C05-3	Uxs1	UDP-	L0066C05	Mm.201248	Chromosome 1	AGAACAAACT
			glucuronate				GGAATTTTATT
			decarboxylase 1				CTGAAGCTTGC
							TTTAAAGACAC
							TGATGTGCCTA
							AACGCT
600.	L0025F08-3	Rgs19	regulator of G-	L0025F08	Mm.20156	Chromosome 2	TATGGTCTTTC
			protein				AGTCACAGTGT
			signaling 19				AGTCACAGTGT
							CATCTTAATCT
							TACTGATCCAA
							TAAAAC
601.	H3076F06-3	Siat4a	sialytransferase	H3076F06	Mm.248334	Chromosome 15	ATCCTCCTGAT
			4A (beta-				TGGTCTGAATG
			galactoside				CATTTCCAATG
			alpha-2, 3-				ATGTCAGGGA
			sialytransferase)				TCAGCC
602.	C0354G01-3		Mus musculus,	C0354G01	Mm.259704	Chromosome 13	TAAGCCCTGTC
			Similar to IQ				TTCTGGGAAAT
			motif				ATCAGTTTTAA
			containing				AGAGAACTTTT
			GTPase				GTGCAATTCCA
			activating				AATGA
			protein 2, clone
			IMAGE:35965
			08, mRNA,
			partial cds
603.	C0191H09-3	Atp6vla1	ATPase, H+	C0191H09	Mm.29771	No Chromosome	GGAAGATTAAT
			transporting			location	TTTCCAGGGAT
			V1 subunit A,			info available	TGTATCAATCA
			isoform 1				GGACCATTTTT
							GTGGGGCACTT
							GGGAC
604.	H3050G04-3	Dpp7	dipeptidyl-	H3050G04	Mm.21440	Chromosome 2	ATGTGATCTAC
			peptidase 7				AGTGGTGTGAC
							AACTTGCCTTG
							TATCTGATGGA
							CTGTCCAGATT
							TATGG
605.	L0219A09-3	Gatm	glycine	L0219A09	Mm.29975	Chromsome 2	AAACGAAGTG
			amidinotransferase				ACTTTCCATGA
			(L-arginine:				ATGCCTTTAAC
			glycine amidino-				ATTCTTGTGTC
			transferase)				AACATTTGGTA
							CTAAAC
606.	J0821E02-3	AU040950	expressed	J0821E02	Mm.17580	Chromosome 13	AATACTCATTA
			sequence				TGCTGTGTGGG
			AU040950				AATTTCCTGAT
							TACTAGAAGCT
							GACCTCTGCTA
							TCCTG
607.	H3080a02-3	Cbfb	core binding	H3080A02	Mm.2018	Chromsome 8	GAATTATTATA
			factor beta				AACAATAATGT
							GTTACAGAAGC
							TGATGCTGACC
							TTGTGTTACTG
							AGCAC
608.	C0276B08-3	Plscr1	phospholipid	C0276B08	Mm.14627	Chromosome 9	TTCTTGAGGTT
			scramblase 1				TAAGGACGAC
							AACTTTATGGA
							CCCTGAATGGA
							AACTGAGGAA
							TCACAAG
609.	C0279E04-3	Srd5a21	steroid 5 alpha-	C0279E04	Mm.86611	Chromosome 5	GTCACATGCCA
			reductase 2-like				ATAAAAACAG
							GAAACTCTGAA
							AATAATATGAA
							TGTACAGTATC
							AGACCG
610.	K043D04-3	Pgd	phosphogluconate	K0434D04	Mm.252080	No Chromosome	CCCTATTGCAA
			dehydrogenase			location	ATTGATTTGTT
						info available	TTCCCTTAACC
							CTGTTCCCTTT
							TAACCCCGGCT
							TTTTT
611.	C0174H01-3	Ddx21	DEAD (Asp-	C0174H01	Mm.25264	Chromosome 10	CATTGCATCGT
			Glu-Ala-Asp)				TTTCCAACATA
			box polypeptide				CTTTTAGATTT
			21				ACAAAGTAAA
							ACCAACCATGG
							ATCTGC
612.	H3085A07-3	BG070224	ESTs	H3085A07	Mm.173217	Chromosome 17	TTGAGAAATTA
			BG070224				AAAACAAATA
							TCCAAAATCGA
							CTTTTCCTCAA
							GGCTATGTGCT
							TCGTCC
613.	K0208E10-3	Mmab	methylmalonic	K0208E10	Mm.105182	Chromosome 5	ACGACTCTTGT
			aciduria				TAATGTGCGTT
			(cobalamin				TCTCATGGAGT
			deficiency) type				AATTTTCAGAG
			B homolog				CCTGAACTTGT
			(human)				AGCAC
614.	H3006F10-3	Cops2	COP9	H3006F10	Mm.3596	Chromosome 2	GTTGGTGTGTC
			(constitutive				CTGAAAGGGA
			photomorphogenic)				TGGAGTTATGG
			homolog,				CAGAAGTGCTT
			subunit 2				TTGTGATCAAC
			(Arabidopisi-				TGGTTT
			thaliana)
615.	C0108A10-3	Nek6	NIMA (never in	C0108A10	Mm.143818	Chromosome 2	CAGAAAACTC
			mitosis gene a)-				AAGTCATGGAC
			related				TATGCGAGTCA
			expressed				AGAATTAAAAT
			kinase 6				ACAACTGTATT
							ATGTGC
616.	H3028H10-3	Ppic	peptidylprolyl-	H3028H10	Mm.4587	Chromosome Multiple	AAATTTCTCAT
			isomerase C			Mappings	TTAATTTTCCA
							GTCTCGATTGC
							AGTAACAAAG
							TCAACCACACA
							GTCAGA
617.	H3121E08-3	Ralgds	ral guanine	H3121E08	Mm.5236	Chromosome 2	GGAGGAAGAC
			nucleotied				AACTGAACATT
			dissociation				TGTATAAAACG
			stimulator				TAAAAGTTTA
							CTGATTGGGGT
							GGGACA
618.	L0266H12-3	Opal	optic atrophy 1	L0266H12	Mm.31402	Chromosome 16	CAGCAGCTTAC
			homolog				AAACACTGAA
			(human)				GTTAGGCGACT
							AGAGAAAAAC
							GTTAAAGAGGT
							ATTAGAA
619.	K0635G02-3	2310046K10Rik	RIKEN cDNA	K0635G02	Mm.68134	Chromosome 14	GAGAAATGTTA
			2310046K10				GTAAAATGGTA
			gene				AAAGGGAATC
							ACGTGACATTC
							AGGGTAGGAA
							GAGCTTG
620.	L0704C05-3	2613018G18Rik	RIKEN cDNA	L0704C05	Mm.180776	Chromosome 3	TCAGGAAAAA
			2610318G18				TGTCATAAGCC
			gene				ATCTGGTAAGT
							TTTCTTAAAGG
							ATGTTGTTAAG
							AAGTCC
621.	C0303D10-3		UNKNOWN	C0303D10	Data not found	No Chromosome	CAAAACAAAT
			C0303D10			location	ACATATTATAA
						info available	AATAAAAGAA
							AAGGCGTGAT
							AAATGGATGTG
							ACAAAATT
622.	K0605C04-3	BM240648	ESTs	K0605C04	Mm.265969	Chromosome 15	GTAGGGAAAA
			MN240648				TATGTCCATAG
							GTTTTAGGAAA
							CACTTAGCCTT
							TAATATACTGG
							TTGTAG
623.	H3071G06-3	BG069012	ESTs	H3071G06	Mm.26430	Chromsome 4	GTATACAGATG
			BG069012				GTAGTTAGAAA
							TACTGGATGAA
							CTGATCAGTTA
							TTGTGTGTAGA
							AAGTG
624.	C0600A01-3	Coro2a	coronin, actin	C0600A01	Mm.171547	Chromosome 4	TTGTATCCCAA
			binding protein				AGGGAAACGG
			2A				GAATCAAGAT
							ACGGACCTATG
							CTTTTCATATG
							AAACCGT
625.	NM_007679.1	Cebpd	CCAAT/enhancer	NM_007679	Mm.4639	Chromosome 16	TGCAGCTAAGG
			binding				TACATTTGTAG
			protein				AAAAGACATTT
			(C/EBP), data				CCGACAGACTT
							TTGTAGATAAG
							AGGAA
626.	H3048A01-3	Kras2	Kirsten rat	H3048A01	Mm.31530	Chromosome 6	GGCAATGGAA
			sarcoma				AATGTTGAAAT
			oncogene 2,				CCATTCGTTT
			expressed				CCATGTTAGCT
							AAATTACTGTA
							AGATCC
627.	C0267D12-3	Tpp2	tripeptidyl-	C0267D12	Mm.28867	Chromosome 1	CCCCAAAGAA
			peptidase II				AACTGGAAAA
							ATTGTTTTCCA
							CTCCTGAAATT
							TCTTGGATGGG
							CCCCCTG
628.	J1012C06-3	AU041997	ESTs	J1012C06	Mm.181004	Chromosome 5	CCAGACAGTGT
			AU041997				ATTCTTCGGAC
							AAATGGTGTGA
							AAGTGAAATA
							AGAATTCATAA
							TGTAAC
629.	L0072f04-3	Vav2	Vav2 oncongene	L0072F04	Mm.179011	Chromosome 2	AGCAAAAGTA
							TGTATATTTTA
							GCTTGTCATGA
							AATGTCAACGA
							AGGACACTGA
							GAAAGAG
630.	L0836H04-3	C030038J10Rik	RIKEN cDNA	L0836H04	Mm.212874	Chromosome 6	TAGAATGGGA
			C030038J10				ATTTTCTGTCT
			gene				CATAGTGACAT
							ATTGCTATGTT
							TAACAGTGAAC
							ACTCAC
631.	K0614A10-3	Sh3kbp1	SH3-domain	K0614A10	Mm.254904	Chromosome X	TGACGGTATAT
			kinase binding				TTGCAAAAAG
			protein 1				AGAAAGAAAA
							ATCTGGTATTT
							GCAATGATCTG
							TGCCTTC
632.	H3156B08-3	6620401D04Rik	RIKEN cDNA	H3156B08	Mm.86150	Chromosome 16	GAAATATCATT
			6620401D04				TGTAGCTTTAA
			gene				GGCTAGAAAA
							TGAAAAAGAA
							TCCAAGCCAGT
							AGAAGGC
633.	C0334C11-3	B230339H12Rik	RIKEN cDNA	C0334C11	Mm.275985	Chromosome 8	ATACCAGGAA
			B230339H12				AATAAAAGTA
			gene				CCAGTAAGGA
							AGCATCAAATC
							AAGATGTCATA
							GTCAGTGG
634.	H3103G05-3	BG071839	ESTs	H3103G05	Mm.17827	Chromosome 3	CAGTGTAAATA
			BG071839				TAGCATATGGT
							TAGGTGGTGAG
							AAAATGATCTT
							GAGACTGATA
							AGAATC
635.	C0205H05-3	1600010D10Rik	RIKEN cDNA	C0205H05	Mm.86385	Chromosome 3	ATCCTTTAGAT
			1600010D10				GTTAGTACAGT
			gene				GTTTATGAGAA
							AACTGTTACTA
							GAAGCTGAAG
							AACAGC
636.	L0513G12-3	Qk	quaking	L0513G12	Mm.2655	Chromsome 17	AGTGTTCTATA
							TGTGTAAATTA
							GTATTTTCAAC
							TGGAAAATGTT
							GGCTGGTGCAA
							AAGGC
637.	C0100E08-3	Pdap1	PDGFA	C0100E08	Mm.188851	Chromosome Multiple	GTCTGGGCTAG
			associated			Mappings	TGCCCGTTTTT
			protein 1				AACCCTACCCA
							TTGATCATTTC
							AAGAAACCTCT
							GGTTA
638.	J0055B04-3		transcribed	J0055B04	Mm.228682	Chromsome 16	TGTAAGACCAT
			sequence with				TTCTAAATTGC
			strong				TGGTAATAGAA
			similarity to				ACTCATGGCAG
			protein				TAAAAATGTAA
			pir:S12207				CCTCG
			(M. musculus)
			S12207
			hypothetical
			protein (B2
			element)-
			mouse
639.	J0008D10-3	Mbp	myelin basic	J0008D10	Mm.2992	Chromosome 18	ACTGGAATAG
			protein				GAATGTGATGG
							GCGTCGCACCC
							TCTGTAAATGT
							GGGAATGTTTG
							TAACTT
640.	K0319D09-3	Mtm1	X-linked	K0319D09	Mm.28580	Chromosome X	TCTACTAGAAG
			myotubular				GGTTAAAAGCC
			myopathy gene				ATATGAATGCA
			1				AGAAATCATTT
							GAGGCTTAAA
							ATGCTG
641.	C0243H05-3	Galnt7	UDP-N-acetyl-	C0243H05	Mm.62886	Chromosome 8	GGACACCATTT
			alpha-D-				TTCATGTTAAA
			galactosamine:				TAGATTTTAAC
			polypeptide N-				CTCGTATCTAT
			acetylgalactosa				GCATAGGCTAA
			minyltransferase				GGTGG
			7
642.	L0841H10-3	BM116846	ESTs	L0841h10	Mm.65363	Chromosome 2	TAGATAAAGCC
			MN116846				CGTATGAGAA
							GAGAAAACCA
							AATTAATCCAC
							TTCAGCAAAAA
							GAAAGCC
643.	K0334D05-3	Ccn1	cyclin D1	K0334D05	Mm.22288	Chromosome 7	CAATGTCAGAC
							TGCCATGTTCA
							AGTTTTAATTT
							CCTCATAGAGT
							GTATTTACAGA
							TGCCC
644.	L0209B01-3		L0209B01-3	L0209B01		No Chromosome	CTTTGGGGGGG
			NIA Mouse			location	GTTTTGGAAAA
			Newborn Ovary			info available	CCGGTTTTTTC
			cDNA Library				GGGGGGGTTTC
			Mus musculus				CTTTTGGGGGG
			cDNA clone				TTTTT
			L0209B01 3′,
			MRNA
			sequence
645.	K0151H10-3	BB129550	EST BB129550	K0151H10	Mm.283461	No Chromosome	GCCATACAGCT
						location	TATATTTGTAC
						info available	TGGTATGTCCA
							GAAATCATGG
							AGGAAAGAAA
							AGTAAAA
646.	L0505B11-3	Ammecr1	Alport	L0505B11	Mm.143724	Chromosome X	TGGTGTTTTGA
			syndrome,				TTACAGTGAGA
			mental				CATCACAGGTT
			retardation,				ATCTAAAAGCC
			midface				CTTCGTTATAA
			hypoplasia and				CCAGC
			eliptocytosis
			chromosomal
			regoion gene 1
			homolog
			(human)
647.	L0944C06-3	BM120800	ESTs	L0944C06	Mm.217092	Chromosome 3: not placed	TATTTGGTGGT
			BM120800				AAAGAATATG
							GTTGAAAATTG
							TCATCCACATG
							CATGCATCAAG
							TAACAC
648.	J0027C07-3	Mrps25	mitochondrial	J0027C07	Mm.87062	Chromosome 6	CGAGGAGTTAT
			ribosomal				TAGGGAGAAT
			protein S25				CATGGAGCCAC
							ATAAGAAAAT
							CTTGGGCAAGA
							AAAGAGG
649.	L0855B04-3	Wdr26	WD repeat	L0855B04	Mm.21126	Chromosome 1	TGGTGACAGG
			domain 26				ATTACGTGAAA
							ATCTCTGACAT
							TGTGATAAACT
							GGATAAAGGCT
							TAAGAG
650.	H3060H05-3		Mus musculus	H3060H05	Mm.11778	Chromosome 1	ACCCTTTGCTT
			cDNA clone				AAATAGTGGG
			MGC:28609				AAAACGTGAA
			IMAGE:42185				TGTTTAGCATA
			51, complete				ATATAAAAAC
			cds				ATGCAGGC
651.	K0330609-3	5830461H18Rik	RIKEN cDNA	K0330G09	Mm.261448	Chromosome 14	GTTGGACTCTA
			5830461H18				ATACAACTGAC
			gene				CATTGAAAAAT
							GAACAACGGC
							TTATTGTTTTG
							TAAACAG
652.	L0803E07-3	Dpys14	dihydropyrmid-	L0803E07	Mm.250414	Chromosome 7	TTCTACAAAG
			inase-like 4				TGTGTTTCTAT
							AGGATTACTAG
							AGTAGCGGTTT
							TGTACTGTGAG
							GAAAC
653.	L0283B01-3	Ivns1abp	influenza virus	L0283B01	Mm.33764	No Chromosome	TAGATAACAGT
			NS1A binding			location	GACTATTGACG
			protein			info available	ATTTTAGTAAA
							AGAAAGTTGA
							CATGCGTACCG
							CTACCT
654.	L0065G02-3	6530401D17Rik	RIKEN cDNA	L0065G02	Mm.27579	Chromosome X	GGGGGGACAG
			6530401D17				TTAATATCGTT
			gene				TGTTAGATACC
							ATAAGTGGTGG
							AAATAAAGTG
							ACTAAAG
655.	C0949A06-3		Mus musculus	C0949A06	Mm.71633	Chromosome 13	AAAGAGGAAA
			0 day neonate				CTGTCCTATTT
			skin cDNA,				CTCAACTGATA
			RIKEN full-				AGTACTCCTGG
			length enriched				TAAGATGTAAT
			library				ATTTGC
			clone:4632424
			N07
			product:unknown
			EST, full
			insert sequence.
656.	H3100C11-3	BG071548	ESTs	H3100C11	Mm.173983	Chromosome Un: not	CAAATGTACTG
			BG071548			placed	AGAAACAAAA
							TCATGAACGAC
							CTTGAAATCAC
							CTTCTTATTTC
							AGCTCC
657.	C0142H08-3	3110020O18Rik	RIKEN cDNA	C0142H08	Mm.117055	Chromosome 5	AACATAAATCA
			3110050O18				AAATATACTTA
			gene				GGAATATTTAC
							AATTAAACATG
							ATGTTTTAAAC
							TTAGT
658.	L0945G09-3	Bcl2111	BCL2-like 11	L0945G09	Mm.141083	Chromosome 2	GACTATTTATT
			(apoptosis				AGATTAGAAA
			facilitator)				GTCATGTTTCA
							CTCGTCAACTG
							AGCCAAATGTC
							TCTGTG
659.	L0848H06-3	E130318E12Rik	RIKEN cDNA	L0848H06	Mm.198119	Chromosome 1	ACAAACACAT
			E130318E12				GAAAAAATCA
			gene				AGTAGGAACT
							GGAGAAACGT
							CTCACAGTTAA
							GAATGTTTG
660.	K0617B02-3	Bmp2k	BMP2	K0617B02	Mm.6156	Chromosome 5	AATTCACAGAT
			inducible				GGCTTACATTT
			kinase				ATGTAAAGAAT
							TCCTGTAAGGC
							ACTCATGTTTG
							ACATC
661.	C0203D07-3	Pftk1	PFTAIRE	C0203D07	Mm.6456	Chromosome 5	TATACCAAACT
			protein kinase 1				GAAAACGTTTA
							AATCTCAAATG
							AAGTAAGCAA
							GGTTTTGTTCT
							CCCTGC
662.	L0267A02-3	2210409B22Rik	RIKEN cDNA	L0267A02	Mm.30015	Chromosome 4	TAGCCATTTAG
			2210409B22				GAGATGTCCCT
			gene				TCAAAGTGACG
							TGATGATGGAC
							TTGCACTTGGG
							AATCA
663.	J0086F05-3		transcribed	J0086F05	Mm.31079	No Chromosome	GCTCAGCTTAG
			sequence with			location	GCTAGACTTTG
			moderate			info available	ACCAGGTAAG
			similarity to				CAGAAGAAAT
			protein				GAGAAACAAA
			sp:P00722 (E.				ACTCAGCA
			coli)
			BGAL_ECOLI
			Beta-
			galactosidase
			(Lactase)
664.	C06606A03-3	Rps23	ribosomal	C0606A03	Mm.295618	Chromosome X	TATCACTGGAA
			protein S23				TATTGAAAGGT
							TGTATGTAGTA
							TGGGAGATCA
							ACTTTCTTCCC
							TAAGGT
665.	L0902D02-3	Ncoaoip	nuclear receptor	L0902D02	Mm.171323	Chromosome 4	ACTGCTGAGAA
			coactivator 6				AAACAAAATTC
			interacting				ACTACATACCT
			protein				CAATAGTTATT
							TACCATGAGAT
							TGGCG
666.	H3060C12-3	BG067974	ESTs	H3060C12	Mm.173106	Chromosome 1	GAAGGAAATG
			BG067974				CAAACACCTTT
							GAACTTCAATT
							CTTTCAGTAGG
							AAAACAAGAA
							TTGTCCC
667.	C0611E01	Tor3a	torsin family 3,	C0611E01	Mm.206737	Chromosome 1	AGAAAAACAC
			member A				TAAACTCCAAA
							TTAGTATAATA
							ACGAGCACTAC
							AGTGGTGAAA
							AAGCTCC
668.	U54984.1	Mmp14	matrix	U54984	Mm.19945	Chromosome 14	AAAGGAATCTT
			metalloproteinase				AAGAGTGTAC
			14				ATTTGGAGGTG
			(membrane-				GAAAGATTGTT
			inserted)				CAGTTTACCCT
							AAAGAC
669.	H3089F08-3	0610013E23Rik	RIKEN cDNA	H3089F08	Mm.182061	Chromosome 11	GAAATGGATTT
			0610013E23				TGAGGCTTTGA
			gene				AAATGAAAAT
							GGCTAGTQTCT
							CAAAGATGTCA
							GTATCC
670.	K0633C04-3	Ebi2	Epstein-Barr	K0633C04	Mm.265618	Chromosome 14	ACTATTTCTTG
			virus induced				TCAATAGTTTG
			gene 2				GCAAAAGACG
							ACTAATTGCAC
							TGTATATTGCC
							AGTGTA
671.	J0943E09-3	Nup62	nucleoporin 62	J0943E09	Mm.22687	Chromosome 7	TCCTCTAAAGA
							TGTGTCTTATA
							TACATGATTGT
							CATTGGTGGGC
							TCAAACAATAA
							GGGTG
672.	L0267D03-3	Dcn	decorin	:0267D03	Mm.56769	Chromosome 10	TTGGAAACTAC
							AAGTAACCCTC
							AGACGGCCTA
							ATTCTTATAAT
							CCGGAAAAAC
							ACCCCAA
673.	L0250B09-3	111031E24Rik	RIKEN cDNA	L0250B09	Mm.34356	Chromosome 8	GTGTGATAATC
			1110031E24				TTTTCATGTTTT
			gene				CTAGAGCAAA
							GACAAAGCAG
							TTACTCTTCTA
							TCGCAA
674.	L0915B12-3	Etv3	ets variant gene	L0915B12	Mm.34510	Chromosome 3	GGCTTTAGAGA
			3				AAACTTCGGTC
							TTCAAAGAACT
							CTTCTAATTAG
							TTCCTTCTTGG
							AAAAA
675.	NM_009403.1	Tnfsf8	tumor necrosis	NM_009403	Mm.4664	Chromosome 4	AAAGTAGGAG
			factor (ligand)				ATGAGATTTAC
			superfamily,				ATTTCCCCAAT
			member 8				ATTTTCTTCAA
							CTCAGAAGAC
							GAGACTG
676.	C0308F04-3	2700064H14Rik	RIKEN cDNA	C0308F04	Mm.24730	Chromosome 2	AGTCCTCTGCA
			2700064H14				TGTTTCCAAAA
			gene				TTTCCTTTACA
							TGAAGGCTATA
							TTGGATCAGAG
							CTTAC
677.	C0288G12-3	6030400A10Rik	RIKEN cDNA	C0288G12	Mm.159840	Chromosome 5	AAGAATAAAT
			6030400A10				CACTTGAAATC
			gene				ATACTGTTTTT
							GGAAATCCAA
							ACTGTTTAAAG
							AAAACTT
678.	H3005A11-3	Fancd2	Fanconi	H3005A11	Mm.291487	Chromosome 6	GTTAGATGCCA
			anemia,				TTGAAGGGGA
			complementation				AATAACTTTGG
			group D2				CTAATAGCTTG
							GAAAACTCAGT
							ACTAAG
679.	H3121H07-3	2810405I11Rik	RIKEN cDNA	H3121H07	Mm.73777	Chromosome 18	AGCAGATATGT
			2810405I11				GACTTCTCATA
			gene				TACACAGTTAC
							GCTAACTCAGG
							TGTATGATGAA
							TACAG
680.	K0124A06-3	BM222608	ESTs	K0124A06	Mm.221709	Chromosome 19	TGTCTATGGGA
			BM222608				GAAGTAATAG
							CCTGAAATAAG
							ATAAGGCTCAA
							ACAAACACTAC
							TTACTT
681.	NM_010835.1	Msx1	homeo box,	NM_010835	Mm.259122	Chromosome 5	GGGAAGAAAA
			msh-like 1				AGAATTGGTCG
							GAAGATGTTCA
							GGTTTTTCGAG
							TTTTTTCTAGA
							TTTACA
682.	K0134C07-3	Falz	fetal Alzheimer	K0134C07	Mm.218530	Chromosome 11	CTTGAAGAAA
			antigen				AGTATATCACG
							TAGGCATAGAT
							GAGAAAGCCG
							TTTGATCAAGT
							CTGGTTA
683.	K0424H02-3	Pfkp	phosphofructok-	K042H02	Mm.108076	Chromosome 13	TCCTTCAGTCA
			inase, platelet				GATATCTGTCC
							CAGAGAAAGG
							AAAATAAGGA
							GCATGGTAAG
							AAATGAGT
684.	H3153G06-3	8030446C20Rik	RIKEN cDNA	H3153G06	Mm.204920	Chromosome 13	TATGGAATGGA
			8030446C20				GAAATAAATA
			gene				CATCTGTGTTG
							AAGAACCTTTT
							GATGGAACTA
							ATACCGC
685.	H3071C09-3	BG068971	ESTs	H3071C09	Mm.162073	Chromosome 6	AGGTCAATGTT
			BG068971				AAGTTTTCTGA
							GTTTAATATAT
							AGTTAGGGTGA
							AAGACTTAGCA
							CACGG
686.	L0243B07-3		Possibly	L0243B07	Data not found	No Chromosome	AATGCTTAACT
			intronic in			location	TTGAGTCACAC
			U008124-			info available	TGTTTACCCTT
			L0243B07				CCTATGAGGTT
							GCATTTTGACA
							ACAAC
687.	C0143D11-3	Ii	Ia-associated	C0143D11	Mm.248267	Chromosome 18	TAAAGGGAAC
			invariant chain				CCCCATTTCTG
							ACCCATTAGTA
							GTCTTGAATGT
							GGGGCTCTGAG
							ATAAAG
688.	L0512A02-3	Snx5	sorting nexin 5	L0512A02	Mm.20847	No Chromosome	CCCCTTTTGT
						location	AACTGGGATAT
						info available	AAATCCTTGAA
							AGAAAGGAGA
							ATTTAGAGTTT
							TGCCCC
689.	K0112C06-3	Atp8a1	ATPase,	K0112C06	Mm.200366	Chromosome 5	GTCAGTGAGTT
			aminophospholipid				GGTTTCCTTTC
			transporter				CATCAGGAAA
			(APLT), class I,				AATGGATTCTG
			type 8A,				TAAAGAGTCA
			member 1				GGGCGTT
690.	H3053A01-3	Tnfsf13b	tumor necrosis	H3053A01	Mm.28835	Chromosome 8	GAAAGCCGTC
			factor (ligand)				AGCGAAAGTTT
			superfamily,				TCTCGTGACCC
			member 13b				GTTGAATCTGA
							TCCAAACCAGG
							AAATAT
691.	C0668F08-3	Atp6ap2	ATPase, H+	C0668F08	Mm.25148	Chromosome X	GAAATATGTTA
			transporting,				ACTAAGAGCA
			lysosomal				GCCCAAAAAT
			accessory				ACTGGATATGC
			protein 2				TTATCCAATCG
							CTTAGTT
692.	K0417E05-3	Osmr	oncostatin M	K0417E05	Mm.10760	Chromosome 15	GTATACAATGC
			receptor				TATTTTTAGGT
							TAAGGCCTAAA
							CTTCTGAAGAT
							CTTGGTAACAG
							CAGAG
693.	NM_010872.1	Birclb	baculoviral IAP	NM_010872	Mm.89961	Chromosome 13	GGATGAAGTG
			repeat-				GAAGATTACTG
			containing 1b				GCAGGTCCAA
							AAACCTGATTT
							TCTAGTACATT
							TCACTCT
694.	L0262G06-3	Cfh	complement	L0262G06	Mm.8655	Chromosome 1	TTCAATCAAGA
			component				AAGTAGATGTA
			factor h				AGTTCTTCAAC
							ATCTGTTTCTA
							TTCAGAACTTT
							CTCAG
695.	J0249F06-3	2210023K21Rik	RIKEN cDNA	J0249F06	Mm.28890	No Chromosome	AAATTTTCTTA
			2210023K21			location	AAGCTATGAAC
						info available	TCTGACTTTTG
							ATTTTGTGTTT
							CCATTTAGTAG
							AAACT
696.	C0170A02-3	Serpinb9	serine (or)	C0170A02	Mm.3368	Chromosome 13	AGAATCTCACT
			cysteine)				ACTAAAGTCAA
			proteinase				GTATAGAAATA
			inhibitor, clade				ACTGTTCTTAT
			B, member 9				GTTTTCCTCCA
							AGGCC
697.	H3076C12-3	Fac14	fatty acid-	H3076C12	Mm.143689	Chromosome X	ATCTTTGGCTA
			Coenzyme A				TATTTTCCTGG
			ligase, long				TAGCATATGAC
			chain 4				AAATGTTTCTA
							CAGTGAGAAG
							CTGAGA
698.	H3155C07-3	1810036L03Rik	RIKEN cDNA	H3155C07	Mm.27385	Chromosome 15	GGGTTATAATG
			1810036L03				CACTGAGATCC
			gene				AGAAGTTGGG
							AAAACTCAATA
							AATGTACAAA
							GGAAAGC
699.	K0331C04-3	Sdccag8	serologically	K0331C04	Mm.171399	Chromosome 1	TACTTGTGTGA
			defined colon				CAAGCTAGAG
			cancer antigen				AAGTTACAGA
			8				AGAGAAATGA
							CGAACTAGAA
							GAGCAATGC
700.	J0538B04-3	Laptm5	lysosomal-	J0538B04	Mm.4554	Chromosome 4	TAAATAATCCC
			associated				TTCCCATGAGC
			protein				CCACTGCTCTG
			transmembrane				AATGGACAAG
			5				CTGTCCTTATC
							TTCAAT
701.	H3014E07-3	1810029G24Rik	RIKEN cDNA	H3014E07	Mm.27800	Chromosome 18	AAATAGTTGTT
			1810029G24				TTTAAGGTTGA
			gene				AGGAAGAGAC
							ATTCCGATAGT
							TCACAGAGTAA
							TCAAGG
702.	K0515H12-3	2900064A13Rik	RIKEN cDNA	K0515H12	Mm.268027	Chromosome 2	TGAATCTACAG
			2900064A13				GCAACTCTTCA
			gene				TCTCTGTAATG
							CTACCTGACTT
							CTCTTGTGAGG
							AGCTG
703.	H3159D10-3	BG076403	ESTs	H3159D10	Mm.103300	Chromosome 14	TGGCAAAGAG
			BG076403				TAGATGAGAA
							AATGTTGGATT
							TAAATCAGCAG
							ACTCATTTCAT
							ACTTTGC
704.	K0127F01-3	Prg	proteoglyan,	K0127F02	Mm.22194	Chromosome 10	ACCACGTTTAA
			secretory				ATGACCAGTCT
			granule				CAGGATAAAG
							AGTTTTACAGA
							AAATTTAAAAT
							GCCTGG
705.	L0919B08-3	Bnip31	BCL2/adenovirus	L0919B08	Mm.29820	Chromosome 14	GACATCGTTTT
			E1B 19kDa-				CTCTCTAAATT
			interacting				CAGTAGCAGTT
			protein 3-like				TCATCGACAGT
							GCCATTGAACT
							ATGGG
706.	J0904A09-3	1110060F11Rik	RIKEN cDNA	J0904A09	Mm.4859	Chromosome 4	TCTGTGGGGTT
			1110060F11				CTCATGCCAGT
			gene				GTCTGAAATCT
							CACCTCACTAG
							AGATGTTTCTC
							GAATT
707.	L0270B06-3	D11Ertd759e	DNA segment,	L0270B06	Mm.30111	Chromosome 11	TTCCAGTTCTC
			Chr 11,				ATGTCTTGAGA
			ERATO Doi				TTTCAAGTAAA
			759, expressed				GATGTGTTAGT
							GTAAGCTCAGA
							TCCGA
708.	K0230D06-3	Eafl	ELL associated	K0230D06	Mm.37770	Chromosome 14	AACCATTGGGA
			factor 1				AAATGCAATAC
							AGATAAACTA
							GAGATTCGTAT
							AATGCCACGTG
							TTAGCT
709.	K0611A03-3	AI447904	expressed	K0611A03	Mm.447	Chromosome 1	GTGAATGGAGT
			sequence				GTTTACTGTAT
			AI447904				GTAAGAAAGA
							AGAAAAGTGG
							AACTACATTTG
							CTATGAG
710.	H3155A07-3	BG076050	ESTs	H3155A07	Mm.182857	Chromosome 5	TTCACAATTTA
			BG076050				GACACAAGATT
							TGGAAGATTGA
							AACTGACATGA
							AAGTCTTCTTC
							CTGAG
711.	H3028H11-3	Ctsh	cathepsin H	H3028H11	Mm.2277	Chromosome Multiple	GAAGATTTTTT
						Mappings	GATGTATAAAA
							GTGGCGTCTAC
							TCCAGTAAATC
							CTGTCATAAAA
							CTCCA
712.	L0001D12-3	4833422F06Rik	RIKEN cDNA	L0001D12	Mm.27436	Chromosome 15	AGAATGAACC
			4833422F06				AGAATGGAGA
			gene				AAACGTAAAA
							TTTGAAGAATC
							TCGTTGAAGAG
							CTATTTGC
713.	L0951G01-3	BG061831	ESTs	L0951G01	Mm.133824	Chromosome 10	TCGACAAGAG
			BG061831				GTAATCCGAGA
							AATGGAGCAG
							AAAACCTCCTT
							GCACTTCAGTG
							ATATACA
714.	H3035G02-3	A1314180	expressed	H3035G02	Mm.27829	Chromosome 4	TATATGCAACT
			sequence				TCATAGATCCT
			A1314180				CTGCAATATGT
							ACTTAGCTACC
							TAAGCATGAA
							ATAGAC
715.	C0925G02-3	Fer113	fer-1-like 3,	C0925G02	Mm.34674	Chromosome 19	CGTCATATATC
			myoferlin (C.				CTATTTGTAAT
			elegans)				CAAGAGGAAA
							GACTACATTAA
							GAAGATAGGG
							TGCATAG
716.	C0103H10-3	Il17r	interleukin 17	C0103H10	Mm.4481	Chromosome 6	CTCAGATCAGT
			receptor				TCTTTAGAAAG
							AGCTGGTATAG
							AAATGGGTGAT
							GTAAAACTTGA
							GAAGC
717.	H3129F05-3	Mrpl16	mitochondrial	H3129F05	Mm.203928	Chromosome 19	AATGAAAATCT
			ribosomal				GCGTCTAACTT
			protein L16				TTGAAAGTAAG
							TGTTAACTTAC
							TTGAATGCTGG
							TTCCC
718.	L0942B12-3		Mus musculus	L0942B12	Mm.214553	Chromosome 15	AATCTTCGACC
			12 days embryo				AGACATTGGAT
			spinal ganglion				ATTTGAACTAT
			cDNA, RIKEN				CCTGAAACATT
			full-length				TTAGAAATATC
			enriched				CAGGC
			library,
			clone:D130046
			C24
			product:unknown
			EST, full
			insert sequence
719.	L0009B09-3	Plcg2	phospholipase	L0009B09	Mm.22370	Chromosome 8	TACCCCATTAA
			C, gamma 2				AGGCATCAAAT
							CCGGGTTTAGA
							TCAGTCCCTCT
							GAAGAATGGG
							TACAGT
720.	C0665B08-3	Sh3bp1	SH3-domain	C0665B08	Mm.4462	Chromosome 15	TTTTTTCTCTTG
			binding protein				CCAATGTATTT
			1				TTGTAAGGCTC
							GTAAATAAATT
							ATTTTGAACAA
							AACA
721.	H3102F04-3	Rgs10	regulator of G-	H3102F04	Mm.18635	Chromosome 7	CACACCCTCTG
			protein				ATGTTCCAAAA
			signalling 10				GCTCCAGGACC
							AGATCTTCAAT
							CTCATGAAGTA
							TGACA
722.	K0547F06-3		transcribed	K0547F06	Mm.162929	Chromosome 19	CCCAGGTATTT
			sequence with				CTAAGCATGCT
			moderate				AGGTTTGAGGT
			similarity to				CATTTACCATG
			protein				TTCAAATAAAA
			sp:P00722 (E.				GACGG
			coli)
			BGAL_ECOLI
			Beta-
			galactosidase
			(Lactase)
723.	H3087C07-3	Glb1	galactosidase,	H3087C07	Mm.255070	Chromosome 9	GGAGCAAAAC
			beta 1				TTGAATAATGT
							CCTTTATCCTG
							ATTTGAAATAA
							TCACGTCATCT
							TTCTGC
724.	J0437D05-3	AU023716	ESTs	J0437D05	Mm.173654	Chromosome X	TGGAATAAGA
			AU023716				AAGAATCTGTG
							GTAGAAATAAT
							AGACTTGCTAC
							ATAGGGTTAGC
							TAAGGC
725.	H3156A09-3	Pex12	peroxisomal	H3156A09	Mm.30664	Chromosome 11	ACCACAGTTTA
			biogenesis				TCAGCATTTGA
			factor 12				AGATTTCCTTG
							ATGATCCATAC
							TTGTCTTGGGA
							TAGGG
726.	G0108H12-3	Ly6e	lymphocyte	G0108H12	Mm.788	Chromosome 15	AGGGTCAGCG
			antigen 6				CCGAATCTTGT
			complex, locus				GGACACACTG
			E				ACAAGGATGTC
							TAATCCAAATA
							GATGTAT
727.	H3098D12-5	Map2k1	mitogen	H3098D12	Mm.248907	Chromosome 9	AGTGGAGTATT
			activated				CAGTCTGGAGT
			protein kinase				TTCAGGATTTT
			kinase 1				GTGAATAAATG
							CTTAATAAAGA
							ACCCT
728.	C0637C02-3	Zmpste24	zinc	C0637C02	Mm.34399	Chromosome 4	TTTGGGCCCTT
			metalloproteinase,				AAAAACATATT
			STE24				TCAGTTTTGCC
			homolog (S.				CAAGTGAGGC
			cerevisiae)				CTTAAAAATTG
							CCCATG
729.	H3119B06-3	Atplb3	ATPase,	H3119B06	Mm.424	Chromosome Multiple	AAAGGAAAAT
			Na+/K+			Mappings	AAAGTGGATCT
			transporting,				GAAAGTAGAC
			beta 3				TCTGCTTCTGC
			polypeptide				GCATGTGTGAG
							TGGTGCC
730.	C0176B06-3	Ubl1	ubiquitin-like 1	C0176B06	Mm.259278	Chromosome Multiple	TTCACTCCTGG
						Mappings	ACTGTGATTTT
							CAGTGGGAGA
							TGGAAATTTTT
							CAGAGAACTG
							AACTGTG
731.	C0626D04-3	9130404D14Rik	RIKEN cDNA	C0626D04	Mm.219676	Chromosome 2	CACCATCCTTC
			9130404D14				CAGAATATGGT
			gene				ATGAAAAATCT
							ATGCAAACTGT
							GTAAGCTTTTG
							CTCAT
732.	H3155E07-3	Dock4	dedicator of	H3155E07	Mm.145306	Chromosome 12	TTGTGGAGTGT
			cytokinesis 4				GAAATAAAGG
							ATAATTGCCTA
							CCTCTAGCAAG
							TGGATCTTATT
							ATGTTG
733.	C0106A05-3	H2-Eb1	histocompatibility	C0106A05	Mm.22564	Chromosome 17	ACCAGAAAGG
			2, class II				ACAGTCTGGAC
			antigen E beta				TTCAGCCAACA
							GGACTCCTGAG
							CTGAGATGAA
							GTAACAA
734.	H3037B09-3		Mus musculus	H3037B09	Mm.274876	Chromosome 7	GATACTGCCGG
			12 days embryo				CTTTGAAAATG
			spinal cord				AAGAACAGAA
			cDNA, RIKEN				GCTAAAATTCC
			full-length				TGAAGCTTATG
			enriched				GGTGGC
			library,
			clone:C530028
			D16
			product:231000
			8H09RIK
			PROTEIN
			homolog [Mus
			musculus], full
			insert sequence.
735.	H3003b09-3	F730017H24Rik	RIKEN cDNA	H3003B09	Mm.205421	Chromosome 14	CCATTTGAGCC
			F730017H24				TCACTGCAATG
			gene				TTAGTGCAGAG
							GAGAAAACAA
							TTTTTAATGTA
							ATCTTG
736.	C0909E10-3	Pign	phosphatidylino-	C0909E10	Mm.268911	Chromosome 1	GGCAACTTGTA
			sitol glycan,				AAGTGTGTTCA
			class N				TTCTAACTGTT
							AAACTGAGAA
							AACTTGAGAAC
							ATACTG
737.	H3045G01-3	BG066588	ESTs	H3045G01	Mm.26804	Chromosome 14	CAGAAGAGAT
			BG066588				TCTGAAAATGT
							TAGTTGTGGTG
							ACTCTAATGTA
							GATCCATAATCT
							GAAAAG
738.	H3006E10-3		transcribed	H3006E10	Mm.218665	Chromosome 15	TATCGTAAGTT
			sequence with				GCACCTATTGT
			weak similarity				TAAGTGGAAA
			to protein				ATGCTCTGATT
			sp:Q9H321				ACACTCAGGA
			(H. sapiens)				AGCTGGG
			VCXC_HUMA
			N VCX-C
			protein
			(Variably
			charged protein
			X-C)
739.	H3098H09-3	2310016E02Rik	RIKEN cDNA	H3098H09	Mm.21450	Chromosome 5	TGTTTTGTCCC
			2310016E02				TAAATCACCAC
			gene				CACTCACTATT
							TCTCCCAGGGT
							CTGATAATGCC
							TTTAC
740.	J0540D09-3	Adam9	a disintegrin	J0540D09	Mm.28908	Chromosome 8	AGCCACTTTAA
			and				CTCTAAACTCG
			metalloproteinase				AATTTCAAAGC
			domain 9				CTTGAGTGAAG
			(meltrin				TCCTCTAGAAT
			gamma)				GTTTA
741.	L0208C06-3	Pknox1	Pbx/knotted 1	L0208C06	Mm.259295	Chromosome 17	GCTTTGTTTAA
			homebox				ATGGTCAGACT
							CCCAAACATTG
							GAGCCTTTTGA
							ATGTGTTCTGA
							GACCT
742.	H3154G05-3	Napg	N-	H3154G05	Mm.154623	Chromosome 18	CCTTAGAAAGA
			ethylmaleimide				TGGTAATTCAC
			sensitive fusion				TTTAGGTAAAA
			protein				GTACTATTTCA
			attachment				CGCCATTATGA
			protein gamma				AACCC
743.	L0854E11-3	1500032M01Rik	RIKEN cDNA	L0854E11	Mm.29628	Chromosome 19	TAAAATGAGG
			1500032M01				CTTTTGGAAAG
			gene				AAAGATGAAA
							ACGTAGAATGT
							AGTGCTAAGA
							ACGTTTCC
744.	H3014C06-3	B2m	beta-2	H3014C06	Mm.163	Chromosome 2	GCAGTTACTCA
			microglobulin				TCTTTGGTCTA
							TCACAACATAA
							GTGACATACTT
							TCCTTTTGGTA
							AAGCA
745.	K0538G12-3	Ccr2	chemokine (C-	K0538G12	Mm.6272	Chromosome 9	TGCTTAGAACT
			C) receptor 2				ACATAGAATCA
							GAAGCAAAAT
							GGATGCCTTAG
							CACTGAGGAA
							AGGTTTC
746.	J0819C09-3	C030002B11Rik	RIKEN cDNA	J0819C09	Mm.70065	Chromosome 10	GGTTTTCGAAC
			C030002B11				CACGTACCTTT
			gene				ATGCCTCGTGA
							TTGTGAAACAT
							TGACTTTTGTA
							AACCC
747.	C0175B11-3	Histlh2bc	histone 1, h2bc	C0175B11	Mm.21579	Chromosome 13	GTTCACTGTAG
							AAATTTGTGAT
							AAGAAAGACA
							CACAGACGTA
							GAAAATGAGA
							ATACTTGC
748.	H3009B11-3	Nufip1	nuclear fragile	H3009B11	Mm.21138	Chromosome 14	AAGACTTTTT
			X mental				TGGACTTAATA
			retardation				CTGATTCTGTG
			protein				AAAACTGAAG
			interacting				AAGTGTAGATG
			protein				TCTCCC
749.	H3135D02-3	Lamp2	lysosomal	H3135D02	Mm.486	Chromosome X	CTGGTGTGGGA
			membrane				TATTTTCCACA
			glycoprotein 2				CTTTAGAATTT
							GTATAAGAAA
							CTGGTCCATGT
							AAGTAC
750.	K0540G08-3	1200013B08Rik	RIKEN cDNA	k0540g08	Mm.247440	Chromosome X	TAAAGGTTTTA
			1200013B08				GTGTCCTAACT
			gene				CCCCAGGATCA
							GGAGATTATCC
							CAACTATTTCT
							GGGGT
751.	H3089H05-3	Lnx2	ligand of numb-	H3089H05	Mm.34462	Chromosome 5	CTGAATTTTGA
			protein X 2				TCACTTGTGGT
							TTCTCATGGTG
							ACCTCCATTTG
							CAACAAAAAG
							ATGTCT
752.	J0203A08-3	C85149	ESTs C85149	J0203A08	Mm.154684	Chromosome 2	TGTGCTTTACC
							AAAATGGGAA
							ATAATTCTGCT
							TTAGAGGATAC
							TATCAAGACAA
							CCTTAC
753.	H3119F01-3	Mcfd2	multiple	H3119F01	Mm.30251	Chromosome 17	TCTGTGAGATG
			coagulation				TTGTAGACATT
			factor				CCGTAAGAGA
			deficiency 2				ATCCAGAATGA
							TAGCAGGATCA
							GGAAAG
754.	H3134C05-3	Mglap	matrix gamma-	H3134C05	Mm.243085	Chromosome 6	CTTACATGATC
			carboxyglutamate				TCCTAAAAGGA
			(gla) protein				TGGGCCCCTCC
							TTCCTTTTGCG
							GGTTGAAAGTA
							ATGAA
755.	C0147D11-3	B230215M10Rik	RIKEN cDNA	C0147D11	Mm.41525	Chromosome 10	CTGTTTAAAAA
			B230215M10				ATGAAATCAG
			gene				GAAGCTTGAA
							GAAGACGATC
							AGACGAAAGA
							CATTTGAGC
756.	C0949H10-3	Sulf1	sulfatase 1	C0949H10	Mm.45563	Chromosome 1	TGAATATAGTA
							GGGCCATGAGT
							ATATAAAATCT
							ATCCAGTCAAA
							ATGGCTAGAAT
							TGTGC
757.	K0114E04-3	BM222075	ESTs	K0114E04	Mm.221705	Chromosome 19	GGGGGAAATT
			BM222075				CTATATGAGCT
							TCGTTTTCTAA
							TGACTTACATG
							GATAGTATGGA
							AACTTC
758.	H3012C03-3	Cappa1	capping protein	H3012C03	Mm.19142	Chromosome Multiple	AAACTTGAAA
			alpha 1			Mappings	ACACAGACATT
							GAAGGAATCA
							TAGGTATTTTT
							GCTTTATGCTC
							TCTGGCA
759.	C0507E11-3	BE824970	ESTs	C0507E11	Mm.139860	Chromosome 16	AATAAGCAGG
			BE824970				AAGAATTTGAC
							TTGGAAAACTA
							ATACACGCATG
							TTAGGCATTCT
							CAAGGC
760.	H3158D06-3	Lnk	linker of T-cell	H3158D06	Mm.200936	Chromosome 5	TCCCACTGTTT
			receptor				ACAGATGTAGT
			pathways				TCTTGTGCACA
							GGTGCCACTAG
							CTGGTACCCTA
							GGCCT
761.	C0174C02-3	Pold3	polymerase	C0174C02	Mm.37562	Chromosome 7	TATTTTTGTCA
			(DNA-				TTGCCTCTAGT
			directed), delta				GATTTTTGTAA
			3, accessory				ATGGGAATGG
			subunit				AAAAGTACAA
							GGCAACC
762.	C0130G10-3	Cklfst7	chemokine-like	C0130G10	Mm.35600	Chromosome 9	TTAACTGGCCT
			factor super				GTCAAACTGGT
			family 7				CTTGAAGCGTC
							TCTAAGTGAAG
							AGCCAGAAGA
							AACCCT
763.	C0137F07-3	Rik3cb	phosphatidylino-	C0137F07	Mm.213128	Chromosome 9	CAATGTGATTT
			sitol 3-kinase,				TTCAATGGTAT
			catalytic, beta				TAGTTCAAATT
			polypeptide				GACGTGGATTC
							ATGCCACATGG
							AAATC
764.	H3115F01-3	2610027O18Rik	RIKEN cDNA	H3115F01	Mm.46501	Chromosome 12	AACTGAATAA
			2610027O18				AGTTGACCAGA
			gene				AAGTGAAAGT
							CTTTAACATGG
							ATGGAAAAGA
							CTTCATCC
765.	H3097F03-3		Mus musculus,	H3097F03	Mm.227202	Chromosome 3	GGATATAAAGT
			clone				GTATTTCTTTC
			IMAGE:53723				AGTGATTTCTC
			38, mRNA				AGTGCATAAG
							AAGTGCATAA
							GTCTCAG
766.	H3059A05-3	Mad211	MAD2 (mitotic	H3059A05	Mm.43444	Chromosome 6	TAGCTTTTTAA
			arrest deficient,				AAGAAGTTTTT
			honolog)-like 1				CTACCTACAGT
			(yeast)				GACCATTGTTA
							AAGGAATCCAT
							CCCAC
767.	L0935E02-3	Syk	spleen tyrosine	L0935E02	Mm.248456	Chromosome 13	ATTTGCAAGGT
			kinase				CAGAAACTAG
							CCAAGGTCCTT
							CTCAGGCATCT
							ATCCTTAACTT
							GGTCTC
768.	C0946F08-3	1110014L17Rik	RIKEN cDNA	C0946F08	Mm.30103	Chromosome 11	TTGGAATTTGA
			1110014L17				GGAGGAGAAA
			gene				TGAAAAAACA
							GTGTGTCCCTG
							GTGTCACCCTG
							GCATCAT
769.	H3079F02-5		Possibly	H3079F02	Data not found	Chromosome 10	TCTTATGATTT
			intronic in				AAGTGATTGGT
			U011488-				GGATAAATGTA
			H3079F02				TAGGAATTTTA
							CACTCCAGCAG
							CATGG
770.	H3137E07-3	III0ra	interleukin 10	H3137E07	Mm.26658	Chromosome 9	GCCTCAAATGG
			receptor, alpha				AACCACAAGT
							GGTGTGTGTTT
							TCATCCTAATA
							AAAAGTCAGG
							TGTTTTG
771.	C0143H12-3	Galns	galactosamine	C0143H12	Mm.34702	Chromosome 8	CCGTACACAAA
			(N-acetyl)-6-				AGTGAAGATTT
			sulfate sulfatase				CAGCGAAATG
							CCAAGGAAGT
							GCCATCTATCT
							GGCTTCT
772.	H3114D03-3	Man2a1	mannosidase 2,	H3114D03	Mm.2433	Chromosome 17	AAGAAATGC
			alpha 1				TGTATGATGTT
							AGAAGACATT
							GTAATTATCAT
							CCCGTGTCTTT
							GCTGTAC
773.	H3041H09-3	BG066348	ESTs	H3041H09	Mm.270044	Chromosome 8	GGCATTTCAGT
			BG066348				TTATCTTGGGT
							TTGTAATTAGT
							TAAAACAAAA
							ACCAACCTAGG
							TCTGTG
774.	C0628H04-3	Slc2a12	solute carrier	C0628H04	Mm.268014	Chromosome 10	ATTAGCCAAGG
			family 2,				AGTCCGGACAT
			memeber 12				AATATTTATCC
							AGATCTCTAAG
							CAGTTAGCTTT
							AAATT
775.	K0125E07-3	Ifngr	interferon	K0125E07	Mm.549	Chromosome 10	TACATTAGCTA
			gamma receptor				ATACTAACCAC
							ATAGAATATCA
							GACTTAGATAC
							GTGAATAGGG
							ATCCTG
776.	G0115E02-3	Sdcbp	syndecan	G0115E02	Mm.276062	Chromosome 4	AAGATTTTCTA
			binding protein				GTCACTGCATA
							AAGGAAACGC
							CTAAGAGTTGC
							CGTATTGCTTT
							CTGAGA
777.	C0032B05-3	Rap2b	RAP2B,	C0032B05	Mm.26939	Chromosome 3	ACAAGAATTCA
			member of				TTCTTAACATT
			RAS oncogene				TGAACGAGTGT
			family				ATTTGCTTAGG
							TCGATGAAAGT
							GTTGC
778.	H3141C08-3	Ofd1	oral-facial-	H3141C08	Mm.2474889	Chromosome X	AGGATTTTCTC
			digital				ATGAAGAACC
			syndrome 1				AGATGACATGT
			gene homolog				GGTAATAACAT
			(human)				TAGCTGTCTAG
							TTTCTC
779.	H3157C05-3	BG076236	ESTs	H3157C05	Mm.182877	Chromosome 1	TAGAGTCTGA
			BG076236				AGAACAGAAA
							TTCAAGGTCAT
							TTTCAATTACA
							GAGTGAGGTTA
							GAGCCA
780.	H3076A01-3	5031439G07Rik	RIKEN cDNA	H3076A01	Mm.121973	Chromosome 15	TCTAAAACATG
			5031439G07				CCAAATGACTT
			gene				ATGTCACAAAG
							AATAGGTCCTA
							ATATACTGTAT
							ACCCC
781.	H3080D06-3	BC01807	cDNA sequence	H3080D06	Mm.139738	Chromosome 13	GTGTTTCTTCC
			BC018507				CATTTGTAAAT
							GTCCTGAACCA
							TAAATTACTAT
							CAGGATTAACT
							GACAG
782.	L0518D04-3	Uap1	UDP-N-	L0518D04	Mm.27969	Chromosome 1	GAAGCTGGAA
			acetylglucosamine				GCATTTGTTTT
			pyrophosphorylase				TGAAGTTGTAC
			1				ATATTGATAAG
							TCAGCGTATGT
							GTCAGA
783.	K0541B11-3	BM239901	ESTs	K0542B11	Mm.222307	Chromosome 2	TTACATGGCAA
			BM239901				ATCTGAAAGG
							AAGACTTAAGC
							AGGGTAAAGTT
							AATTGAAAGG
							AGGAGCT
784.	L0959D03-3	Tnfrsfla	tumor necrosis	L0959D03	Mm.1258	Chromosome 6	AGCAATCTTTG
			factor receptor				TATCAATTATA
			superfamily,				TCACACTAATG
			member 1a				GATGAACTGTG
							TAAGGTAAGG
							ACAAGC
785.	H3035C07-3	BG065787	ESTs	H3035C07	Mm.24933	Chromosome 1	GGTGTAGGAA
			BG065787				ATAAAGTTTAG
							TCAATGTTGAA
							AATCTCTCCTG
							GTTGAATGACT
							TGCTC
786	M29855.1	Csf2rb2	colony	M29855	Mm.1940	Chromosome 15	CTTTCAGTCTC
			stimulating				CTTCTGTGTCT
			factor 2				CGAACCTTGAA
			receptor, beta 2				CAGGATGTGAT
			low-affinity				AACTTTTCTAG
			(granulocyte-				ACCAC
			macrophage)
787.	C0352C11-3	BM197981	ESTs	C0352C11	Mm.215584	Chromosome 2	GACTGTTTCTG
			BM197981				GGAAAATAAG
							TATGTGAAGTG
							ATGCAGAAAA
							TCCATCTAGAC
							AGTTGAG
788.	L0846B10-3	BM117093	ESTs	L0846B10	Mm.216113	No Chromosome	TGGTGGCTTGA
			MN117093			location	TTGATTTGATC
						info available	TGAGAGCAGTT
							TATAACATAAT
							GGAGAACTGTT
							TGCAG
789.	L0227C06-3	Serpinb6a	serine (or	L0227C06	Mm.2623	Chromosome 13	AGAAGTCTACC
			cysteine)				TTTAAGATGAC
			proteinase				CTATATTGGAG
			inhibitor, clade				AGATATTCACT
			B, member 6a				AAGATTCTGTT
							GCTTC
790.	J0214H09-3	Serpina3g	serine (or	J0214H09	Mm.264709	No Chromosome	ACTCTCTGGTC
			cysteine)			location	ATGATGGTTTT
			proteinase			info available	CCGAAATCAG
			inhibitor, clade				GTTCCTGACCT
			A, member 3G				GAAAATTTGGG
							TTAATC
791.	H3077F12-3	Arhh	ras homolog	H3077F12	Mm.20323	Chromosome 5	GTTTTTCAT-
			gene family,				GCT
			member H				TTGGAAGTCTT
							TTCTTTGAAAA
							GGCAAACTGCT
							GTATGAGGAG
							AAAATA
792.	C0341D05-3	BM196992	ESTs	C0341D05	Mm.222093	Chromosome 1	GTGTGTAGGAA
			BM196992				AATGTAATTAA
							GTACAAGGCTT
							GTTTATGGGTG
							GCTATGGAATG
							CAGTC
793.	H3043H11-3	BG066522	ESTs	H3043H11	Mm.25035	Chromosome 6	GTTTCCTCATC
			BG066522				AGGTGTAATGG
							CGTGTCCTAAT
							GAAGCTATTC
							TTATGTATAAC
							AGAGA
794.	K0507D06-3		Mus musculus,	K0507d06	Mm.103545	Chromosome 11	TGAAAAAATG
			clone				AAAAGAATCA
			IMAGE:12632				GAGATGAAAT
			53, mRNA				AGGAGCGCTC
							AGAAGTTTTTA
							TGTTCTCCC
795.	J0535D11-3	AU020606	ESTs	J0535D11	Mm.26229	Chromosome 11	AAAGAAATGA
			AU020606				AAACCGTCATT
							TGCGATTTTCA
							GGGTACGTTTC
							TAATGTATCCA
							GAAGTC
796.	H3152F04-3	Sepp1	selenoprotein P,	H3152F04	Mm.22699	Chromosome 15	TTTCCAGTGTT
			plasma, 1				CTAGTTACATT
							AATGAGAACA
							GAAACATAAA
							CTATGACCTAG
							GGGTTTC
797.	L0701F07-3	H2-Ab1	histocompatilility	L0701F07	Mm.275510	Chromosome 17	TTTTGACTCAG
			2, class II				TTGACTGTCTC
			antigen A, beta				AGACTGTAAG
			1				ACCTGAATGTC
							TCTGCTCCGAA
							TTCCTG
798	L0227H07-3	Clca1	chloride	L0227H07	Mm.275745	Chromosome 3	CCCGAGTTACT
			channel calcium				AACAACATTCT
			activated 1				TTTGCTATATG
							TAGATCAAGAT
							TAACAGTTCCT
							CATTC
799.	J1014C11-3	2900036G02Rik	RIKEN cDNA	J1014C11	Mm.80676	No Chromosome	GTTTTGGTGCA
			2900036G02			location	AAAGTCGTCCT
			gene			info available	GTGTCTCTTGT
							TCCCTTCATTA
							GAAAACATGCT
							AGAGG
800.	H3134H09-3	BG074421	ESTs	H3134H09	Mm.197381	Chromosome 12	AGGAAGGAAA
			BG074421				ATAGGCTTTGT
							TGTATGTACAT
							AAGTGGAATTA
							ACAAGAGTCTT
							TAGTCC
801.	G0116A07-3	Atp6vblc1	ATPase, H+	G0116A07	Mm.276618	Chromosome 15	TACAGGGAAT
			transporting				GGTCTAAGCAT
			V1 subunit C,				ACCATTTCATT
			isoform 1				CACTGTATTAG
							TAGACATAACT
							GTTGAG
802.	L0942F05-3	Ostm1	osteopetrosis	L0942F05	Mm.46636	Chromosome 10	GAAACGGGCTT
			associated				TGTTGTAAAGG
			transmembrane				TAATGAATAGG
			protein 1				AAACTCCTCAG
							ATTCAATGGTT
							AAGAA
803.	C0912H10-3	0610041E09Rik	RIKEN cDNA	C0912H10	Mm.132926	Chromosome 13	AAGTTAAGGA
			0610041E09				AATACTGAGA
			gene				ATCGGTCAGTT
							AACACTCTGAA
							AAGCTATTCAA
							AGCATAG
804.	C0304E12-3	Pde1b	phosphodiesterase	C0304E12	Mm.62	Chromosome 15	AAATACATGCA
			1B, Ca2+-				TTTGTACAGTG
			calmoduin				GGCCCTGTTCT
			dependent				TGTGAAGTCCA
							TCTCCATGGTC
							ATTAG
805.	L0605C12-3	4930579K19Rik	RIKEN cDNA	L0605C12	Mm.117473	Chromosome 9	CCGTTTTATTG
			4930579K19				ATTGGAAATGT
			gene				AAGACTCAAA
							GAACTCAGGTT
							TACTGGCCAAG
							ATGGCA
806.	K0539A07-3	Cd53	CD53 antigen	K0529A07	Mm.2692	Chromosome 3	GGAAAGAGAG
							ATCAAACTAGG
							AACCTACAAG
							ATAGTTCACTA
							GCCTAAGATCT
							TTACTTG
807.	L0228H12-3	6430628I05Rik	RIKEN cDNA	L0228H12	Mm.196533	Chromosome 9	TTGATTGGTGT
			6430658I05				TTCTGAGCATT
			gene				CAGACTCCGCA
							CCCTCATTTCT
							AATAAATGCA
							ACATTG
808.	L0855B10-3	BM117713	ESTs	L0855B10	Mm.216997	Chromosome 10	CTAGTGAAATT
			BM117713				TATGTCAGAAT
							GACATATCTGA
							ACTCTGAATTC
							ATCTCTAGTTT
							CCACG
809.	H3075B10-3	2810404F18Rik	RIKEN cDNA	H3075B10	Mm.29476	Chromosome 11	TAGTTAATACT
			2810404F18				TCTCTGAAATA
			gene				CATGGTAACAA
							CTAGTAAGCAA
							GAGATACCGC
							AGATTG
810.	L0022G07-3		L0033G07-3	L0022G07		No Chromosome	TGGATTATTCC
			NIA Mouse			location	CGCCAAAGCA
			E12.5 Female			info available	CCCAAGTCGGC
			Mesonephros				CTGTTTAATTG
			and Gonads				GAGAAAGATG
			cDNA Library				GAATTAA
			Mus musculus
			cDNA clone
			L0022G07 3′,
			MRNA
			sequence
811.	H3107C11-3	Efemp2	epidermal	H3107C11	Mm.471781	Chromosome 19	GATCCAGGCA
			growth factor-				ACCTCTGTTTA
			containing				CCCTGGGGCCT
			fibulin-like				ACAATGCCTTT
			extracellular				CAGATCCGTTC
			matrix protein 2				TGGAAA
812.	H3025H12-3	1200003O06Rik	RIKEN cDNA	H3025H12	Mm.142104	Chromosome 3	GTTCCATCTGA
			1200003O06				CTTAAACAAAA
			gene				ACCGTAGTTTC
							CAGCTCAGAAT
							CATCCTAACAT
							AGAAA
813.	J0040E05-3	Stx3	syntaxin 3	J0040E05	Mm.203928	Chromosome 19	GTAGGGGAAT
							AACTAACCAA
							AGTAGAGGGA
							ATTCTAAGTTT
							AGTAGTAAATG
							TGGCTTGG
814.	H3075F03-3	Cls	complement	H3075F03	Mm.24128	Chromosome 6	GGTGTGGGACT
			component 1, s				TATGGGGTCTA
			subcomponent				CACAAAGGTA
							AAGAATTACGT
							GGACTGGATCC
							TGAAAA
815.	L0600G09-3	BM125147	ESTs	L0600G09	Mm.221784	Chromosome 1	AGGTATGACAT
			BM125147				TTTACATCCTT
							GAATCTTACTT
							ACTATGTGCTA
							AACAATTGGCA
							GAAGG
816.	K0115H01-3	KLHL6	kelch-like 6	K0115H01	Mm.86699	Chromosome 16	TGCTTGTGTGA
							ACTACCTCAGG
							ATGAAGGGTA
							ATGTTTAACAT
							TCCATACATGC
							CTACTG
817.	H3015B10-2	Gus	beta-	H3015B10	Mm.3317	Chromosome 5	CGATGGACCCA
			glucuronidase				AGATACCGAC
							ATGAGAGTAGT
							GTTGAGGATCA
							ACAGTGCCCAT
							TATTAT
818.	H3108A12-3	0910001A06Rik	RIKEN cDNA	H3108A12	Mm.22383	Chromosome 15	GCAGCCAAAA
			0910001A06				TGGAAATGTTT
			gene				AAATTAACTGT
							GTTGTACAAT
							GACCCAACAC
							AAAACC
819.	H3108H90-5		UNKNOWN:	H3108H09	Data not found	Chromosome 13	TTGACATGATA
			Similar to				CATTACGCCTT
			Homo sapiens				TGCAGTGAGCT
			KIAA1577				AATAAGCTAAC
			protein				ATTTGTGCACA
			(KIAA1577),				GATAA
			mRNA
820.	K0645H01-3	Fyb	FYN binding	K0645H01	Mm.257567	Chromosome 15	TCTCAACTCAT
			protein				CTCAGATTAGG
							AAGTATTTGGC
							AGTATTAGCA
							TCATGTGTCCC
							TGTGA
821.	H3029A02-3	Shyc	selective	H3029A02	Mm.12912	Chromosome 7	ATTTTCATGCC
			hybridizing				GAATATTCCAG
			clone				CAGCTATTATA
							AAATGCTAAAT
							TCACTCATCCT
							GTACG
822.	K0410D10-3	Cxcl12	chemokine (C-	K0410D10	Mm.465	Chromosome 6	GAGAATTAATC
			X-C motif)				ATAAACGGAA
			ligand 12				GTTTAAATGAG
							GATTTGGACTT
							TGGTAATTGTC
							CCTGAG
823.	H3118H11-3	Snrpg	small nuclear	H3118H11	Mm.21764	Chromosome 18	CATGAGCAAA
			ribonucleoprotein				GCCCACCCTCC
			polypeptide G				CGAGCTGAAG
							AAGTTTATGGA
							CAAGAAGTTAT
							CATTGAA
824.	K0517D08	BM238427	ESTs	K0517D08	Mm.222266	Chromosome 19	CTCTGTAAAGT
			BM238427				CAAGTTGCATT
							GCATTTACAGT
							TAATTATGGAA
							AAGTCCTAAAT
							CTGGC
825.	L0227G11-3	Sh3d1B	SH3 domain	L0227G11	Mm.40285	Chromosome 12	TTTTCAGGGCT
			protein 1B				ATAAAAGTATT
							ATGTGGAAATG
							AGGCATCAGA
							CCACCGGACGT
							TACCAC
826.	H3134B10-3	6530409L22Rik	RIKEN cDNA	H3134b10	Mm.41940	Chromosome Multiple	AAGAAGCTGA
			6530409L22			Mappings	GGAAAAACAG
			gene				GAGAGTGAGA
							AACCGCTTTTG
							GAACTATGAGT
							TCTGCTCT
827.	H3115A08-3	Ly6a	lymphocyte	H3115A08	Mm.263124	Chromosome 15	CCTGATGGAGT
			antigen 6				CTGTGTTACTC
			complex, locus				AGGAGGCAGC
			A				AGTTATTGTGG
							ATTCTCAAACA
							AGGAAA
828.	C0120G03-3	Csk	c-src tyrosin	C0120G03	Mm.21974	Chromosome 9	AGCAAATGGG
			kinase				CATTTTACAAG
							AAGTACGAATC
							TTATTTTTCCT
							GTCCTGCCCCT
							GGGGGT
829.	H3094G08-3	Tigd2	tigger	H3094G08	Mm.25843	Chromosome 6	CTGCACTTGAA
			transposable				TGGACTGAAA
			element derived				ACTTGCTGGAT
			2				TATCTAGAACA
							ACAAGATGAC
							ATGCTAC
830.	NM_008362.1	IIlr1	interleukin 1	NM_008362	Mm.896	Chromosome 1	AGATTTCACCG
			receptor, type 1				TACTTTCTGAT
							GGTGTTTTTAA
							AAGGCCAAGT
							GTTGCAAAAGT
							TTGCAC
831.	C0300E10-3	Trps1	trichorhinophal	C0300E10	Mm.30466	Chromosome 15	ATAAAACCAC
			angeal				AAACTAGTATC
			syndrome I				ATGCTTATAAG
			(human)				TGCACAGTAGA
							AGTATAGAACT
							GATGGG
832.	L0274A03-3	Ptpn2	protein tyrosine	L0274A03	Mm.260433	Chromosome 18	ACCTAAATGTT
			phosphate,				CATGACTTGAG
			non-receptor				ACATTCTGCA
			type 2				GCTATAAAATT
							TGAACCTTTGA
							TGTGC
833.	H3005H07-3	1810031K02Rik	RIKEN cDNA	H3005H07	Mm.145384	Chromosome 4	TTTATAGTTCT
			1810031K02				AGGTTTACACC
			gene				AGAGAGGAGT
							TAATTTATCAA
							CAGCCTAAAAC
							TGTTGC
834.	H3109H12-3	1810009M01Rik	RIKEN cDNA	H3109H12	Mm.28385	Chromosome Multiple	TTCTTCCACGA
			1810009M01			Mappings	ACAGATATTAT
			gene				GTCATTTTATC
							CAATGCCCGATA
							AAGGAGAAAC
							AACTTG
835.	J0008D01-3	Enpp1	ectonucleotide	J0008D01	Mm.27254	Chromosome 10	TACGTGGTCTG
			pyrophosphatase/				GGGACCTGATG
			phosphodiesterase				TTGGAATCCTA
			1				TTGTTGTTAAT
							AAAACTGAGT
							AAAGGA
836.	H3119HO5-3	Mafb	v-maf	H3119H05	Mm.233891	Chromosome 10	ACCAACTTCTG
			musculoaponiurotic				TCAAAGAACA
			fibrosarcoma				GTAAAGAACTT
			oncogene				GAGATACATCC
			family, protein				ATCTTTGTCAA
			B (avian)				ATAGTC
837.	H3048G11-3	Blvrb	biliverdin	H3048G11	Mm.24021	Chromosome 7	TGACACAAATA
			reductase B				GAGGGGTCAA
			(flavin				TAAATTTTTAG
			reductase				CCAAAAGCTTC
			(NADPH))				AAATTCTTTCA
							GGAAGC
838.	H3107D05-3	1110004C05Rik	RIKEN cDNA	H3107D05	Mm.14102	Chromosome 7	ATCACCATTGT
			1110004C05				TAGTGTCATCA
			gene				TCATTGTTCTT
							AACGCTCAAA
							ACCTTCACACT
							TAATAG
839.	H3006B01-3	Cklfsf3	chemokine-like	H3006B01	Mm.292081	Chromosome 8	GCCGCTTTTTT
			factor super				GTAACCTAAAA
			family 3				GGCCCCATGAA
							TAAGGGCCCAT
							GTTTTGGGCAT
							TTGTA
840.	L0853H04-3		transcribed	L0853H04	Mm.275315	Chromosome 12	CCAAGAACAA
			sequence with				GTATAAACTTA
			weak similarity				AGCTCTGTAGA
			to protein				ACTGAAATTCT
			pir:A43932				TTCAAGTCCTT
			(H. sapiens)				TCGATC
			A43932 mucin
			2 precursor,
			intestinal-
			human
			(fragments)
841.	C0949G05-3	BM221093	ESTs	C0949G05	Mm.221696	Chromosome 6	AGGACATCTTG
			BM221093				CAACTTCTATG
							CASATAATAAG
							GATTTCCATCT
							GACAAATAAG
							ACAAGTG
842.	K0648D10-3	tlr1	toll-like	K0648D10	Mm.33922	Chromosome 5	GGGGAGTTCTA
			receptor 1				ATAATAGTACC
							ATTCATATCAG
							CAAGAACCTA
							AAAATGGTTCT
							GACTTT
843.	H3014E09-3	BC016443	cDNA sequence	H3014E09	Mm.27182	Chromsome 11	TGCCACTAGTT
			BC017643				CTGACTTGGGG
							AATATGGTCCC
							TTAAACATGCC
							AAAGTGAGCTT
							TTTAA
844.	H3022D06-3	Il2rg	interleukin 2	H3022D06	Mm.2923	Chromosome X	CATCAATCCTT
			receptor,				TGATGGAACCT
			gamma chain				CAAAGTCCTAT
							AGTCCTAAGTG
							ACGCTAACCTC
							CCCTA
845.	L0201A03-3	2410004H05Rik	RIKEN cDNA	L0201A03	Mm.8766	Chromosome 14	CAGTTGGAAA
			241114H05				AATGGATGAA
			gene				GCTCAATGTAG
							AAGAGGGATT
							ATACAAGCAGA
							ACTCTGGCA
846.	H3026E03-5		Mus musculus	H3026E03	Mm.249306	Chromosome Un: not	TCAGTCAAATG
			2 days neonate			placed	TGCATAACTGT
			thymus thymic				AAATCAACACT
			cells cDNA,				AAGAGCTCTGG
			RIKEN full-				AAGGTTAAAA
			length enriched				AGGTCA
			library,
			clone:E430039
			C10
			product:unknown
			EST, full
			insert sequence.
847.	H3091E12-3	Abhd2	abhydrolase	H3091E12	Mm.87337	Chromosome 7	AGCAGGTGTTT
			domain				CGGACTTGCAA
			containing 2				TGAGCAATGCA
							ATTTTTTCTAA
							ATATGAGGATA
							TTTAC
848.	H3003E01-3	Cutl1	cut-like 1	H3003E01	Mm.258225	Chromosome 5	CTTGCTTCTTT
			(Drosophila)				AGCAAAATATT
							CTGGTTTCTAG
							AAGAGGAAGT
							CTGTCCAACAA
							GGCCCC
849.	H3016H08-5	Crsp9	cofactor	H3016H08	Mm.24159	Chromosome 11	TCTCAATTTTC
			required for				AAGGTGTATTT
			Sp1				CCTATCAGGAA
			transcriptional				ACTTGAAGATA
			activation				ATATGGTCTGA
			subunit 9,				ACCCA
			33kDa
850.	C0118E09-3	Oas1a	2′-5′	C0118E09	Mm.14301	Chromosome 5	ACTGGACAAA
			oligoadenylate				GTATTATGACT
			synthetase 1A				TTCAACACCAG
							GAGGTCTCCAA
							ATACCTGCACA
							GACAGC
851.	L0535B02-3	Coll5a1	procollagen,	L0535B02	Mm.233547	Chromosome 4	GGCTGTTGAGT
			type XV				GTAAAATGTGC
							TTTGTGTTTGC
							TTACAACATCA
							GCTTTTAGACA
							CACAG
852.	L0500E02-3	Sgcg	sarcoglycan,	L0500E02	Mm.72173	Chromosome 14	TGAGTGCAATG
			gamma				TGTCAGATTTC
			(dystrophin-				ACCAAGAGAT
			associated				CTCCAAGGTT
			glycoprotein)				GTAGGTAATTT
							GTGGTT
853.	H3077B08-3	5330431K02Rik	RIKEN cDNA	H3077B08	Mm.101992	Chromosome Multiple	GTCATTGTCCA
			5330431K02			Mappings	AGGTGACAGG
			gene				AGGAACTCAGT
							CGTTAAAATGA
							CGAGCCTTATT
							TCATGA
854.	J0209G02-3	Gnb4	guanine	J0209G02	Mm.9336	Chromosome 3	TCTTAGAATT
			nucleotide				GGAATTGAGTG
			binding protein,				CCATATTTTCT
			beta 4				GTTCTCCAATG
							ATACCTGGAGA
							AATCC
855.	C0661E01-3	Lcn7	lipocalin 7	C0661E01	Mm.15801	Chromosome 4	TGCTTTCTTAT
							TCTTTAAAGAT
							ATTTATTTTTCT
							TCTCATTAAAA
							TAAAACCAAA
							GTATT
856.	K0221E09-3	Scml2	sex, comb on	K0221E09	Mm.159173	Chromosome X	CTGCATGTTAT
			midleg-like 2				AACTTTATATG
			(Drosophila)				ATGGTGTAGTG
							CATATAAGCTA
							TGAGAATCATT
							TATAC
857.	C0184F12-3	D8Ertd594e	DNA segment,	C0184F12	Mm.235074	Chromosome 8	CGTGCTGGAGG
			Chr 8, ERATO				ACGAGAGATTC
			Doi 594,				CAGAAGCTTCT
			expressed				GAAGCAAGCA
							GAGAAGCAGG
							CTGAACA
858.	L0602B03	Myoz2	myozenin 2	L0602B03	Mm.141157	Chromosome 3	TGGAGGCTTTG
							TACCCAAAACT
							TTTCAAGCCTG
							AAGGAAAAGC
							AGAACTGCGG
							GATTACA
859.	C0944F04-3	1110055E19Rik	RIKEN cDNA	C0944F04	Mm.39046	Chromosome 6	TGGAGGATCTG
			1110055E19				TGTGAAAAAG
			gene				AAGTCACCCTC
							ACAAACCGCC
							GTGCCTAAGGA
							CTCTGTC
860.	L0004A03-3	Gli2	GL1-kruppel	L0004A03	Mm.12090	Chromosome 1	CTATTTTGTGT
			family member				AGACATCGTCT
			GL12				TGCCTGAATAG
							ACTGTGGGTGA
							ATCCAAATTTG
							GTCCA
861.	L0860B03-3		ESTs	L0860B03	Mm.221891	Chromosome 5: not	TAATTATCTAC
			AV321020			placed	ATTGGGGTAAT
							TGAAGTAGAA
							AGATCCATCTT
							AACTACGGTAA
							TCTCCG
862.	L0841F10-3	2310045A20Rik	RIKEN cDNA	L0841F10	Mm.235050	Chromosome 5	TTGGGTATCGT
			2310045A20				TTATGTTTCCCA
			gene				TCATAACACAT
							TCATAACACAT
							GCAATAACATC
							TAGGAAATCTT
863.	L0008H10-3	Agrn	agrin	L0008H10	Mm.269006	Chromosome 4	TCTGATGTGGA
							AGTGCGGTCAT
							TCCTGGTTTAA
							CTCACAGCAAC
							TTTTAATTGGT
							CTAAG
864.	C0128B02-3	Casq1	calsequestrin 1	C0128B02	Mm.12829	Chromosome 1	ATCTCCTGTTA
							ATGTATTTGGG
							TCAAATGCAAG
							GCCTTAATAAA
							GAAATCTGGG
							GCAGAA
865.	C0645C09-3	BM209340	ESTs	C0645C09	Mm.222131	No Chromosome	GCAGCAAGAG
			BM209340			location	AAAAGAGCAA
						info available	GAGAGCCAAA
							GGCAAGAAAT
							CTCTCTGTCAC
							TCCCTTTTA
866.	H3082B03-3	Mylk	myosin, light	H3082B03	Mm.288200	Chromosome 16	TGAGGAAAAG
			polypeptide				CCCCATGTGAA
			kinase				ACCTTATTTCT
							CTAAGACCATC
							CGTGATCTGGA
							AGTCGT
867	C0309D09-3		transcribed	C0309D09	Mm.213420	Chromosome 11	ACCGGCTGTAC
			sequence with				CCAAATAGAA
			moderate				CGTCATTTTGA
			similarity to				TATGAAGGATT
			protein				TCAGCCCCTGA
			sp:P00722 (E.				AGATTT
			coli)
			BGAL_ECOLI
			Beta-
			galatosidase
			(Lactase)
868.	H3157H09-3	BG076287	ESTs	H3157H09	Mm.131026	Chromosome 2	ATGGTTTCTTC
			BG076287				CAGCAATTTAG
							CATTGCCTGAG
							GGGTCTAAAA
							GAATAAGTTGG
							TTCTTG
869.	H3061D03-3	Pcsk5	proprotein	H3061D03	Mm.3401	Chromosome 19	ACAATCTCTGT
			convertase				CAGCGAAAAG
			subtilisin/kexin				TTCTACAACAG
			type 5				CTGTGCTGCAA
							AACATGTACAT
							TCCAAG
870.	L0843D01-3	3732412D22Rik	RIKEN cDNA	L0843D01	Mm.18830	No Chromosome	AACTGTTACTG
			3732412D22			location	GATTGAAATTC
			gene			info available	CCATCCCCTTT
							CCCTAAAAATT
							GTGCCTTAGAA
							AACCC
871.	L0702H07-3	5830415L20Rik	RIKEN cDNA	L0702H07	Mm.46184	Chromosome 5	CGACTGAGGTT
			5830415L20				ATGACATCCTT
			gene				AGACTTTGTTG
							TATGCTGCTTC
							GAATGAACCA
							GAGATA
872.	L0548G08-3	Xin	cardiac	L0548G08	Mm.10117	Chromosome 9	TGCCTCTTCAT
			morphogenesis				CGCCAGTGGTC
							CAAAGGGCGC
							AGAGAGCGCA
							CTAGCAGTCAA
							TAGTGTT
873.	L0803E02-3	Nkdl	naked cuticle 1	L0803E02	Mm.30219	Chromosome 8	CCACTAATATT
			homolog				TAGCCAGCCTT
			(Drosophila)				CATGTAGAAG
							ACACATGGAA
							ACACAGAAGT
							AAACTTTT
874.	C0925G12-3	Fbxo30	F-box protein	C0925G12	Mm.276229	Chromosome 10	AGAAATGAAC
			30				ATACATTGTCA
							GCATTTAGAAG
							TAAGTTGTGAA
							GACAGGGACA
							TTAAGTG
875	L0911A11-3	2010313D22Rik	RIKEN cDNA	L0911A11	Mm.260594	Chromosome 5	CAAACGGGAT
			2010313D22				CCTGTCTTCTT
			gene				CTTTTCTAATA
							GAATTTTGTAA
							AGGAAATGAA
							TGTAGCC
876.	AF084466.1	rrad	Ras-related	Af084466	Mm.29467	Chromosome 8	ACCGTTCTATC
			associated with				ACTGTGGATGG
			diabetes				AGAAGAAGCG
							TCACTATTGGT
							CTATGACATTT
							GGGAAG
877.	H3073G09-3	1600029N02Rik	RIKEN cDNA	H0373G09	Mm.154121	Chromosome 7	CTATTTTTGGG
			1600029N02				AGATGTCTATT
			gene				GCGGAGTACA
							GTAATATATAC
							CCAGAGTATGT
							CTATAG
878.	L0815B08-3	1100001D19Rik	RIKEN cDNA	L0815B08	Mm.260515	Chromosome X	ACCCAACTCCA
			110001D19				GTGCTCTCTGT
			gene				CTTTTAGTACA
							GGATTTTCACC
							CATGTGCATGA
							AAAAT
879.	J1037H05-3	D230016N13Rik	RIKEN cDNA	J1037H05	Mm.21685	Chromosome 13	TTACCATTTTT
			D230016N13				GGTTAAATGGC
			gene				CAAATTCAGAA
							AATAACTCCAT
							TTGAATCTCCA
							GCAGG
880.	K0421F09-3		transcribed	K0421F09	Mm.222196	Chromosome 6	TCACCATACTT
			sequence with				TGAAAGTGTAA
			weak similarity				ACTACCACATA
			to protein				TTAACATGTGT
			ref:NP_081764.1				GATTTAAGACC
			(M. musculus)				CTCAG
			RIKEN cDNA
			5730493B19
			[Mus musculus]
881.	H3082E06-3	1110003B01Rik	RIKEN cDNA	H3082E06	Mm.275648	Chromosome 13	TGTTGCCCTCA
			1110003B01				GATATGTCAGA
			gene				TCAACTTGGAA
							GGAAAGACCTT
							CTACTCCAAGA
							AGGAC
882.	C0935B04-3	Hhip	Hedgehog-	C0935B04	Mm.254493	Chromosome 8	TCTAACAAGTG
			interacting				TATTTGTGTTA
			protein				TCTTTAAAATA
							GAACAATTGTA
							TCTTGAAATGG
							TAAAT
883.	H3116B02-3	1110007C05Rik	RIKEN cDNA	H3116B02	Mm.27571	Chromosome 7	CGACACTGGGT
			1110007C05				GGCCCTGCGAC
			gene				AGGTAGATGG
							CATCTACTATA
							ATCTGGACTCA
							AAGCTG
884.	C0945G10-3	Tp53il1	tumor protein	C0945G10	Mm.41033	Chromosome 2	TCTCAGAGGTG
			p53 inducible				TTGAAGATTTA
			protein 11				TCATCTTGAAT
							CCTCCACAAAT
							ACAGATACAGT
							CCCAA
885.	K0440609-3	Tgfb3	transforming	K0440G09	Mm.3992	Chromosome 12	TCTTTTCACCT
			growth factor				CGATCAGCATC
			beta 3				ATGAGTCATCA
							CAGATCATGTA
							ATTAGTTTCTG
							GGCCA
886.	L0916G12-3	BM118833	ESTs	L0916G12	Mm.221415	Chromosome 6	TGGGAATTGCA
			BM118833				TTTAGGATAGA
							ATTGTATCTGA
							TTTGCAAAATC
							CATAAGCTCTC
							ATGCC
887.	L0505A04-3	Dnajb5	DnaJ (Hsp40)	L0505A04	Mm.20437	Chromosome 4	TACTCCCACAG
			homolog				TTGTATAGAAG
			subfamily B,				TCGAATAGTGA
			member 5				AGGAGCTGGG
							AGAAAACTGCT
							TCAGCT
888.	L0542E08-3	Usmg4	unpregulated	L0542E08	Mm.27881	Chromosome 3	CCGCACTTAGC
			during skeletal				CTAGACCTTT
			muscle growth 4				CTTACATGATC
							TCAAGTTGAAC
							CGACTTCCTTA
							ACTCT
889.	L0223E12-3	Sparcll	SPARC-like 1	L0223E12	Mm.29027	Chromosome 5	GCTTTGGAATT
			(mast9, hevin)				AAAGAGGAGG
							ATATAGATGAA
							AACCCCCTCTT
							TTGAATTAAGA
							TTTGAG
890.	K0349C07-3	4631423F02Rik	RIKEN cDNA	K0349C07	Mm.68617	Chromosome 1	AAATCAGATAT
			4631423F02				GCAGGTCATCT
			gene				GATAAATGAGT
							TAATGTTTGAT
							ATTCGGGGTAT
							CTCAC
891.	C0302A11-3		EST B1988881	C0302A11	Mm.260261	No Chromosome	GAACCATATGC
						location	TGGAATGAAA
						info available	CATAAGAGTTT
							TCAACAGTTAT
							CCTCTCACCTC
							TGTATG
892.	C0930C11-3	Fgfl3	fibroblast	C0930C11	Mm.7995	Chromosome X	GTATCGTCAAT
			growth factor				CCCAGTCAGTA
			13				AGATAAGTTGA
							AACAAGATTAT
							CCTCAAGTGTA
							GATTT
893.	H3022A11-3	Cald1	caldesmon 1	H3022A11	Mm.130433	Chromosome 6	GTCAAAAACG
							CCTTCAGGAAG
							CCTTAGAGCGT
							CAGAAGGAGT
							TTGATCCGACC
							ATAACAG
894.	C0660B06-3	Csrp1	cysteine and	C0660B06	Mm.196484	Chromosome 1	AATAGAATCTT
			glycine-rich				TTCACTTAGGA
			protein1				ATGGAGAACA
							AGCCAGTTCAG
							AGGACCCCAA
							AGTCTAG
895.	L0949F12-3	Heyl	hairy/enhancer-	L0949F12	Mm.103615	Chromosome 4	CGTGGAGGAT
			of-split related				GGGCTAGCCTG
			with YRPW				AGCTCTGGGAC
			motif-like				TAATCTTTATT
							ACATACTTGTT
							AATGAG
896.	K0225B06-3	Unc5c	unc-5 homolog	K0225B06	Mm.24430	Chromosome 3	CTTATAGGGAG
			C (C. elgans)				AATGTTCTATT
							CCTCAATCCAT
							ACTCATTCCTA
							CAGTATGCGCT
							CTGGA
897.	K0541E04-3	Herc3	hect domain	K0541E04	Mm.33788	Chromosome 6	AGCAGGGGGA
			and RLD 3				TTATGTTAAGT
							CAAATGCGTGT
							GTCTCAAAAGT
							GACATGTTTAA
							CTGCTC
898.	C0151A03-3	BC026744	cDNA sequence	C0151A03	Mm.4079	Chromosome 5	ACTCTGTACCC
			BC026744				TACTGGAACCA
							CTCTGTAAAGA
							GACAAAGCTGT
							ATGTGCCACTT
							CAGTA
899.	L0045C07-3	6-Sep	septin 6	L0045C07	Mm.258618	Chromosome X	TTACAGGTCAC
							TGTTTGTCACT
							TTTGTGTACCA
							GCTTCCCCATT
							AGAATTCAACC
							GATAC
900.	L0509E03-3	Ryr2	ryanodine	L0509E03	Mm.195900	Chromosome 13	ATGGAAGCGA
			receptor 2,				GGTCATTCTGC
			cardiac				GAACATTGGA
							GATCTTTTATT
							ACAAGTCTGCT
							TGTTAAT
901.	H3049B08-3	Tes	tetis derived	H3049B08	Mm.271829	Chromosome 6	TAAAATTAGTG
			transcript				TCCTGGGAGAG
							ATGACCATTTT
							AACTTCTATGC
							TTATTTCACAT
							GGGAA
902.	L0533C09-3	BM123974	ESTs	L0533C09	Mm.213265	Chromosome 14	TCGACGTCAA
			BM123974				CTTACCTCTCT
							AGGCAACATGT
							TATCCCCGGAT
							GATCAGAAATT
							CCCAA
903.	H3108C01-3	4930444A02Rik	RIKEN cDNA	H3108C01	Mm.17631	Chromosome 8	ACCTGTGTTTT
			4930444A02				GTTTTTGTTTT
			gene				AAGAAACCAA
							AGTGCACCAA
							GATAGCATGCT
							CTTGAGA
904.	C0110C06-3	Epb4.111	erythrocyte	C0110C06	Mm.20852	Chromosome 2	CTGCAGGTAAC
			protein band				TCTCATTGGAA
			4.1-like 1				GAAAAAGAAA
							CTACAAGAGC
							AAACAGAAGC
							CATGGGAA
905.	C032H08-3	Enah	enabled	C0324H08	Mm.87759	Chromosome Multiple	AAAGATTTCAT
			homolog			Mappings	CCACGTCTGGC
			(Drosophila)				GTAGTGGAAA
							ACCCGAAGGG
							AATATGTAATG
							ATCTTTC
906.	C0917A09-3		ESTs	C0917A09	Mm.242207	No Chromosome	GTGTTGTACCC
			BB231855			location	TAATTTGAATT
						info available	TAAAGTAGGC
							AGTAGGTAGG
							GTTAATTGGTA
							GACTATC
907.	L0854B10-3	Anks1	ankyrin repeat	L0854B10	Mm.32556	Chromosome 17	CTTGGGTTTGA
			and SAM				GCACTCAGAAC
			domain				ACATGGCTGCA
			containing 1				ATCATCAAGAC
							AGTTCACAGTT
							AGCTT
908.	K0326D08-3	Ly75	lymphocyte	K0326D08	Mm.2074	Chromosome 2	CCCTAAGACAA
			antigen 75				TGAAACTCAGA
							ACTCTGTGATT
							CCTGTGGAAAT
							ATTTAAAACTG
							AAATG
909.	H3074H01-3	C430017H16	hypothetical	H3074H01	Mm.268854	Chromosome 3	ATTTATAGAGG
			protein				TATCCTTAACA
			C430017H16				TGCTGACTTCA
							GTAACTGCCCT
							TGTTTCTAAGG
							AAGTC
910.	H3131D02-3	Tnk2	tyrosine kinase,	H3131D02	Mm.1483	Chromosome 16	ACCTGTAGCTT
			non-receptor				CACTGTGAACT
							TGTGGGCTTGG
							CTGGTCTTAGG
							AACTTGTACCT
							ATAAA
911.	C0112B03-3	Heyl	hairy/enhancer-	C0112B03	Mm.103615	Chromosome 4	TAATCCCTGGC
			of-split related				AAAGTCAAGA
			with YRPW				CTGTGGGAAAC
			motif-like				TAGAACTGGTT
							ACTCACTACTG
							CTGGTA
912.	L0514A09-3	6430511F03	hypothetical	L0514A09	Mm.19738	Chromosome X	TTAGTCCCATG
			protein				ACCCCAAGGTT
			6430511F03				AAGGTTCTGCC
							AACAAGCATTC
							TGCCTGACATC
							TACTT
913.	C0234D07-3	Fbxo30	F-box protein	C0234D07	Mm.276229	Chromosome 10	AATAAAGGCC
			30				CCTTAGAAGCT
							ACTGTAAGCT
							CTTCAAAGTTT
							TCATGTAATCA
							TAGGCA
914.	H3152A02-3	St6ga11	beta galactoside	h3152A02	Mm.149029	Chromosome 16	AGAGATGGAG
			alpha 2, 6				ACTACACTGGG
			sialyltransferase				TAGATTCTAGT
			1				TTTTAGTTCTT
							ATTAATGTGGG
							GGAGTA
915.	H3075C04-3	Ches1	checkpoint	H3075C04	Mm.268534	Chromosome 12	TATGGCCATTT
			suppressor 1				GGTTTCAGCAT
							GTCAGGAGATT
							TCTAATGATTT
							GATGGCAATATC
							AGCAA
916.	L0600E02-3	BM125123	ESTs	L0600E02	Mm.221782	Chromosome 19	TGTGTCAAGAT
			BM125123				AATCCTGAGTC
							AACCTGGACAC
							TTAATCCCTTT
							GGACCTCTATC
							TGGAG
917.	K0501F10-3	BM237456	ESTs	K0501F10	Mm.34527	Chromosome X	CCACCCATTAA
			BM237456				AATGACAGTAC
							AAGTAGACCA
							CAGTTTAAAT
							AGTTAGTCTAA
							TTCTAC
918.	K0301H08-3	Oxct	3-oxoacid CoA	K0301H08	Mm.13445	Chromosome 15	CATAGTGGAA
			transferase				ATATGCTCATC
							TTTTATGCTAT
							ATGTATTAAAC
							CTCGACTTAGC
							CCTGAA
919.	L0229E07-3	Lu	Lutheran blood	L0229E07	Mm.29236	Chromosome 7	GTTGAGGCTGA
			group				CGACCTCCCAG
			(Auberger b				AGGCAATCTCT
			antigen				GGATCTGGAAC
			included)				TTTGGGCATCA
							TCGGA
920.	H3077C06-3	4931430I01Rik	RIKEN cDNA	H3077C06	Mm.12454	Chromosome 1	ACCAACCAGG
			4931430I01				GACTAGTTTGA
			gene				TGCTATCTTTG
							CCTGTCTCTTG
							GCTCTTAACAA
							TGCCTA
921.	J0807D02-3		Mus musculus	J0807D02	Mm.125975	Chromosome 7	CCAGGGAAGG
			10 days neonate				AACGATCCATT
			cerebellum				CAGTGGTTTTA
			cDNA, RIKEN				AAATATCTCTT
			full-length				CCTCAACAGAA
			enriched				AAAGAT
			library,
			clone:B930022I
			23
			product:unclass
			ifiable, full
			insert sequence.
922.	H3118G11-3	C130068N17	hypothetical	H3118G11	Mm.138073	Chromosome 2	GGTGCAAGCTA
			protein				GTACTCACACT
			C130068N17				GTCACACCTTT
							ACGCATGCGA
							AAGGTAATGTG
							CTAAAT
923.	L0818F01-3	Smarcd3	SWI/SNF	L0818F01	Mm.140672	Chromosome	AGATCAGTGCT
			related, matrix				CTGGACAGTAA
			associated,				GATCCATGAGA
			actin dependent				CGATTGAGTCC
			regulator of				ATAAACCAGCT
			chromatin,				CAAGA
			subfamily d,
			member 3
924.	C0359A10-3	BM198389	ESTs	C0359A10	Mm.218312	Chromosome 1	ATACCCTGCT
			BM198389				AACTTAACAGC
							AGTTAGTTTCC
							TTGTTATGAAT
							AAAAATGACA
							GTCTGG
925.	G0108E12-3	1190009E20Rik	RIKEN cDNA	G0108E12	Mm.260102	AAAGCAAATG
			1190009E20				TTAGTAAAAAG
			gene				CTGGTGTGCAT
							AGTCTTGTTAC
							ATTGATGCAGT
							TTTTCC
926	C0941C09-3	Gja7	gap, junction	C0941C09	Mm.3096	Chromosome 11	CAACTTGCTGA
			membrane				ATAATGACTTC
			channel protein				CATTGAGTAAA
			alpha 7				CATTTGGCTCT
							GGTTATCTTCA
							GGGAT
927.	H3111BO305		UNKNOWN	H3111B03	Data not found	No Chromosome	AGGAATTAGTA
			H3111B03			location	ACGTTTCATCC
						info available	AAGTAACCTTG
							TTACAGTGAAC
							AAGTGTCAAGT
							GCTCA

The following Examples are intended to illustrate, but not limit, the invention.

EXAMPLES

Example 1

Signature Patterns of Gene Expression in Mouse Atherosclerosis and their Correlation to Human Coronary Disease

Mouse genetic models of atherosclerosis allow systematic analysis of gene expression, and provide a good representation of the human disease process (Breslow (1996) Science 272: 685-688). ApoE-deficient mice predictably develop spontaneous atherosclerotic plaques with numerous features similar to human lesions (Nakashima et al. (1994) Arterioscler Thromb 14: 133-140; Napoli et al. (2000) Nutr Metab Cardiovasc Dis 10: 209-215; Reddick et al. (1994) Arterioscler Thromb 14: 141-147. On a high-fat diet, the rate and extent of progression of lesions are accelerated. In addition to environmental influences such as diet, the genetic background of mice has also been found to have an important role in disease development and progression. Whereas C57B1/6 (C57) mice are susceptible to developing atherosclerosis, the C3H/HeJ (C3H) strain of mice is resistant (Grimsditch et al. (2000) Atherosclerosis 151:389-397. Previously, genetic-based diet and age induced transcriptional differences have been demonstrated between these two strains (Tabibiazar et L. (2005) Arterioscler Thromb Vasc Biol 25:302-308.

To more fully characterize the vascular wall gene expression patterns that are associated with atherosclerosis, a systematic large scale transcriptional profiling study was undertaken to take advantage of a longitudinal experimental design, and mouse genetic model and diet combinations that provide varying susceptibility to atherosclerosis. In this experiment, atherosclerosis-associated genes were studied independent of other variables. Primarily, these studies investigated differential gene expression over time in apoE-deficient mice on an atherogenic diet, with comparison to apoe-deficient mice (C57BL/6J-Apoe^tmlUnc) on normal diet as well as C57B1/6 and C3H/HeJ mice on both normal chow and atherogenic diet. Identification of atherosclerosis-associated genes was facilitated by development of permutation-based statistical tools for microarray analysis which takes advantage of the statistical power of time-course experimental design and multiple biological and technical replicates. Using these tools, hundreds of known and novel genes that are involved in all stages of atherosclerotic plaque, from fatty streak to end stage lesions, were identified. To further examine the expression of individual genes in the context of particular biological or molecular pathways, a pathway enrichment methodology with gene ontology (GO) terms for functional annotation was utilized. Using classification algorithms, a signature pattern of expression for a core group of mouse atherosclerosis genes was identified, and the significance of these classifier genes was validated with additional mouse and human atherosclerosis samples. These studies identified atherosclerosis related genes and molecular pathways.

Methods

Atherosclerotic Lesion Analysis

For select time points for various experimental groups, 5 to 7 female mice were used for histological lesion analysis. Atherosclerosis lesion area was determined as described previously (Tabibiazar et al. (2005), supra). Briefly, the arterial tree was perfused with PBS (pH 7.3) and then perfusion-fixed with phosphate-buffered paraformaldehyde (3%, pH 7.3). The heart and full length of the aorta to iliac bifurcation was exposed and dissected carefully from any surrounding tissues. Aortas were then opened along the ventral midline and dissected free of the animal and pinned out flat, intimal side up, onto black wax. Aortic images were captured with a Polaroid digital camera (DMC1) mounted on a Leica MZ6 stereo microscope, and analyzed using Fovea Pro (Reindeer Graphics, Inc. P. O. Box 2281, Asheville, N.C. 28802). Percent lesion area was calculated as total lesion area/total surface area.

Experimental Design, RNA Preparation and Hybridization to Microarrays

All experiments were performed following Stanford University animal care guidelines (Saadeddin et al. (2002) Med Sci Monit 8:RA5-12). Three week old female apoE knock-out mice (C57BL/6J-Apoe^tmlUnc), C57Bl/6J, and C3H/HeJ mice were purchased from Jackson Labs (Bar Harbor, Me.). At four weeks of age the mice were either continued on normal chow or were fed high fat diet which included 21% anhydrous milkfat and 0.15% cholesterol (Dyets #101511, Dyets Inc., Bethlehem, Pa.) for maximum period of 40 weeks. At each of the time-points, including 0 (baseline), 4, 10, 24 and 40 weeks, for each of the conditions (strain-diet combination), 15 mice (3 pools of 5) were harvested for RNA isolation (total of 405 mice). Additional mice were used for histology for quantification of atherosclerotic lesions as described above. A separate cohort of sixteen-week-old apoE-deficient mice on high fat diet for two weeks (4 pools of 3 aortas) was also used for classification purposes.

After perfusion of mice with saline, the aortas were carefully dissected in their entireties from the aortic root to the common iliac and subsequently were flash frozen in liquid nitrogen. Total RNA was isolated as described previously (Tabibiazar et al. (2003) Circ Res 93:1192-1201) using a modified two-step purification protocol. RNA integrity was also assessed using the Agilent 2100 Bioanalyzer System with RNA 6000 Pico LabChip Kit (Agilent).

First strand cDNA was synthesized from 10 μg of total RNA from each pool and from a whole 17.5-day embryo for reference RNA in the presence of Cy5 or Cy3 dCTP, respectively. Hybridization to a mouse 60mer oligo microarray (G4120A, Agilent Technologies, Palo Alto, Calif.) (Carter et al. (2003) Genome Res 13:1011-1021) was performed following manufacture's instructions, generating three biological replicates for each of the time points. The RNA from the group of sixteen-week-old mice was linearly amplified and hybridized to a different array (G4121A, Agilent Technologies). Technical validation of the microarray has been performed previously using quantitative real-time reverse transcriptase polymerase chain reaction (results reported in Tabibiazar et al. (2005), supra). Primers and probes for 10 representative differentially expressed genes were obtained from Applied Biosystems Assays-on-Demand. A total of 90 reactions, including triplicate assays on three pools of five aortas, was performed from representative RNA samples used for microarray experiments, demonstrating a high correlation between the two platforms (Pearson correlation of 0.82).

Data Processing

Image acquisition of the mouse oligo microarrays was performed on an Agilent G2565AA Microarray Scanner System and feature extraction was performed with Agilent feature extraction software (version A.6. 1.1, Agilent Technologies). Normalization was carried out using a LOWESS algorithm. Dye-normalized signals of Cy3 and Cy5 channels were used in calculating log ratios. Features with reference values of <2.5 standard deviation for the negative control features were regarded as missing values. Those features with values in at least ⅔ of the experiments and present in at least one of the replicates were retained for further analysis. Reproducibility of microarray results, as measured by the variation between arrays for signal intensities, was assessed using box plots (GeneData,Inc., South San Francisco, Calif.). For further statistical analysis of the data, a K-nearest-neighbor (KNN) algorithm was applied to impute missing values (Troyansakaya et al. (2001) Bioinformatics 17:520-525). Numerical raw data were then migrated into an Oracle relational database (CoBi) that has been designed specifically for microarray data analysis (GeneData, Inc.). Heat maps were generated using “HeatMap Builder” software (Blake and Ridker (2002) J Intern Med 252:283-294). All microarray data were submitted to the National Center for Biotechnology information's Gene Expression Omnibus (GEO GSE1560; www.ncbi.nlm.nih.gov/geo/).

Data Analysis

• i) Principal components analysis

For each gene the average log expression values were computed at the four post-baseline observation times, 4, 10, 24, and 40 weeks. This was done separately for the six different (diet, strain) combinations, for example ApoE on high fat, presumably the most atherogenic combination. Differences of these vectors were taken for various interesting contrasts, e.g., for ApoE, high-fat minus C3H, normal chow, giving N=20280 vectors of length 4, one for each gene. Principal components analysis of the N vectors showed a consistent pattern, with the first principal vector indicating a roughly linear increase with observation time.

• ii) Time course regression analysis

A standard ANACOVA model was fit separately to the log expression values for each gene, using a model incorporating strain, diet, and time period effects. A single important “z value” was extracted from each ANACOVA analysis, for example corresponding to the significance of the time slope difference between the ApoE, high-fat combination and the average of the other five combinations. The N z-values were then analyzed simultaneously, using empirical Bayes false discovery rate methods described previously (Efron (2004) J Amer Stat Assoc 99:82-95; Efron and Tibshirani (2002) Genetic Epidemiology 23:70-86; Efron et al. (2001) J Amer Stat Assoc 96:1151-1160. These analyses identified a set of several hundred genes clearly associated with atherosclerosis progression.

• iii) Time course area under the curve analysis

Area under the curve (AUC) analysis was employed as described previously (Tabibiazar et al. (2005), supra). For each sequence of 4 triplicate gene expression measurements over time, the measurement at time 0 was subtracted from all values. The signed area under the curve was then computed. The area is a natural measure of change over time. These areas were then used to compute an F-statistic for the 6 groups (3 mouse strains and 2 diets) and 3 replicates (between sum of squares/within sum of squares). A permutation analysis, similar to that employed in Significance Analysis of Microarrays (SAM) (Tusher et al. Proc Natl Acad Sci 98:5116-5121), was carried out to estimate the false discovery rate (q-value or “FDR”) for different levels of the F-statistic.

• iv) Enrichment analysis

For enrichment analysis, the Expressionist software (GeneData, Inc.), which employs the Fisher exact test to derive biological themes within particular gene sets defined by functional annotation with Gene Ontology (GO) terms (www.geneontology.org) and Biocarta pathways (www.biocarta.com/genes/allpathways.asp), was used. In this way, over-representation of a particular annotation term corresponding to a group of genes was quantified.

• v) Support vector machine for gene selection

For supervised analyses, the Expressionist software (GeneData USA), which employs Support Vector Machine (SVM) algorithm (Burges (1998) Data Mining and Knowledge Discovery 2:121-167),was used to rank genes based on their utility for class discrimination between time points 0, 4, 10, 24, and 40 weeks in apoE mice on high-fat diet. SVM is a binary classifier, so in order to classify multiple categories, N classifiers were created that classify one group vs. a combination of the rest of the groups (“one vs. all” classifiers) (Ramaswamy et al. (2001) Proc Natl Acad Sci 98:15149-15154). The larger set of genes identified by the time-course analysis was used for this analysis. This method was then used to determine the optimal number of ranked genes to classify the experiments into their correct groups at minimal error rate. The optimal error rate or misclassification is calculated by cross-validation with 25% of the experiments as the test group and the rest as the training group. This is reiterated 1000 times (FIG. 5A). In this study, a linear Kernel was used, since a nonlinear Gaussian kernel yielded similar results. This minimal subset of classifier genes was then used for cross-validation as well as classification of other independent gene expression profiling datasets.

• vi) Analysis of independent datasets.

The SVM algorithm was utilized for classification of independent groups of experiments (Yeang et al. (2001) Bioinformatics 17 Suppl 1:S316-322). In this analysis, the primary time-course experiments were used (corresponding to 5 time points mentioned above) as the training set and the independent set of experiments (different array and labeling methodology) as the test set. SVM output for each experiment based on one-versus-all comparisons was represented graphically in a heatmap format (FIG. 5B), which is the normalized margin value for each of the 5 SVM classifiers mentioned above. The SVM output permits classification of a new experiment according to the 5 SVM hyperplane. The SVM algorithm (Linear Kernel) was also utilized for external validation by classifying different sets of human expression data. In these analyses, a confusion matrix was generated using cross validation with repeated splits into 75% training and 25% test sets to determine the accuracy of classification based on the small subset of genes identified earlier. Results are represented in tabular fashion (Table 3).

Transcriptional Profiling of Human Atherosclerotic Tissue and Atherectomy Samples

For one set of samples, coronary arteries were dissected from explanted hearts of patients undergoing orthotopic heart transplantation. Arteries were divided into 1.5 cm segments, classified as lesion or non-lesion after inspection of the luminal surface under a dissecting microscope. RNA was isolated from each individual sample and hybridized to a microarray. A central portion (1-2mm) of each segment was removed and stored in OCT for later histological staining (hematoxylin and eosin, Masson's trichrome). Samples (n=40) were derived from 17 patients (male 13, female 4, mean age 43 years). Six patients had a diagnosis of ischemic cardiomyopathy, while 11 were classified as non-ischemic, although some vessel segments from the latter had microscopic evidence of coronary artery disease. Of 21 diseased segments, 7 were classified as grade I, 4 grade III and 9 grade V, according to the modified American Heart Association criteria (Virmani et al. (2000) Arterioscler Thromb Vasc Biol 20:1262-1275), and one sample had only macroscopic information available. For a second set of tissues, coronary atherectomy samples were obtained with a cutting atherectomy catheter system (Fox Hollow Inc., Redwood City, Calif.), for chronic atherosclerosis lesions (n=28) and in-stent restonsis lesions (n=14). Patient characteristics in both groups were similar (male 78% vs. 71%, mean age 64 vs. 67). RNA was isolated from each individual sample, labeled by direct or linear amplification methods, and hybridized as described above to a 22k feature custom cardiovascular oligonucleotide microarray designed in conjunction with Agilent Technologies (G2509A, Agilent Inc., Palo Alto, Calif.). Common reference RNA for all human hybridizations was a mixture of 80% HeLa cell RNA and 20% human umbilical vein endothelial cell RNA. Data processing and analysis were performed as described above. For 2-class comparison of gene expression, Significance Analysis of Microarrays (SAM) was used (www-stat.stanford.edu/tibs/SAM/; Tabibiazar et al. (2003), supra; Tusher et al. (2002), supra).

Results and Discussion

Atherosclerosis in the Genetic Models

To correlate the gene expression results with the extent of disease in each experimental group, the total atherosclerotic plaque burden in the aorta was determined by calculating a percent lesion area from the ratio of atherosclerotic area to total surface area. ApoE-deficient mice (C57BL/6J-Apoe^tmlUnc) (n=7) on high-fat diet were compared to other control mice (n=5-7 for each mouse-diet combination). Representative time-intervals were used for analysis, including baseline measurements in mice prior to initiation of high-fat diet at 4 weeks and end-point measurements corresponding to 40 weeks on either high-fat or normal diet (FIGS. 1, 2). Gross histological evaluation of these mice demonstrated increased atherosclerotic lesions in ApoE-deficient mice on high-fat diet involving about 50% of the entire aorta, and lesser area involved in ApoE-deficient mice on normal diet (FIG. 2). As expected, the control mice on either diet did not demonstrate evidence of atherosclerosis throughout the course of the experiment (Jawien et al. (2004) J Physiol Pharmacol 55:503-517; Nishina et al. (1990) J Lipid Res 31:859-869). Although some fatty infiltrates were noted on histological evaluation of the aortic root in C57 mice on high-fat diet, there were no obvious changes in inflammatory cell infiltrate (Tabibiazar et al. (2005), supra). The metabolic and lipid profiles of these mice were not obtained in this study, since they are well described in the literature (Grimsditch et al., supra; Nishina et al. (1990), supra; Nishina et al. (1993) Lipids 28:599-605).

Temporal Patterns of Gene Expression

Employing a number of mouse models with different propensity to develop atherosclerosis, two different diets, and a longitudinal experimental design, it was possible to factor out differentially regulated genes that are unlikely to be related to the vascular disease process in the apoE deficient model. For instance, age-related and diet-related gene expression patterns that are not linked to vascular disease were eliminated by virtue of their expression in the genetic models that did not develop atherosclerosis. However, the complexity of the experimental design provided significant difficulties related to statistical analysis. Although analytic methods have been proposed to address a single set of time-course microarray data (Luan and Li (2003) Bioinformatics 19:474-482; Park et al. (2003) Bioinformatics 19:694-703; Peddada et al. (2003) Bioinformatics 19:834-841; Xu and Li (2003) Bioinformatics 19:1284-1289), there was no accepted algorithm for comparing differences in patterns of gene expression across multiple longitudinal datasets.

Using principle component analysis, it was determined that the greatest variation in the data was between time points, correlating with the progression of disease described previously for the apoE knockout mouse on high fat diet (Nakashima et al. (1994) Arterioscler Thromb 14:133-140; Reddick et al. (1994) Arterioscler Thromb 14:141-147). Given this finding, a linear regression model was utilized to identify genes that were differentially expressed in ApoE-deficient mice on high-fat diet, compared with all other experimental groups across time. This comparison across strains and dietary groups was employed to focus the analysis on atherosclerosis-specific genes, taking into account gene expression changes in the vessel wall associated with aging, diet, and genetic background. Empirical Bayes and permutation methods were employed to derive a false discovery rate (FDR) and minimize false detection due to multiple testing. With high stringency limits, global FDR<0.05 and local FDR<0.3, 667 genes demonstrated a linear increase with time, whereas only 64 genes showed the opposite profile (FIG. 3).

Genes with Increased Expression in the Atherosclerotic Vessel Wall

The identification of known genes previously linked to atherosclerosis validated the methodology and analysis algorithm. Most striking in this regard were inflammatory genes, including chemokines and chemokine receptors, such as Ccl2, Ccl9, CCr2, CCr5, Cklfsf7, Cxcl1, Cxcl12, Cxcl16, and Cxcr4 (FIG. 3). Also upregulated were interleukin receptor genes, including IL1r, IL2rg, IL4ra, IL7r, IL10ra, IL13ra, and IL15ra, and major histocompatibility complex (MHC) molecules such as H2-EB1 and H2-Ab. The value of transcriptional profiling in this disease was demonstrated by the identification of numerous inflammatory genes not previously linked to atherosclerosis, including CD38, Fcer1g, oncostatin M (Osm) and its receptor (Osmr).

Oncostatin M (Osm) and its cognate receptor (Osmr) are likely to have significant roles in atherosclerosis, based on number of studies that suggest several important related functions for these genes (Mirshahi et al. (2002) Blood Coagul Fibrinolysis 13:449-455. Osm is a member of a cytokine family that regulates production of other cytokines by endothelial cells, including Il6, G-CSF and GM-CSF. Osm also induces Mmp3 and Timp3 gene expression via JAK/STAT signaling (Li et al. (2001) J Immunol 166:3491-3498). It induces cyclooxygenase-2 expression in human vascular smooth muscle cells (Bernard et al. (1999) Circ Res 85:1124-1131), as well as Abcal in HepG2 cells (Langmann et al. (2002) J Biol Chem 277:14443-14450). Interestingly, Stat1, Jak3, Cox2, and Abca1 were among the disease-associated upregulated genes. Additionally, Osm produced by macrophages may contribute to development of vascular calcification (Shioi et al. (2002) Circ Res91:9-16). This may occur via regulation of osteopontin or osteoprotegerin (Palmqvist et al. (2002) J Immunol 169:3353-3362, both of which have demonstrated significant changes in the dataset described herein. Osteopontin (Spp1) is thought to mediate type-1 immune responses (Ashkar et al. (2000) Science 287:860-864. While Spp1 has been extensively studied in atherosclerosis and other immune diseases, some of the osteopontin-related genes identified through these studies are novel and provide additional links between inflammation and calcification. Some of these include Cd44, Hgf; osteoprotegerin, Mglap, Il10ra, Infgr, Runx2, and Ccnd1. Ibsp, (sialoprotein II), was also noted to be upregulated in these studies. Despite its similar expression profile to Spp1 in various cancer types and its binding to the same alpha-v/beta-3 integrin, the role of Ibsp in atherosclerosis has not been elucidated.

Known and novel genes were identified for many other protein classes that have been studied in atherosclerosis. Genes encoding endothelial cell adhesion molecules were among these groups, including Alcam and Vcam1. Extracellular matrix and matrix remodeling proteins were found to be upregulated, including fibronectin, Col8al, Ibsp, Igsf4, Itga6, and thrombospondin-1. Matrix metalloproteinase genes such as Mmp2 and Mmp14 as well as those encoding tissue inhibitors of metalloproteinases, including Timp1, were also among the upregulated genes. Many transcription factors, lipid metabolism and vascular calcification genes, as well as macrophage and smooth muscle cell specific genes, were among those found to be upregulated. New genes were identified in each of these classes, for example, members of the ATP-binding-cassette family that were not previously associated with atherosclerosis were identified through these studies, including Abcc3 and Abcb1b.

Interesting genes linked to atherosclerosis for the first time through these studies encode a variety of functional classes of proteins. For example, genes encoding transcription factors Runx2 and Runx3 were linked to atherosclerosis in these studies. Cytoplasmic signaling molecules Vav1, Hras1, and Kras2 are factors that are well known to have critical signaling functions, but their role in atherosclerosis has not yet been defined. Wispl is a secreted wnt-stimulated cysteine-rich protein that is a member of a family of factors with oncogenic and angiogenic activity. Rgs10 is a member of a family of cytoplasmic factors that regulate signaling through Toll-like receptors and chemokine receptors in immune cells. Among the new classes of genes identified through these studies to be upregulated in atherosclerosis were those encoding histone deacetylases. Among those genes identified were Hdac7and Hdac2. Although there is significant evidence that HDACs have important functions regulating growth, differentiation and inflammation, these molecules have not been well studied in the context of atherosclerosis (Dressel et al. (2001) J Biol Chem 276:17007-17013); Ito et al. (2002) Proc Natl Acad Sci 99:8921-8926). Histone deacetylase inhibitors have been postulated to modulate inflammatory responses (Suuronen et al. (2003) Neurochem 87:407-416).

The data from the experiments described herein has also yielded numerous ESTs and uncharacterized genes. These genes may be attractive candidates for further characterization. One example of such ESTs is 2510004L01Rik, a gene termed “viral hemorrhagic septicemia virus induced gene” (VHSV), which was originally cloned from interferon-stimulated macrophages. This gene is enriched in bone marrow macrophages, is upregulated by CMV infection and is similar to human inflammatory response protein 6 (Chin and Cresswell (2001) Proc Natl Acad Sci 98:15125-15130). Several ESTs such as 5930412E23Rik and 2700094L05Rik have been cloned from hematopoietic stem cells (genome-www5.stanford.edu/cgi-bin/source/sourceSearch), consistent with data suggesting cells in the diseased vessel wall may emanate from the bone marrow (Rauscher et al. (2003) Circulation 108:457-463.

Genes with Decreased Expression in the Atherosclerotic Vessel Wall

The 64 genes that showed decreased expression during progression of atherosclerosis were of interest, given the lack of previous attention to such genes. Sparcl1 (Hevin) is an extracellular matrix protein which is downregulated in the dataset described herein, and may have antiadhesive (Girard and Springer (1996) J Biol Chem 271:4511-4517) and antiproliferative (Claeskens et al. (2000) Br J Cancer 82:1123-1130) properties. It has been shown to be downregulated in neointimal formation and suggested to have a possible protective effect in the vessel wall (Geary et al. (2002) Arterioscler Thromb Vasc Biol 22:2010-2016). Another gene with decreased expression, Tgfb3, may also have a protective effect. The factor encoded by this gene has been shown to decrease scar formation, and to exert an inhibitory effect on G-CSF, suggesting an anti-inflammatory role that would counter pro-inflammatory factors in the vascular wall (Hosokawa et al. (2003) J Dent Res 82:558-564); Jacobsen et al. (1993) JImmunol 151:4534-4544).

Interestingly, numerous genes characteristic of various muscle lineages were shown to be downregulated. For smooth muscle cells, this might reflect decreased expression of differentiation markers. For example, the smooth muscle cell gene caldesmon encodes a marker of differentiated smooth muscle cells (Sobue et al. (1999) Mol Cell Biochem 190:105-118), and previous studies have noted that the population of differentiated contractile smooth muscle cells that express caldesmon is relatively lower in atherosclerotic plaque (Glukhova et al. (1988) Proc Natl Acad Sci 85:9542-9546). Other potential smooth muscle cell marker genes with decreased expression included Csrp1 and Mylk. Other downregulated skeletal and cardiac muscle genes included calsequesterin, which is expressed in fast-twitch skeletal muscle, Usmg4, which is upregulated during skeletal muscle growth, Xin, which is related to cardiac and skeletal muscle development, and Sgcg, that is strongly expressed in skeletal and heart muscle as well as proliferating myoblasts. The possible association of these and other myocyte related genes identified in this study to normal vascular function is not known.

Pathways Analysis

To identify important biological themes represented by genes differentially expressed in the atherosclerotic lesions, the genes were functionally annotated using Gene Ontology (GO) terms (www.geneontology.org) and curated pathway information. Enrichment analysis with the Fisher Exact Test demonstrated several statistically significant ontologies (Table 3), including several associated with inflammation. Inflammatory processes such as immune response, chemotaxis, defense response, antigen processing, inflammatory response, as well as molecular functions such as interleukin receptor activity, cytokine activity, cytokine binding, chemokine and chemokine receptor activity, Tnf-receptor, and MHC I and II receptor activity were noted to be significantly over-represented in the group of genes upregulated with atherosclerosis. Subanalysis of the inflammatory response pathways revealed genes characteristic of the macrophage lineage, as well as both the TH-1 and TH-2 T-cell populations, to be over-represented. Biocarta terms further delineated novel genes that were associated with pathways within the inflammation category, including classical complement, Rac-CyclinD, Egf, and Mrp pathways, as well as those known to be differentially regulated in atherosclerosis, such as Il2, Il7, Il22, Cxcr4, CCr3, Ccr5, Fcer1, and Infg pathways.

In addition to inflammation, other biological processes and molecular functions were over-represented in the group of differentially upregulated genes. These included expected pathways such as wound healing, ossification, proteo- and peptidolysis, apoptosis, nitric oxide mediated signal transduction, cell adhesion and migration, and scavenger receptor activity. However, several pathways that are less known for their role in atherosclerosis were also identified, including carbohydrate metabolism, complement activation, calcium ion hemostasis, collagen catabolism, glycosyl bonds and hydrolase activity, taurine transporter activity, heparin activity, etc. The lack of oxygen radical metabolism among the significant processes was surprising, but consistent with up-regulation of genes related to oxygen radical metabolism in all groups with aging.

Taken together, these pathway analyses support prior observations regarding the importance of inflammatory molecular pathways in atherosclerosis, but additionally, expand the repertoire of molecular pathways that are involved in this disease process.

Identification of Other Time-related Patterns of Gene Expression in Atherosclerosis

The above analysis examined in detail genes with increased expression levels which correlate with atherosclerotic plaque development. However, additional patterns of gene expression were also identified in these longitudinal studies, to identify classes of genes and pathways not previously identified. For these analyses, the AUC algorithm was employed, which measured expression changes over time, made comparisons between the different strain/diet longitudinal datasets to identify gene expression changes specific for the apoE knockout model, and employed permutation to estimate the FDR (Tabibiazar et al. (2005), supra). Using this methodology several distinct gene expression patterns and pathways that reflect particular biological processes were identified (FIG. 4). For instance, some disease-related pathways were upregulated very early in the disease process and downregulated thereafter (Pattern 6). Others were upregulated early and maintained at relative high expression throughout the time course of the disease (Pattern 8). Whereas the earlier pattern is enriched in pathways representing biological processes such as extracellular matrix and collagen metabolism, as well as DNA replication and response to stress, the later pattern is enriched in pathways representing biological processes such as fatty acid metabolism, oxidoreductase activity and heat-shock protein activity. Some disease related pathways were upregulated in both early and late phases of disease development (Pattern 3), including those associated with metabolism, such as glycolysis and gluconeogenesis. Other patterns (Pattern 4) are represented by key pathways regulating plaque development, including growth factor, cytokine, and cell adhesion activity. Interestingly, inflammation is represented in almost all of the patterns described herein.

Identification of Stage Specific Gene Expression Signature Patterns

Classification approaches to human cancer have provided significant insights regarding the clinical features of the tumor, including propensity to metastasis, drug responsiveness, and long term prognosis (Golub et al. (1999) Science 286:531-537; Lapointe et al. (2004) Proc Natl Acad Sci 101:811-816; Paik et al. (2004) N Engl JMed (“Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer”); Sorlie et al. (2001) Proc Natl Acad Sci 98:10869-10874). For atherosclerosis, the clinical utility of classification algorithms will include prediction of future events. To establish a panel of genes whose expression in the vessel wall can accurately classify disease stage, and which may thus be useful for clinical genomic and biomarker applications, the support vector machines algorithm was employed on this comprehensive mouse model disease data set. Employing the SVM classification algorithm, 38 genes were identified that were able to accurately classify each experiment with one of five defined stages of atherosclerosis in mice (FIG. 5A). The results demonstrated that these genes can distinguish normal from severe lesions with 100% accuracy. The intermediate stages of the disease are also distinguished from the other stages with a high degree of accuracy (88-97%) (Table 3).

To validate the classifier genes, their ability to accurately categorize an independent group of 16 week old apoE knockout mice, which were evaluated with a different array and labeling methodology, was evaluated. The microarray utilized different probes for some of the same genes. Moreover, the labeling methodology used a linear amplification step which may introduce further variability in the data. Using the SVM classification algorithm, each of the 4 replicate experiments was accurately classified with the correct stage of the disease process (FIG. 5B). As indicated by the greater correlation between gene expression in this independent group of mice and gene expression patterns in the original experimental group aged 24 weeks, the classifier genes accurately matched this validation dataset to the closest timepoint in the database.

Identification of Mouse Disease Gene Expression Patterns in Human Coronary Atherosclerosis

The expression profile of differentially regulated mouse genes was investigated in human coronary artery atherosclerosis. For transcriptional profiling of human atherosclerotic plaque, 40 coronary artery samples, dissected from explanted hearts of 17 patients undergoing orthotopic heart transplantation, were used. Of the 21 diseased segments, lesions ranged in severity from grade I to V (modified American Heart Association criteria based on morphological description (Virmani et al., supra)). For the purpose of this analysis, human artery segments were classified as non-lesion or lesion (combined all grades). Atherosclerosis related mouse genes were matched to human orthologs by gene symbol or by known homology (www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=homologene). Comparison of expression of the mouse genes between lesion and non-lesion human samples using the significance analysis of microarrays algorithm (FDR<0.025) revealed more than 100 mouse genes with higher expression in the diseased human tissue (FIG. 6). In view of the differences between the tissue samples used in these gene expression experiments, these constitute an important common set of disease relevant genes.

To further test the relevance of our findings in mouse atherosclerosis, the accuracy of the mouse classifier genes was assessed in human atherosclerotic disease, employing established statistical methods. The mouse classifier genes were first used to predict various stages of coronary artery disease in the human arterial samples. The results demonstrated a high degree of accuracy in predicting atherosclerotic disease severity (71.2 to 84.7% accuracy) (Table 3).

Additionally, the mouse classifier genes were used to categorize human atherectomy tissue obtained from coronary vessels treated for chronic atherosclerosis or in-stent restenosis. The pathophysiological basis of restenosis is quite distinct from that of chronic coronary atherosclerosis, and it was of interest to demonstrate that the classifier genes could distinguish the disease processes (Rajagopal and Rockson (2003) Am J Med 115:547-553). The results (Table 3) demonstrated significant accuracy in distinguishing the two types of lesions (85.4 to 93.7% accuracy), further validating the significance of the mouse atherosclerosis gene expression patterns in human disease. The greater accuracy of classification with these samples compared to the arterial segments likely reflects less variation in the clinical profile of the patients, which have much less complex medication and comorbid features than the pre-cardiac transplant patients in the above analysis.

TABLE 2
Biological themes in atherosclerosis. Enrichment analysis of atherosclerosis-related genes
annotated with Gene Ontology and Biocarta terms demonstrates involvement of multiple
molecular pathways and biological processes. Probabilities (p-values) were derived using
Fisher exact test. 8478 of the entire microarray and 513 of genes in our set (including
additional 183 genes which demonstrated Pearson correlation >0.8 with the upregulated
pattern) were annotated with GO, Biocarta, or other terms.
	List gene #	Total gene #	p-value
Biological Process (GO annotation)
immune response	19	78	<0.0001
chemotaxis	10	23	<0.0001
cell surface receptor linked signal transduction	12	38	<0.0001
defense response	15	60	<0.0001
carbohydrate metabolism	14	67	<0.0001
antigen processing	5	9	<0.0001
locomotory behavior	4	6	<0.0001
inflammatory response	8	30	<0.0001
complement activation	5	12	<0.0001
proteolysis and peptidolysis	25	204	0.001
antigen presentation	4	10	0.002
intracellular signaling cascade	28	269	0.003
zinc ion homeostasis	2	2	0.004
transmembrane receptor protein	2	2	0.004
tyrosine kinase activatio
hormone metabolism	2	2	0.004
hair cell differentiation	2	2	0.004
cell death	2	2	0.004
exogenous antigen via MHC class II	3	7	0.006
ossification	4	14	0.008
collagen catabolism	3	8	0.010
classical pathway	3	8	0.010
vesicle transport along actin filament	2	3	0.011
taurine transport	2	3	0.011
nitric oxide mediated signal transduction	2	3	0.011
negative regulation of angiogenesis	2	3	0.011
endogenous antigen via MHC class I	2	3	0.011
endogenous antigen	2	3	0.011
cellular defense response (sensu Vertebrsta)	2	3	0.011
beta-alanine transport	2	3	0.011
lymph gland development	4	17	0.017
perception of pain	2	4	0.020
myeloid blood cell differentiation	2	4	0.020
female gamete generation	2	4	0.020
cytolysis	2	4	0.020
ATP biosynthesis	4	19	0.025
regulation of peptidyl-tyrosine phosphorylation	3	11	0.025
neurotransmitter transport	3	12	0.032
sex differentiation	2	5	0.032
exogenous antigen	2	5	0.032
call adhesion	20	217	0.039
regulation of cell migration	3	13	0.040
wound healing	2	6	0.047
ureteric bud branching	2	6	0.047
cellular defense response	2	6	0.047
acute-phase response	2	6	0.047
regulation of transcription from Pot II promoter	6	44	0.048
hydrogen transport	3	14	0.049
calcium ion homeostesis	3	14	0.049
Molecular Function (GO annotation)
acting on glycosyl bonds	12	31	<0.0001
interleukin receptor activity	8	13	<0.0001
hydrolase activity	67	641	<0.0001
cytokine activity	13	57	<0.0001
hematopoietin	9	32	<0.0001
complement activity	5	9	<0.0001
cytokine binding	3	3	<0.0001
C-C chemokine receptor activity	3	3	<0.0001
chemokine activity	4	7	<0.0001
cysteine-type endopeptidase activity	11	63	0.001
tumor necrosis factor receptor activity	3	5	0.002
platelet-derived growth factor receptor binding	2	2	0.004
cathepsin D activity	2	2	0.004
beta-N-acetylhexosaminidase activity	2	2	0.004
antimicrobial peptide activity	2	2	0.004
scavenger receptor activity	3	6	0.004
cysteine-type peptidase activity	9	56	0.006
mannosyl-oligosaccharide	3	7	0.006
1,2-alpha-mannosidase activi
recepter activity	42	479	0.009
taurine:sodium symporter activity	2	3	0.011
taurine transporter activity	2	3	0.011
myosin ATPase activity	2	3	0.011
MHC class I receptor activity	2	3	0.011
cathepsin B activity	2	3	0.011
calcium channel regulator activity	2	3	0.011
beta-alanine transporter activity	2	3	0.011
catalytic activity	23	230	0.012
solute:hydrogen antiporter activity	2	4	0.020
protein kinase C activity	2	4	0.020
tumor necrosis factor receptor binding	3	11	0.025
hydrogen-exporting ATPase activity	5	29	0.028
neurotransmitter:sodium symporter activity	2	5	0.032
MHC class II receptor activity	2	5	0.32
heparin binding	5	31	0.037
endopeptidase inhibitor activity	4	22	0.041
protein-tyrosine-phosphatase activity	7	54	0.043
hydrogen ion transporter activity	5	33	0.046
sulfuric ester hydrolase activity	2	6	0.047
Cellular Component (GO annotation)
extracellular space	139	1148	<0.0001
lysosome	26	66	<0.0001
extracellular	23	117	<0.0001
integral to membrane	138	1637	<0.0001
membrane	77	862	<0.0001
integral to plasma membrane	22	205	0.006
extracellular matrix	14	114	0.009
external side of plasma membrane	3	9	0.014
Biocarta Pathways
classicPathway	3	3	<0.0001
il22bppathway	4	7	<0.0001
nktPathway	5	12	<0.0001
Ccr5Pathway	5	13	0.001
reckPathway	4	8	0.001
compPathway	3	4	0.001
il7Pathway	4	10	0.002
TPOPathway	5	17	0.003
cxcr4Pathway	5	17	0.003
blymphocytePathway	2	2	0.004
il10Pathway	3	7	0.006
pdgfPathway	5	22	0.009
ionPathway	2	3	0.011
egfPathway	5	23	0.011
biopeptidesPathway	5	23	0.011
bcrPathway	5	25	0.015
ghPathway	4	17	0.017
fcer1Pathway	5	26	0.018
spryPathway	3	10	0.019
neutrophilPathway	2	4	0.020
mrpPathway	2	4	0.020
trkaPathway	3	11	0.025
pmlPathway	3	11	0.025
srcRPTPPathway	3	12	0.032
plcdPathway	2	5	0.032
itngPathway	2	5	0.032
il2Pathway	3	13	0.040
RacCycDPathway	4	22	0.041
lymphocytePathway	2	6	0.047
nuclearRsPathway	3	14	0.049
cdMacPathway	3	14	0.049
CCR3Pathway	3	14	0.049
Summary annotation for Inflammatory genes
defense	15	54	<0.0001
chemokine	9	22	<0.0001
interleukin	9	38	<0.0001
cytokine	18	144	0.003
TNF	4	13	0.006
TH2	4	15	0.011
TH1	4	16	0.013
macrophage	3	13	0.040

TABLE 3
Classification of mouse and human atherosclerotic tissues employing mouse classifier genes.
To validate the accuracy of mouse classifier genes in predicting disease severity we utilized
various mouse and human expression datasets. The SVM algorithm was utilized for cross
validation of mouse experiments grouped on the basis of (A) stage of disease (no disease-
apoE time 0, mild disease-apoE at 4 and 10 weeks on normal diet, mild-moderate disease-
apoE at 4 and 10 weeks on highfat diet, moderate disease-apoE at 24 and 40 weeks on normal
diet, and severe disease-apoE at 24 and 40 weeks on high fat diet); (B) 3 different time points
(apoE at 0 vs. 10, vs. 40 weeks); (C) Human coronary artery with lesion vs. no lesion; and (D)
atherectomy samples derived from in-stent restenosis vs. native atherosclerotic lesions.
For each analysis, the accuracy of classification is represented in tabular fashion with the
confusion matrix generated using N-fold cross validation methods.
A	TRUE	TRUE	TRUE	TRUE	TRUE
PREDICTED	No dz	Mild_dz	Mild_mod dz	Mod_dz	Severe_dz	Correct [%]
No dz	64	0	1	0	0	98.5
Mild_dz	2	140	0	0	0	98.6
Mild_mod dz	0	0	148	20	0	88.1
Mod_dz	0	0	3	149	0	98.0
Severe_dz	0	0	0	0	173	100.0
Correct [%]	97.0	100.0	97.4	88.2	100.0
B	TRUE	TRUE	TRUE
PREDICTED	ApoE_T00_NC	ApoE_T10_HF	ApoE_T40_HF	Correct [%]
ApoE_T00_NC	68	0	0	100
ApoE_T10_HF	0	56	0	100
ApoE_T40_HF	0	0	76	100
Correct [%]	100	100	100
	C	TRUE	TRUE
	PREDICTED	Lesion	No lesion	Correct [%]
	Lesion	183	33	84.7
	No lesion	53	131	71.2
	Correct [%]	77.5	79.9
	D	TRUE	TRUE
	PREDICTED	ISR	De novo	Correct [%]
	ISR	345	44	88.7
	De novo	59	652	91.7
	Correct [%]	85.4	93.7

Example 2

Mouse Strain—Specific Differences in Vascular Wall Gene Expression and Their Relationship to Vascular Disease

Methods

RNA Preparation and Hybridization to the Microarray

Three-week old female C3H/HeJ, C57B1/6J, and apoE knock-out mice (C57BL/6J-Apoe^tmlUnc) were purchased from Jackson Labs (JAX® Mice and Services, Bar Harbor, Me.). At four weeks of age the mice were either continued on normal chow or switched to non-cholate containing high-fat diet which included 21% anhydrous milkfat and 0.15% cholesterol (Dyets #101511, Dyets Inc., Bethlehem, Pa.) for a maximum period of 40 weeks. At each of the time-points, including 0 (baseline), 4, 10, 24 and 40 weeks, for each of the conditions (strain-diet combination), 15 mice were harvested for RNA isolation, for a total of 450 mice. Following Stanford University animal care guidelines, the mice were anesthetized with Avertin and perfused with normal saline. The aortas from the root to the common iliacs were carefully dissected, flash frozen in liquid nitrogen, and divided into three pools of five aortas for further RNA isolation. Total RNA was isolated as described in Tabibiazar et al. (2003) Circ Res 93:1193-1201. First strand cDNA was synthesized from 10 μg of total RNA from each pool and from whole 17.5-day embryo for reference RNA in the presence of Cy5 or Cy3 dCTP, respectively, and hybridized to a mouse 60mer oligo microarray (G4120A, Agilent Technologies, Palo Alto, Calif.), generating three biological replicates for each time point.

Data Processing

Array image acquisition and feature extraction was performed using the Agilent G2565AA Microarray Scanner and feature extraction software version A.6.1.1. Normalization was carried out using a LOWESS algorithm, and Dye-normalized signals were used in calculating log ratios. Features with reference values of<2.5 standard deviations above background for the negative control features were regarded as missing values. Those features with values in at least ⅔ of the experiments and present in at least one of the replicates were retained for further analysis. For SAM analyses, a K-nearest-neighbor (KNN) algorithm was applied to impute for missing values. (Tabibiazar et al. (2003), supra.)

Data Analysis

Experimental design and analysis flow chart is depicted in FIG. 7. Significance Analysis of Microarrays (SAM) was employed to identify genes with statistically different expression between the C3H and C57 mice at baseline. (Tabibiazar et al. (2003), supra; Tusher et al. (2001) PNAS 98:5116-5121; Chen et al. (2003) Circulation 108:1432-1439.) For partitioning clustering of the genes with K-Means and self-organizing-maps (SOM), we used positive correlation for distance determination and required complete linkage, which uses the greatest distance between genes to ascribe similarity. SOM and K-Means analyses were performed using Expressionist software (GeneData, Inc., USA). Heatmaps were generated using HeatMap Builder. For enrichment analysis we used the EASE analysis software which employs Gene Ontology (GO) annotation and the Fisher's exact test to derive biological themes within particular gene sets. (Hosack et al. (2003) Genome Biol. 4:R70.) For time-course study, a new statistical algorithm, the Area-Under-Curve (AUC) analysis was devised. For each sequence of 4 triplicate gene expression measurements over time, we first subtracted the measurement at time 0 from all values. We then computed the signed area under the curve. The area is a natural measure of change over time. These areas were then used to compute an F-statistic for comparing C57 and C3H mice across the different diets. A permutation analysis, similar to that employed in SAM, was carried out to estimate the false discovery rate (q-value or “FDR”) for different levels of the F-statistic. For ease of presentation, genes which meet our FDR cutoffs will be referred to as “significant” throughout the remainder of the article. All microarray data were submitted to the NCBI Gene Expression Omnibus (GEO GSE1560; http://www.ncbi.nlm.nih.gov/geo/).

Aortic Lesion Analysis

For select time points within various experimental groups, 5 to 7 female mice were used for histological lesion analysis. Atherosclerosis lesion area was determined as described in Tangirala et al. (1995) 36:2320-2328.

Quantitative Real-Time Reverse Transcriptase-Polymerase Chain Reaction

Primers and probes for 10 representative differentially expressed genes were obtained from Applied Biosystems Assays-on-Demand. A Total of 90 reactions were performed from representative RNA samples used for microarray experiments. These included triplicate assay on three pools of five aortas. cDNA was synthesized and Taqman was performed as described in Tabibiazar et al. (2003), supra.

Results

Baseline Differences in Gene Expression Patterns between the Mouse Strains

Differences in gene expression levels between the two strains at baseline, before effects of aging or diet become apparent, may identify genes that play a role in determining vascular wall disease susceptibility. To identify such genes SAM was used to compare the vascular wall gene expression of C3H vs. C57 mice at 4 weeks of age, with all animals on normal chow diet. SAM identified 311 genes as being significantly differentially expressed (FDR<0.1 with>1.5 fold difference), and expression patterns of these genes provided a clear partition between C3H and C57 mice (FIG. 8). A separate 2-class comparison (SAM, FDR<0.1) between C57 and apoE-deficient mice with a C57B1/6 genetic background revealed only a few genes, including Apo-E, which were differentially expressed in the 2 groups of mice (data not shown).

Comparison of C3H and C57 vascular wall gene expression at baseline provided a list of compelling candidate genes which reflected differences in biological processes such as growth, differentiation, and inflammation as well as molecular functions such as cathecholamine synthesis, phosphatase activity, peroxisome function, insulin like growth factor activity, and antigen presentation (FIG. 8). These processes were exemplified by higher expression of genes such as Cdknla, Pparbp, protein tyrosine phosphatase-4a2, and Socs5 in C3H mice, compared with genes such as ABCC1, H2-D1, Bat5, IGFBP1, SCD1, and Serpine6b which demonstrated higher expression in C57 mice. These fundamental baseline gene expression differences may determine disease susceptibility as the mice are exposed to age-related stimuli or dietary challenges.

Age-related Differences in Gene Expression Patterns between the Mouse Strains

To further examine the vascular wall gene expression differences between C57 and C3H mice, an analysis was performed to identify genes differentially expressed in response to aging (FIG. 9). Data was collected at five time points over a 40 week period. To identify such genes, we developed the Area Under the Curve (AUC) analysis. The AUC analysis relies on a permutation procedure to reduce the number of potential false positives generated due to multiple testing, but still utilizes the increase in statistical power of time-course experimental design. Comparing C57 vs. C3H time-course differences on normal diet with a rigid cutoff (FDR<0.05) did not identify any genes. However, relaxing the AUC stringency (f-statistic>10, FDR <0.45) allowed a large number of genes (413) to be included for pathway over-representation analysis using GO annotation. Functional annotation and group over-representation analysis (Fisher test p-value <0.02) of the resultant differentially expressed genes revealed differences in a number of biological processes, including growth and development, as well as a number of molecular fimctions such as cell cycle control, regulation of mitosis, and metabolism (FIG. 9b). Some of these processes are exemplified by genes with higher expression in C57 mice, such as Aocl (pro-oxidative stress), Bub1 (cell cycle check point), Cyclin B2, as well as genes with higher expression in C3H, including INHBA and INHBB.

Temporally variable genes identified by AUC analysis were further characterized with K-Means clustering to identify dynamic patterns of expression during the aging process (FIG. 3c). Clusters 1, 4, and 9 revealed either higher overall expression or temporally increasing levels of expression in C3H mice compared with C57 mice. In contrast, clusters 2, 6, and 14 revealed the opposite pattern. Of the genes which were noted to be differentially expressed in the two strains during aging, 51 genes were also differentially expressed at baseline, suggesting that baseline differences of certain genes can further be affected with aging.

Diet-related Differences in Gene Expression Patterns between the Mouse Strains

Differential vascular wall response to atherogenic stimuli was determined by comparing temporal gene expression patterns in C57 vs. C3H mice on high-fat diet (FIG. 10A). Comparing C57 vs. C3H time-course differences on high-fat diet with a rigid cutoff (FDR<0.05) identified 35 genes, including Hgfl and Tgf4, which were down regulated in C57 on high-fat diet. Additional known genes, as well as a number of ESTs were also identified. Employing a less stringent AUC cutoff allowed identification of a larger number of genes, which could be evaluated with pathway over-representation analysis using GO annotation. At this level of stringency (f-statistic>10, FDR<0.35), a total of 650 genes with temporally variable expression were identified. Genes that were also differentially regulated by the aging process (141 of 650 genes) were excluded from further analysis of this group. 38 of the remaining 509 genes were among those differentially expressed at baseline. Functional annotation and group over-representation analysis (Fisher test p-value<0.02) of these differentially expressed genes revealed differences in biological processes such as catabolism, oxygen reactive species and superoxide metabolism, and proteo- and peptidolysis as well as molecular functions such as fatty acid metabolism, oxidoreductase and methyltransferase activities (FIG. 10B). Interestingly, this analysis suggested important differences between the two mouse strains with respect to the activity of the peroxisome, microbody and lysosome. Some of these processes were exemplified by genes with higher expression in C3H mice, such as Ccs, Ephx2, Gpx4, Prdx6 (anti-oxidants), Sirt3 (transcriptional repressor), PPARa, and Mcd, as well as genes with higher expression in C57 mice, such as Lysyl oxidase and Cdkn1a. K-means clustering of these genes identified a small number of distinct expression patterns (FIG. 10C), with clusters 3 and 9 revealing increased gene expression in C3H mice and clusters 8 and 10 showing the opposite pattern.

Evaluation of Strain-specific Differentially Regulated Genes in the ApoE Model

Using these techniques, a significant number of genes have been identified that are differentially expressed in the atherosclerosis resistant C3H and susceptible C57 mice, some of which are likely involved in atherogenesis and some of which are likely irrelevant to the process. To further select genes most likely to be involved in atherogenesis, expression in apoE-deficient mice fed normal or high-fat diet over a period of 40 weeks was investigated (FIG. 11). We utilized SOM analysis to visualize the expression profiles of these subsets of genes throughout the development and progression of atherosclerosis in the ApoE-deficient mice. The analysis revealed several patterns of gene expression. For example, SOM cluster 8 demonstrated a consistently increasing pattern of expression which correlated with disease progression in the apoE-deficient mice (FIG. 11). As evidenced by the pie chart, this cluster is enriched with genes that were identified as more highly expressed in C57 versus C3H mice at baseline (i.e., potentially atherogenic). In contrast, clusters 4, 5, and 6 showed decreasing expression with disease progression. The decreased expression of genes in cluster 4 was somewhat attenuated with high-fat challenge of the ApoE-deficient mice. This cluster is particularly enriched with genes that had revealed a higher expression in C3H mice (i.e., potentially atheroprotective) with atherogenic stimuli and with aging.

Given C3H resistance and C57 susceptibility to atherosclerosis, as an initial hypothesis it was postulated that genes with higher expression in C3H mice confer resistance, whereas genes with higher expression in C57 mice may have a pro-atherogenic role. With this point of reference, gene clusters were further examined. For example, limiting the list of genes in SOM cluster 8 (genes with increased expression with atherosclerosis) to those that also had higher baseline expression in C57 mice yielded an interesting set of genes that may be atherogenic. This group included inflammation related genes such as H2-D1, Pdgfc, Paf, and Cd47. Other compelling genes included Agpt2, Mglap, Xdh, Th, and Ctsc. Conversely, limiting the list of genes in clusters 4 and 5 to those with higher expression in C3H mice identified a group of genes with potential athero-protective function. Some of those genes included Pparα, Pparbp, as well as Ptp4a1, and Mcd.

Lesion Analysis in the Genetic Models

To address whether some of the gene expression differences are related to presence of atherosclerotic lesion in C57 mice, the total atherosclerotic burden was determined in the aorta by calculating a percent lesion area in aortas of C57 (n=5) and C3H (n=5) mice. Comparisons were made at time 0 and 40 weeks on normal or high-fat diet. Non-cholate containing high-fat diet was used to prevent caustic effects on the vascular wall. As expected, C57 and C3H mice on either diet did not demonstrate evidence of atherosclerosis throughout the course of the experiment, suggesting that observed gene expression changes cannot be explained by different cellular composition of the vessel wall. Although minimal fatty infiltrates were noted on histological evaluation of the aortic root in C57 mice on high-fat diet, there were no obvious changes in inflammatory cell infiltrate.

Quantitative RT-PCR Validation of Expression Differences

To validate the array results with quantitative RT-PCR and assure that the statistical analyses were identifying truly differentially expressed genes, ten representative genes were assayed by quantitative RT-PCR. Several genes were used from each group of significant genes. There is high degree of correlation between the two methodologies (Pearson correlation of 0.86), validating the results of the microarray analyses.

Although the foregoing invention has been described in some detail by way of illustration and examples for purposes of clarity of understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practiced without departing from the spirit and scope of the invention. Therefore, the description should not be construed as limiting the scope of the invention.

All publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent or patent application were specifically and individually indicated to be so incorporated by reference.

Claims

1. A system for detecting gene expression, comprising at least two isolated polynucleotide molecules, wherein each of said at least two isolated polynucleotide molecules detects an expressed gene product from a gene that is differentially expressed in atherosclerotic disease in a mammal, wherein said gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 1-927.

2. A system for detecting gene expression, comprising at least two isolated polynucleotide sequences, wherein each of said at least two isolated polynucleotide molecules detects an expressed gene product from a gene that is differentially expressed in atherosclerotic disease in a mammal, wherein said gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

3. A system for detecting gene expression according to claim 1, wherein at least one of said isolated polynucleotide molecules detects a expressed gene product from a gene selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

4. A system according to claim 1, wherein the isolated polynucleotide molecules are immobilized on an array.

5. A system according to claim 4, wherein the array is selected from the group consisting of a chip array, a plate array, a bead array, a pin array, a membrane array, a solid surface array, a liquid array, an oligonucleotide array, polynucleotide array or a cDNA array, a microtiter plate, a membrane, and a chip.

6. A system according to claim 1, wherein the isolated polynucleotides are selected from the group consisting of synthetic DNA, genomic DNA, cDNA, RNA, or PNA.

7. A kit comprising the system of claim 1.

8. A kit comprising the system of claim 4.

9. A method of monitoring atherosclerotic disease in an individual, comprising detecting the expression level of at least one gene selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 1-927.

10. The method of claim 9, wherein said at least one gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

11. The method of claim 9, comprising detecting the expression level of at least two of said genes.

12. The method of claim 11, wherein at least one of said at least two genes is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

13. The method of claim 9, comprising detecting the expression level of at least ten of said genes.

14. The method of claim 13, wherein at least one of said at least ten genes is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

15. The method of claim 9, comprising detecting the expression level of at least one hundred of said genes.

16. The method of claim 15, wherein at least one of said at least one hundred genes is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

17. The method of claim 9, wherein said atherosclerotic disease comprises coronary artery disease.

18. The method of claim 9, wherein said atherosclerotic disease comprises carotid atherosclerosis.

19. The method of claim 9, wherein said atherosclerotic disease comprises peripheral vascular disease.

20. The method of claim 9, wherein said expression level is detected by measuring the RNA level expressed by said one or more genes.

21. The method of claim 20, comprising isolating RNA from said individual prior to detecting the RNA expression level.

22. The method of claim 20, wherein said detection of said RNA expression level comprises amplifying RNA from said individual.

23. The method of claim 22, wherein amplification of RNA comprises polymerase chain reaction (PCR).

24. The method of claim 20, wherein detection of said RNA expression level comprises hybridization of RNA from said individual to a polynucleotide corresponding to said at least one gene selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 1-927.

25. The method of claim 20, wherein said expression level is detected by measuring the protein level expressed by said one or more genes.

26. The method of claim 9, further comprising selecting an appropriate therapy for said atherosclerotic disease.

27. The method of claim 9, comprising detecting the expression of said at least one gene in serum from said individual.

28. The method of claim 20, comprising measuring said RNA level in serum from said individual.

29. The method of claim 25, comprising measuring said protein level in serum from said individual.

30. A method of monitoring atherosclerotic disease in an individual, comprising detecting RNA expressed from at least one gene selected from the group of genes corresponding to at least one polynucleotide sequence depicted in SEQ ID NOs: 1-927.

31. The method of claim 30, wherein said at least one gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

32. The method of claim 30, comprising measuring said RNA in serum from said individual.

33. A method of monitoring atherosclerotic disease in an individual, comprising detecting protein expressed from at least one gene selected from the group of genes corresponding to at least one polynucleotide sequence depicted in SEQ ID NOs: 1-927.

34. The method of claim 33, wherein said at least one gene is selected from the group of genes corresponding to the polynucleotide sequences depicted in SEQ ID NOs: 8, 14, 26, 32, 50, 64, 83, 99, 142, 154, 159, 161, 177, 181, 200, 390, 430, 434, 439, 440, 476, 491, 508, 530, 534, 565, 567, 572, 624, 647, 657, 690, 733, 745, 806, 824, 886, 882, 901, 905, 913, and 927.

35. The method of claim 33, comprising measuring said protein in serum from said individual.